ID   CSF1R_MOUSE             Reviewed;         977 AA.
AC   P09581; Q3U3P1; Q9DBH9;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2002, sequence version 3.
DT   20-JAN-2016, entry version 192.
DE   RecName: Full=Macrophage colony-stimulating factor 1 receptor;
DE   AltName: Full=CSF-1 receptor;
DE            Short=CSF-1-R;
DE            Short=CSF-1R;
DE            Short=M-CSF-R;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Fms;
DE   AltName: CD_antigen=CD115;
DE   Flags: Precursor;
GN   Name=Csf1r; Synonyms=Csfmr, Fms;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2966922;
RA   Rothwell V.M., Rohrschneider L.R.;
RT   "Murine c-fms cDNA: cloning, sequence analysis and retroviral
RT   expression.";
RL   Oncogene Res. 1:311-324(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Rothwell V.M.;
RL   Submitted (SEP-1988) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=8441691; DOI=10.1093/nar/21.3.750;
RA   de Parseval N., Bordereaux D., Gisselbrecht S., Sola B.;
RT   "Reassessment of the murine c-fms proto-oncogene sequence.";
RL   Nucleic Acids Res. 21:750-750(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Liver, and Urinary bladder;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=8497248;
RA   Yue X., Favot P., Dunn T.L., Cassady A.I., Hume D.A.;
RT   "Expression of mRNA encoding the macrophage colony-stimulating factor
RT   receptor (c-fms) is controlled by a constitutive promoter and tissue-
RT   specific transcription elongation.";
RL   Mol. Cell. Biol. 13:3191-3201(1993).
RN   [7]
RP   PHOSPHORYLATION AT TYR-706 AND TYR-807.
RX   PubMed=2160591;
RA   van der Geer P., Hunter T.;
RT   "Identification of tyrosine 706 in the kinase insert as the major
RT   colony-stimulating factor 1 (CSF-1)-stimulated autophosphorylation
RT   site in the CSF-1 receptor in a murine macrophage cell line.";
RL   Mol. Cell. Biol. 10:2991-3002(1990).
RN   [8]
RP   FUNCTION IN CELL PROLIFERATION AND PHOSPHORYLATION OF PIK3R1,
RP   INTERACTION WITH PIK3R1, PHOSPHORYLATION AT TYR-706 AND TYR-807, AND
RP   MUTAGENESIS OF TYR-706 AND TYR-807.
RX   PubMed=1652061;
RA   van der Geer P., Hunter T.;
RT   "Tyrosine 706 and 807 phosphorylation site mutants in the murine
RT   colony-stimulating factor-1 receptor are unaffected in their ability
RT   to bind or phosphorylate phosphatidylinositol-3 kinase but show
RT   differential defects in their ability to induce early response gene
RT   transcription.";
RL   Mol. Cell. Biol. 11:4698-4709(1991).
RN   [9]
RP   FUNCTION AS CSF1 RECEPTOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   PHOSPHORYLATION AT TYR-697; TYR-706; TYR-721 AND TYR-807, MUTAGENESIS
RP   OF LYS-614; TYR-697 AND TYR-721, AND INTERACTION WITH GRB2.
RX   PubMed=8262059;
RA   van der Geer P., Hunter T.;
RT   "Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase
RT   binding site, abrogates signal transduction by the murine CSF-1
RT   receptor expressed in Rat-2 fibroblasts.";
RL   EMBO J. 12:5161-5172(1993).
RN   [10]
RP   FUNCTION AS CSF1 RECEPTOR IN CELL PROLIFERATION AND IN ACTIVATION OF
RP   AKT1; MAPK1/ERK2; MAPK3/ERK1; STAT3; STAT5A AND STAT5B, INTERACTION
RP   WITH CBL; YES1; FYN AND SRC, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, PHOSPHORYLATION AT TYR-559 AND TYR-807,
RP   UBIQUITINATION, AND MUTAGENESIS OF TYR-559.
RX   PubMed=8007983;
RA   Myles G.M., Brandt C.S., Carlberg K., Rohrschneider L.R.;
RT   "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for
RT   kinase activity and macrophage colony-stimulating factor-dependent
RT   internalization.";
RL   Mol. Cell. Biol. 14:4843-4854(1994).
RN   [11]
RP   FUNCTION IN MACROPHAGE PROLIFERATION; MACROPHAGE DIFFERENTIATION;
RP   PHOSPHORYLATION OF PLCG2; PHOSPHORYLATION OF PIK3R1 AND
RP   PHOSPHORYLATION OF GRB2, CATALYTIC ACTIVITY, INTERACTION WITH PIK3R1;
RP   GRB2; PLCG2 AND FYN, AND MUTAGENESIS OF LYS-614; TYR-697; TYR-721 AND
RP   TYR-807.
RX   PubMed=9312046; DOI=10.1093/emboj/16.19.5880;
RA   Bourette R.P., Myles G.M., Choi J.L., Rohrschneider L.R.;
RT   "Sequential activation of phoshatidylinositol 3-kinase and
RT   phospholipase C-gamma2 by the M-CSF receptor is necessary for
RT   differentiation signaling.";
RL   EMBO J. 16:5880-5893(1997).
RN   [12]
RP   INTERACTION WITH THOC5, AND MUTAGENESIS OF TYR-544; LYS-614; TYR-706;
RP   TYR-721 AND TYR-807.
RX   PubMed=10597251; DOI=10.1038/sj.onc.1203062;
RA   Tamura T., Mancini A., Joos H., Koch A., Hakim C., Dumanski J.,
RA   Weidner K.M., Niemann H.;
RT   "FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage
RT   differentiation.";
RL   Oncogene 18:6488-6495(1999).
RN   [13]
RP   FUNCTION.
RX   PubMed=10958675; DOI=10.1128/MCB.20.18.6779-6798.2000;
RA   Lee A.W., States D.J.;
RT   "Both src-dependent and -independent mechanisms mediate
RT   phosphatidylinositol 3-kinase regulation of colony-stimulating factor
RT   1-activated mitogen-activated protein kinases in myeloid
RT   progenitors.";
RL   Mol. Cell. Biol. 20:6779-6798(2000).
RN   [14]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=11756160; DOI=10.1182/blood.V99.1.111;
RA   Dai X.M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G.,
RA   Kapp S., Sylvestre V., Stanley E.R.;
RT   "Targeted disruption of the mouse colony-stimulating factor 1 receptor
RT   gene results in osteopetrosis, mononuclear phagocyte deficiency,
RT   increased primitive progenitor cell frequencies, and reproductive
RT   defects.";
RL   Blood 99:111-120(2002).
RN   [15]
RP   INTERACTION WITH CBL, AND PHOSPHORYLATION AT TYR-974.
RX   PubMed=11850825; DOI=10.1038/sj.onc.1205166;
RA   Wilhelmsen K., Burkhalter S., van der Geer P.;
RT   "C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel
RT   phosphorylation site in the receptor's carboxy-terminus.";
RL   Oncogene 21:1079-1089(2002).
RN   [16]
RP   MUTAGENESIS OF TYR-559, PHOSPHORYLATION AT TYR-559, DOMAIN, AND ENZYME
RP   REGULATION.
RX   PubMed=15297464; DOI=10.1074/jbc.M314170200;
RA   Rohde C.M., Schrum J., Lee A.W.;
RT   "A juxtamembrane tyrosine in the colony stimulating factor-1 receptor
RT   regulates ligand-induced Src association, receptor kinase function,
RT   and down-regulation.";
RL   J. Biol. Chem. 279:43448-43461(2004).
RN   [17]
RP   INTERACTION WITH INPPL1.
RX   PubMed=15557176; DOI=10.4049/jimmunol.173.11.6820;
RA   Wang Y., Keogh R.J., Hunter M.G., Mitchell C.A., Frey R.S., Javaid K.,
RA   Malik A.B., Schurmans S., Tridandapani S., Marsh C.B.;
RT   "SHIP2 is recruited to the cell membrane upon macrophage colony-
RT   stimulating factor (M-CSF) stimulation and regulates M-CSF-induced
RT   signaling.";
RL   J. Immunol. 173:6820-6830(2004).
RN   [18]
RP   FUNCTION.
RX   PubMed=16950670; DOI=10.1016/j.bone.2006.06.012;
RA   Sakai H., Chen Y., Itokawa T., Yu K.P., Zhu M.L., Insogna K.;
RT   "Activated c-Fms recruits Vav and Rac during CSF-1-induced
RT   cytoskeletal remodeling and spreading in osteoclasts.";
RL   Bone 39:1290-1301(2006).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-491.
RC   STRAIN=C57BL/6J; TISSUE=Plasma;
RX   PubMed=16944957; DOI=10.1021/pr060186m;
RA   Ghesquiere B., Van Damme J., Martens L., Vandekerckhove J.,
RA   Gevaert K.;
RT   "Proteome-wide characterization of N-glycosylation events by diagonal
RT   chromatography.";
RL   J. Proteome Res. 5:2438-2447(2006).
RN   [20]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=16705167; DOI=10.1128/MCB.01932-05;
RA   Simoncic P.D., Bourdeau A., Lee-Loy A., Rohrschneider L.R.,
RA   Tremblay M.L., Stanley E.R., McGlade C.J.;
RT   "T-cell protein tyrosine phosphatase (Tcptp) is a negative regulator
RT   of colony-stimulating factor 1 signaling and macrophage
RT   differentiation.";
RL   Mol. Cell. Biol. 26:4149-4160(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF SLA2, INTERACTION WITH SLA2 AND CBL,
RP   SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=17353186; DOI=10.1074/jbc.M701182200;
RA   Pakuts B., Debonneville C., Liontos L.M., Loreto M.P., McGlade C.J.;
RT   "The Src-like adaptor protein 2 regulates colony-stimulating factor-1
RT   receptor signaling and down-regulation.";
RL   J. Biol. Chem. 282:17953-17963(2007).
RN   [22]
RP   FUNCTION, MUTAGENESIS OF TYR-559, AND PHOSPHORYLATION AT TYR-921.
RX   PubMed=17420255; DOI=10.1074/jbc.M610938200;
RA   Takeshita S., Faccio R., Chappel J., Zheng L., Feng X., Weber J.D.,
RA   Teitelbaum S.L., Ross F.P.;
RT   "c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation
RT   of primary macrophages.";
RL   J. Biol. Chem. 282:18980-18990(2007).
RN   [23]
RP   FUNCTION.
RX   PubMed=17420256; DOI=10.1074/jbc.M610937200;
RA   Faccio R., Takeshita S., Colaianni G., Chappel J., Zallone A.,
RA   Teitelbaum S.L., Ross F.P.;
RT   "M-CSF regulates the cytoskeleton via recruitment of a multimeric
RT   signaling complex to c-Fms Tyr-559/697/721.";
RL   J. Biol. Chem. 282:18991-18999(2007).
RN   [24]
RP   FUNCTION, AND SIGNALING PATHWAY.
RX   PubMed=17972959; DOI=10.1038/sj.leu.2404986;
RA   Bourgin-Hierle C., Gobert-Gosse S., Therier J., Grasset M.F.,
RA   Mouchiroud G.;
RT   "Src-family kinases play an essential role in differentiation
RT   signaling downstream of macrophage colony-stimulating factor receptors
RT   mediating persistent phosphorylation of phospholipase C-gamma2 and MAP
RT   kinases ERK1 and ERK2.";
RL   Leukemia 22:161-169(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [26]
RP   FUNCTION IN OSTEOCLAST DIFFERENTIATION, ROLE IN DISEASE, AND ENZYME
RP   REGULATION.
RX   PubMed=18814279; DOI=10.1002/ijc.23903;
RA   Hiraga T., Nakamura H.;
RT   "Imatinib mesylate suppresses bone metastases of breast cancer by
RT   inhibiting osteoclasts through the blockade of c-Fms signals.";
RL   Int. J. Cancer 124:215-222(2009).
RN   [27]
RP   ROLE IN DISEASE.
RX   PubMed=20181277; DOI=10.1186/ar2940;
RA   Paniagua R.T., Chang A., Mariano M.M., Stein E.A., Wang Q.,
RA   Lindstrom T.M., Sharpe O., Roscow C., Ho P.P., Lee D.M.,
RA   Robinson W.H.;
RT   "c-Fms-mediated differentiation and priming of monocyte lineage cells
RT   play a central role in autoimmune arthritis.";
RL   Arthritis Res. Ther. 12:R32-R32(2010).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-711, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [29]
RP   FUNCTION AS IL34 AND CSF1 RECEPTOR, FUNCTION IN ACTIVATION OF
RP   MAPK1/ERK2 AND MAPK3/ERK1, PHOSPHORYLATION AT TYR-559; TYR-807 AND
RP   TYR-721, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=20504948; DOI=10.1189/jlb.1209822;
RA   Wei S., Nandi S., Chitu V., Yeung Y.G., Yu W., Huang M.,
RA   Williams L.T., Lin H., Stanley E.R.;
RT   "Functional overlap but differential expression of CSF-1 and IL-34 in
RT   their CSF-1 receptor-mediated regulation of myeloid cells.";
RL   J. Leukoc. Biol. 88:495-505(2010).
RN   [30]
RP   FUNCTION.
RX   PubMed=21727904; DOI=10.1038/icb.2011.58;
RA   Lenzo J.C., Turner A.L., Cook A.D., Vlahos R., Anderson G.P.,
RA   Reynolds E.C., Hamilton J.A.;
RT   "Control of macrophage lineage populations by CSF-1 receptor and GM-
RT   CSF in homeostasis and inflammation.";
RL   Immunol. Cell Biol. 90:429-440(2012).
RN   [31]
RP   UBIQUITINATION.
RX   PubMed=21041311; DOI=10.1074/jbc.M110.166702;
RA   Xiong Y., Song D., Cai Y., Yu W., Yeung Y.G., Stanley E.R.;
RT   "A CSF-1 receptor phosphotyrosine 559 signaling pathway regulates
RT   receptor ubiquitination and tyrosine phosphorylation.";
RL   J. Biol. Chem. 286:952-960(2011).
RN   [32]
RP   FUNCTION IN REGULATION OF CELL MOTILITY; CELL SHAPE; ACTIN
RP   CYTOSKELETON REORGANIZATION; PHOSPHORYLATION OF AKT1 AND REGULATION OF
RP   PHOSPHATIDYLINOSITOL METABOLISM, INTERACTION WITH PIK3R1 AND PLCG2,
RP   PHOSPHORYLATION AT TYR-706 AND TYR-721, AND MUTAGENESIS OF TYR-721.
RX   PubMed=21610095; DOI=10.1242/jcs.075309;
RA   Sampaio N.G., Yu W., Cox D., Wyckoff J., Condeelis J., Stanley E.R.,
RA   Pixley F.J.;
RT   "Phosphorylation of CSF-1R Y721 mediates its association with PI3K to
RT   regulate macrophage motility and enhancement of tumor cell invasion.";
RL   J. Cell Sci. 124:2021-2031(2011).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 20-296 IN COMPLEX WITH CSF1,
RP   GLYCOSYLATION AT ASN-45 AND ASN-73, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=19017797; DOI=10.1073/pnas.0807762105;
RA   Chen X., Liu H., Focia P.J., Shim A.H., He X.;
RT   "Structure of macrophage colony stimulating factor bound to FMS:
RT   diverse signaling assemblies of class III receptor tyrosine kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:18267-18272(2008).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for CSF1 and IL34 and plays an essential role in the
CC       regulation of survival, proliferation and differentiation of
CC       hematopoietic precursor cells, especially mononuclear phagocytes,
CC       such as macrophages and monocytes. Promotes the release of
CC       proinflammatory chemokines in response to IL34 and CSF1, and
CC       thereby plays an important role in innate immunity and in
CC       inflammatory processes. Plays an important role in the regulation
CC       of osteoclast proliferation and differentiation, the regulation of
CC       bone resorption, and is required for normal bone and tooth
CC       development. Required for normal male and female fertility, and
CC       for normal development of milk ducts and acinar structures in the
CC       mammary gland during pregnancy. Promotes reorganization of the
CC       actin cytoskeleton, regulates formation of membrane ruffles, cell
CC       adhesion and cell migration, and promotes cancer cell invasion.
CC       Activates several signaling pathways in response to ligand
CC       binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL.
CC       Activation of PLCG2 leads to the production of the cellular
CC       signaling molecules diacylglycerol and inositol 1,4,5-
CC       trisphosphate, that then lead to the activation of protein kinase
CC       C family members, especially PRKCD. Phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase, leads to
CC       activation of the AKT1 signaling pathway. Activated CSF1R also
CC       mediates activation of the MAP kinases MAPK1/ERK2 and/or
CC       MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1.
CC       Activated CSF1R transmits signals both via proteins that directly
CC       interact with phosphorylated tyrosine residues in its
CC       intracellular domain, or via adapter proteins, such as GRB2.
CC       Promotes activation of STAT family members STAT3, STAT5A and/or
CC       STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-
CC       1. Receptor signaling is down-regulated by protein phosphatases,
CC       such as INPP5D/SHIP-1, that dephosphorylate the receptor and its
CC       downstream effectors, and by rapid internalization of the
CC       activated receptor. {ECO:0000269|PubMed:10958675,
CC       ECO:0000269|PubMed:11756160, ECO:0000269|PubMed:1652061,
CC       ECO:0000269|PubMed:16950670, ECO:0000269|PubMed:17353186,
CC       ECO:0000269|PubMed:17420255, ECO:0000269|PubMed:17420256,
CC       ECO:0000269|PubMed:17972959, ECO:0000269|PubMed:18814279,
CC       ECO:0000269|PubMed:20181277, ECO:0000269|PubMed:20504948,
CC       ECO:0000269|PubMed:21610095, ECO:0000269|PubMed:21727904,
CC       ECO:0000269|PubMed:8007983, ECO:0000269|PubMed:8262059,
CC       ECO:0000269|PubMed:9312046}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:8007983,
CC       ECO:0000269|PubMed:8262059, ECO:0000269|PubMed:9312046}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. CSF1 or IL34 binding leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib/STI-571 (Gleevec), dasatinib,
CC       sunitinib/SU11248, lestaurtinib/CEP-701, midostaurin/PKC-412,
CC       Ki20227, linifanib/ABT-869, Axitinib/AG013736, sorafenib/BAY 43-
CC       9006 and GW2580. {ECO:0000269|PubMed:15297464,
CC       ECO:0000269|PubMed:18814279}.
CC   -!- SUBUNIT: Monomer. Homodimer. Interacts with CSF1 and IL34.
CC       Interaction with dimeric CSF1 or IL34 leads to receptor
CC       homodimerization. Interacts with INPPL1/SHIP2 and THOC5. Interacts
CC       (tyrosine phosphorylated) with PLCG2 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with PIK3R1 (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with FYN, YES1 and SRC (via SH2 domain).
CC       Interacts (tyrosine phosphorylated) with CBL, GRB2 and SLA2.
CC       {ECO:0000269|PubMed:10597251, ECO:0000269|PubMed:11850825,
CC       ECO:0000269|PubMed:15557176, ECO:0000269|PubMed:1652061,
CC       ECO:0000269|PubMed:17353186, ECO:0000269|PubMed:19017797,
CC       ECO:0000269|PubMed:21610095, ECO:0000269|PubMed:8007983,
CC       ECO:0000269|PubMed:8262059, ECO:0000269|PubMed:9312046}.
CC   -!- INTERACTION:
CC       P07141:Csf1; NbExp=4; IntAct=EBI-6305373, EBI-777188;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17353186,
CC       ECO:0000269|PubMed:8007983}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:17353186, ECO:0000269|PubMed:8007983}.
CC       Note=The autophosphorylated receptor is ubiquitinated and
CC       internalized, leading to its degradation.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:20504948}.
CC   -!- DOMAIN: The juxtamembrane domain functions as autoinhibitory
CC       region. Phosphorylation of tyrosine residues in this region leads
CC       to a conformation change and activation of the kinase (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: The activation loop plays an important role in the
CC       regulation of kinase activity. Phosphorylation of tyrosine
CC       residues in this region leads to a conformation change and
CC       activation of the kinase (By similarity). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated in response to CSF1 or IL34 binding.
CC       Phosphorylation at Tyr-559 is important for normal down-regulation
CC       of signaling by ubiquitination, internalization and degradation.
CC       Phosphorylation at Tyr-559 and Tyr-807 is important for
CC       interaction with SRC family members, including FYN, YES1 and SRC,
CC       and for subsequent activation of these protein kinases.
CC       Phosphorylation at Tyr-697 and Tyr-921 is important for
CC       interaction with GRB2. Phosphorylation at Tyr-721 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-721 and Tyr-807 is
CC       important for interaction with PLCG2. Phosphorylation at Tyr-974
CC       is important for interaction with CBL. Dephosphorylation by PTPN2
CC       negatively regulates downstream signaling and macrophage
CC       differentiation. {ECO:0000269|PubMed:11850825,
CC       ECO:0000269|PubMed:15297464, ECO:0000269|PubMed:1652061,
CC       ECO:0000269|PubMed:17420255, ECO:0000269|PubMed:20504948,
CC       ECO:0000269|PubMed:2160591, ECO:0000269|PubMed:21610095,
CC       ECO:0000269|PubMed:8007983, ECO:0000269|PubMed:8262059}.
CC   -!- PTM: Ubiquitinated. Becomes rapidly polyubiquitinated after
CC       autophosphorylation, leading to its degradation.
CC   -!- DISRUPTION PHENOTYPE: Mice are born at slightly less than the
CC       expected Mendelian rate, and the number of surviving mice is
CC       significantly reduced after three weeks. Mice are considerably
CC       smaller than wild-type littermates and suffer from general
CC       skeletal deformities with shortened limbs, increased bone density,
CC       and decreased volume of femoral bone marrow. Mice have decreased
CC       numbers of circulating monocytes and lymphocytes, decreased
CC       numbers of tissue macrophages, paired with an increase in the
CC       number of circulating granulocytes. In addition, mice are deaf and
CC       have reduced male and female fertility. In females, the duration
CC       of the diestrous period is increased, and in pregnant females the
CC       lactating mammary gland fails to develop normally. Males mate less
CC       frequently and give rise to fewer pregnant females.
CC       {ECO:0000269|PubMed:11756160}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06368; CAA29666.1; -; mRNA.
DR   EMBL; AK004947; BAB23691.1; -; mRNA.
DR   EMBL; AK079247; BAC37587.1; -; mRNA.
DR   EMBL; AK143545; BAE25430.1; -; mRNA.
DR   EMBL; AK154653; BAE32744.1; -; mRNA.
DR   EMBL; BC043054; AAH43054.1; -; mRNA.
DR   EMBL; S62219; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS29280.1; -.
DR   PIR; S01880; TVMSMD.
DR   RefSeq; NP_001032948.2; NM_001037859.2.
DR   RefSeq; XP_006525647.1; XM_006525584.1.
DR   RefSeq; XP_006525648.1; XM_006525585.2.
DR   RefSeq; XP_006525649.1; XM_006525586.2.
DR   UniGene; Mm.22574; -.
DR   PDB; 3EJJ; X-ray; 2.40 A; X=20-296.
DR   PDB; 4EXP; X-ray; 2.80 A; X=20-298.
DR   PDBsum; 3EJJ; -.
DR   PDBsum; 4EXP; -.
DR   ProteinModelPortal; P09581; -.
DR   SMR; P09581; 20-916.
DR   BioGrid; 198928; 15.
DR   DIP; DIP-46415N; -.
DR   IntAct; P09581; 5.
DR   MINT; MINT-8013693; -.
DR   STRING; 10090.ENSMUSP00000025523; -.
DR   BindingDB; P09581; -.
DR   ChEMBL; CHEMBL5570; -.
DR   iPTMnet; P09581; -.
DR   PhosphoSite; P09581; -.
DR   MaxQB; P09581; -.
DR   PaxDb; P09581; -.
DR   PRIDE; P09581; -.
DR   Ensembl; ENSMUST00000025523; ENSMUSP00000025523; ENSMUSG00000024621.
DR   Ensembl; ENSMUST00000115268; ENSMUSP00000110923; ENSMUSG00000024621.
DR   GeneID; 12978; -.
DR   KEGG; mmu:12978; -.
DR   UCSC; uc008fbn.1; mouse.
DR   CTD; 1436; -.
DR   MGI; MGI:1339758; Csf1r.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000112008; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P09581; -.
DR   KO; K05090; -.
DR   OMA; WKIIESY; -.
DR   OrthoDB; EOG7KSX7R; -.
DR   PhylomeDB; P09581; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   ChiTaRS; Csf1r; mouse.
DR   EvolutionaryTrace; P09581; -.
DR   NextBio; 282750; -.
DR   PRO; PR:P09581; -.
DR   Proteomes; UP000000589; Chromosome 18.
DR   Bgee; P09581; -.
DR   CleanEx; MM_CSF1R; -.
DR   ExpressionAtlas; P09581; baseline and differential.
DR   Genevisible; P09581; MM.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:1990682; C:CSF1-CSF1R complex; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005622; C:intracellular; IMP:GOC.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0005011; F:macrophage colony-stimulating factor receptor activity; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0008283; P:cell proliferation; ISO:MGI.
DR   GO; GO:0045217; P:cell-cell junction maintenance; ISO:MGI.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IMP:UniProtKB.
DR   GO; GO:0036006; P:cellular response to macrophage colony-stimulating factor stimulus; IMP:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISO:MGI.
DR   GO; GO:0021879; P:forebrain neuron differentiation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0030097; P:hemopoiesis; ISO:MGI.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0038145; P:macrophage colony-stimulating factor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0021772; P:olfactory bulb development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0030316; P:osteoclast differentiation; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; IMP:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:2000147; P:positive regulation of cell motility; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0090197; P:positive regulation of chemokine secretion; ISO:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:MGI.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IMP:UniProtKB.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; ISO:MGI.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0045124; P:regulation of bone resorption; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0031529; P:ruffle organization; IMP:UniProtKB.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IMP:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR030658; CSF-1_receptor.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF47; PTHR24416:SF47; 3.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500947; CSF-1_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 5.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 4.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Complete proteome;
KW   Disulfide bond; Glycoprotein; Immunity; Immunoglobulin domain;
KW   Inflammatory response; Innate immunity; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    977       Macrophage colony-stimulating factor 1
FT                                receptor.
FT                                /FTId=PRO_0000016766.
FT   TOPO_DOM     20    515       Extracellular. {ECO:0000255}.
FT   TRANSMEM    516    536       Helical. {ECO:0000255}.
FT   TOPO_DOM    537    977       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24    104       Ig-like C2-type 1.
FT   DOMAIN      107    197       Ig-like C2-type 2.
FT   DOMAIN      204    298       Ig-like C2-type 3.
FT   DOMAIN      299    397       Ig-like C2-type 4.
FT   DOMAIN      398    503       Ig-like C2-type 5.
FT   DOMAIN      580    913       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     586    594       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      540    572       Regulatory juxtamembrane domain.
FT                                {ECO:0000250}.
FT   REGION      794    816       Activation loop. {ECO:0000250}.
FT   ACT_SITE    776    776       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     614    614       ATP. {ECO:0000305}.
FT   MOD_RES     544    544       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     559    559       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15297464,
FT                                ECO:0000269|PubMed:20504948,
FT                                ECO:0000269|PubMed:8007983}.
FT   MOD_RES     697    697       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8262059}.
FT   MOD_RES     706    706       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1652061,
FT                                ECO:0000269|PubMed:2160591,
FT                                ECO:0000269|PubMed:21610095,
FT                                ECO:0000269|PubMed:8262059}.
FT   MOD_RES     711    711       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     721    721       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20504948,
FT                                ECO:0000269|PubMed:21610095,
FT                                ECO:0000269|PubMed:8262059}.
FT   MOD_RES     807    807       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1652061,
FT                                ECO:0000269|PubMed:20504948,
FT                                ECO:0000269|PubMed:2160591,
FT                                ECO:0000269|PubMed:8007983,
FT                                ECO:0000269|PubMed:8262059}.
FT   MOD_RES     921    921       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:17420255}.
FT   MOD_RES     974    974       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11850825}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19017797}.
FT   CARBOHYD     73     73       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19017797}.
FT   CARBOHYD    302    302       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    335    335       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    389    389       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    410    410       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    449    449       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    478    478       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    491    491       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16944957}.
FT   DISULFID     42     84       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:19017797}.
FT   DISULFID    127    177       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:19017797}.
FT   DISULFID    224    278       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:19017797}.
FT   DISULFID    417    483       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   MUTAGEN     544    544       Y->F: No effect on binding to THOC5.
FT                                {ECO:0000269|PubMed:10597251}.
FT   MUTAGEN     559    559       Y->F: Reduced interaction with CBL.
FT                                Prolonged signaling, due to reduced
FT                                internalization and degradation. Reduced
FT                                interaction with FYN. Promotes cell
FT                                proliferation. Reduced
FT                                autophosphorylation at Tyr-807.
FT                                {ECO:0000269|PubMed:15297464,
FT                                ECO:0000269|PubMed:17420255,
FT                                ECO:0000269|PubMed:8007983}.
FT   MUTAGEN     614    614       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:10597251,
FT                                ECO:0000269|PubMed:8262059,
FT                                ECO:0000269|PubMed:9312046}.
FT   MUTAGEN     614    614       K->M: Loss of kinase activity. Abolishes
FT                                binding to THOC5.
FT                                {ECO:0000269|PubMed:10597251,
FT                                ECO:0000269|PubMed:8262059,
FT                                ECO:0000269|PubMed:9312046}.
FT   MUTAGEN     697    697       Y->F: Abolishes interaction with GRB2.
FT                                {ECO:0000269|PubMed:8262059,
FT                                ECO:0000269|PubMed:9312046}.
FT   MUTAGEN     706    706       Y->F: No effect on binding to THOC5.
FT                                Slightly reduced enhancement of cell
FT                                proliferation.
FT                                {ECO:0000269|PubMed:10597251,
FT                                ECO:0000269|PubMed:1652061}.
FT   MUTAGEN     706    706       Y->G: Slightly impaired signaling.
FT                                {ECO:0000269|PubMed:10597251,
FT                                ECO:0000269|PubMed:1652061}.
FT   MUTAGEN     721    721       Y->F: Abolishes interaction with PIK3R1.
FT                                Strongly reduced phosphorylation of
FT                                PLCG2. No effect on binding to THOC5.
FT                                {ECO:0000269|PubMed:10597251,
FT                                ECO:0000269|PubMed:21610095,
FT                                ECO:0000269|PubMed:8262059,
FT                                ECO:0000269|PubMed:9312046}.
FT   MUTAGEN     807    807       Y->F: Reduced kinase activity. Strongly
FT                                reduced phosphorylation of PLCG2.
FT                                Diminishes binding to THOC5.
FT                                {ECO:0000269|PubMed:10597251,
FT                                ECO:0000269|PubMed:1652061,
FT                                ECO:0000269|PubMed:9312046}.
FT   MUTAGEN     807    807       Y->G: May alter protein folding or
FT                                stability. Loss of kinase activity. No
FT                                effect on interaction with PIK3R1.
FT                                {ECO:0000269|PubMed:10597251,
FT                                ECO:0000269|PubMed:1652061,
FT                                ECO:0000269|PubMed:9312046}.
FT   CONFLICT     57     57       Y -> I (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT     72     72       R -> S (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    162    162       F -> S (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    446    447       QV -> HL (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    474    474       T -> P (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    660    660       I -> Y (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    669    669       L -> H (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    744    744       A -> H (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    814    814       Missing (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    830    830       Y -> I (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   CONFLICT    858    858       L -> H (in Ref. 1; CAA29666).
FT                                {ECO:0000305}.
FT   STRAND       22     25       {ECO:0000244|PDB:3EJJ}.
FT   STRAND       27     32       {ECO:0000244|PDB:3EJJ}.
FT   STRAND       38     43       {ECO:0000244|PDB:3EJJ}.
FT   STRAND       49     51       {ECO:0000244|PDB:3EJJ}.
FT   STRAND       55     60       {ECO:0000244|PDB:3EJJ}.
FT   STRAND       64     66       {ECO:0000244|PDB:4EXP}.
FT   STRAND       68     73       {ECO:0000244|PDB:3EJJ}.
FT   HELIX        76     78       {ECO:0000244|PDB:3EJJ}.
FT   STRAND       80     85       {ECO:0000244|PDB:3EJJ}.
FT   STRAND       95    101       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      107    111       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      113    118       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      123    125       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      127    130       {ECO:0000244|PDB:3EJJ}.
FT   HELIX       132    136       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      137    142       {ECO:0000244|PDB:3EJJ}.
FT   HELIX       143    145       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      154    157       {ECO:0000244|PDB:3EJJ}.
FT   TURN        158    160       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      161    166       {ECO:0000244|PDB:3EJJ}.
FT   HELIX       169    171       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      173    181       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      184    187       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      191    198       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      204    213       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      216    218       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      220    231       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      234    239       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      248    252       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      254    267       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      270    272       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      274    281       {ECO:0000244|PDB:3EJJ}.
FT   STRAND      286    294       {ECO:0000244|PDB:3EJJ}.
SQ   SEQUENCE   977 AA;  109179 MW;  7EDF8310CCF98906 CRC64;
     MELGPPLVLL LATVWHGQGA PVIEPSGPEL VVEPGETVTL RCVSNGSVEW DGPISPYWTL
     DPESPGSTLT TRNATFKNTG TYRCTELEDP MAGSTTIHLY VKDPAHSWNL LAQEVTVVEG
     QEAVLPCLIT DPALKDSVSL MREGGRQVLR KTVYFFSPWR GFIIRKAKVL DSNTYVCKTM
     VNGRESTSTG IWLKVNRVHP EPPQIKLEPS KLVRIRGEAA QIVCSATNAE VGFNVILKRG
     DTKLEIPLNS DFQDNYYKKV RALSLNAVDF QDAGIYSCVA SNDVGTRTAT MNFQVVESAY
     LNLTSEQSLL QEVSVGDSLI LTVHADAYPS IQHYNWTYLG PFFEDQRKLE FITQRAIYRY
     TFKLFLNRVK ASEAGQYFLM AQNKAGWNNL TFELTLRYPP EVSVTWMPVN GSDVLFCDVS
     GYPQPSVTWM ECRGHTDRCD EAQALQVWND THPEVLSQKP FDKVIIQSQL PIGTLKHNMT
     YFCKTHNSVG NSSQYFRAVS LGQSKQLPDE SLFTPVVVAC MSVMSLLVLL LLLLLYKYKQ
     KPKYQVRWKI IERYEGNSYT FIDPTQLPYN EKWEFPRNNL QFGKTLGAGA FGKVVEATAF
     GLGKEDAVLK VAVKMLKSTA HADEKEALMS ELKIMSHLGQ HENIVNLLGA CTHGGPVLVI
     TEYCCYGDLL NFLRRKAEAM LGPSLSPGQD SEGDSSYKNI HLEKKYVRRD SGFSSQGVDT
     YVEMRPVSTS SSDSFFKQDL DKEASRPLEL WDLLHFSSQV AQGMAFLASK NCIHRDVAAR
     NVLLTSGHVA KIGDFGLARD IMNDSNYVVK GNARLPVKWM APESIFDCVY TVQSDVWSYG
     ILLWEIFSLG LNPYPGILVN NKFYKLVKDG YQMAQPVFAP KNIYSIMQSC WDLEPTRRPT
     FQQICFLLQE QARLERRDQD YANLPSSGGS SGSDSGGGSS GGSSSEPEEE SSSEHLACCE
     PGDIAQPLLQ PNNYQFC
//
ID   SORT_HUMAN              Reviewed;         831 AA.
AC   Q99523; B4DWI3; C0JYZ0; Q8IZ49;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 3.
DT   17-FEB-2016, entry version 156.
DE   RecName: Full=Sortilin;
DE   AltName: Full=100 kDa NT receptor;
DE   AltName: Full=Glycoprotein 95;
DE            Short=Gp95;
DE   AltName: Full=Neurotensin receptor 3;
DE            Short=NT3;
DE            Short=NTR3;
DE   Flags: Precursor;
GN   Name=SORT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE,
RP   INTERACTION WITH LRPAP1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   GLYCOSYLATION.
RC   TISSUE=T-cell;
RX   PubMed=9013611; DOI=10.1074/jbc.272.6.3599;
RA   Petersen C.M., Nielsen M.S., Nykjaer A., Jacobsen L., Tommerup N.,
RA   Rasmussen H.H., Roeigaard H., Gliemann J., Madsen P., Moestrup S.K.;
RT   "Molecular identification of a novel candidate sorting receptor
RT   purified from human brain by receptor-associated protein affinity
RT   chromatography.";
RL   J. Biol. Chem. 272:3599-3605(1997).
RN   [2]
RP   SEQUENCE REVISION.
RA   Madsen P.;
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 78-100, AND IDENTIFICATION AS A NEUROTENSIN
RP   RECEPTOR.
RC   TISSUE=Brain;
RX   PubMed=9756851; DOI=10.1074/jbc.273.41.26273;
RA   Mazella J., Zsurger N., Navarro V., Chabry J., Kaghad M., Caput D.,
RA   Ferrara P., Vita M., Gully D., Maffrand J.-P., Vincent J.-P.;
RT   "The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-
RT   coupled receptor.";
RL   J. Biol. Chem. 273:26273-26276(1998).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE, INTERACTION WITH LRPAP1, MUTAGENESIS OF
RP   74-ARG--ARG-77 AND 76-ARG-ARG-77, CLEAVAGE BY FURIN, AND
RP   GLYCOSYLATION.
RX   PubMed=9927419; DOI=10.1093/emboj/18.3.595;
RA   Petersen C.M., Nielsen M.S., Jacobsen C., Tauris J., Jacobsen L.,
RA   Gliemann J., Moestrup S.K., Madsen P.;
RT   "Propeptide cleavage conditions sortilin/neurotensin receptor-3 for
RT   ligand binding.";
RL   EMBO J. 18:595-604(1999).
RN   [9]
RP   INTERACTION WITH LRPAP1.
RX   PubMed=9657377; DOI=10.1016/S0014-5793(98)00559-6;
RA   Tauris J., Ellgaard L., Jacobsen C., Nielsen M.S., Madsen P.,
RA   Thoegersen H.C., Gliemann J., Petersen C.M., Moestrup S.K.;
RT   "The carboxy-terminal domain of the receptor-associated protein binds
RT   to the Vps10p domain of sortilin.";
RL   FEBS Lett. 429:27-30(1998).
RN   [10]
RP   FUNCTION.
RX   PubMed=10085125; DOI=10.1074/jbc.274.13.8832;
RA   Nielsen M.S., Jacobsen C., Olivecrona G., Gliemann J., Petersen C.M.;
RT   "Sortilin/neurotensin receptor-3 binds and mediates degradation of
RT   lipoprotein lipase.";
RL   J. Biol. Chem. 274:8832-8836(1999).
RN   [11]
RP   FUNCTION, INTERACTION WITH GGA2, AND MUTAGENESIS OF TYR-792; LEU-795
RP   AND 829-LEU-LEU-830.
RX   PubMed=11331584; DOI=10.1093/emboj/20.9.2180;
RA   Nielsen M.S., Madsen P., Christensen E.I., Nykjaer A., Gliemann J.,
RA   Kasper D., Pohlmann R., Petersen C.M.;
RT   "The sortilin cytoplasmic tail conveys Golgi-endosome transport and
RT   binds the VHS domain of the GGA2 sorting protein.";
RL   EMBO J. 20:2180-2190(2001).
RN   [12]
RP   FUNCTION, INTERACTION WITH GGA1 AND GGA2, AND MUTAGENESIS OF
RP   823-ASP-ASP-824; SER-825; 826-ASP--ASP-828 AND 829-LEU-LEU-830.
RX   PubMed=11390366; DOI=10.1074/jbc.C100218200;
RA   Takatsu H., Katoh Y., Shiba Y., Nakayama K.;
RT   "Golgi-localizing, gamma-adaptin ear homology domain, ADP-ribosylation
RT   factor-binding (GGA) proteins interact with acidic dileucine sequences
RT   within the cytoplasmic domains of sorting receptors through their
RT   Vps27p/Hrs/STAM (VHS) domains.";
RL   J. Biol. Chem. 276:28541-28545(2001).
RN   [13]
RP   CLEAVAGE OF THE EXTRACELLULAR DOMAIN.
RX   PubMed=12419319; DOI=10.1016/S0006-291X(02)02564-0;
RA   Navarro V., Vincent J.-P., Mazella J.;
RT   "Shedding of the luminal domain of the neurotensin receptor-3/sortilin
RT   in the HT29 cell line.";
RL   Biochem. Biophys. Res. Commun. 298:760-764(2002).
RN   [14]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=12209882; DOI=10.1002/jcp.10151;
RA   Maeda S., Nobukuni T., Shimo-Onoda K., Hayashi K., Yone K., Komiya S.,
RA   Inoue I.;
RT   "Sortilin is upregulated during osteoblastic differentiation of
RT   mesenchymal stem cells and promotes extracellular matrix
RT   mineralization.";
RL   J. Cell. Physiol. 193:73-79(2002).
RN   [15]
RP   INTERACTION WITH GGA1.
RX   PubMed=11859376; DOI=10.1038/415937a;
RA   Shiba T., Takatsu H., Nogi T., Matsugaki N., Kawasaki M., Igarashi N.,
RA   Suzuki M., Kato R., Earnest T., Nakayama K., Wakatsuki S.;
RT   "Structural basis for recognition of acidic-cluster dileucine sequence
RT   by GGA1.";
RL   Nature 415:937-941(2002).
RN   [16]
RP   FUNCTION, INTERACTION WITH GM2A AND PSAP, AND SUBCELLULAR LOCATION.
RX   PubMed=14657016; DOI=10.1093/emboj/cdg629;
RA   Lefrancois S., Zeng J., Hassan A.J., Canuel M., Morales C.R.;
RT   "The lysosomal trafficking of sphingolipid activator proteins (SAPs)
RT   is mediated by sortilin.";
RL   EMBO J. 22:6430-6437(2003).
RN   [17]
RP   ERRATUM.
RA   Lefrancois S., Zeng J., Hassan A.J., Canuel M., Morales C.R.;
RL   EMBO J. 23:1680-1680(2004).
RN   [18]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12598608;
RA   Martin S., Vincent J.-P., Mazella J.;
RT   "Involvement of the neurotensin receptor-3 in the neurotensin-induced
RT   migration of human microglia.";
RL   J. Neurosci. 23:1198-1205(2003).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15313463; DOI=10.1016/j.biocel.2004.04.013;
RA   Morinville A., Martin S., Lavallee M., Vincent J.-P., Beaudet A.,
RA   Mazella J.;
RT   "Internalization and trafficking of neurotensin via NTS3 receptors in
RT   HT29 cells.";
RL   Int. J. Biochem. Cell Biol. 36:2153-2168(2004).
RN   [20]
RP   INTERACTION WITH LRPAP1 AND NGFB, SUBCELLULAR LOCATION, DISULFIDE
RP   BONDS, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15364913; DOI=10.1074/jbc.M408873200;
RA   Westergaard U.B., Soerensen E.S., Hermey G., Nielsen M.S., Nykjaer A.,
RA   Kirkegaard K., Jacobsen C., Gliemann J., Madsen P., Petersen C.M.;
RT   "Functional organization of the sortilin Vps10p domain.";
RL   J. Biol. Chem. 279:50221-50229(2004).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH NGFB AND NGFR.
RX   PubMed=14985763; DOI=10.1038/nature02319;
RA   Nykjaer A., Lee R., Teng K.K., Jansen P., Madsen P., Nielsen M.S.,
RA   Jacobsen C., Kliemannel M., Schwarz E., Willnow T.E., Hempstead B.L.,
RA   Petersen C.M.;
RT   "Sortilin is essential for proNGF-induced neuronal cell death.";
RL   Nature 427:843-848(2004).
RN   [22]
RP   FUNCTION.
RX   PubMed=15930396; DOI=10.1523/JNEUROSCI.5123-04.2005;
RA   Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D.,
RA   Kermani P., Torkin R., Chen Z.-Y., Lee F.S., Kraemer R.T., Nykjaer A.,
RA   Hempstead B.L.;
RT   "ProBDNF induces neuronal apoptosis via activation of a receptor
RT   complex of p75NTR and sortilin.";
RL   J. Neurosci. 25:5455-5463(2005).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH BDNF.
RX   PubMed=15987945; DOI=10.1523/JNEUROSCI.1017-05.2005;
RA   Chen Z.-Y., Ieraci A., Teng H., Dall H., Meng C.-X., Herrera D.G.,
RA   Nykjaer A., Hempstead B.L., Lee F.S.;
RT   "Sortilin controls intracellular sorting of brain-derived neurotrophic
RT   factor to the regulated secretory pathway.";
RL   J. Neurosci. 25:6156-6166(2005).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-162.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-825, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-162 AND ASN-163.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [28]
RP   TISSUE SPECIFICITY.
RX   PubMed=20048080; DOI=10.1158/0008-5472.CAN-09-1252;
RA   Swift S.L., Burns J.E., Maitland N.J.;
RT   "Altered expression of neurotensin receptors is associated with the
RT   differentiation state of prostate cancer.";
RL   Cancer Res. 70:347-356(2010).
RN   [29]
RP   INVOLVEMENT IN LDLCQ6.
RX   PubMed=20686565; DOI=10.1038/nature09270;
RA   Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C.,
RA   Stylianou I.M., Koseki M., Pirruccello J.P., Ripatti S., Chasman D.I.,
RA   Willer C.J., Johansen C.T., Fouchier S.W., Isaacs A., Peloso G.M.,
RA   Barbalic M., Ricketts S.L., Bis J.C., Aulchenko Y.S., Thorleifsson G.,
RA   Feitosa M.F., Chambers J., Orho-Melander M., Melander O., Johnson T.,
RA   Li X., Guo X., Li M., Shin Cho Y., Jin Go M., Jin Kim Y., Lee J.Y.,
RA   Park T., Kim K., Sim X., Twee-Hee Ong R., Croteau-Chonka D.C.,
RA   Lange L.A., Smith J.D., Song K., Hua Zhao J., Yuan X., Luan J.,
RA   Lamina C., Ziegler A., Zhang W., Zee R.Y., Wright A.F., Witteman J.C.,
RA   Wilson J.F., Willemsen G., Wichmann H.E., Whitfield J.B.,
RA   Waterworth D.M., Wareham N.J., Waeber G., Vollenweider P.,
RA   Voight B.F., Vitart V., Uitterlinden A.G., Uda M., Tuomilehto J.,
RA   Thompson J.R., Tanaka T., Surakka I., Stringham H.M., Spector T.D.,
RA   Soranzo N., Smit J.H., Sinisalo J., Silander K., Sijbrands E.J.,
RA   Scuteri A., Scott J., Schlessinger D., Sanna S., Salomaa V.,
RA   Saharinen J., Sabatti C., Ruokonen A., Rudan I., Rose L.M.,
RA   Roberts R., Rieder M., Psaty B.M., Pramstaller P.P., Pichler I.,
RA   Perola M., Penninx B.W., Pedersen N.L., Pattaro C., Parker A.N.,
RA   Pare G., Oostra B.A., O'Donnell C.J., Nieminen M.S., Nickerson D.A.,
RA   Montgomery G.W., Meitinger T., McPherson R., McCarthy M.I.,
RA   McArdle W., Masson D., Martin N.G., Marroni F., Mangino M.,
RA   Magnusson P.K., Lucas G., Luben R., Loos R.J., Lokki M.L., Lettre G.,
RA   Langenberg C., Launer L.J., Lakatta E.G., Laaksonen R., Kyvik K.O.,
RA   Kronenberg F., Konig I.R., Khaw K.T., Kaprio J., Kaplan L.M.,
RA   Johansson A., Jarvelin M.R., Janssens A.C., Ingelsson E., Igl W.,
RA   Kees Hovingh G., Hottenga J.J., Hofman A., Hicks A.A.,
RA   Hengstenberg C., Heid I.M., Hayward C., Havulinna A.S., Hastie N.D.,
RA   Harris T.B., Haritunians T., Hall A.S., Gyllensten U., Guiducci C.,
RA   Groop L.C., Gonzalez E., Gieger C., Freimer N.B., Ferrucci L.,
RA   Erdmann J., Elliott P., Ejebe K.G., Doring A., Dominiczak A.F.,
RA   Demissie S., Deloukas P., de Geus E.J., de Faire U., Crawford G.,
RA   Collins F.S., Chen Y.D., Caulfield M.J., Campbell H., Burtt N.P.,
RA   Bonnycastle L.L., Boomsma D.I., Boekholdt S.M., Bergman R.N.,
RA   Barroso I., Bandinelli S., Ballantyne C.M., Assimes T.L.,
RA   Quertermous T., Altshuler D., Seielstad M., Wong T.Y., Tai E.S.,
RA   Feranil A.B., Kuzawa C.W., Adair L.S., Taylor H.A. Jr., Borecki I.B.,
RA   Gabriel S.B., Wilson J.G., Holm H., Thorsteinsdottir U., Gudnason V.,
RA   Krauss R.M., Mohlke K.L., Ordovas J.M., Munroe P.B., Kooner J.S.,
RA   Tall A.R., Hegele R.A., Kastelein J.J., Schadt E.E., Rotter J.I.,
RA   Boerwinkle E., Strachan D.P., Mooser V., Stefansson K., Reilly M.P.,
RA   Samani N.J., Schunkert H., Cupples L.A., Sandhu M.S., Ridker P.M.,
RA   Rader D.J., van Duijn C.M., Peltonen L., Abecasis G.R., Boehnke M.,
RA   Kathiresan S.;
RT   "Biological, clinical and population relevance of 95 loci for blood
RT   lipids.";
RL   Nature 466:707-713(2010).
RN   [30]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO MYOCARDIAL INFARCTION.
RX   PubMed=20686566; DOI=10.1038/nature09266;
RA   Musunuru K., Strong A., Frank-Kamenetsky M., Lee N.E., Ahfeldt T.,
RA   Sachs K.V., Li X., Li H., Kuperwasser N., Ruda V.M., Pirruccello J.P.,
RA   Muchmore B., Prokunina-Olsson L., Hall J.L., Schadt E.E.,
RA   Morales C.R., Lund-Katz S., Phillips M.C., Wong J., Cantley W.,
RA   Racie T., Ejebe K.G., Orho-Melander M., Melander O., Koteliansky V.,
RA   Fitzgerald K., Krauss R.M., Cowan C.A., Kathiresan S., Rader D.J.;
RT   "From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol
RT   locus.";
RL   Nature 466:714-719(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   INTERACTION WITH NTRK1.
RX   PubMed=21102451; DOI=10.1038/nn.2689;
RA   Vaegter C.B., Jansen P., Fjorback A.W., Glerup S., Skeldal S.,
RA   Kjolby M., Richner M., Erdmann B., Nyengaard J.R., Tessarollo L.,
RA   Lewin G.R., Willnow T.E., Chao M.V., Nykjaer A.;
RT   "Sortilin associates with Trk receptors to enhance anterograde
RT   transport and neurotrophin signaling.";
RL   Nat. Neurosci. 14:54-61(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-819 AND SER-825, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 78-756 IN COMPLEX WITH NTS,
RP   SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-406 AND ASN-582.
RX   PubMed=19122660; DOI=10.1038/nsmb.1543;
RA   Quistgaard E.M., Madsen P., Groftehauge M.K., Nissen P.,
RA   Petersen C.M., Thirup S.S.;
RT   "Ligands bind to Sortilin in the tunnel of a ten-bladed beta-propeller
RT   domain.";
RL   Nat. Struct. Mol. Biol. 16:96-98(2009).
CC   -!- FUNCTION: Functions as a sorting receptor in the Golgi compartment
CC       and as a clearance receptor on the cell surface. Required for
CC       protein transport from the Golgi apparatus to the lysosomes by a
CC       pathway that is independent of the mannose-6-phosphate receptor
CC       (M6PR). Also required for protein transport from the Golgi
CC       apparatus to the endosomes. Promotes neuronal apoptosis by
CC       mediating endocytosis of the proapoptotic precursor forms of BDNF
CC       (proBDNF) and NGFB (proNGFB). Also acts as a receptor for
CC       neurotensin. May promote mineralization of the extracellular
CC       matrix during osteogenic differentiation by scavenging
CC       extracellular LPL. Probably required in adipocytes for the
CC       formation of specialized storage vesicles containing the glucose
CC       transporter SLC2A4/GLUT4 (GLUT4 storage vesicles, or GSVs). These
CC       vesicles provide a stable pool of SLC2A4 and confer increased
CC       responsiveness to insulin. May also mediate transport from the
CC       endoplasmic reticulum to the Golgi. {ECO:0000269|PubMed:10085125,
CC       ECO:0000269|PubMed:11331584, ECO:0000269|PubMed:11390366,
CC       ECO:0000269|PubMed:12209882, ECO:0000269|PubMed:12598608,
CC       ECO:0000269|PubMed:14657016, ECO:0000269|PubMed:14985763,
CC       ECO:0000269|PubMed:15313463, ECO:0000269|PubMed:15930396,
CC       ECO:0000269|PubMed:15987945}.
CC   -!- SUBUNIT: Interacts with LPL and SLC2A4 (By similarity). Interacts
CC       with the cytosolic adapter proteins GGA1 and GGA2. Interacts with
CC       numerous ligands including the receptor-associated protein
CC       LRPAP1/RAP, GM2A, NTS and PSAP. Forms a complex with NGFR which
CC       binds specifically to the precursor forms of NGFB (proNGFB) and
CC       BDNF (proBDNF). Interacts with the Trk receptors NTRK1, NTRK2 and
CC       NTRK3; may regulate their anterograde axonal transport and
CC       signaling. {ECO:0000250, ECO:0000269|PubMed:11331584,
CC       ECO:0000269|PubMed:11390366, ECO:0000269|PubMed:11859376,
CC       ECO:0000269|PubMed:14657016, ECO:0000269|PubMed:14985763,
CC       ECO:0000269|PubMed:15364913, ECO:0000269|PubMed:15987945,
CC       ECO:0000269|PubMed:19122660, ECO:0000269|PubMed:21102451,
CC       ECO:0000269|PubMed:9013611, ECO:0000269|PubMed:9657377,
CC       ECO:0000269|PubMed:9927419}.
CC   -!- INTERACTION:
CC       Q9UJY5:GGA1; NbExp=2; IntAct=EBI-1057058, EBI-447141;
CC       P11151:LPL (xeno); NbExp=6; IntAct=EBI-1057058, EBI-8794090;
CC       P01138:NGF; NbExp=4; IntAct=EBI-1057058, EBI-1028250;
CC       P04629:NTRK1; NbExp=3; IntAct=EBI-1057058, EBI-1028226;
CC       Q16288:NTRK3; NbExp=2; IntAct=EBI-1057058, EBI-3936704;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane {ECO:0000305}; Single-pass
CC       type I membrane protein {ECO:0000305}. Endosome membrane
CC       {ECO:0000305}; Single-pass type I membrane protein {ECO:0000305}.
CC       Golgi apparatus, Golgi stack membrane {ECO:0000305}; Single-pass
CC       type I membrane protein {ECO:0000305}. Nucleus membrane
CC       {ECO:0000305}; Single-pass type I membrane protein {ECO:0000305}.
CC       Cell membrane; Single-pass type I membrane protein; Extracellular
CC       side. Lysosome membrane {ECO:0000305}; Single-pass type I membrane
CC       protein {ECO:0000305}. Note=Localized to membranes of the
CC       endoplasmic reticulum, endosomes, Golgi stack, lysosomes and
CC       nucleus. A small fraction of the protein is also localized to the
CC       plasma membrane. May also be found in SLC2A4/GLUT4 storage
CC       vesicles (GSVs) in adipocytes. Localization to the plasma membrane
CC       in adipocytes may be enhanced by insulin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q99523-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q99523-2; Sequence=VSP_046239, VSP_046240;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain and prostate (at protein
CC       level). Expressed at high levels in brain, spinal cord, heart,
CC       skeletal muscle, thyroid, placenta and testis. Expressed at lower
CC       levels in lymphoid organs, kidney, colon and liver.
CC       {ECO:0000269|PubMed:20048080, ECO:0000269|PubMed:9013611}.
CC   -!- INDUCTION: During osteoblast differentiation.
CC       {ECO:0000269|PubMed:12209882}.
CC   -!- DOMAIN: The N-terminal propeptide may facilitate precursor
CC       transport within the Golgi stack. Intrachain binding of the N-
CC       terminal propeptide and the extracellular domain may also inhibit
CC       premature ligand binding.
CC   -!- DOMAIN: The extracellular domain may be shed following protease
CC       cleavage in some cell types.
CC   -!- PTM: The N-terminal propeptide is cleaved by furin and possibly
CC       other homologous proteases. {ECO:0000269|PubMed:12419319,
CC       ECO:0000269|PubMed:9927419}.
CC   -!- POLYMORPHISM: Genetic variations in SORT1 influence low density
CC       lipoprotein cholesterol (LDL-C) variability and contribute to the
CC       low density lipoprotein cholesterol level quantitative trait locus
CC       6 (LDLCQ6) [MIM:613589].
CC   -!- DISEASE: Note=A common polymorphism located in a non-coding region
CC       between CELSR2 and PSRC1 alters a CEBP transcription factor
CC       binding site and is responsible for changes in hepatic expression
CC       of SORT1. Altered SORT1 expression in liver affects low density
CC       lipoprotein cholesterol levels in plasma and is associated with
CC       susceptibility to myocardial infarction.
CC   -!- SIMILARITY: Belongs to the VPS10-related sortilin family. SORT1
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 9 BNR repeats. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X98248; CAA66904.2; -; mRNA.
DR   EMBL; FJ525881; ACN81319.1; -; Genomic_DNA.
DR   EMBL; AK301548; BAG63045.1; -; mRNA.
DR   EMBL; AL390252; CAI13180.1; -; Genomic_DNA.
DR   EMBL; BC023542; AAH23542.1; -; mRNA.
DR   CCDS; CCDS55618.1; -. [Q99523-2]
DR   CCDS; CCDS798.1; -. [Q99523-1]
DR   RefSeq; NP_001192157.1; NM_001205228.1. [Q99523-2]
DR   RefSeq; NP_002950.3; NM_002959.6. [Q99523-1]
DR   UniGene; Hs.485195; -.
DR   UniGene; Hs.703487; -.
DR   PDB; 3F6K; X-ray; 2.00 A; A=78-756.
DR   PDB; 3G2U; X-ray; 2.30 A; C/D=819-831.
DR   PDB; 3G2V; X-ray; 2.10 A; C/D=819-831.
DR   PDB; 4MSL; X-ray; 2.70 A; A=78-756.
DR   PDB; 4N7E; X-ray; 2.70 A; A=78-756.
DR   PDB; 4PO7; X-ray; 2.66 A; A=78-756.
DR   PDBsum; 3F6K; -.
DR   PDBsum; 3G2U; -.
DR   PDBsum; 3G2V; -.
DR   PDBsum; 4MSL; -.
DR   PDBsum; 4N7E; -.
DR   PDBsum; 4PO7; -.
DR   ProteinModelPortal; Q99523; -.
DR   SMR; Q99523; 88-749.
DR   BioGrid; 112180; 11.
DR   DIP; DIP-41798N; -.
DR   IntAct; Q99523; 133.
DR   MINT; MINT-197682; -.
DR   STRING; 9606.ENSP00000256637; -.
DR   BindingDB; Q99523; -.
DR   ChEMBL; CHEMBL3091; -.
DR   iPTMnet; Q99523; -.
DR   PhosphoSite; Q99523; -.
DR   SwissPalm; Q99523; -.
DR   BioMuta; SORT1; -.
DR   DMDM; 84028263; -.
DR   MaxQB; Q99523; -.
DR   PaxDb; Q99523; -.
DR   PRIDE; Q99523; -.
DR   DNASU; 6272; -.
DR   Ensembl; ENST00000256637; ENSP00000256637; ENSG00000134243. [Q99523-1]
DR   Ensembl; ENST00000538502; ENSP00000438597; ENSG00000134243. [Q99523-2]
DR   GeneID; 6272; -.
DR   KEGG; hsa:6272; -.
DR   UCSC; uc001dxm.2; human. [Q99523-1]
DR   UCSC; uc010ovi.2; human.
DR   CTD; 6272; -.
DR   GeneCards; SORT1; -.
DR   HGNC; HGNC:11186; SORT1.
DR   HPA; CAB011498; -.
DR   HPA; HPA006889; -.
DR   MIM; 602458; gene.
DR   MIM; 613589; phenotype.
DR   neXtProt; NX_Q99523; -.
DR   PharmGKB; PA36023; -.
DR   eggNOG; ENOG410ISX8; Eukaryota.
DR   eggNOG; ENOG410ZJ6Q; LUCA.
DR   GeneTree; ENSGT00510000046443; -.
DR   HOGENOM; HOG000231347; -.
DR   HOVERGEN; HBG080235; -.
DR   InParanoid; Q99523; -.
DR   KO; K12388; -.
DR   OMA; EDGCILG; -.
DR   OrthoDB; EOG7RBZ7S; -.
DR   PhylomeDB; Q99523; -.
DR   TreeFam; TF324918; -.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   ChiTaRS; SORT1; human.
DR   EvolutionaryTrace; Q99523; -.
DR   GeneWiki; Sortilin_1; -.
DR   GenomeRNAi; 6272; -.
DR   NextBio; 24343; -.
DR   PRO; PR:Q99523; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q99523; -.
DR   CleanEx; HS_SORT1; -.
DR   Genevisible; Q99523; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IDA:BHF-UCL.
DR   GO; GO:0005905; C:coated pit; IDA:BHF-UCL.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; IDA:BHF-UCL.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0030140; C:trans-Golgi network transport vesicle; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0048406; F:nerve growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0010465; F:nerve growth factor receptor activity; IDA:BHF-UCL.
DR   GO; GO:0030379; F:neurotensin receptor activity, non-G-protein coupled; IDA:BHF-UCL.
DR   GO; GO:0006897; P:endocytosis; IDA:BHF-UCL.
DR   GO; GO:0008333; P:endosome to lysosome transport; IDA:BHF-UCL.
DR   GO; GO:0032509; P:endosome transport via multivesicular body sorting pathway; IDA:BHF-UCL.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0046323; P:glucose import; IMP:BHF-UCL.
DR   GO; GO:0006895; P:Golgi to endosome transport; IDA:BHF-UCL.
DR   GO; GO:0007275; P:multicellular organismal development; IEA:UniProtKB-KW.
DR   GO; GO:0014902; P:myotube differentiation; IMP:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0051005; P:negative regulation of lipoprotein lipase activity; IDA:BHF-UCL.
DR   GO; GO:0038180; P:nerve growth factor signaling pathway; IDA:GOC.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0001503; P:ossification; IEA:UniProtKB-KW.
DR   GO; GO:0048227; P:plasma membrane to endosome transport; IDA:BHF-UCL.
DR   GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0032868; P:response to insulin; IMP:BHF-UCL.
DR   GO; GO:0016050; P:vesicle organization; IDA:BHF-UCL.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR031777; Sortilin_C.
DR   InterPro; IPR031778; Sortilin_N.
DR   InterPro; IPR006581; VPS10.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   Pfam; PF15902; Sortilin-Vps10; 1.
DR   Pfam; PF15901; Sortilin_C; 1.
DR   SMART; SM00602; VPS10; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; Endocytosis; Endoplasmic reticulum; Endosome;
KW   Glycoprotein; Golgi apparatus; Lysosome; Membrane; Nucleus;
KW   Osteogenesis; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix; Transport.
FT   SIGNAL        1     33       {ECO:0000255}.
FT   PROPEP       34     77       Removed in mature form.
FT                                {ECO:0000269|PubMed:9756851}.
FT                                /FTId=PRO_0000033162.
FT   CHAIN        78    831       Sortilin.
FT                                /FTId=PRO_0000033163.
FT   TOPO_DOM     78    755       Extracellular. {ECO:0000255}.
FT   TRANSMEM    756    778       Helical. {ECO:0000255}.
FT   TOPO_DOM    779    831       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      145    156       BNR 1.
FT   REPEAT      198    209       BNR 2.
FT   REPEAT      240    251       BNR 3.
FT   REPEAT      287    298       BNR 4.
FT   REPEAT      328    339       BNR 5.
FT   REPEAT      377    388       BNR 6.
FT   REPEAT      428    439       BNR 7.
FT   REPEAT      506    517       BNR 8.
FT   REPEAT      548    559       BNR 9.
FT   REGION       50     61       Intrachain binding of the propeptide and
FT                                the extracellular domain.
FT   REGION      612    756       Interactions with LRPAP1 and NGFB.
FT   REGION      779    831       Golgi to endosome transport and
FT                                interactions with GGA1 and GGA2.
FT   MOTIF       787    792       Endocytosis signal. {ECO:0000305}.
FT   MOD_RES     819    819       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     825    825       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:21406692}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...). {ECO:0000305}.
FT   CARBOHYD    162    162       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    163    163       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    274    274       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19122660}.
FT   CARBOHYD    582    582       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19122660}.
FT   CARBOHYD    684    684       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     86    556
FT   DISULFID    257    277
FT   DISULFID    448    458
FT   DISULFID    612    651
FT   DISULFID    634    666
FT   DISULFID    668    723
FT   DISULFID    675    688
FT   DISULFID    702    740
FT   VAR_SEQ       1    136       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046239.
FT   VAR_SEQ     278    279       KA -> T (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046240.
FT   VARIANT     358    358       D -> Y (in dbSNP:rs2228605).
FT                                /FTId=VAR_053681.
FT   MUTAGEN      74     77       RWRR->GWRA: Abrogates propeptide
FT                                cleavage. {ECO:0000269|PubMed:9927419}.
FT   MUTAGEN      76     77       RR->GG: Abrogates propeptide cleavage.
FT                                {ECO:0000269|PubMed:9927419}.
FT   MUTAGEN     792    792       Y->A: Reduces endocytosis and Golgi to
FT                                endosome sorting; when associated with A-
FT                                795. {ECO:0000269|PubMed:11331584}.
FT   MUTAGEN     795    795       L->A: Reduces endocytosis and Golgi to
FT                                endosome sorting; when associated with A-
FT                                792. {ECO:0000269|PubMed:11331584}.
FT   MUTAGEN     823    824       DD->NN: Reduces interaction with GGA1.
FT                                {ECO:0000269|PubMed:11390366}.
FT   MUTAGEN     825    825       S->A: Reduces interaction with GGA1.
FT                                {ECO:0000269|PubMed:11390366}.
FT   MUTAGEN     826    828       DED->NQN: Abrogates interaction with GGA1
FT                                and impairs localization to the Golgi.
FT                                {ECO:0000269|PubMed:11390366}.
FT   MUTAGEN     829    830       LL->AA: Abrogates interaction with GGA1
FT                                and impairs localization to the Golgi.
FT                                {ECO:0000269|PubMed:11331584,
FT                                ECO:0000269|PubMed:11390366}.
FT   MUTAGEN     829    830       Missing: Abrogates interaction with GGA2.
FT                                Reduces endocytosis and Golgi to endosome
FT                                sorting; when associated with A-792 and
FT                                A-795. {ECO:0000269|PubMed:11331584,
FT                                ECO:0000269|PubMed:11390366}.
FT   CONFLICT    650    650       V -> M (in Ref. 1; CAA66904).
FT                                {ECO:0000305}.
FT   HELIX        92     97       {ECO:0000244|PDB:3F6K}.
FT   STRAND      100    106       {ECO:0000244|PDB:3F6K}.
FT   STRAND      110    116       {ECO:0000244|PDB:3F6K}.
FT   STRAND      118    121       {ECO:0000244|PDB:3F6K}.
FT   STRAND      124    130       {ECO:0000244|PDB:3F6K}.
FT   STRAND      136    138       {ECO:0000244|PDB:4PO7}.
FT   STRAND      141    149       {ECO:0000244|PDB:3F6K}.
FT   HELIX       158    161       {ECO:0000244|PDB:3F6K}.
FT   HELIX       168    170       {ECO:0000244|PDB:3F6K}.
FT   STRAND      172    174       {ECO:0000244|PDB:3F6K}.
FT   STRAND      182    186       {ECO:0000244|PDB:3F6K}.
FT   STRAND      196    202       {ECO:0000244|PDB:3F6K}.
FT   STRAND      208    211       {ECO:0000244|PDB:3F6K}.
FT   STRAND      216    218       {ECO:0000244|PDB:3F6K}.
FT   STRAND      221    223       {ECO:0000244|PDB:3F6K}.
FT   STRAND      226    234       {ECO:0000244|PDB:3F6K}.
FT   STRAND      239    244       {ECO:0000244|PDB:3F6K}.
FT   STRAND      247    261       {ECO:0000244|PDB:3F6K}.
FT   HELIX       263    265       {ECO:0000244|PDB:4PO7}.
FT   STRAND      267    271       {ECO:0000244|PDB:3F6K}.
FT   STRAND      273    275       {ECO:0000244|PDB:3F6K}.
FT   TURN        277    282       {ECO:0000244|PDB:3F6K}.
FT   STRAND      283    291       {ECO:0000244|PDB:3F6K}.
FT   STRAND      297    309       {ECO:0000244|PDB:3F6K}.
FT   STRAND      312    318       {ECO:0000244|PDB:3F6K}.
FT   STRAND      320    322       {ECO:0000244|PDB:4PO7}.
FT   STRAND      325    332       {ECO:0000244|PDB:3F6K}.
FT   STRAND      351    356       {ECO:0000244|PDB:3F6K}.
FT   STRAND      361    366       {ECO:0000244|PDB:3F6K}.
FT   STRAND      368    370       {ECO:0000244|PDB:4PO7}.
FT   STRAND      372    379       {ECO:0000244|PDB:3F6K}.
FT   STRAND      385    395       {ECO:0000244|PDB:3F6K}.
FT   TURN        397    399       {ECO:0000244|PDB:3F6K}.
FT   STRAND      414    419       {ECO:0000244|PDB:3F6K}.
FT   STRAND      421    423       {ECO:0000244|PDB:4N7E}.
FT   STRAND      425    432       {ECO:0000244|PDB:3F6K}.
FT   STRAND      438    441       {ECO:0000244|PDB:3F6K}.
FT   STRAND      453    456       {ECO:0000244|PDB:4PO7}.
FT   STRAND      459    462       {ECO:0000244|PDB:3F6K}.
FT   HELIX       465    469       {ECO:0000244|PDB:3F6K}.
FT   STRAND      488    497       {ECO:0000244|PDB:3F6K}.
FT   STRAND      504    510       {ECO:0000244|PDB:3F6K}.
FT   STRAND      516    521       {ECO:0000244|PDB:3F6K}.
FT   STRAND      523    528       {ECO:0000244|PDB:3F6K}.
FT   HELIX       529    531       {ECO:0000244|PDB:3F6K}.
FT   STRAND      533    538       {ECO:0000244|PDB:3F6K}.
FT   STRAND      546    552       {ECO:0000244|PDB:3F6K}.
FT   STRAND      558    561       {ECO:0000244|PDB:3F6K}.
FT   STRAND      567    573       {ECO:0000244|PDB:3F6K}.
FT   STRAND      581    590       {ECO:0000244|PDB:3F6K}.
FT   STRAND      595    603       {ECO:0000244|PDB:3F6K}.
FT   HELIX       604    606       {ECO:0000244|PDB:3F6K}.
FT   HELIX       614    616       {ECO:0000244|PDB:3F6K}.
FT   STRAND      617    621       {ECO:0000244|PDB:3F6K}.
FT   TURN        630    633       {ECO:0000244|PDB:3F6K}.
FT   STRAND      638    645       {ECO:0000244|PDB:3F6K}.
FT   STRAND      661    665       {ECO:0000244|PDB:3F6K}.
FT   HELIX       670    672       {ECO:0000244|PDB:3F6K}.
FT   STRAND      673    675       {ECO:0000244|PDB:3F6K}.
FT   STRAND      683    685       {ECO:0000244|PDB:3F6K}.
FT   HELIX       696    704       {ECO:0000244|PDB:3F6K}.
FT   HELIX       707    710       {ECO:0000244|PDB:3F6K}.
FT   STRAND      714    717       {ECO:0000244|PDB:3F6K}.
FT   STRAND      724    726       {ECO:0000244|PDB:4MSL}.
FT   STRAND      734    736       {ECO:0000244|PDB:3F6K}.
FT   HELIX       737    740       {ECO:0000244|PDB:3F6K}.
FT   HELIX       741    743       {ECO:0000244|PDB:3F6K}.
SQ   SEQUENCE   831 AA;  92068 MW;  91F96A3035A4B43A CRC64;
     MERPWGAADG LSRWPHGLGL LLLLQLLPPS TLSQDRLDAP PPPAAPLPRW SGPIGVSWGL
     RAAAAGGAFP RGGRWRRSAP GEDEECGRVR DFVAKLANNT HQHVFDDLRG SVSLSWVGDS
     TGVILVLTTF HVPLVIMTFG QSKLYRSEDY GKNFKDITDL INNTFIRTEF GMAIGPENSG
     KVVLTAEVSG GSRGGRIFRS SDFAKNFVQT DLPFHPLTQM MYSPQNSDYL LALSTENGLW
     VSKNFGGKWE EIHKAVCLAK WGSDNTIFFT TYANGSCKAD LGALELWRTS DLGKSFKTIG
     VKIYSFGLGG RFLFASVMAD KDTTRRIHVS TDQGDTWSMA QLPSVGQEQF YSILAANDDM
     VFMHVDEPGD TGFGTIFTSD DRGIVYSKSL DRHLYTTTGG ETDFTNVTSL RGVYITSVLS
     EDNSIQTMIT FDQGGRWTHL RKPENSECDA TAKNKNECSL HIHASYSISQ KLNVPMAPLS
     EPNAVGIVIA HGSVGDAISV MVPDVYISDD GGYSWTKMLE GPHYYTILDS GGIIVAIEHS
     SRPINVIKFS TDEGQCWQTY TFTRDPIYFT GLASEPGARS MNISIWGFTE SFLTSQWVSY
     TIDFKDILER NCEEKDYTIW LAHSTDPEDY EDGCILGYKE QFLRLRKSSV CQNGRDYVVT
     KQPSICLCSL EDFLCDFGYY RPENDSKCVE QPELKGHDLE FCLYGREEHL TTNGYRKIPG
     DKCQGGVNPV REVKDLKKKC TSNFLSPEKQ NSKSNSVPII LAIVGLMLVT VVAGVLIVKK
     YVCGGRFLVH RYSVLQQHAE ANGVDGVDAL DTASHTNKSG YHDDSDEDLL E
//
ID   TLR2_MOUSE              Reviewed;         784 AA.
AC   Q9QUN7; Q3U400; Q9DBC4;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   17-FEB-2016, entry version 142.
DE   RecName: Full=Toll-like receptor 2;
DE   AltName: CD_antigen=CD282;
DE   Flags: Precursor;
GN   Name=Tlr2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF PRO-681.
RX   PubMed=10548109; DOI=10.1038/44605;
RA   Underhill D.M., Ozinsky A., Hajjar A.M., Stevens A., Wilson C.B.,
RA   Bassetti M., Aderem A.;
RT   "The Toll-like receptor 2 is recruited to macrophage phagosomes and
RT   discriminates between pathogens.";
RL   Nature 401:811-815(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Macrophage;
RX   PubMed=10358136;
RA   Heine H., Kirschning C.J., Lien E., Monks B.G., Rothe M.,
RA   Golenbock D.T.;
RT   "Cells that carry a null allele for Toll-like receptor 2 are capable
RT   of responding to endotoxin.";
RL   J. Immunol. 162:6971-6975(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Macrophage;
RX   PubMed=10666214;
RA   Matsuguchi T., Takagi K., Musikacharoen T., Yoshikai Y.;
RT   "Gene expressions of lipopolysaccharide receptors, Toll-like receptors
RT   2 and 4, are differently regulated in mouse T lymphocytes.";
RL   Blood 95:1378-1385(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Adipocyte;
RX   PubMed=10823826; DOI=10.1074/jbc.M002137200;
RA   Lin Y., Lee H., Berg A.H., Lisanti M.P., Shapiro L., Scherer P.E.;
RT   "The lipopolysaccharide-activated Toll-like receptor (TLR)-4 induces
RT   synthesis of the closely related receptor TLR-2 in adipocytes.";
RL   J. Biol. Chem. 275:24255-24263(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Liver;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   PROTEIN SEQUENCE OF 405-413 AND 754-759, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [7]
RP   SUBCELLULAR LOCATION.
RC   STRAIN=BALB/cJ; TISSUE=Macrophage;
RX   PubMed=11095740; DOI=10.1073/pnas.250476497;
RA   Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D.,
RA   Wilson C.B., Schroeder L., Aderem A.;
RT   "The repertoire for pattern recognition of pathogens by the innate
RT   immune system is defined by cooperation between Toll-like receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:13766-13771(2000).
RN   [8]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=15690042; DOI=10.1038/nature03253;
RA   Hoebe K., Georgel P., Rutschmann S., Du X., Mudd S., Crozat K.,
RA   Sovath S., Shamel L., Hartung T., Zaehringer U., Beutler B.;
RT   "CD36 is a sensor of diacylglycerides.";
RL   Nature 433:523-527(2005).
RN   [9]
RP   INTERACTION WITH CNPY3.
RX   PubMed=18780723; DOI=10.1093/intimm/dxn098;
RA   Kiyokawa T., Akashi-Takamura S., Shibata T., Matsumoto F.,
RA   Nishitani C., Kuroki Y., Seto Y., Miyake K.;
RT   "A single base mutation in the PRAT4A gene reveals differential
RT   interaction of PRAT4A with Toll-like receptors.";
RL   Int. Immunol. 20:1407-1415(2008).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Macrophage;
RX   PubMed=19362712; DOI=10.1016/j.cellimm.2009.03.008;
RA   Drage M.G., Pecora N.D., Hise A.G., Febbraio M., Silverstein R.L.,
RA   Golenbock D.T., Boom W.H., Harding C.V.;
RT   "TLR2 and its co-receptors determine responses of macrophages and
RT   dendritic cells to lipoproteins of Mycobacterium tuberculosis.";
RL   Cell. Immunol. 258:29-37(2009).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 27-506, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-147; ASN-414 AND ASN-442.
RX   PubMed=17889651; DOI=10.1016/j.cell.2007.09.008;
RA   Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.-G., Lee H.,
RA   Lee J.-O.;
RT   "Crystal structure of the TLR1-TLR2 heterodimer induced by binding of
RT   a tri-acylated lipopeptide.";
RL   Cell 130:1071-1082(2007).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 1-506 IN COMPLEX WITH TLR6
RP   AND LIPOPEPTIDE, DISULFIDE BONDS, GLYCOSYLATION AT ASN-147; ASN-414
RP   AND ASN-442, FUNCTION, LRR REPEATS, AND SUBUNIT.
RX   PubMed=19931471; DOI=10.1016/j.immuni.2009.09.018;
RA   Kang J.Y., Nan X., Jin M.S., Youn S.J., Ryu Y.H., Mah S., Han S.H.,
RA   Lee H., Paik S.G., Lee J.O.;
RT   "Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like
RT   receptor 6 heterodimer.";
RL   Immunity 31:873-884(2009).
CC   -!- FUNCTION: Cooperates with LY96 to mediate the innate immune
CC       response to bacterial lipoproteins and other microbial cell wall
CC       components. Cooperates with TLR1 or TLR6 to mediate the innate
CC       immune response to bacterial lipoproteins or lipopeptides. Acts
CC       via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine
CC       secretion and the inflammatory response (By similarity)
CC       (PubMed:15690042). May also promote apoptosis in response to
CC       lipoproteins (By similarity). Forms activation clusters composed
CC       of several receptors depending on the ligand, these clusters
CC       trigger signaling from the cell surface and subsequently are
CC       targeted to the Golgi in a lipid-raft dependent pathway. Forms the
CC       cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides
CC       and TLR2:TLR1:CD14 in response to triacylated lipopeptides (By
CC       similarity). Acts as the major receptor for M.tuberculosis
CC       lipoproteins LprA, LprG, LpqH and PhoS1 (pstS1), in conjunction
CC       with TLR1 and for some but not all lipoproteins CD14 and/or CD36.
CC       The lipoproteins act as agonists to modulate antigen presenting
CC       cell functions in response to the pathogen (PubMed:19362712). Lung
CC       macrophages which express low levels of TLR2 respond poorly to
CC       stimulation by LpqH (PubMed:19362712).
CC       {ECO:0000250|UniProtKB:O60603, ECO:0000269|PubMed:15690042,
CC       ECO:0000269|PubMed:19362712}.
CC   -!- SUBUNIT: Interacts with LY96, TLR1 and TLR6 (via extracellular
CC       domain). TLR2 seems to exist in heterodimers with either TLR1 or
CC       TLR6 before stimulation by the ligand (PubMed:19931471). The
CC       heterodimers form bigger oligomers in response to their
CC       corresponding ligands as well as further heterotypic associations
CC       with other receptors such as CD14 and/or CD36 (By similarity).
CC       Binds MYD88 (via TIR domain). Interacts with TICAM1 (By
CC       similarity). Interacts with CNPY3 (PubMed:18780723). Interacts
CC       with ATG16L1 (By similarity). {ECO:0000250|UniProtKB:O60603,
CC       ECO:0000269|PubMed:18780723, ECO:0000269|PubMed:19931471}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11095740};
CC       Single-pass type I membrane protein {ECO:0000255}. Cytoplasmic
CC       vesicle, phagosome membrane {ECO:0000269|PubMed:11095740}; Single-
CC       pass type I membrane protein {ECO:0000255}. Membrane raft
CC       {ECO:0000250|UniProtKB:O60603}. Note=Does not reside in lipid
CC       rafts before stimulation but accumulates increasingly in the raft
CC       upon the presence of the microbial ligand. In response to
CC       diacylated lipoproteins, TLR2:TLR6 heterodimers are recruited in
CC       lipid rafts, this recruitment determine the intracellular
CC       targeting to the Golgi apparatus. Triacylated lipoproteins induce
CC       the same mechanism for TLR2:TLR1 heterodimers.
CC       {ECO:0000250|UniProtKB:O60603}.
CC   -!- TISSUE SPECIFICITY: Detected in a macrophage cell line, smooth
CC       muscle, lung, spleen, thymus, brain and adipose tissue. Cell
CC       surface expression detected in lung alveolar macrophages,
CC       dendritic macrophages and at lower levels in lung macrophages (at
CC       protein level) (PubMed:19362712). {ECO:0000269|PubMed:19362712}.
CC   -!- DOMAIN: Ester-bound lipid substrates are bound through a crevice
CC       formed between the LRR 11 and LRR 12.
CC   -!- DOMAIN: The ATG16L1-binding motif mediates interaction with
CC       ATG16L1. {ECO:0000250}.
CC   -!- PTM: Glycosylation of Asn-442 is critical for secretion of the N-
CC       terminal ectodomain of TLR2. {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mutants succumb to Staphylococcus aureus
CC       infection within 5 days. {ECO:0000269|PubMed:15690042}.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 19 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 TIR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00204}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF185284; AAF04277.1; -; mRNA.
DR   EMBL; AF124741; AAD46481.1; -; mRNA.
DR   EMBL; AF216289; AAF28345.1; -; mRNA.
DR   EMBL; AF165189; AAD49335.1; -; mRNA.
DR   EMBL; AK005043; BAB23770.1; -; mRNA.
DR   EMBL; AK154504; BAE32635.1; -; mRNA.
DR   CCDS; CCDS17435.1; -.
DR   RefSeq; NP_036035.3; NM_011905.3.
DR   UniGene; Mm.87596; -.
DR   PDB; 2Z81; X-ray; 1.80 A; A=27-506.
DR   PDB; 2Z82; X-ray; 2.60 A; A=27-506.
DR   PDB; 3A79; X-ray; 2.90 A; A=1-506.
DR   PDB; 3A7B; X-ray; 2.53 A; A=1-506.
DR   PDB; 3A7C; X-ray; 2.40 A; A=1-506.
DR   PDB; 5D3I; X-ray; 3.20 A; A=25-589.
DR   PDBsum; 2Z81; -.
DR   PDBsum; 2Z82; -.
DR   PDBsum; 3A79; -.
DR   PDBsum; 3A7B; -.
DR   PDBsum; 3A7C; -.
DR   PDBsum; 5D3I; -.
DR   ProteinModelPortal; Q9QUN7; -.
DR   SMR; Q9QUN7; 27-784.
DR   DIP; DIP-61222N; -.
DR   IntAct; Q9QUN7; 4.
DR   STRING; 10090.ENSMUSP00000029623; -.
DR   ChEMBL; CHEMBL3137289; -.
DR   PhosphoSite; Q9QUN7; -.
DR   SwissPalm; Q9QUN7; -.
DR   MaxQB; Q9QUN7; -.
DR   PaxDb; Q9QUN7; -.
DR   PRIDE; Q9QUN7; -.
DR   GeneID; 24088; -.
DR   KEGG; mmu:24088; -.
DR   CTD; 7097; -.
DR   MGI; MGI:1346060; Tlr2.
DR   eggNOG; KOG4641; Eukaryota.
DR   eggNOG; COG4886; LUCA.
DR   HOGENOM; HOG000110611; -.
DR   HOVERGEN; HBG108574; -.
DR   InParanoid; Q9QUN7; -.
DR   KO; K10159; -.
DR   PhylomeDB; Q9QUN7; -.
DR   EvolutionaryTrace; Q9QUN7; -.
DR   NextBio; 304101; -.
DR   PRO; PR:Q9QUN7; -.
DR   Proteomes; UP000000589; Unplaced.
DR   CleanEx; MM_TLR2; -.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; ISO:MGI.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0035354; C:Toll-like receptor 1-Toll-like receptor 2 protein complex; ISO:MGI.
DR   GO; GO:0035355; C:Toll-like receptor 2-Toll-like receptor 6 protein complex; IPI:MGI.
DR   GO; GO:0042498; F:diacyl lipopeptide binding; IDA:MGI.
DR   GO; GO:0001530; F:lipopolysaccharide binding; ISO:MGI.
DR   GO; GO:0070891; F:lipoteichoic acid binding; IDA:MGI.
DR   GO; GO:0042834; F:peptidoglycan binding; ISO:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:MGI.
DR   GO; GO:0004872; F:receptor activity; ISO:MGI.
DR   GO; GO:0008329; F:signaling pattern recognition receptor activity; ISO:MGI.
DR   GO; GO:0035325; F:Toll-like receptor binding; ISO:MGI.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR   GO; GO:0042497; F:triacyl lipopeptide binding; IDA:MGI.
DR   GO; GO:0002752; P:cell surface pattern recognition receptor signaling pathway; IMP:MGI.
DR   GO; GO:0071221; P:cellular response to bacterial lipopeptide; TAS:BHF-UCL.
DR   GO; GO:0071726; P:cellular response to diacyl bacterial lipopeptide; ISS:UniProtKB.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IMP:MGI.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IMP:MGI.
DR   GO; GO:0071727; P:cellular response to triacyl bacterial lipopeptide; ISS:UniProtKB.
DR   GO; GO:0042892; P:chloramphenicol transport; IMP:MGI.
DR   GO; GO:0002374; P:cytokine secretion involved in immune response; ISO:MGI.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IMP:MGI.
DR   GO; GO:0042496; P:detection of diacyl bacterial lipopeptide; ISO:MGI.
DR   GO; GO:0042495; P:detection of triacyl bacterial lipopeptide; ISO:MGI.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; ISO:MGI.
DR   GO; GO:0052063; P:induction by symbiont of defense-related host nitric oxide production; IMP:MGI.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; TAS:BHF-UCL.
DR   GO; GO:0032613; P:interleukin-10 production; ISO:MGI.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; IGI:MGI.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IMP:MGI.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IMP:MGI.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IMP:MGI.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IMP:MGI.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; IGI:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:MGI.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IEA:InterPro.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:BHF-UCL.
DR   GO; GO:0032741; P:positive regulation of interleukin-18 production; IDA:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISO:MGI.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IMP:MGI.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IMP:MGI.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; ISO:MGI.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISO:MGI.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IMP:MGI.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:MGI.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0034123; P:positive regulation of toll-like receptor signaling pathway; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; IMP:MGI.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:BHF-UCL.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISO:MGI.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IMP:MGI.
DR   GO; GO:0002730; P:regulation of dendritic cell cytokine production; IDA:MGI.
DR   GO; GO:0009617; P:response to bacterium; IMP:MGI.
DR   GO; GO:0002238; P:response to molecule of fungal origin; IMP:MGI.
DR   GO; GO:0032494; P:response to peptidoglycan; IMP:MGI.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IEA:InterPro.
DR   Gene3D; 3.40.50.10140; -; 1.
DR   Gene3D; 3.80.10.10; -; 3.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR027185; TLR2.
DR   InterPro; IPR017241; Toll-like_receptor.
DR   PANTHER; PTHR24365:SF17; PTHR24365:SF17; 1.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF01582; TIR; 1.
DR   PIRSF; PIRSF037595; Toll-like_receptor; 1.
DR   SMART; SM00369; LRR_TYP; 2.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF52200; SSF52200; 1.
DR   PROSITE; PS51450; LRR; 9.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Leucine-rich repeat; Membrane;
KW   Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25    784       Toll-like receptor 2.
FT                                /FTId=PRO_0000034712.
FT   TOPO_DOM     25    587       Extracellular. {ECO:0000255}.
FT   TRANSMEM    588    608       Helical. {ECO:0000255}.
FT   TOPO_DOM    609    784       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       54     77       LRR 1. {ECO:0000269|PubMed:19931471}.
FT   REPEAT       78    101       LRR 2. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      102    125       LRR 3. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      126    150       LRR 4. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      151    175       LRR 5. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      176    199       LRR 6. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      200    223       LRR 7. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      224    250       LRR 8. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      251    278       LRR 9. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      279    308       LRR 10. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      309    337       LRR 11. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      338    361       LRR 12. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      362    388       LRR 13. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      389    414       LRR 14. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      415    437       LRR 15. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      438    457       LRR 16. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      458    478       LRR 17. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      479    500       LRR 18. {ECO:0000269|PubMed:19931471}.
FT   REPEAT      501    524       LRR 19. {ECO:0000269|PubMed:19931471}.
FT   DOMAIN      525    576       LRRCT.
FT   DOMAIN      639    784       TIR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00204}.
FT   MOTIF       761    778       ATG16L1-binding motif.
FT   SITE        349    349       Interaction with bacterial lipopeptide.
FT                                {ECO:0000250}.
FT   CARBOHYD    147    147       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17889651,
FT                                ECO:0000269|PubMed:19931471}.
FT   CARBOHYD    414    414       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17889651,
FT                                ECO:0000269|PubMed:19931471}.
FT   CARBOHYD    442    442       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17889651,
FT                                ECO:0000269|PubMed:19931471}.
FT   DISULFID     30     36
FT   DISULFID    353    382
FT   DISULFID    432    454
FT   MUTAGEN     681    681       P->H: Abolishes MYD88-binding and
FT                                response to microbial cell wall
FT                                components.
FT                                {ECO:0000269|PubMed:10548109}.
FT   CONFLICT     59     59       L -> P (in Ref. 5; BAB23770).
FT                                {ECO:0000305}.
FT   CONFLICT     82     82       I -> M (in Ref. 5; BAB23770).
FT                                {ECO:0000305}.
FT   STRAND       34     37       {ECO:0000244|PDB:2Z81}.
FT   STRAND       44     46       {ECO:0000244|PDB:3A79}.
FT   STRAND       56     58       {ECO:0000244|PDB:2Z81}.
FT   STRAND       71     74       {ECO:0000244|PDB:3A7C}.
FT   STRAND       80     82       {ECO:0000244|PDB:2Z81}.
FT   TURN         93     98       {ECO:0000244|PDB:2Z81}.
FT   STRAND      104    106       {ECO:0000244|PDB:2Z81}.
FT   HELIX       117    120       {ECO:0000244|PDB:2Z81}.
FT   STRAND      128    130       {ECO:0000244|PDB:2Z81}.
FT   STRAND      137    139       {ECO:0000244|PDB:2Z81}.
FT   STRAND      153    161       {ECO:0000244|PDB:2Z81}.
FT   TURN        167    172       {ECO:0000244|PDB:2Z81}.
FT   STRAND      175    183       {ECO:0000244|PDB:2Z81}.
FT   TURN        191    196       {ECO:0000244|PDB:2Z81}.
FT   STRAND      198    206       {ECO:0000244|PDB:2Z81}.
FT   STRAND      208    210       {ECO:0000244|PDB:2Z81}.
FT   HELIX       213    219       {ECO:0000244|PDB:2Z81}.
FT   TURN        221    223       {ECO:0000244|PDB:2Z81}.
FT   STRAND      224    231       {ECO:0000244|PDB:2Z81}.
FT   STRAND      245    247       {ECO:0000244|PDB:3A7C}.
FT   STRAND      253    258       {ECO:0000244|PDB:2Z81}.
FT   STRAND      260    262       {ECO:0000244|PDB:2Z81}.
FT   HELIX       263    270       {ECO:0000244|PDB:2Z81}.
FT   HELIX       271    275       {ECO:0000244|PDB:2Z81}.
FT   STRAND      281    286       {ECO:0000244|PDB:2Z81}.
FT   STRAND      288    290       {ECO:0000244|PDB:2Z81}.
FT   TURN        299    301       {ECO:0000244|PDB:2Z81}.
FT   HELIX       304    306       {ECO:0000244|PDB:3A7C}.
FT   STRAND      311    316       {ECO:0000244|PDB:2Z81}.
FT   HELIX       322    324       {ECO:0000244|PDB:2Z81}.
FT   HELIX       330    334       {ECO:0000244|PDB:2Z81}.
FT   STRAND      340    346       {ECO:0000244|PDB:2Z81}.
FT   HELIX       353    358       {ECO:0000244|PDB:2Z81}.
FT   STRAND      364    366       {ECO:0000244|PDB:2Z81}.
FT   HELIX       374    380       {ECO:0000244|PDB:2Z81}.
FT   STRAND      391    393       {ECO:0000244|PDB:2Z81}.
FT   HELIX       402    408       {ECO:0000244|PDB:2Z81}.
FT   HELIX       409    411       {ECO:0000244|PDB:2Z81}.
FT   STRAND      417    419       {ECO:0000244|PDB:2Z81}.
FT   STRAND      440    442       {ECO:0000244|PDB:2Z81}.
FT   STRAND      460    463       {ECO:0000244|PDB:2Z81}.
FT   STRAND      481    483       {ECO:0000244|PDB:2Z81}.
FT   HELIX       495    497       {ECO:0000244|PDB:2Z81}.
FT   STRAND      503    505       {ECO:0000244|PDB:2Z81}.
FT   HELIX       516    521       {ECO:0000244|PDB:5D3I}.
FT   STRAND      527    529       {ECO:0000244|PDB:5D3I}.
FT   HELIX       539    547       {ECO:0000244|PDB:5D3I}.
FT   HELIX       549    553       {ECO:0000244|PDB:5D3I}.
FT   TURN        556    561       {ECO:0000244|PDB:5D3I}.
FT   STRAND      564    567       {ECO:0000244|PDB:5D3I}.
FT   TURN        568    572       {ECO:0000244|PDB:5D3I}.
SQ   SEQUENCE   784 AA;  89449 MW;  606D56BF85F320A2 CRC64;
     MLRALWLFWI LVAITVLFSK RCSAQESLSC DASGVCDGRS RSFTSIPSGL TAAMKSLDLS
     FNKITYIGHG DLRACANLQV LILKSSRINT IEGDAFYSLG SLEHLDLSDN HLSSLSSSWF
     GPLSSLKYLN LMGNPYQTLG VTSLFPNLTN LQTLRIGNVE TFSEIRRIDF AGLTSLNELE
     IKALSLRNYQ SQSLKSIRDI HHLTLHLSES AFLLEIFADI LSSVRYLELR DTNLARFQFS
     PLPVDEVSSP MKKLAFRGSV LTDESFNELL KLLRYILELS EVEFDDCTLN GLGDFNPSES
     DVVSELGKVE TVTIRRLHIP QFYLFYDLST VYSLLEKVKR ITVENSKVFL VPCSFSQHLK
     SLEFLDLSEN LMVEEYLKNS ACKGAWPSLQ TLVLSQNHLR SMQKTGEILL TLKNLTSLDI
     SRNTFHPMPD SCQWPEKMRF LNLSSTGIRV VKTCIPQTLE VLDVSNNNLD SFSLFLPRLQ
     ELYISRNKLK TLPDASLFPV LLVMKIRENA VSTFSKDQLG SFPKLETLEA GDNHFVCSCE
     LLSFTMETPA LAQILVDWPD SYLCDSPPRL HGHRLQDARP SVLECHQAAL VSGVCCALLL
     LILLVGALCH HFHGLWYLRM MWAWLQAKRK PKKAPCRDVC YDAFVSYSEQ DSHWVENLMV
     QQLENSDPPF KLCLHKRDFV PGKWIIDNII DSIEKSHKTV FVLSENFVRS EWCKYELDFS
     HFRLFDENND AAILVLLEPI ERKAIPQRFC KLRKIMNTKT YLEWPLDEGQ QEVFWVNLRT
     AIKS
//
ID   PGFRA_MOUSE             Reviewed;        1089 AA.
AC   P26618; Q3TQ37; Q62046; Q7TSJ3; Q8C4N3;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   26-FEB-2008, sequence version 3.
DT   17-FEB-2016, entry version 166.
DE   RecName: Full=Platelet-derived growth factor receptor alpha;
DE            Short=PDGF-R-alpha;
DE            Short=PDGFR-alpha;
DE            EC=2.7.10.1;
DE   AltName: Full=Alpha platelet-derived growth factor receptor;
DE   AltName: Full=Alpha-type platelet-derived growth factor receptor;
DE   AltName: Full=CD140 antigen-like family member A;
DE   AltName: Full=Platelet-derived growth factor alpha receptor;
DE   AltName: CD_antigen=CD140a;
DE   Flags: Precursor;
GN   Name=Pdgfra;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2174116;
RA   Stiles C.D., Wang C.;
RT   "Retinoic acid promotes transcription of the platelet-derived growth
RT   factor alpha-receptor gene.";
RL   Mol. Cell. Biol. 10:6781-6784(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1321404;
RA   Do M.S., Fitzer-Attas C., Gubbay J., Greenfeld L., Feldman M.,
RA   Eisenbach L.;
RT   "Mouse platelet-derived growth factor alpha receptor: sequence,
RT   tissue-specific expression and correlation with metastatic
RT   phenotype.";
RL   Oncogene 7:1567-1575(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6J;
RC   TISSUE=Cerebellum, Colon, Embryonic head, and Placenta;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=9226440;
RA   Soriano P.;
RT   "The PDGF alpha receptor is required for neural crest cell development
RT   and for normal patterning of the somites.";
RL   Development 124:2691-2700(1997).
RN   [6]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=10903171;
RA   Karlsson L., Lindahl P., Heath J.K., Betsholtz C.;
RT   "Abnormal gastrointestinal development in PDGF-A and PDGFR-(alpha)
RT   deficient mice implicates a novel mesenchymal structure with putative
RT   instructive properties in villus morphogenesis.";
RL   Development 127:3457-3466(2000).
RN   [7]
RP   INTERACTION WITH SHB.
RX   PubMed=10837138; DOI=10.1006/excr.2000.4896;
RA   Hooshmand-Rad R., Lu L., Heldin C.-H., Claesson-Welsh L., Welsh M.;
RT   "Platelet-derived growth factor-mediated signaling through the Shb
RT   adaptor protein: effects on cytoskeletal organization.";
RL   Exp. Cell Res. 257:245-254(2000).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=14514732; DOI=10.1097/01.ASN.0000089828.73014.C8;
RA   Taneda S., Hudkins K.L., Topouzis S., Gilbertson D.G.,
RA   Ophascharoensuk V., Truong L., Johnson R.J., Alpers C.E.;
RT   "Obstructive uropathy in mice and humans: potential role for PDGF-D in
RT   the progression of tubulointerstitial injury.";
RL   J. Am. Soc. Nephrol. 14:2544-2555(2003).
RN   [9]
RP   REVIEW ON FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=15207813; DOI=10.1016/j.cytogfr.2004.03.005;
RA   Betsholtz C.;
RT   "Insight into the physiological functions of PDGF through genetic
RT   studies in mice.";
RL   Cytokine Growth Factor Rev. 15:215-228(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=19030102; DOI=10.1371/journal.pone.0003794;
RA   Wu E., Palmer N., Tian Z., Moseman A.P., Galdzicki M., Wang X.,
RA   Berger B., Zhang H., Kohane I.S.;
RT   "Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR
RT   genetically defined cells.";
RL   PLoS ONE 3:E3794-E3794(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Lung;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [12]
RP   FUNCTION.
RX   PubMed=20110689; DOI=10.1159/000276562;
RA   Schneider L., Cammer M., Lehman J., Nielsen S.K., Guerra C.F.,
RA   Veland I.R., Stock C., Hoffmann E.K., Yoder B.K., Schwab A., Satir P.,
RA   Christensen S.T.;
RT   "Directional cell migration and chemotaxis in wound healing response
RT   to PDGF-AA are coordinated by the primary cilium in fibroblasts.";
RL   Cell. Physiol. Biochem. 25:279-292(2010).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for PDGFA, PDGFB and PDGFC and plays an essential role in
CC       the regulation of embryonic development, cell proliferation,
CC       survival and chemotaxis. Depending on the context, promotes or
CC       inhibits cell proliferation and cell migration. Plays an important
CC       role in the differentiation of bone marrow-derived mesenchymal
CC       stem cells. Required for normal skeleton development and cephalic
CC       closure during embryonic development. Required for normal
CC       development of the mucosa lining the gastrointestinal tract, and
CC       for recruitment of mesenchymal cells and normal development of
CC       intestinal villi. Plays a role in cell migration and chemotaxis in
CC       wound healing. Plays a role in platelet activation, secretion of
CC       agonists from platelet granules, and in thrombin-induced platelet
CC       aggregation. Binding of its cognate ligands - homodimeric PDGFA,
CC       homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or
CC       homodimeric PDGFC -leads to the activation of several signaling
CC       cascades; the response depends on the nature of the bound ligand
CC       and is modulated by the formation of heterodimers between PDGFRA
CC       and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation
CC       of PLCG1 leads to the production of the cellular signaling
CC       molecules diacylglycerol and inositol 1,4,5-trisphosphate,
CC       mobilization of cytosolic Ca(2+) and the activation of protein
CC       kinase C. Phosphorylates PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase, and thereby mediates activation of
CC       the AKT1 signaling pathway. Mediates activation of HRAS and of the
CC       MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of
CC       STAT family members STAT1, STAT3 and STAT5A and/or STAT5B.
CC       Receptor signaling is down-regulated by protein phosphatases that
CC       dephosphorylate the receptor and its down-stream effectors, and by
CC       rapid internalization of the activated receptor.
CC       {ECO:0000269|PubMed:10903171, ECO:0000269|PubMed:19030102,
CC       ECO:0000269|PubMed:20110689, ECO:0000269|PubMed:9226440}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of PDGFA and/or PDGFB leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib, nilotinib and sorafenib (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with homodimeric PDGFA, PDGFB and PDGFC, and
CC       with heterodimers formed by PDGFA and PDGFB. Monomer in the
CC       absence of bound ligand. Interaction with dimeric PDGFA, PDGFB
CC       and/or PDGFC leads to receptor dimerization, where both PDGFRA
CC       homodimers and heterodimers with PDGFRB are observed. Interacts
CC       (tyrosine phosphorylated) with SHB (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with SHF (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with SRC (via SH2 domain). Interacts
CC       (tyrosine phosphorylated) with PIK3R1. Interacts (tyrosine
CC       phosphorylated) with PLCG1 (via SH2 domain). Interacts (tyrosine
CC       phosphorylated) with CRK, GRB2 and GRB7 (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Note=The activated receptor is rapidly internalized and
CC       degraded. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P26618-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P26618-2; Sequence=VSP_031877, VSP_031878;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Focally expressed in cortical interstitial
CC       cells and highly expressed in the interstitium of the papillary
CC       region. Also expressed by adventitial cells in arterial vessels.
CC       Up-regulated in areas of renal fibrosis. In mice with unilateral
CC       ureteral obstruction, expression in cortical interstitial cells
CC       becomes prominent at day 4 which increases progressively until day
CC       14. {ECO:0000269|PubMed:14514732}.
CC   -!- PTM: Ubiquitinated, leading to its degradation. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-731 and Tyr-742 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-720 and Tyr-754 is
CC       important for interaction with PTPN11. Phosphorylation at Tyr-762
CC       is important for interaction with CRK. Phosphorylation at Tyr-572
CC       and Tyr-574 is important for interaction with SRC and SRC family
CC       members. Phosphorylation at Tyr-988 and Tyr-1018 is important for
CC       interaction with PLCG1 (By similarity). {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Embryonically lethal. Most embryos survive
CC       up to 13 dpc, but display important defects in skeleton
CC       development, including spina bifida, fusions of cervical vertebrae
CC       and ribs, and incomplete fusion of the skull parietal bone.
CC       Embryos display also abnormal mucosa lining the gastrointestinal
CC       tract, including fewer and misshapen villi and loss of pericryptal
CC       mesenchyme. At about 16 dpc, embryos display extensive
CC       hemorrhaging. {ECO:0000269|PubMed:10903171,
CC       ECO:0000269|PubMed:15207813, ECO:0000269|PubMed:9226440}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M57683; AAA39733.1; -; mRNA.
DR   EMBL; M84607; AAA39904.1; -; mRNA.
DR   EMBL; AK081664; BAC38283.1; -; mRNA.
DR   EMBL; AK136490; BAE23004.1; -; mRNA.
DR   EMBL; AK147267; BAE27808.1; -; mRNA.
DR   EMBL; AK163952; BAE37548.1; -; mRNA.
DR   EMBL; BC053036; AAH53036.1; -; mRNA.
DR   CCDS; CCDS19351.1; -. [P26618-1]
DR   PIR; I57511; S33727.
DR   RefSeq; NP_001076785.1; NM_001083316.1. [P26618-1]
DR   RefSeq; NP_035188.2; NM_011058.2. [P26618-1]
DR   RefSeq; XP_006504324.1; XM_006504261.2. [P26618-1]
DR   RefSeq; XP_006504325.1; XM_006504262.2. [P26618-1]
DR   RefSeq; XP_006504326.1; XM_006504263.2. [P26618-1]
DR   UniGene; Mm.221403; -.
DR   ProteinModelPortal; P26618; -.
DR   SMR; P26618; 551-694, 769-951.
DR   BioGrid; 202088; 1.
DR   IntAct; P26618; 3.
DR   MINT; MINT-4107325; -.
DR   STRING; 10090.ENSMUSP00000000476; -.
DR   BindingDB; P26618; -.
DR   ChEMBL; CHEMBL2096980; -.
DR   GuidetoPHARMACOLOGY; 1803; -.
DR   iPTMnet; P26618; -.
DR   PhosphoSite; P26618; -.
DR   SwissPalm; P26618; -.
DR   MaxQB; P26618; -.
DR   PaxDb; P26618; -.
DR   PRIDE; P26618; -.
DR   Ensembl; ENSMUST00000000476; ENSMUSP00000000476; ENSMUSG00000029231. [P26618-1]
DR   Ensembl; ENSMUST00000168162; ENSMUSP00000127173; ENSMUSG00000029231. [P26618-1]
DR   Ensembl; ENSMUST00000201711; ENSMUSP00000143891; ENSMUSG00000029231. [P26618-2]
DR   Ensembl; ENSMUST00000202681; ENSMUSP00000143906; ENSMUSG00000029231. [P26618-2]
DR   GeneID; 18595; -.
DR   KEGG; mmu:18595; -.
DR   UCSC; uc008xub.1; mouse. [P26618-2]
DR   UCSC; uc008xuc.1; mouse. [P26618-1]
DR   CTD; 5156; -.
DR   MGI; MGI:97530; Pdgfra.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112009; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P26618; -.
DR   KO; K04363; -.
DR   OMA; DSAIIPC; -.
DR   OrthoDB; EOG71G9T1; -.
DR   PhylomeDB; P26618; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   ChiTaRS; Pdgfra; mouse.
DR   NextBio; 294480; -.
DR   PRO; PR:P26618; -.
DR   Proteomes; UP000000589; Chromosome 5.
DR   Bgee; P26618; -.
DR   Genevisible; P26618; MM.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; ISO:MGI.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0005902; C:microvillus; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005018; F:platelet-derived growth factor alpha-receptor activity; IDA:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; ISO:MGI.
DR   GO; GO:0032403; F:protein complex binding; IDA:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; ISO:MGI.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; ISO:MGI.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; ISO:MGI.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0030325; P:adrenal gland development; IGI:MGI.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IMP:MGI.
DR   GO; GO:0055003; P:cardiac myofibril assembly; IGI:UniProtKB.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:MGI.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; ISO:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:UniProtKB.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; IMP:UniProtKB.
DR   GO; GO:0008210; P:estrogen metabolic process; IGI:MGI.
DR   GO; GO:0030198; P:extracellular matrix organization; IMP:MGI.
DR   GO; GO:0060325; P:face morphogenesis; IMP:MGI.
DR   GO; GO:0008585; P:female gonad development; IGI:MGI.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0033327; P:Leydig cell differentiation; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0001553; P:luteinization; IMP:MGI.
DR   GO; GO:0030539; P:male genitalia development; IMP:MGI.
DR   GO; GO:0072277; P:metanephric glomerular capillary formation; IGI:UniProtKB.
DR   GO; GO:0010544; P:negative regulation of platelet activation; ISS:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR   GO; GO:0009887; P:organ morphogenesis; IMP:MGI.
DR   GO; GO:0060021; P:palate development; IMP:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0035790; P:platelet-derived growth factor receptor-alpha signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; ISO:MGI.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0050920; P:regulation of chemotaxis; ISO:MGI.
DR   GO; GO:2000739; P:regulation of mesenchymal stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:0034097; P:response to cytokine; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010035; P:response to inorganic substance; IEA:Ensembl.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; IGI:UniProtKB.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IDA:MGI.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IMP:MGI.
DR   GO; GO:0042060; P:wound healing; IMP:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027290; PDGFRA.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF52; PTHR24416:SF52; 3.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF13895; Ig_2; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500950; Alpha-PDGF_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Chemotaxis;
KW   Complete proteome; Developmental protein; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25   1089       Platelet-derived growth factor receptor
FT                                alpha.
FT                                /FTId=PRO_0000016761.
FT   TOPO_DOM     25    528       Extracellular. {ECO:0000255}.
FT   TRANSMEM    529    549       Helical. {ECO:0000255}.
FT   TOPO_DOM    550   1089       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25    113       Ig-like C2-type 1.
FT   DOMAIN      117    201       Ig-like C2-type 2.
FT   DOMAIN      202    306       Ig-like C2-type 3.
FT   DOMAIN      319    410       Ig-like C2-type 4.
FT   DOMAIN      414    517       Ig-like C2-type 5.
FT   DOMAIN      593    954       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     599    607       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    818    818       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     627    627       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     572    572       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     574    574       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     720    720       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES     731    731       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     742    742       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     754    754       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     762    762       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     768    768       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     849    849       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     988    988       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P16234}.
FT   MOD_RES    1018   1018       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P16234}.
FT   CARBOHYD     42     42       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     76     76       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     89     89       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    179    179       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    359    359       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    458    458       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    506    506       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     49    100       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    150    189       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    235    290       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    435    501       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     775    790       DSEVKNLLSDDDSEGL -> GKSAHAHSGKYDLSVV (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:16141072}.
FT                                /FTId=VSP_031877.
FT   VAR_SEQ     791   1089       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:16141072}.
FT                                /FTId=VSP_031878.
FT   CONFLICT     65     65       D -> E (in Ref. 1; AAA39733 and 2;
FT                                AAA39904). {ECO:0000305}.
FT   CONFLICT    192    192       T -> A (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    202    202       E -> A (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    252    252       E -> G (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    271    271       L -> V (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    322    322       G -> S (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    326    326       A -> P (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    439    440       GT -> EG (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    472    472       I -> V (in Ref. 3; BAE37548).
FT                                {ECO:0000305}.
FT   CONFLICT    529    529       A -> E (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    737    737       A -> D (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    849    849       Y -> D (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    936    936       E -> D (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT    950    950       V -> L (in Ref. 1; AAA39733).
FT                                {ECO:0000305}.
FT   CONFLICT   1005   1005       G -> S (in Ref. 2; AAA39904).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1089 AA;  122683 MW;  07AAFD2BAA12533A CRC64;
     MGTSHQVFLV LSCLLTGPGL ISCQLLLPSI LPNENEKIVQ LNSSFSLRCV GESEVSWQHP
     MSEEDDPNVE IRSEENNSGL FVTVLEVVNA SAAHTGWYTC YYNHTQTDES EIEGRHIYIY
     VPDPDMAFVP LGMTDSLVIV EEDDSAIIPC RTTDPETQVT LHNNGRLVPA SYDSRQGFNG
     TFSVGPYICE ATVKGRTFKT SEFNVYALKA TSELNLEMDA RQTVYKAGET IVVTCAVFNN
     EVVDLQWTYP GEVRNKGITM LEEIKLPSIK LVYTLTVPKA TVKDSGEYEC AARQATKEVK
     EMKRVTISVH EKGFVEIEPT FGQLEAVNLH EVREFVVEVQ AYPTPRISWL KDNLTLIENL
     TEITTDVQKS QETRYQSKLK LIRAKEEDSG HYTIIVQNED DVKSYTFELS TLVPASILDL
     VDDHHGSGGG QTVRCTAEGT PLPEIDWMIC KHIKKCNNDT SWTVLASNVS NIITELPRRG
     RSTVEGRVSF AKVEETIAVR CLAKNNLSVV ARELKLVAPT LRSELTVAAA VLVLLVIVIV
     SLIVLVVIWK QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFPR DGLVLGRILG
     SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH LGPHLNIVNL
     LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFMSQHPEK PKKDLDIFGL NPADESTRSY
     VILSFENNGD YMDMKQADTT QYVPMLERKE VSKYSDIQRS LYDRPASYKK KSMLDSEVKN
     LLSDDDSEGL TLLDLLSFTY QVARGMEFLA SKNCVHRDLA ARNVLLAQGK IVKICDFGLA
     RDIMHDSNYV SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM
     VDSTFYNKIK SGYRMAKPDH ATSEVYEIMV QCWNSEPEKR PSFYHLSEIV ENLLPGQYKK
     SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL KDWEGGLDEQ RLSADSGYII
     PLPDIDPVPE EEDLGKRNRH SSQTSEESAI ETGSSSSTFI KREDETIEDI DMMDDIGIDS
     SDLVEDSFL
//
ID   LRP1_HUMAN              Reviewed;        4544 AA.
AC   Q07954; Q2PP12; Q86SW0; Q8IVG8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   17-FEB-2016, entry version 179.
DE   RecName: Full=Prolow-density lipoprotein receptor-related protein 1;
DE            Short=LRP-1;
DE   AltName: Full=Alpha-2-macroglobulin receptor;
DE            Short=A2MR;
DE   AltName: Full=Apolipoprotein E receptor;
DE            Short=APOER;
DE   AltName: CD_antigen=CD91;
DE   Contains:
DE     RecName: Full=Low-density lipoprotein receptor-related protein 1 85 kDa subunit;
DE              Short=LRP-85;
DE   Contains:
DE     RecName: Full=Low-density lipoprotein receptor-related protein 1 515 kDa subunit;
DE              Short=LRP-515;
DE   Contains:
DE     RecName: Full=Low-density lipoprotein receptor-related protein 1 intracellular domain;
DE              Short=LRPICD;
DE   Flags: Precursor;
GN   Name=LRP1; Synonyms=A2MR, APR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT PRO-2900.
RC   TISSUE=Liver;
RX   PubMed=3266596;
RA   Herz J., Hamann U., Rogne S., Myklebost O., Gausepohl H.,
RA   Stanley K.K.;
RT   "Surface location and high affinity for calcium of a 500-kd liver
RT   membrane protein closely related to the LDL-receptor suggest a
RT   physiological role as lipoprotein receptor.";
RL   EMBO J. 7:4119-4127(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7534747; DOI=10.1006/geno.1994.1584;
RA   Van Leuven F., Stas L., Hilliker C., Lorent K., Umans L., Serneels L.,
RA   Overbergh L., Torrekens S., Moechars D., De Strooper B.,
RA   Van den Berghe H.;
RT   "Structure of the gene (LRP1) coding for the human alpha 2-
RT   macroglobulin receptor lipoprotein receptor-related protein.";
RL   Genomics 24:78-89(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PRO-2900.
RX   PubMed=9782078; DOI=10.1006/geno.1998.5408;
RA   Van Leuven F., Stas L., Thiry E., Nelissen B., Miyake Y.;
RT   "Strategy to sequence the 89 exons of the human LRP1 gene coding for
RT   the lipoprotein receptor related protein: identification of one
RT   expressed mutation among 48 polymorphisms.";
RL   Genomics 52:138-144(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PRO-2900.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-11.
RX   PubMed=2597675;
RA   Kutt H., Herz J., Stanley K.K.;
RT   "Structure of the low-density lipoprotein receptor-related protein
RT   (LRP) promoter.";
RL   Biochim. Biophys. Acta 1009:229-236(1989).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-11.
RC   TISSUE=Blood;
RA   Glaeser C.;
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PROTEIN SEQUENCE OF 150-166; 234-252; 685-695; 902-916; 1096-1109;
RP   1743-1756; 2863-2874; 2949-2960; 3023-3039 AND 3277-3291.
RC   TISSUE=Placenta;
RX   PubMed=1698775;
RA   Strickland D.K., Ashcom J.D., Williams S., Burgess W.H.,
RA   Migliorini M., Argraves W.S.;
RT   "Sequence identity between the alpha 2-macroglobulin receptor and low
RT   density lipoprotein receptor-related protein suggests that this
RT   molecule is a multifunctional receptor.";
RL   J. Biol. Chem. 265:17401-17404(1990).
RN   [10]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=2112085;
RA   Herz J., Kowal R.C., Goldstein J.L., Brown M.S.;
RT   "Proteolytic processing of the 600 kd low density lipoprotein
RT   receptor-related protein (LRP) occurs in a trans-Golgi compartment.";
RL   EMBO J. 9:1769-1776(1990).
RN   [11]
RP   FUNCTION.
RX   PubMed=1702392; DOI=10.1016/0014-5793(90)80530-V;
RA   Kristensen T., Moestrup S.K., Gliemann J., Bendtsen L., Sand O.,
RA   Sottrup-Jensen L.;
RT   "Evidence that the newly cloned low-density-lipoprotein receptor
RT   related protein (LRP) is the alpha 2-macroglobulin receptor.";
RL   FEBS Lett. 276:151-155(1990).
RN   [12]
RP   FUNCTION AS A RECEPTOR FOR P.AERUGINOSA EXOA TOXIN.
RX   PubMed=1618748;
RA   Kounnas M.Z., Morris R.E., Thompson M.R., FitzGerald D.J.,
RA   Strickland D.K., Saelinger C.B.;
RT   "The alpha 2-macroglobulin receptor/low density lipoprotein receptor-
RT   related protein binds and internalizes Pseudomonas exotoxin A.";
RL   J. Biol. Chem. 267:12420-12423(1992).
RN   [13]
RP   INTERACTION WITH GULP1, AND MUTAGENESIS OF ASN-4470 AND ASN-4504.
RX   PubMed=11729193; DOI=10.1074/jbc.M109336200;
RA   Su H.P., Nakada-Tsukui K., Tosello-Trampont A.-C., Li Y., Bu G.,
RA   Henson P.M., Ravichandran K.S.;
RT   "Interaction of CED-6/GULP, an adapter protein involved in engulfment
RT   of apoptotic cells with CED-1 and CD91/low density lipoprotein
RT   receptor-related protein (LRP).";
RL   J. Biol. Chem. 277:11772-11779(2002).
RN   [14]
RP   PHOSPHORYLATION AT TYR-4507, MUTAGENESIS OF 4470-ASN--TYR-4473 AND
RP   4504-ASN--TYR-4507, AND INTERACTION WITH PDGF.
RX   PubMed=11854294; DOI=10.1074/jbc.M200427200;
RA   Loukinova E., Ranganathan S., Kuznetsov S., Gorlatova N.,
RA   Migliorini M.M., Loukinov D., Ulery P.G., Mikhailenko I.,
RA   Lawrence D.A., Strickland D.K.;
RT   "Platelet-derived growth factor (PDGF)-induced tyrosine
RT   phosphorylation of the low density lipoprotein receptor-related
RT   protein (LRP). Evidence for integrated co-receptor function between
RT   LRP and the PDGF.";
RL   J. Biol. Chem. 277:15499-15506(2002).
RN   [15]
RP   FUNCTION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=11907044; DOI=10.1074/jbc.M201979200;
RA   May P., Reddy Y.K., Herz J.;
RT   "Proteolytic processing of low density lipoprotein receptor-related
RT   protein mediates regulated release of its intracellular domain.";
RL   J. Biol. Chem. 277:18736-18743(2002).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12888553; DOI=10.1074/jbc.M306403200;
RA   Kinoshita A., Shah T., Tangredi M.M., Strickland D.K., Hyman B.T.;
RT   "The intracellular domain of the low density lipoprotein receptor-
RT   related protein modulates transactivation mediated by amyloid
RT   precursor protein and Fe65.";
RL   J. Biol. Chem. 278:41182-41188(2003).
RN   [17]
RP   FUNCTION.
RX   PubMed=12713657; DOI=10.1034/j.1600-0854.2003.00086_4_5.x;
RA   May P., Herz J.;
RT   "LDL receptor-related proteins in neurodevelopment.";
RL   Traffic 4:291-301(2003).
RN   [18]
RP   PHOSPHORYLATION AT THR-4460; SER-4517; SER-4520 AND SER-4523,
RP   MUTAGENESIS OF THR-4460; THR-4472; SER-4517; SER-4520 AND SER-4523,
RP   AND INTERACTION WITH SHC1; GULP1 AND DAB1.
RX   PubMed=15272003; DOI=10.1074/jbc.M407592200;
RA   Ranganathan S., Liu C.-X., Migliorini M.M., Von Arnim C.A.F.,
RA   Peltan I.D., Mikhailenko I., Hyman B.T., Strickland D.K.;
RT   "Serine and threonine phosphorylation of the low density lipoprotein
RT   receptor-related protein by protein kinase Calpha regulates
RT   endocytosis and association with adaptor molecules.";
RL   J. Biol. Chem. 279:40536-40544(2004).
RN   [19]
RP   INTERACTION WITH SNX17.
RX   PubMed=15769472; DOI=10.1016/j.jmb.2005.02.004;
RA   Knauth P., Schlueter T., Czubayko M., Kirsch C., Florian V.,
RA   Schreckenberger S., Hahn H., Bohnensack R.;
RT   "Functions of sorting nexin 17 domains and recognition motif for P-
RT   selectin trafficking.";
RL   J. Mol. Biol. 347:813-825(2005).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-446; ASN-729; ASN-2127 AND
RP   ASN-3048.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [21]
RP   IDENTIFICATION IN A COMPLEX WITH CUBN AND PID1, AND INTERACTION WITH
RP   CUBN AND PID1.
RX   PubMed=17124247; DOI=10.1074/mcp.M600289-MCP200;
RA   Caratu G., Allegra D., Bimonte M., Schiattarella G.G., D'Ambrosio C.,
RA   Scaloni A., Napolitano M., Russo T., Zambrano N.;
RT   "Identification of the ligands of protein interaction domains through
RT   a functional approach.";
RL   Mol. Cell. Proteomics 6:333-345(2007).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-446; ASN-729; ASN-1511;
RP   ASN-1575; ASN-1616; ASN-1645; ASN-1763; ASN-2127; ASN-2815; ASN-3048;
RP   ASN-3089; ASN-3488; ASN-3788; ASN-3953; ASN-4075 AND ASN-4125.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   GLYCOSYLATION AT ASN-729 AND ASN-1511.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4520, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   STRUCTURE BY NMR OF 1059-1100 IN COMPLEX WITH CALCIUM IONS, AND
RP   DISULFIDE BONDS.
RX   PubMed=10318830; DOI=10.1074/jbc.274.20.14130;
RA   Huang W., Dolmer K., Gettins P.G.W.;
RT   "NMR solution structure of complement-like repeat CR8 from the low
RT   density lipoprotein receptor-related protein.";
RL   J. Biol. Chem. 274:14130-14136(1999).
RN   [27]
RP   STRUCTURE BY NMR OF 851-893 IN COMPLEX WITH CALCIUM IONS, AND
RP   DISULFIDE BONDS.
RX   PubMed=10652313; DOI=10.1074/jbc.275.5.3264;
RA   Dolmer K., Huang W., Gettins P.G.W.;
RT   "NMR solution structure of complement-like repeat CR3 from the low
RT   density lipoprotein receptor-related protein. Evidence for specific
RT   binding to the receptor binding domain of human alpha(2)-
RT   macroglobulin.";
RL   J. Biol. Chem. 275:3264-3269(2000).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1012-1054 IN COMPLEX WITH
RP   CALCIUM IONS, AND DISULFIDE BONDS.
RX   PubMed=11735395; DOI=10.1021/bi015688m;
RA   Simonovic M., Dolmer K., Huang W., Strickland D.K., Volz K.,
RA   Gettins P.G.;
RT   "Calcium coordination and pH dependence of the calcium affinity of
RT   ligand-binding repeat CR7 from the LRP. Comparison with related
RT   domains from the LRP and the LDL receptor.";
RL   Biochemistry 40:15127-15134(2001).
RN   [29]
RP   STRUCTURE BY NMR OF 932-1013 IN COMPLEX WITH LRPAP1 AND CALCIUM IONS,
RP   AND DISULFIDE BONDS.
RX   PubMed=16938309; DOI=10.1016/j.jmb.2006.07.013;
RA   Jensen G.A., Andersen O.M.J.J., Bonvin A.M., Bjerrum-Bohr I.,
RA   Etzerodt M., Thoegersen H.C., O'Shea C., Poulsen F.M., Kragelund B.B.;
RT   "Binding site structure of one LRP-RAP complex: implications for a
RT   common ligand-receptor binding motif.";
RL   J. Mol. Biol. 362:700-716(2006).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-869 AND HIS-3760.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [31]
RP   VARIANT GLN-3258.
RX   PubMed=23033978; DOI=10.1056/NEJMoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P.,
RA   Gilissen C., del Rosario M., Hoischen A., Scheffer H., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
CC   -!- FUNCTION: Endocytic receptor involved in endocytosis and in
CC       phagocytosis of apoptotic cells. Required for early embryonic
CC       development. Involved in cellular lipid homeostasis. Involved in
CC       the plasma clearance of chylomicron remnants and activated LRPAP1
CC       (alpha 2-macroglobulin), as well as the local metabolism of
CC       complexes between plasminogen activators and their endogenous
CC       inhibitors. May modulate cellular events, such as APP metabolism,
CC       kinase-dependent intracellular signaling, neuronal calcium
CC       signaling as well as neurotransmission.
CC   -!- FUNCTION: Functions as a receptor for Pseudomonas aeruginosa
CC       exotoxin A.
CC   -!- SUBUNIT: Heterodimer of an 85-kDa membrane-bound carboxyl subunit
CC       and a non-covalently attached 515-kDa N-terminal subunit.
CC       Intracellular domain interacts with MAFB (By similarity). Found in
CC       a complex with PID1/PCLI1, LRP1 and CUBNI. Interacts with SNX17,
CC       PID1/PCLI1, PDGF and CUBN. The intracellular domain interacts with
CC       SHC1, GULP1 and DAB1. Interacts with LRPAP1. Can weakly interact
CC       (via NPXY motif) with DAB2 (via PID domain); the interaction is
CC       enhanced by tyrosine phosphorylation of the NPXY motif. Interacts
CC       with bacterial exotoxins. {ECO:0000250,
CC       ECO:0000269|PubMed:10318830, ECO:0000269|PubMed:10652313,
CC       ECO:0000269|PubMed:11729193, ECO:0000269|PubMed:11735395,
CC       ECO:0000269|PubMed:11854294, ECO:0000269|PubMed:15272003,
CC       ECO:0000269|PubMed:15769472, ECO:0000269|PubMed:16938309,
CC       ECO:0000269|PubMed:17124247}.
CC   -!- INTERACTION:
CC       O00213:APBB1; NbExp=3; IntAct=EBI-1046087, EBI-81694;
CC       Q15485:FCN2; NbExp=2; IntAct=EBI-1046087, EBI-7468784;
CC       Q63722:Jag1 (xeno); NbExp=4; IntAct=EBI-1046087, EBI-4567800;
CC       P11226:MBL2; NbExp=5; IntAct=EBI-1046087, EBI-5325353;
CC       Q03350:Thbs2 (xeno); NbExp=2; IntAct=EBI-1046087, EBI-4567830;
CC   -!- SUBCELLULAR LOCATION: Low-density lipoprotein receptor-related
CC       protein 1 85 kDa subunit: Cell membrane; Single-pass type I
CC       membrane protein. Membrane, coated pit.
CC   -!- SUBCELLULAR LOCATION: Low-density lipoprotein receptor-related
CC       protein 1 515 kDa subunit: Cell membrane; Peripheral membrane
CC       protein; Extracellular side. Membrane, coated pit.
CC   -!- SUBCELLULAR LOCATION: Low-density lipoprotein receptor-related
CC       protein 1 intracellular domain: Cytoplasm. Nucleus. Note=After
CC       cleavage, the intracellular domain (LRPICD) is detected both in
CC       the cytoplasm and in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q07954-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q07954-2; Sequence=VSP_056919, VSP_056920;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Most abundant in liver, brain and lung.
CC   -!- PTM: Cleaved into a 85 kDa membrane-spanning subunit (LRP-85) and
CC       a 515 kDa large extracellular domain (LRP-515) that remains non-
CC       covalently associated. Gamma-secretase-dependent cleavage of LRP-
CC       85 releases the intracellular domain from the membrane.
CC       {ECO:0000269|PubMed:11907044, ECO:0000269|PubMed:2112085}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- PTM: Phosphorylated on serine and threonine residues.
CC   -!- PTM: Phosphorylated on tyrosine residues upon stimulation with
CC       PDGF. Tyrosine phosphorylation promotes interaction with SHC1.
CC   -!- SIMILARITY: Belongs to the LDLR family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 22 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 31 LDL-receptor class A domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00124}.
CC   -!- SIMILARITY: Contains 34 LDL-receptor class B repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00461}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13916; CAA32112.1; -; mRNA.
DR   EMBL; AF058427; AAC64265.1; -; Genomic_DNA.
DR   EMBL; DQ314873; ABC40732.1; -; Genomic_DNA.
DR   EMBL; AC023237; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137628; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137834; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC045107; AAH45107.1; -; mRNA.
DR   EMBL; X15424; CAA33464.1; -; Genomic_DNA.
DR   EMBL; Y18524; CAD57169.1; -; Genomic_DNA.
DR   CCDS; CCDS8932.1; -. [Q07954-1]
DR   PIR; S02392; S02392.
DR   RefSeq; NP_002323.2; NM_002332.2. [Q07954-1]
DR   UniGene; Hs.162757; -.
DR   PDB; 1CR8; NMR; -; A=1059-1100.
DR   PDB; 1D2L; NMR; -; A=851-893.
DR   PDB; 1J8E; X-ray; 1.85 A; A=1011-1054.
DR   PDB; 2FYJ; NMR; -; A=932-1013.
DR   PDB; 2FYL; NMR; -; B=932-1013.
DR   PDB; 2KNX; NMR; -; A=2770-2817.
DR   PDB; 2KNY; NMR; -; A=2770-2817.
DR   PDBsum; 1CR8; -.
DR   PDBsum; 1D2L; -.
DR   PDBsum; 1J8E; -.
DR   PDBsum; 2FYJ; -.
DR   PDBsum; 2FYL; -.
DR   PDBsum; 2KNX; -.
DR   PDBsum; 2KNY; -.
DR   ProteinModelPortal; Q07954; -.
DR   SMR; Q07954; 851-893, 932-1054, 1059-1100, 2770-2815.
DR   BioGrid; 110215; 106.
DR   DIP; DIP-50613N; -.
DR   IntAct; Q07954; 23.
DR   MINT; MINT-5004471; -.
DR   STRING; 9606.ENSP00000243077; -.
DR   DrugBank; DB00025; Antihemophilic Factor (Recombinant).
DR   DrugBank; DB00100; Coagulation Factor IX.
DR   DrugBank; DB00031; Tenecteplase.
DR   iPTMnet; Q07954; -.
DR   PhosphoSite; Q07954; -.
DR   BioMuta; LRP1; -.
DR   DMDM; 317373384; -.
DR   MaxQB; Q07954; -.
DR   PaxDb; Q07954; -.
DR   PRIDE; Q07954; -.
DR   Ensembl; ENST00000243077; ENSP00000243077; ENSG00000123384. [Q07954-1]
DR   Ensembl; ENST00000338962; ENSP00000341264; ENSG00000123384. [Q07954-2]
DR   GeneID; 4035; -.
DR   KEGG; hsa:4035; -.
DR   UCSC; uc001snd.3; human. [Q07954-1]
DR   UCSC; uc010sre.2; human.
DR   CTD; 4035; -.
DR   GeneCards; LRP1; -.
DR   HGNC; HGNC:6692; LRP1.
DR   HPA; CAB018621; -.
DR   HPA; HPA004182; -.
DR   HPA; HPA022903; -.
DR   MIM; 107770; gene.
DR   neXtProt; NX_Q07954; -.
DR   PharmGKB; PA233; -.
DR   eggNOG; KOG1215; Eukaryota.
DR   eggNOG; ENOG410XP34; LUCA.
DR   GeneTree; ENSGT00760000118968; -.
DR   HOGENOM; HOG000230574; -.
DR   HOVERGEN; HBG006292; -.
DR   InParanoid; Q07954; -.
DR   KO; K04550; -.
DR   OMA; AYFEGPR; -.
DR   OrthoDB; EOG790FZT; -.
DR   PhylomeDB; Q07954; -.
DR   TreeFam; TF315253; -.
DR   Reactome; R-HSA-2168880; Scavenging of heme from plasma.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   ChiTaRS; LRP1; human.
DR   EvolutionaryTrace; Q07954; -.
DR   GeneWiki; LRP1; -.
DR   GenomeRNAi; 4035; -.
DR   NextBio; 15806; -.
DR   PRO; PR:Q07954; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; Q07954; -.
DR   CleanEx; HS_LRP1; -.
DR   ExpressionAtlas; Q07954; baseline and differential.
DR   Genevisible; Q07954; HS.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IEA:Ensembl.
DR   GO; GO:0005905; C:coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0034185; F:apolipoprotein binding; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0070325; F:lipoprotein particle receptor binding; IC:BHF-UCL.
DR   GO; GO:0042954; F:lipoprotein transporter activity; NAS:UniProtKB.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0032403; F:protein complex binding; IDA:BHF-UCL.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0043277; P:apoptotic cell clearance; ISS:BHF-UCL.
DR   GO; GO:0097242; P:beta-amyloid clearance; TAS:BHF-UCL.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IEA:Ensembl.
DR   GO; GO:0042953; P:lipoprotein transport; NAS:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:2000587; P:negative regulation of platelet-derived growth factor receptor-beta signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; ISS:BHF-UCL.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; ISS:BHF-UCL.
DR   GO; GO:0032370; P:positive regulation of lipid transport; ISS:BHF-UCL.
DR   GO; GO:0051222; P:positive regulation of protein transport; IEA:Ensembl.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL.
DR   GO; GO:0032374; P:regulation of cholesterol transport; ISS:BHF-UCL.
DR   GO; GO:0032429; P:regulation of phospholipase A2 activity; ISS:BHF-UCL.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   Gene3D; 2.120.10.30; -; 8.
DR   Gene3D; 4.10.400.10; -; 29.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR026823; cEGF.
DR   InterPro; IPR032485; DUF5050.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   Pfam; PF12662; cEGF; 1.
DR   Pfam; PF16472; DUF5050; 1.
DR   Pfam; PF07645; EGF_CA; 2.
DR   Pfam; PF00057; Ldl_recept_a; 29.
DR   Pfam; PF00058; Ldl_recept_b; 12.
DR   PRINTS; PR00261; LDLRECEPTOR.
DR   SMART; SM00181; EGF; 18.
DR   SMART; SM00179; EGF_CA; 3.
DR   SMART; SM00192; LDLa; 31.
DR   SMART; SM00135; LY; 35.
DR   SUPFAM; SSF57184; SSF57184; 9.
DR   SUPFAM; SSF57424; SSF57424; 30.
DR   PROSITE; PS00010; ASX_HYDROXYL; 3.
DR   PROSITE; PS00022; EGF_1; 5.
DR   PROSITE; PS01186; EGF_2; 8.
DR   PROSITE; PS50026; EGF_3; 6.
DR   PROSITE; PS01187; EGF_CA; 2.
DR   PROSITE; PS01209; LDLRA_1; 27.
DR   PROSITE; PS50068; LDLRA_2; 31.
DR   PROSITE; PS51120; LDLRB; 34.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Calcium;
KW   Cell membrane; Coated pit; Complete proteome; Cytoplasm;
KW   Developmental protein; Direct protein sequencing; Disulfide bond;
KW   EGF-like domain; Endocytosis; Glycoprotein; Membrane; Metal-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20   4544       Prolow-density lipoprotein receptor-
FT                                related protein 1.
FT                                /FTId=PRO_0000017317.
FT   CHAIN        20  ?3943       Low-density lipoprotein receptor-related
FT                                protein 1 515 kDa subunit.
FT                                /FTId=PRO_0000302750.
FT   CHAIN     ?3944   4544       Low-density lipoprotein receptor-related
FT                                protein 1 85 kDa subunit.
FT                                /FTId=PRO_0000302751.
FT   CHAIN     ?4441   4544       Low-density lipoprotein receptor-related
FT                                protein 1 intracellular domain.
FT                                /FTId=PRO_0000302752.
FT   TOPO_DOM     20   4419       Extracellular. {ECO:0000255}.
FT   TRANSMEM   4420   4444       Helical. {ECO:0000255}.
FT   TOPO_DOM   4445   4544       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25     66       LDL-receptor class A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN       70    110       LDL-receptor class A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      111    149       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      150    189       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   REPEAT      292    334       LDL-receptor class B 1.
FT   REPEAT      335    378       LDL-receptor class B 2.
FT   REPEAT      379    422       LDL-receptor class B 3.
FT   DOMAIN      474    520       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT      571    613       LDL-receptor class B 4.
FT   REPEAT      614    659       LDL-receptor class B 5.
FT   REPEAT      660    710       LDL-receptor class B 6.
FT   REPEAT      711    754       LDL-receptor class B 7.
FT   DOMAIN      803    843       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      852    892       LDL-receptor class A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      893    933       LDL-receptor class A 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      934    973       LDL-receptor class A 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      974   1013       LDL-receptor class A 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1013   1053       LDL-receptor class A 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1060   1099       LDL-receptor class A 8.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1102   1142       LDL-receptor class A 9.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1143   1182       LDL-receptor class A 10.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1183   1222       EGF-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1223   1262       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1309   1355       LDL-receptor class B 8.
FT   REPEAT     1356   1398       LDL-receptor class B 9.
FT   REPEAT     1399   1445       LDL-receptor class B 10.
FT   REPEAT     1446   1490       LDL-receptor class B 11.
FT   REPEAT     1491   1531       LDL-receptor class B 12.
FT   DOMAIN     1536   1579       EGF-like 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1627   1669       LDL-receptor class B 13.
FT   REPEAT     1670   1713       LDL-receptor class B 14.
FT   REPEAT     1714   1753       LDL-receptor class B 15.
FT   REPEAT     1754   1798       LDL-receptor class B 16.
FT   DOMAIN     1846   1887       EGF-like 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1934   1976       LDL-receptor class B 17.
FT   REPEAT     1977   2019       LDL-receptor class B 18.
FT   REPEAT     2020   2063       LDL-receptor class B 19.
FT   REPEAT     2064   2107       LDL-receptor class B 20.
FT   DOMAIN     2155   2195       EGF-like 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     2253   2294       LDL-receptor class B 21.
FT   REPEAT     2295   2343       LDL-receptor class B 22.
FT   REPEAT     2344   2388       LDL-receptor class B 23.
FT   REPEAT     2389   2431       LDL-receptor class B 24.
FT   REPEAT     2432   2473       LDL-receptor class B 25.
FT   DOMAIN     2478   2518       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     2522   2563       LDL-receptor class A 11.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2564   2602       LDL-receptor class A 12.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2603   2641       LDL-receptor class A 13.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2642   2690       LDL-receptor class A 14.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2694   2732       LDL-receptor class A 15.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2732   2771       LDL-receptor class A 16.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2772   2814       LDL-receptor class A 17.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2816   2855       LDL-receptor class A 18.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2856   2899       LDL-receptor class A 19.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2902   2940       LDL-receptor class A 20.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     2941   2981       EGF-like 11. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     2982   3022       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   REPEAT     3069   3113       LDL-receptor class B 26.
FT   REPEAT     3114   3156       LDL-receptor class B 27.
FT   REPEAT     3157   3200       LDL-receptor class B 28.
FT   REPEAT     3201   3243       LDL-receptor class B 29.
FT   REPEAT     3244   3284       LDL-receptor class B 30.
FT   DOMAIN     3290   3331       EGF-like 13. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     3332   3371       LDL-receptor class A 21.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3372   3410       LDL-receptor class A 22.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3411   3450       LDL-receptor class A 23.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3451   3491       LDL-receptor class A 24.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3492   3533       LDL-receptor class A 25.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3534   3572       LDL-receptor class A 26.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3573   3611       LDL-receptor class A 27.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3611   3649       LDL-receptor class A 28.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3652   3692       LDL-receptor class A 29.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3693   3733       LDL-receptor class A 30.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3739   3778       LDL-receptor class A 31.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     3781   3823       EGF-like 14. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     3824   3861       EGF-like 15. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     3912   3954       LDL-receptor class B 31.
FT   REPEAT     3970   4012       LDL-receptor class B 32.
FT   REPEAT     4013   4056       LDL-receptor class B 33.
FT   REPEAT     4057   4101       LDL-receptor class B 34.
FT   DOMAIN     4147   4183       EGF-like 16. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4196   4232       EGF-like 17. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4232   4268       EGF-like 18. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4268   4304       EGF-like 19. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4304   4340       EGF-like 20. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4340   4375       EGF-like 21. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     4373   4409       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REGION     4445   4544       Interaction with MAFB. {ECO:0000250}.
FT   MOTIF      3940   3943       Recognition site for proteolytical
FT                                processing. {ECO:0000255}.
FT   MOTIF      4502   4507       NPXY motif.
FT   METAL       871    871       Calcium 1; via carbonyl oxygen.
FT   METAL       874    874       Calcium 1.
FT   METAL       876    876       Calcium 1; via carbonyl oxygen.
FT   METAL       878    878       Calcium 1.
FT   METAL       884    884       Calcium 1.
FT   METAL       885    885       Calcium 1.
FT   METAL      1032   1032       Calcium 2; via carbonyl oxygen.
FT   METAL      1035   1035       Calcium 2.
FT   METAL      1037   1037       Calcium 2; via carbonyl oxygen.
FT   METAL      1039   1039       Calcium 2.
FT   METAL      1045   1045       Calcium 2.
FT   METAL      1046   1046       Calcium 2.
FT   METAL      1080   1080       Calcium 3; via carbonyl oxygen.
FT   METAL      1083   1083       Calcium 3.
FT   METAL      1085   1085       Calcium 3; via carbonyl oxygen.
FT   METAL      1087   1087       Calcium 3.
FT   METAL      1093   1093       Calcium 3.
FT   METAL      1094   1094       Calcium 3.
FT   MOD_RES    2009   2009       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q91ZX7}.
FT   MOD_RES    4460   4460       Phosphothreonine.
FT                                {ECO:0000305|PubMed:15272003}.
FT   MOD_RES    4507   4507       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:11854294}.
FT   MOD_RES    4517   4517       Phosphoserine.
FT                                {ECO:0000305|PubMed:15272003}.
FT   MOD_RES    4520   4520       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    4523   4523       Phosphoserine.
FT                                {ECO:0000305|PubMed:15272003}.
FT   CARBOHYD    114    114       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    136    136       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    185    185       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    239    239       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    274    274       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    357    357       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    446    446       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    729    729       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    928    928       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1050   1050       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1154   1154       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1155   1155       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1195   1195       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1218   1218       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1511   1511       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1558   1558       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1575   1575       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1616   1616       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1645   1645       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1723   1723       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1733   1733       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1763   1763       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1825   1825       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1933   1933       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1995   1995       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2048   2048       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2117   2117       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2127   2127       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2472   2472       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2502   2502       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2521   2521       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2539   2539       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2601   2601       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2620   2620       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2638   2638       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2815   2815       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2905   2905       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3048   3048       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3089   3089       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3264   3264       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3333   3333       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3488   3488       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3662   3662       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3788   3788       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   3839   3839       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3953   3953       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   4075   4075       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   4125   4125       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   4179   4179       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4278   4278       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4279   4279       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   4364   4364       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     27     40       {ECO:0000250}.
FT   DISULFID     34     53       {ECO:0000250}.
FT   DISULFID     47     64       {ECO:0000250}.
FT   DISULFID     72     85       {ECO:0000250}.
FT   DISULFID     79     98       {ECO:0000250}.
FT   DISULFID     92    108       {ECO:0000250}.
FT   DISULFID    115    124       {ECO:0000250}.
FT   DISULFID    120    133       {ECO:0000250}.
FT   DISULFID    135    148       {ECO:0000250}.
FT   DISULFID    154    164       {ECO:0000250}.
FT   DISULFID    160    173       {ECO:0000250}.
FT   DISULFID    175    188       {ECO:0000250}.
FT   DISULFID    478    493       {ECO:0000250}.
FT   DISULFID    489    504       {ECO:0000250}.
FT   DISULFID    506    519       {ECO:0000250}.
FT   DISULFID    807    818       {ECO:0000250}.
FT   DISULFID    814    827       {ECO:0000250}.
FT   DISULFID    829    842       {ECO:0000250}.
FT   DISULFID    854    866
FT   DISULFID    861    879
FT   DISULFID    873    890
FT   DISULFID    895    907       {ECO:0000250}.
FT   DISULFID    902    920       {ECO:0000250}.
FT   DISULFID    914    931       {ECO:0000250}.
FT   DISULFID    936    948
FT   DISULFID    943    961
FT   DISULFID    955    971
FT   DISULFID    976    989
FT   DISULFID    984   1002
FT   DISULFID    996   1011
FT   DISULFID   1015   1027
FT   DISULFID   1022   1040
FT   DISULFID   1034   1051
FT   DISULFID   1062   1075
FT   DISULFID   1069   1088
FT   DISULFID   1082   1097
FT   DISULFID   1104   1118       {ECO:0000250}.
FT   DISULFID   1112   1131       {ECO:0000250}.
FT   DISULFID   1125   1140       {ECO:0000250}.
FT   DISULFID   1145   1159       {ECO:0000250}.
FT   DISULFID   1152   1172       {ECO:0000250}.
FT   DISULFID   1166   1182       {ECO:0000250}.
FT   DISULFID   1185   1196       {ECO:0000250}.
FT   DISULFID   1192   1206       {ECO:0000250}.
FT   DISULFID   1208   1221       {ECO:0000250}.
FT   DISULFID   1227   1237       {ECO:0000250}.
FT   DISULFID   1233   1246       {ECO:0000250}.
FT   DISULFID   1248   1261       {ECO:0000250}.
FT   DISULFID   1540   1553       {ECO:0000250}.
FT   DISULFID   1549   1563       {ECO:0000250}.
FT   DISULFID   1565   1578       {ECO:0000250}.
FT   DISULFID   1850   1861       {ECO:0000250}.
FT   DISULFID   1857   1871       {ECO:0000250}.
FT   DISULFID   1873   1886       {ECO:0000250}.
FT   DISULFID   2159   2170       {ECO:0000250}.
FT   DISULFID   2166   2180       {ECO:0000250}.
FT   DISULFID   2182   2194       {ECO:0000250}.
FT   DISULFID   2482   2493       {ECO:0000250}.
FT   DISULFID   2489   2503       {ECO:0000250}.
FT   DISULFID   2505   2517       {ECO:0000250}.
FT   DISULFID   2524   2537       {ECO:0000250}.
FT   DISULFID   2532   2550       {ECO:0000250}.
FT   DISULFID   2544   2561       {ECO:0000250}.
FT   DISULFID   2566   2578       {ECO:0000250}.
FT   DISULFID   2573   2591       {ECO:0000250}.
FT   DISULFID   2585   2600       {ECO:0000250}.
FT   DISULFID   2605   2617       {ECO:0000250}.
FT   DISULFID   2612   2630       {ECO:0000250}.
FT   DISULFID   2624   2639       {ECO:0000250}.
FT   DISULFID   2644   2666       {ECO:0000250}.
FT   DISULFID   2660   2679       {ECO:0000250}.
FT   DISULFID   2673   2688       {ECO:0000250}.
FT   DISULFID   2696   2708       {ECO:0000250}.
FT   DISULFID   2703   2721       {ECO:0000250}.
FT   DISULFID   2715   2730       {ECO:0000250}.
FT   DISULFID   2734   2746       {ECO:0000250}.
FT   DISULFID   2741   2759       {ECO:0000250}.
FT   DISULFID   2753   2769       {ECO:0000250}.
FT   DISULFID   2774   2787       {ECO:0000250}.
FT   DISULFID   2781   2800       {ECO:0000250}.
FT   DISULFID   2794   2812       {ECO:0000250}.
FT   DISULFID   2818   2830       {ECO:0000250}.
FT   DISULFID   2825   2843       {ECO:0000250}.
FT   DISULFID   2837   2853       {ECO:0000250}.
FT   DISULFID   2858   2870       {ECO:0000250}.
FT   DISULFID   2865   2884       {ECO:0000250}.
FT   DISULFID   2878   2897       {ECO:0000250}.
FT   DISULFID   2904   2917       {ECO:0000250}.
FT   DISULFID   2912   2930       {ECO:0000250}.
FT   DISULFID   2924   2939       {ECO:0000250}.
FT   DISULFID   2944   2956       {ECO:0000250}.
FT   DISULFID   2952   2965       {ECO:0000250}.
FT   DISULFID   2967   2980       {ECO:0000250}.
FT   DISULFID   2986   2996       {ECO:0000250}.
FT   DISULFID   2992   3005       {ECO:0000250}.
FT   DISULFID   3007   3021       {ECO:0000250}.
FT   DISULFID   3294   3305       {ECO:0000250}.
FT   DISULFID   3301   3315       {ECO:0000250}.
FT   DISULFID   3317   3330       {ECO:0000250}.
FT   DISULFID   3334   3346       {ECO:0000250}.
FT   DISULFID   3341   3359       {ECO:0000250}.
FT   DISULFID   3353   3369       {ECO:0000250}.
FT   DISULFID   3374   3386       {ECO:0000250}.
FT   DISULFID   3381   3399       {ECO:0000250}.
FT   DISULFID   3393   3408       {ECO:0000250}.
FT   DISULFID   3413   3426       {ECO:0000250}.
FT   DISULFID   3420   3439       {ECO:0000250}.
FT   DISULFID   3433   3448       {ECO:0000250}.
FT   DISULFID   3453   3466       {ECO:0000250}.
FT   DISULFID   3460   3479       {ECO:0000250}.
FT   DISULFID   3473   3489       {ECO:0000250}.
FT   DISULFID   3494   3507       {ECO:0000250}.
FT   DISULFID   3501   3520       {ECO:0000250}.
FT   DISULFID   3514   3531       {ECO:0000250}.
FT   DISULFID   3536   3548       {ECO:0000250}.
FT   DISULFID   3543   3561       {ECO:0000250}.
FT   DISULFID   3555   3570       {ECO:0000250}.
FT   DISULFID   3575   3587       {ECO:0000250}.
FT   DISULFID   3582   3600       {ECO:0000250}.
FT   DISULFID   3594   3609       {ECO:0000250}.
FT   DISULFID   3613   3625       {ECO:0000250}.
FT   DISULFID   3620   3638       {ECO:0000250}.
FT   DISULFID   3632   3647       {ECO:0000250}.
FT   DISULFID   3654   3666       {ECO:0000250}.
FT   DISULFID   3661   3679       {ECO:0000250}.
FT   DISULFID   3673   3690       {ECO:0000250}.
FT   DISULFID   3695   3709       {ECO:0000250}.
FT   DISULFID   3703   3722       {ECO:0000250}.
FT   DISULFID   3716   3731       {ECO:0000250}.
FT   DISULFID   3741   3754       {ECO:0000250}.
FT   DISULFID   3749   3767       {ECO:0000250}.
FT   DISULFID   3761   3776       {ECO:0000250}.
FT   DISULFID   3785   3798       {ECO:0000250}.
FT   DISULFID   3792   3807       {ECO:0000250}.
FT   DISULFID   3809   3822       {ECO:0000250}.
FT   DISULFID   3828   3838       {ECO:0000250}.
FT   DISULFID   3834   3847       {ECO:0000250}.
FT   DISULFID   3849   3860       {ECO:0000250}.
FT   DISULFID   4151   4160       {ECO:0000250}.
FT   DISULFID   4156   4169       {ECO:0000250}.
FT   DISULFID   4171   4182       {ECO:0000250}.
FT   DISULFID   4200   4210       {ECO:0000250}.
FT   DISULFID   4204   4220       {ECO:0000250}.
FT   DISULFID   4222   4231       {ECO:0000250}.
FT   DISULFID   4236   4246       {ECO:0000250}.
FT   DISULFID   4240   4256       {ECO:0000250}.
FT   DISULFID   4258   4267       {ECO:0000250}.
FT   DISULFID   4272   4282       {ECO:0000250}.
FT   DISULFID   4276   4292       {ECO:0000250}.
FT   DISULFID   4294   4303       {ECO:0000250}.
FT   DISULFID   4308   4318       {ECO:0000250}.
FT   DISULFID   4312   4328       {ECO:0000250}.
FT   DISULFID   4330   4339       {ECO:0000250}.
FT   DISULFID   4344   4352       {ECO:0000250}.
FT   DISULFID   4347   4363       {ECO:0000250}.
FT   DISULFID   4365   4374       {ECO:0000250}.
FT   DISULFID   4377   4387       {ECO:0000250}.
FT   DISULFID   4381   4397       {ECO:0000250}.
FT   DISULFID   4399   4408       {ECO:0000250}.
FT   VAR_SEQ     281    292       HVEQMAIDWLTG -> LCVFSKSQQEMG (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056919.
FT   VAR_SEQ     293   4544       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056920.
FT   VARIANT     166    166       N -> D (in dbSNP:rs2306691).
FT                                /FTId=VAR_021885.
FT   VARIANT     217    217       A -> V (in dbSNP:rs1800127).
FT                                /FTId=VAR_014725.
FT   VARIANT     869    869       E -> K (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035994.
FT   VARIANT    2059   2059       V -> L (in dbSNP:rs2229278).
FT                                /FTId=VAR_029181.
FT   VARIANT    2080   2080       D -> N (in dbSNP:rs34577247).
FT                                /FTId=VAR_047525.
FT   VARIANT    2900   2900       Q -> P (in dbSNP:rs7397167).
FT                                {ECO:0000269|PubMed:3266596,
FT                                ECO:0000269|PubMed:9782078,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_047526.
FT   VARIANT    3258   3258       H -> Q (found in a patient with severe
FT                                mental retardation, seizures, stereotypic
FT                                behavior, high pain threshold and sleep
FT                                disturbances).
FT                                {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069388.
FT   VARIANT    3760   3760       R -> H (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035995.
FT   VARIANT    4536   4536       E -> G (in dbSNP:rs17357542).
FT                                /FTId=VAR_047527.
FT   MUTAGEN    4460   4460       T->A: Strongly reduced phosphorylation
FT                                and loss of interaction with SHC1; when
FT                                associated with A-4517; A-4520 and A-
FT                                4523. {ECO:0000269|PubMed:15272003}.
FT   MUTAGEN    4470   4473       NPTY->APTA: No effect on tyrosine
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:11854294}.
FT   MUTAGEN    4470   4470       N->A: No effect on interaction with
FT                                GULP1. {ECO:0000269|PubMed:11729193}.
FT   MUTAGEN    4472   4472       T->A: No detectable effect on
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:15272003}.
FT   MUTAGEN    4504   4507       NPVY->APVA: Loss of tyrosine
FT                                phosphorylation. Abolishes interaction
FT                                with SHC1 and GULP1.
FT                                {ECO:0000269|PubMed:11854294}.
FT   MUTAGEN    4504   4504       N->A: Loss of interaction with GULP1.
FT                                {ECO:0000269|PubMed:11729193}.
FT   MUTAGEN    4517   4517       S->A: Strongly reduced phosphorylation
FT                                and loss of interaction with SHC1; when
FT                                associated with A-4460; A-4520 and A-
FT                                4523. {ECO:0000269|PubMed:15272003}.
FT   MUTAGEN    4520   4520       S->A: Strongly reduced phosphorylation
FT                                and loss of interaction with SHC1; when
FT                                associated with A-4460; A-4517 and A-
FT                                4523. {ECO:0000269|PubMed:15272003}.
FT   MUTAGEN    4523   4523       S->A: Strongly reduced phosphorylation
FT                                and loss of interaction with SHC1; when
FT                                associated with A-4460; A-4517 and A-
FT                                4520. {ECO:0000269|PubMed:15272003}.
FT   CONFLICT    685    685       D -> G (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1743   1743       G -> S (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   2871   2872       LS -> IA (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   3036   3036       R -> M (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   TURN        853    857       {ECO:0000244|PDB:1D2L}.
FT   STRAND      859    861       {ECO:0000244|PDB:1D2L}.
FT   TURN        862    864       {ECO:0000244|PDB:1D2L}.
FT   STRAND      865    867       {ECO:0000244|PDB:1D2L}.
FT   HELIX       869    871       {ECO:0000244|PDB:1D2L}.
FT   STRAND      874    876       {ECO:0000244|PDB:1D2L}.
FT   TURN        878    881       {ECO:0000244|PDB:1D2L}.
FT   STRAND      934    936       {ECO:0000244|PDB:2FYJ}.
FT   STRAND      940    942       {ECO:0000244|PDB:2FYJ}.
FT   TURN        944    946       {ECO:0000244|PDB:2FYL}.
FT   STRAND      948    950       {ECO:0000244|PDB:2FYJ}.
FT   STRAND      953    956       {ECO:0000244|PDB:2FYJ}.
FT   STRAND      958    961       {ECO:0000244|PDB:2FYJ}.
FT   TURN        964    968       {ECO:0000244|PDB:2FYJ}.
FT   TURN        969    971       {ECO:0000244|PDB:2FYL}.
FT   STRAND      974    976       {ECO:0000244|PDB:2FYJ}.
FT   STRAND      978    983       {ECO:0000244|PDB:2FYJ}.
FT   TURN        985    987       {ECO:0000244|PDB:2FYL}.
FT   STRAND      989    991       {ECO:0000244|PDB:2FYJ}.
FT   STRAND      995   1000       {ECO:0000244|PDB:2FYJ}.
FT   STRAND     1003   1007       {ECO:0000244|PDB:2FYJ}.
FT   STRAND     1009   1011       {ECO:0000244|PDB:2FYL}.
FT   STRAND     1013   1015       {ECO:0000244|PDB:1J8E}.
FT   STRAND     1019   1021       {ECO:0000244|PDB:1J8E}.
FT   STRAND     1027   1029       {ECO:0000244|PDB:1J8E}.
FT   HELIX      1030   1032       {ECO:0000244|PDB:1J8E}.
FT   STRAND     1035   1037       {ECO:0000244|PDB:1J8E}.
FT   STRAND     1040   1043       {ECO:0000244|PDB:1J8E}.
FT   HELIX      1044   1046       {ECO:0000244|PDB:1J8E}.
FT   HELIX      1048   1051       {ECO:0000244|PDB:1J8E}.
FT   TURN       1070   1072       {ECO:0000244|PDB:1CR8}.
FT   HELIX      1078   1080       {ECO:0000244|PDB:1CR8}.
FT   STRAND     1081   1085       {ECO:0000244|PDB:1CR8}.
FT   STRAND     1088   1091       {ECO:0000244|PDB:1CR8}.
FT   TURN       1092   1096       {ECO:0000244|PDB:1CR8}.
FT   STRAND     2778   2781       {ECO:0000244|PDB:2KNX}.
FT   TURN       2782   2785       {ECO:0000244|PDB:2KNX}.
FT   STRAND     2786   2789       {ECO:0000244|PDB:2KNX}.
FT   TURN       2790   2794       {ECO:0000244|PDB:2KNX}.
FT   STRAND     2795   2797       {ECO:0000244|PDB:2KNX}.
FT   STRAND     2800   2803       {ECO:0000244|PDB:2KNY}.
FT   HELIX      2804   2806       {ECO:0000244|PDB:2KNX}.
FT   HELIX      2808   2810       {ECO:0000244|PDB:2KNX}.
FT   STRAND     2813   2816       {ECO:0000244|PDB:2KNY}.
SQ   SEQUENCE   4544 AA;  504606 MW;  5A11CC02FAB127BE CRC64;
     MLTPPLLLLL PLLSALVAAA IDAPKTCSPK QFACRDQITC ISKGWRCDGE RDCPDGSDEA
     PEICPQSKAQ RCQPNEHNCL GTELCVPMSR LCNGVQDCMD GSDEGPHCRE LQGNCSRLGC
     QHHCVPTLDG PTCYCNSSFQ LQADGKTCKD FDECSVYGTC SQLCTNTDGS FICGCVEGYL
     LQPDNRSCKA KNEPVDRPPV LLIANSQNIL ATYLSGAQVS TITPTSTRQT TAMDFSYANE
     TVCWVHVGDS AAQTQLKCAR MPGLKGFVDE HTINISLSLH HVEQMAIDWL TGNFYFVDDI
     DDRIFVCNRN GDTCVTLLDL ELYNPKGIAL DPAMGKVFFT DYGQIPKVER CDMDGQNRTK
     LVDSKIVFPH GITLDLVSRL VYWADAYLDY IEVVDYEGKG RQTIIQGILI EHLYGLTVFE
     NYLYATNSDN ANAQQKTSVI RVNRFNSTEY QVVTRVDKGG ALHIYHQRRQ PRVRSHACEN
     DQYGKPGGCS DICLLANSHK ARTCRCRSGF SLGSDGKSCK KPEHELFLVY GKGRPGIIRG
     MDMGAKVPDE HMIPIENLMN PRALDFHAET GFIYFADTTS YLIGRQKIDG TERETILKDG
     IHNVEGVAVD WMGDNLYWTD DGPKKTISVA RLEKAAQTRK TLIEGKMTHP RAIVVDPLNG
     WMYWTDWEED PKDSRRGRLE RAWMDGSHRD IFVTSKTVLW PNGLSLDIPA GRLYWVDAFY
     DRIETILLNG TDRKIVYEGP ELNHAFGLCH HGNYLFWTEY RSGSVYRLER GVGGAPPTVT
     LLRSERPPIF EIRMYDAQQQ QVGTNKCRVN NGGCSSLCLA TPGSRQCACA EDQVLDADGV
     TCLANPSYVP PPQCQPGEFA CANSRCIQER WKCDGDNDCL DNSDEAPALC HQHTCPSDRF
     KCENNRCIPN RWLCDGDNDC GNSEDESNAT CSARTCPPNQ FSCASGRCIP ISWTCDLDDD
     CGDRSDESAS CAYPTCFPLT QFTCNNGRCI NINWRCDNDN DCGDNSDEAG CSHSCSSTQF
     KCNSGRCIPE HWTCDGDNDC GDYSDETHAN CTNQATRPPG GCHTDEFQCR LDGLCIPLRW
     RCDGDTDCMD SSDEKSCEGV THVCDPSVKF GCKDSARCIS KAWVCDGDND CEDNSDEENC
     ESLACRPPSH PCANNTSVCL PPDKLCDGND DCGDGSDEGE LCDQCSLNNG GCSHNCSVAP
     GEGIVCSCPL GMELGPDNHT CQIQSYCAKH LKCSQKCDQN KFSVKCSCYE GWVLEPDGES
     CRSLDPFKPF IIFSNRHEIR RIDLHKGDYS VLVPGLRNTI ALDFHLSQSA LYWTDVVEDK
     IYRGKLLDNG ALTSFEVVIQ YGLATPEGLA VDWIAGNIYW VESNLDQIEV AKLDGTLRTT
     LLAGDIEHPR AIALDPRDGI LFWTDWDASL PRIEAASMSG AGRRTVHRET GSGGWPNGLT
     VDYLEKRILW IDARSDAIYS ARYDGSGHME VLRGHEFLSH PFAVTLYGGE VYWTDWRTNT
     LAKANKWTGH NVTVVQRTNT QPFDLQVYHP SRQPMAPNPC EANGGQGPCS HLCLINYNRT
     VSCACPHLMK LHKDNTTCYE FKKFLLYARQ MEIRGVDLDA PYYNYIISFT VPDIDNVTVL
     DYDAREQRVY WSDVRTQAIK RAFINGTGVE TVVSADLPNA HGLAVDWVSR NLFWTSYDTN
     KKQINVARLD GSFKNAVVQG LEQPHGLVVH PLRGKLYWTD GDNISMANMD GSNRTLLFSG
     QKGPVGLAID FPESKLYWIS SGNHTINRCN LDGSGLEVID AMRSQLGKAT ALAIMGDKLW
     WADQVSEKMG TCSKADGSGS VVLRNSTTLV MHMKVYDESI QLDHKGTNPC SVNNGDCSQL
     CLPTSETTRS CMCTAGYSLR SGQQACEGVG SFLLYSVHEG IRGIPLDPND KSDALVPVSG
     TSLAVGIDFH AENDTIYWVD MGLSTISRAK RDQTWREDVV TNGIGRVEGI AVDWIAGNIY
     WTDQGFDVIE VARLNGSFRY VVISQGLDKP RAITVHPEKG YLFWTEWGQY PRIERSRLDG
     TERVVLVNVS ISWPNGISVD YQDGKLYWCD ARTDKIERID LETGENREVV LSSNNMDMFS
     VSVFEDFIYW SDRTHANGSI KRGSKDNATD SVPLRTGIGV QLKDIKVFNR DRQKGTNVCA
     VANGGCQQLC LYRGRGQRAC ACAHGMLAED GASCREYAGY LLYSERTILK SIHLSDERNL
     NAPVQPFEDP EHMKNVIALA FDYRAGTSPG TPNRIFFSDI HFGNIQQIND DGSRRITIVE
     NVGSVEGLAY HRGWDTLYWT SYTTSTITRH TVDQTRPGAF ERETVITMSG DDHPRAFVLD
     ECQNLMFWTN WNEQHPSIMR AALSGANVLT LIEKDIRTPN GLAIDHRAEK LYFSDATLDK
     IERCEYDGSH RYVILKSEPV HPFGLAVYGE HIFWTDWVRR AVQRANKHVG SNMKLLRVDI
     PQQPMGIIAV ANDTNSCELS PCRINNGGCQ DLCLLTHQGH VNCSCRGGRI LQDDLTCRAV
     NSSCRAQDEF ECANGECINF SLTCDGVPHC KDKSDEKPSY CNSRRCKKTF RQCSNGRCVS
     NMLWCNGADD CGDGSDEIPC NKTACGVGEF RCRDGTCIGN SSRCNQFVDC EDASDEMNCS
     ATDCSSYFRL GVKGVLFQPC ERTSLCYAPS WVCDGANDCG DYSDERDCPG VKRPRCPLNY
     FACPSGRCIP MSWTCDKEDD CEHGEDETHC NKFCSEAQFE CQNHRCISKQ WLCDGSDDCG
     DGSDEAAHCE GKTCGPSSFS CPGTHVCVPE RWLCDGDKDC ADGADESIAA GCLYNSTCDD
     REFMCQNRQC IPKHFVCDHD RDCADGSDES PECEYPTCGP SEFRCANGRC LSSRQWECDG
     ENDCHDQSDE APKNPHCTSQ EHKCNASSQF LCSSGRCVAE ALLCNGQDDC GDSSDERGCH
     INECLSRKLS GCSQDCEDLK IGFKCRCRPG FRLKDDGRTC ADVDECSTTF PCSQRCINTH
     GSYKCLCVEG YAPRGGDPHS CKAVTDEEPF LIFANRYYLR KLNLDGSNYT LLKQGLNNAV
     ALDFDYREQM IYWTDVTTQG SMIRRMHLNG SNVQVLHRTG LSNPDGLAVD WVGGNLYWCD
     KGRDTIEVSK LNGAYRTVLV SSGLREPRAL VVDVQNGYLY WTDWGDHSLI GRIGMDGSSR
     SVIVDTKITW PNGLTLDYVT ERIYWADARE DYIEFASLDG SNRHVVLSQD IPHIFALTLF
     EDYVYWTDWE TKSINRAHKT TGTNKTLLIS TLHRPMDLHV FHALRQPDVP NHPCKVNNGG
     CSNLCLLSPG GGHKCACPTN FYLGSDGRTC VSNCTASQFV CKNDKCIPFW WKCDTEDDCG
     DHSDEPPDCP EFKCRPGQFQ CSTGICTNPA FICDGDNDCQ DNSDEANCDI HVCLPSQFKC
     TNTNRCIPGI FRCNGQDNCG DGEDERDCPE VTCAPNQFQC SITKRCIPRV WVCDRDNDCV
     DGSDEPANCT QMTCGVDEFR CKDSGRCIPA RWKCDGEDDC GDGSDEPKEE CDERTCEPYQ
     FRCKNNRCVP GRWQCDYDND CGDNSDEESC TPRPCSESEF SCANGRCIAG RWKCDGDHDC
     ADGSDEKDCT PRCDMDQFQC KSGHCIPLRW RCDADADCMD GSDEEACGTG VRTCPLDEFQ
     CNNTLCKPLA WKCDGEDDCG DNSDENPEEC ARFVCPPNRP FRCKNDRVCL WIGRQCDGTD
     NCGDGTDEED CEPPTAHTTH CKDKKEFLCR NQRCLSSSLR CNMFDDCGDG SDEEDCSIDP
     KLTSCATNAS ICGDEARCVR TEKAAYCACR SGFHTVPGQP GCQDINECLR FGTCSQLCNN
     TKGGHLCSCA RNFMKTHNTC KAEGSEYQVL YIADDNEIRS LFPGHPHSAY EQAFQGDESV
     RIDAMDVHVK AGRVYWTNWH TGTISYRSLP PAAPPTTSNR HRRQIDRGVT HLNISGLKMP
     RGIAIDWVAG NVYWTDSGRD VIEVAQMKGE NRKTLISGMI DEPHAIVVDP LRGTMYWSDW
     GNHPKIETAA MDGTLRETLV QDNIQWPTGL AVDYHNERLY WADAKLSVIG SIRLNGTDPI
     VAADSKRGLS HPFSIDVFED YIYGVTYINN RVFKIHKFGH SPLVNLTGGL SHASDVVLYH
     QHKQPEVTNP CDRKKCEWLC LLSPSGPVCT CPNGKRLDNG TCVPVPSPTP PPDAPRPGTC
     NLQCFNGGSC FLNARRQPKC RCQPRYTGDK CELDQCWEHC RNGGTCAASP SGMPTCRCPT
     GFTGPKCTQQ VCAGYCANNS TCTVNQGNQP QCRCLPGFLG DRCQYRQCSG YCENFGTCQM
     AADGSRQCRC TAYFEGSRCE VNKCSRCLEG ACVVNKQSGD VTCNCTDGRV APSCLTCVGH
     CSNGGSCTMN SKMMPECQCP PHMTGPRCEE HVFSQQQPGH IASILIPLLL LLLLVLVAGV
     VFWYKRRVQG AKGFQHQRMT NGAMNVEIGN PTYKMYEGGE PDDVGGLLDA DFALDPDKPT
     NFTNPVYATL YMGGHGSRHS LASTDEKREL LGRGPEDEIG DPLA
//
ID   FGFR4_HUMAN             Reviewed;         802 AA.
AC   P22455; G3JVM2; G3JVM5; G3JVM7; G3JVM9; O43785; Q14309; Q71TW8;
AC   Q8TDA0; Q96KE5;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   27-APR-2001, sequence version 2.
DT   20-JAN-2016, entry version 180.
DE   RecName: Full=Fibroblast growth factor receptor 4;
DE            Short=FGFR-4;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD334;
DE   Flags: Precursor;
GN   Name=FGFR4; Synonyms=JTK2, TKF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1709094;
RA   Partanen J.M., Maekelae T.P., Eerola E., Korhonen J., Hirvonen H.,
RA   Claesson-Welsh L., Alitalo K.;
RT   "FGFR-4, a novel acidic fibroblast growth factor receptor with a
RT   distinct expression pattern.";
RL   EMBO J. 10:1347-1354(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS RECEPTOR FOR
RP   FGF1 AND FGF2.
RC   TISSUE=Mammary gland;
RX   PubMed=7680645;
RA   Ron D., Reich R., Chedid M., Lengel C., Cohen O.E., Chan A.M.,
RA   Neufeld G., Miki T., Tronick S.R.;
RT   "Fibroblast growth factor receptor 4 is a high affinity receptor for
RT   both acidic and basic fibroblast growth factor but not for
RT   keratinocyte growth factor.";
RL   J. Biol. Chem. 268:5388-5394(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT LEU-136, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Intestine;
RX   PubMed=10631118; DOI=10.1006/bbrc.1999.2010;
RA   Takaishi S., Sawada M., Morita Y., Seno H., Fukuzawa H., Chiba T.;
RT   "Identification of a novel alternative splicing of human FGF receptor
RT   4: soluble-form splice variant expressed in human gastrointestinal
RT   epithelial cells.";
RL   Biochem. Biophys. Res. Commun. 267:658-662(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9457674; DOI=10.1007/s003359900703;
RA   Kostrzewa M., Muller U.;
RT   "Genomic structure and complete sequence of the human FGFR4 gene.";
RL   Mamm. Genome 9:131-135(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), SUBCELLULAR LOCATION (ISOFORM
RP   3), AND VARIANT ARG-388.
RC   TISSUE=Pituitary;
RX   PubMed=11781352; DOI=10.1172/JCI14036;
RA   Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.;
RT   "Targeted expression of a human pituitary tumor-derived isoform of FGF
RT   receptor-4 recapitulates pituitary tumorigenesis.";
RL   J. Clin. Invest. 109:69-78(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ILE-10; LEU-136
RP   AND ARG-388.
RX   PubMed=21882254; DOI=10.1002/mc.20848;
RA   Marshall A.D., van der Ent M.A., Grosveld G.C.;
RT   "PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.";
RL   Mol. Carcinog. 51:807-815(2012).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-136.
RA   Lind D.L., Cox D.R.;
RT   "Sequence variation in fibroblast growth factor receptors 3 and 4.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-10; LEU-136 AND
RP   ARG-388.
RG   NIEHS SNPs program;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-136.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 609-676.
RC   TISSUE=Blood;
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [13]
RP   PROTEIN SEQUENCE OF 22-38.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [14]
RP   FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF SIGNALING VIA PLCG1 AND
RP   PIK3R1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-754, AND
RP   MUTAGENESIS OF TYR-754.
RX   PubMed=7518429;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G.,
RA   Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [15]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF6; FGF8 AND FGF9, AND FUNCTION
RP   IN CELL PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [16]
RP   FUNCTION IN CELL DIFFERENTIATION, MUTAGENESIS OF LYS-503, CATALYTIC
RP   ACTIVITY, AND IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1;
RP   FRS2; SRC; SHC; GAP43 AND CTTN.
RX   PubMed=11433297; DOI=10.1038/35083041;
RA   Cavallaro U., Niedermeyer J., Fuxa M., Christofori G.;
RT   "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-
RT   receptor signalling.";
RL   Nat. Cell Biol. 3:650-657(2001).
RN   [17]
RP   INTERACTION WITH FGF1; FGF17; FGF18; FGF19; FGF21 AND FGF23, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [18]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN SIGNALING AND
RP   IN REGULATION OF CYP7A1 AND BILE ACID SYNTHESIS.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [19]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   LYS-503, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [20]
RP   CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF
RP   PLCG1; FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ENZYME REGULATION,
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18480409; DOI=10.1091/mbc.E07-12-1219;
RA   Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.;
RT   "Ubiquitination of fibroblast growth factor receptor 1 is required for
RT   its intracellular sorting but not for its endocytosis.";
RL   Mol. Biol. Cell 19:3390-3403(2008).
RN   [21]
RP   CATALYTIC ACTIVITY, FUNCTION AS FGF2 RECEPTOR AND IN STIMULATION OF
RP   CELL PROLIFERATION, SUBCELLULAR LOCATION, INTERACTION WITH FGF2 AND
RP   HIP1, PHOSPHORYLATION AT TYR-642 AND TYR-643, AND CHARACTERIZATION OF
RP   VARIANT ARG-388.
RX   PubMed=18670643; DOI=10.1593/neo.08450;
RA   Wang J., Yu W., Cai Y., Ren C., Ittmann M.M.;
RT   "Altered fibroblast growth factor receptor 4 stability promotes
RT   prostate cancer progression.";
RL   Neoplasia 10:847-856(2008).
RN   [22]
RP   FUNCTION IN FGF19 SIGNALING AND IN REGULATION OF BILE ACID SYNTHESIS
RP   VIA CYP7A1, INTERACTION WITH FGF19; KL AND KLB, AUTOPHOSPHORYLATION,
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=20683963; DOI=10.1002/hep.23708;
RA   Triantis V., Saeland E., Bijl N., Oude-Elferink R.P., Jansen P.L.;
RT   "Glycosylation of fibroblast growth factor receptor 4 is a key
RT   regulator of fibroblast growth factor 19-mediated down-regulation of
RT   cytochrome P450 7A1.";
RL   Hepatology 52:656-666(2010).
RN   [23]
RP   FUNCTION IN HEPATOCYTE PROLIFERATION AND FGF19 SIGNALING.
RX   PubMed=20018895; DOI=10.1074/jbc.M109.068783;
RA   Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R.,
RA   Gupte J., Hager T., Wang Z., Lindberg R., Li Y.;
RT   "FGF19-induced hepatocyte proliferation is mediated through FGFR4
RT   activation.";
RL   J. Biol. Chem. 285:5165-5170(2010).
RN   [24]
RP   FUNCTION IN DOWN-REGULATION OF MMP14, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH MMP14.
RX   PubMed=20798051; DOI=10.1073/pnas.0914459107;
RA   Sugiyama N., Varjosalo M., Meller P., Lohi J., Chan K.M., Zhou Z.,
RA   Alitalo K., Taipale J., Keski-Oja J., Lehti K.;
RT   "FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a
RT   membrane type 1 matrix metalloproteinase-FGFR4 complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15786-15791(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   FUNCTION IN FGF19 SIGNALING, FUNCTION IN STIMULATION OF CELL
RP   PROLIFERATION AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND
RP   INTERACTION WITH FGF19; KLB AND SULFATED GLYCOSAMINOGLYCANS.
RX   PubMed=21653700; DOI=10.1074/jbc.M111.251140;
RA   Nakamura M., Uehara Y., Asada M., Honda E., Nagai N., Kimata K.,
RA   Suzuki M., Imamura T.;
RT   "Sulfated glycosaminoglycans are required for specific and sensitive
RT   fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and
RT   betaKlotho.";
RL   J. Biol. Chem. 286:26418-26423(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-10; LEU-136; ALA-179; SER-426;
RP   ASN-516; MET-550; THR-712 AND ASN-772.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [29]
RP   REVIEW ON LIGAND SELECTIVITY AND SIGNALING.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [30]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [31]
RP   CHARACTERIZATION OF VARIANT ARG-388, AND FUNCTION IN TUMOR CELL
RP   INVASION.
RX   PubMed=20876804; DOI=10.1158/0008-5472.CAN-10-1223;
RA   Sugiyama N., Varjosalo M., Meller P., Lohi J., Hyytiainen M.,
RA   Kilpinen S., Kallioniemi O., Ingvarsen S., Engelholm L.H., Taipale J.,
RA   Alitalo K., Keski-Oja J., Lehti K.;
RT   "Fibroblast growth factor receptor 4 regulates tumor invasion by
RT   coupling fibroblast growth factor signaling to extracellular matrix
RT   degradation.";
RL   Cancer Res. 70:7851-7861(2010).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays a role in the
CC       regulation of cell proliferation, differentiation and migration,
CC       and in regulation of lipid metabolism, bile acid biosynthesis,
CC       glucose uptake, vitamin D metabolism and phosphate homeostasis.
CC       Required for normal down-regulation of the expression of CYP7A1,
CC       the rate-limiting enzyme in bile acid synthesis, in response to
CC       FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the
CC       activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Promotes SRC-dependent phosphorylation of the matrix
CC       protease MMP14 and its lysosomal degradation. FGFR4 signaling is
CC       down-regulated by receptor internalization and degradation; MMP14
CC       promotes internalization and degradation of FGFR4. Mutations that
CC       lead to constitutive kinase activation or impair normal FGFR4
CC       inactivation lead to aberrant signaling.
CC       {ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:18670643,
CC       ECO:0000269|PubMed:20018895, ECO:0000269|PubMed:20683963,
CC       ECO:0000269|PubMed:20798051, ECO:0000269|PubMed:20876804,
CC       ECO:0000269|PubMed:21653700, ECO:0000269|PubMed:7518429,
CC       ECO:0000269|PubMed:7680645, ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11433297,
CC       ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:18670643}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues.
CC       {ECO:0000269|PubMed:18480409}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with
CC       FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, FGF19,
CC       FGF21 and FGF23 (in vitro). Binding affinity for FGF family
CC       members is enhanced by interactions between FGFs and heparan
CC       sulfate proteoglycans. Interacts with KLB; this strongly increases
CC       the affinity for FGF19 and FGF23. Affinity for FGF19 is strongly
CC       increased by KLB and sulfated glycosaminoglycans. KLB and KL both
CC       interact with the core-glycosylated FGFR4 in the endoplasmic
CC       reticulum and promote its degradation, so that only FGFR4 with
CC       fully mature N-glycans is expressed at the cell surface.
CC       Identified in a complex with NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1,
CC       GAP43 and CTTN. Interacts with MMP14 and HIP1.
CC       {ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18670643,
CC       ECO:0000269|PubMed:20683963, ECO:0000269|PubMed:20798051,
CC       ECO:0000269|PubMed:21653700, ECO:0000269|PubMed:7518429,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endosome. Endoplasmic reticulum. Note=Internalized from
CC       the cell membrane to recycling endosomes, and from there back to
CC       the cell membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm
CC       {ECO:0000269|PubMed:11781352}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P22455-1; Sequence=Displayed;
CC       Name=2; Synonyms=Soluble-form;
CC         IsoId=P22455-2; Sequence=VSP_035108;
CC       Name=3;
CC         IsoId=P22455-3; Sequence=VSP_053542;
CC         Note=Lacks a signal peptide. Constitutively phosphorylated.;
CC   -!- TISSUE SPECIFICITY: Expressed in gastrointestinal epithelial
CC       cells, pancreas, and gastric and pancreatic cancer cell lines.
CC       {ECO:0000269|PubMed:10631118}.
CC   -!- PTM: N-glycosylated. Full maturation of the glycan chains in the
CC       Golgi is essential for high affinity interaction with FGF19.
CC   -!- PTM: Ubiquitinated. Subject to proteasomal degradation when not
CC       fully glycosylated. {ECO:0000269|PubMed:18480409}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer. {ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:7518429}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr4/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR4ID512ch5q35.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57205; CAA40490.1; -; mRNA.
DR   EMBL; L03840; AAB59389.1; -; mRNA.
DR   EMBL; AF202063; AAF27432.1; -; mRNA.
DR   EMBL; Y13901; CAA74200.1; -; Genomic_DNA.
DR   EMBL; AF359246; AAK51435.1; -; mRNA.
DR   EMBL; JN007471; AEO19712.1; -; mRNA.
DR   EMBL; JN007472; AEO19713.1; -; mRNA.
DR   EMBL; JN007473; AEO19714.1; -; mRNA.
DR   EMBL; JN007474; AEO19715.1; -; mRNA.
DR   EMBL; JN007475; AEO19716.1; -; mRNA.
DR   EMBL; JN007476; AEO19717.1; -; mRNA.
DR   EMBL; JN007477; AEO19718.1; -; mRNA.
DR   EMBL; JN007478; AEO19719.1; -; mRNA.
DR   EMBL; JN007479; AEO19720.1; -; mRNA.
DR   EMBL; JN007480; AEO19721.1; -; mRNA.
DR   EMBL; JN007481; AEO19722.1; -; mRNA.
DR   EMBL; JN007482; AEO19723.1; -; mRNA.
DR   EMBL; AF487555; AAM13666.1; -; Genomic_DNA.
DR   EMBL; EF571596; ABQ01235.1; -; Genomic_DNA.
DR   EMBL; AC027314; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471195; EAW85036.1; -; Genomic_DNA.
DR   EMBL; BC011847; AAH11847.1; -; mRNA.
DR   EMBL; M59373; AAA63208.1; -; mRNA.
DR   CCDS; CCDS4410.1; -. [P22455-1]
DR   CCDS; CCDS4411.1; -. [P22455-2]
DR   PIR; S15345; TVHUF4.
DR   RefSeq; NP_001278909.1; NM_001291980.1.
DR   RefSeq; NP_002002.3; NM_002011.4. [P22455-1]
DR   RefSeq; NP_075252.2; NM_022963.3. [P22455-2]
DR   RefSeq; NP_998812.1; NM_213647.2. [P22455-1]
DR   RefSeq; XP_005265895.1; XM_005265838.2. [P22455-1]
DR   UniGene; Hs.165950; -.
DR   PDB; 1QCT; Model; -; B/E=36-353.
DR   PDB; 4QQ5; X-ray; 2.20 A; A=445-753.
DR   PDB; 4QQC; X-ray; 2.40 A; A=445-753.
DR   PDB; 4QQJ; X-ray; 1.68 A; A=445-753.
DR   PDB; 4QQT; X-ray; 1.50 A; A=445-753.
DR   PDB; 4QRC; X-ray; 1.90 A; A=445-753.
DR   PDB; 4R6V; X-ray; 2.35 A; A=445-753.
DR   PDB; 4TYE; X-ray; 2.80 A; A=447-753.
DR   PDB; 4TYG; X-ray; 2.40 A; A=447-753.
DR   PDB; 4TYI; X-ray; 3.40 A; A=447-753.
DR   PDB; 4TYJ; X-ray; 2.45 A; A=447-753.
DR   PDB; 4UXQ; X-ray; 1.85 A; A=447-753.
DR   PDB; 4XCU; X-ray; 1.71 A; A=449-751.
DR   PDBsum; 1QCT; -.
DR   PDBsum; 4QQ5; -.
DR   PDBsum; 4QQC; -.
DR   PDBsum; 4QQJ; -.
DR   PDBsum; 4QQT; -.
DR   PDBsum; 4QRC; -.
DR   PDBsum; 4R6V; -.
DR   PDBsum; 4TYE; -.
DR   PDBsum; 4TYG; -.
DR   PDBsum; 4TYI; -.
DR   PDBsum; 4TYJ; -.
DR   PDBsum; 4UXQ; -.
DR   PDBsum; 4XCU; -.
DR   ProteinModelPortal; P22455; -.
DR   SMR; P22455; 21-355, 454-750.
DR   BioGrid; 108555; 12.
DR   DIP; DIP-5149N; -.
DR   IntAct; P22455; 22.
DR   STRING; 9606.ENSP00000292408; -.
DR   BindingDB; P22455; -.
DR   ChEMBL; CHEMBL3973; -.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB08901; Ponatinib.
DR   GuidetoPHARMACOLOGY; 1811; -.
DR   iPTMnet; P22455; -.
DR   PhosphoSite; P22455; -.
DR   BioMuta; FGFR4; -.
DR   DMDM; 13432140; -.
DR   MaxQB; P22455; -.
DR   PaxDb; P22455; -.
DR   PRIDE; P22455; -.
DR   DNASU; 2264; -.
DR   Ensembl; ENST00000292408; ENSP00000292408; ENSG00000160867. [P22455-1]
DR   Ensembl; ENST00000393637; ENSP00000377254; ENSG00000160867. [P22455-2]
DR   Ensembl; ENST00000502906; ENSP00000424960; ENSG00000160867. [P22455-1]
DR   GeneID; 2264; -.
DR   KEGG; hsa:2264; -.
DR   UCSC; uc003mfl.3; human. [P22455-1]
DR   UCSC; uc003mfo.3; human. [P22455-2]
DR   CTD; 2264; -.
DR   GeneCards; FGFR4; -.
DR   HGNC; HGNC:3691; FGFR4.
DR   HPA; CAB005196; -.
DR   HPA; HPA027273; -.
DR   HPA; HPA027369; -.
DR   HPA; HPA028251; -.
DR   MIM; 134935; gene.
DR   neXtProt; NX_P22455; -.
DR   PharmGKB; PA28130; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P22455; -.
DR   KO; K05095; -.
DR   OMA; QDFHGEH; -.
DR   OrthoDB; EOG7NGQ9N; -.
DR   PhylomeDB; P22455; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1307965; betaKlotho-mediated ligand binding.
DR   Reactome; R-HSA-1839128; FGFR4 mutant receptor activation.
DR   Reactome; R-HSA-190322; FGFR4 ligand binding and activation.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4.
DR   Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling.
DR   Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4.
DR   Reactome; R-HSA-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   ChiTaRS; FGFR4; human.
DR   GeneWiki; Fibroblast_growth_factor_receptor_4; -.
DR   GenomeRNAi; 2264; -.
DR   NextBio; 35516406; -.
DR   PRO; PR:P22455; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P22455; -.
DR   CleanEx; HS_FGFR4; -.
DR   ExpressionAtlas; P22455; baseline and differential.
DR   Genevisible; P22455; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030133; C:transport vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0055062; P:phosphate ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0048554; P:positive regulation of metalloenzyme activity; IMP:UniProtKB.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0070857; P:regulation of bile acid biosynthetic process; IMP:UniProtKB.
DR   GO; GO:2000188; P:regulation of cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     21       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        22    802       Fibroblast growth factor receptor 4.
FT                                /FTId=PRO_0000016787.
FT   TOPO_DOM     22    369       Extracellular. {ECO:0000255}.
FT   TRANSMEM    370    390       Helical. {ECO:0000255}.
FT   TOPO_DOM    391    802       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       22    118       Ig-like C2-type 1.
FT   DOMAIN      152    240       Ig-like C2-type 2.
FT   DOMAIN      249    349       Ig-like C2-type 3.
FT   DOMAIN      467    755       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     473    481       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    612    612       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     503    503       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     573    573       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     642    642       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18670643}.
FT   MOD_RES     643    643       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18670643}.
FT   MOD_RES     754    754       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:7518429}.
FT   CARBOHYD    112    112       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    258    258       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    290    290       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     57    101       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    172    224       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    271    333       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1    210       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11781352}.
FT                                /FTId=VSP_053542.
FT   VAR_SEQ     353    416       EEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQ
FT                                ALHGRHPRPPATVQKLSRFPLAR -> GTGRIPHLTCDSLT
FT                                PAGRTKSPTL (in isoform 2).
FT                                {ECO:0000303|PubMed:10631118}.
FT                                /FTId=VSP_035108.
FT   VARIANT      10     10       V -> I (in dbSNP:rs1966265).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21882254,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_029185.
FT   VARIANT     136    136       P -> L (in dbSNP:rs376618).
FT                                {ECO:0000269|PubMed:10631118,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21882254,
FT                                ECO:0000269|Ref.10, ECO:0000269|Ref.7,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_042211.
FT   VARIANT     179    179       T -> A (in dbSNP:rs55675160).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042212.
FT   VARIANT     388    388       G -> R (prolonged FGFR4 activity,
FT                                increased cell motility and tumor cell
FT                                invasion, possibly due to increased
FT                                stability of the protease MMP14;
FT                                dbSNP:rs351855).
FT                                {ECO:0000269|PubMed:11781352,
FT                                ECO:0000269|PubMed:18670643,
FT                                ECO:0000269|PubMed:20876804,
FT                                ECO:0000269|PubMed:21882254,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_014797.
FT   VARIANT     426    426       G -> S (in dbSNP:rs55879131).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046102.
FT   VARIANT     516    516       D -> N (in dbSNP:rs34158682).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042213.
FT   VARIANT     529    529       R -> Q (in dbSNP:rs34284947).
FT                                /FTId=VAR_049720.
FT   VARIANT     550    550       V -> M (in breast pleomorphic lobular
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046103.
FT   VARIANT     712    712       P -> T (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046104.
FT   VARIANT     772    772       S -> N (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046105.
FT   MUTAGEN     503    503       K->R: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11433297,
FT                                ECO:0000269|PubMed:17311277}.
FT   MUTAGEN     754    754       Y->F: Loss of interaction with PLCG1.
FT                                {ECO:0000269|PubMed:7518429}.
FT   CONFLICT    121    121       L -> S (in Ref. 3; AAF27432).
FT                                {ECO:0000305}.
FT   CONFLICT    194    194       E -> G (in Ref. 3; AAF27432).
FT                                {ECO:0000305}.
FT   CONFLICT    297    297       D -> V (in Ref. 1; CAA40490).
FT                                {ECO:0000305}.
FT   HELIX       445    448       {ECO:0000244|PDB:4QQ5}.
FT   TURN        458    460       {ECO:0000244|PDB:4QQT}.
FT   HELIX       464    466       {ECO:0000244|PDB:4QQT}.
FT   STRAND      467    474       {ECO:0000244|PDB:4QQT}.
FT   STRAND      480    487       {ECO:0000244|PDB:4QQT}.
FT   STRAND      490    493       {ECO:0000244|PDB:4TYG}.
FT   STRAND      497    504       {ECO:0000244|PDB:4QQT}.
FT   HELIX       511    527       {ECO:0000244|PDB:4QQT}.
FT   STRAND      536    540       {ECO:0000244|PDB:4QQT}.
FT   STRAND      542    544       {ECO:0000244|PDB:4QQT}.
FT   STRAND      547    551       {ECO:0000244|PDB:4QQT}.
FT   HELIX       558    563       {ECO:0000244|PDB:4QQT}.
FT   STRAND      572    574       {ECO:0000244|PDB:4TYE}.
FT   HELIX       586    605       {ECO:0000244|PDB:4QQT}.
FT   HELIX       615    617       {ECO:0000244|PDB:4QQT}.
FT   STRAND      618    620       {ECO:0000244|PDB:4QQT}.
FT   STRAND      626    628       {ECO:0000244|PDB:4QQT}.
FT   TURN        631    635       {ECO:0000244|PDB:4XCU}.
FT   HELIX       637    639       {ECO:0000244|PDB:4QQT}.
FT   STRAND      642    644       {ECO:0000244|PDB:4UXQ}.
FT   HELIX       652    655       {ECO:0000244|PDB:4QQT}.
FT   HELIX       658    663       {ECO:0000244|PDB:4QQT}.
FT   HELIX       668    683       {ECO:0000244|PDB:4QQT}.
FT   STRAND      689    692       {ECO:0000244|PDB:4TYJ}.
FT   HELIX       695    703       {ECO:0000244|PDB:4QQT}.
FT   HELIX       716    725       {ECO:0000244|PDB:4QQT}.
FT   HELIX       730    732       {ECO:0000244|PDB:4QQT}.
FT   HELIX       736    748       {ECO:0000244|PDB:4QQT}.
SQ   SEQUENCE   802 AA;  87954 MW;  B22B259831BB889F CRC64;
     MRLLLALLGV LLSVPGPPVL SLEASEEVEL EPCLAPSLEQ QEQELTVALG QPVRLCCGRA
     ERGGHWYKEG SRLAPAGRVR GWRGRLEIAS FLPEDAGRYL CLARGSMIVL QNLTLITGDS
     LTSSNDDEDP KSHRDPSNRH SYPQQAPYWT HPQRMEKKLH AVPAGNTVKF RCPAAGNPTP
     TIRWLKDGQA FHGENRIGGI RLRHQHWSLV MESVVPSDRG TYTCLVENAV GSIRYNYLLD
     VLERSPHRPI LQAGLPANTT AVVGSDVELL CKVYSDAQPH IQWLKHIVIN GSSFGADGFP
     YVQVLKTADI NSSEVEVLYL RNVSAEDAGE YTCLAGNSIG LSYQSAWLTV LPEEDPTWTA
     AAPEARYTDI ILYASGSLAL AVLLLLAGLY RGQALHGRHP RPPATVQKLS RFPLARQFSL
     ESGSSGKSSS SLVRGVRLSS SGPALLAGLV SLDLPLDPLW EFPRDRLVLG KPLGEGCFGQ
     VVRAEAFGMD PARPDQASTV AVKMLKDNAS DKDLADLVSE MEVMKLIGRH KNIINLLGVC
     TQEGPLYVIV ECAAKGNLRE FLRARRPPGP DLSPDGPRSS EGPLSFPVLV SCAYQVARGM
     QYLESRKCIH RDLAARNVLV TEDNVMKIAD FGLARGVHHI DYYKKTSNGR LPVKWMAPEA
     LFDRVYTHQS DVWSFGILLW EIFTLGGSPY PGIPVEELFS LLREGHRMDR PPHCPPELYG
     LMRECWHAAP SQRPTFKQLV EALDKVLLAV SEEYLDLRLT FGPYSPSGGD ASSTCSSSDS
     VFSHDPLPLG SSSFPFGSGV QT
//
ID   HYAL2_HUMAN             Reviewed;         473 AA.
AC   Q12891; B3KRZ2; O15177; Q9BW29;
DT   15-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 4.
DT   11-NOV-2015, entry version 151.
DE   RecName: Full=Hyaluronidase-2;
DE            Short=Hyal-2;
DE            EC=3.2.1.35;
DE   AltName: Full=Hyaluronoglucosaminidase-2;
DE   AltName: Full=Lung carcinoma protein 2;
DE            Short=LuCa-2;
DE   Flags: Precursor;
GN   Name=HYAL2; Synonyms=LUCA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND VARIANT
RP   ALA-18.
RX   PubMed=9712871; DOI=10.1074/jbc.273.35.22466;
RA   Lepperdinger G., Strobl B., Kreil G.;
RT   "HYAL2, a human gene expressed in many cells, encodes a lysosomal
RT   hyaluronidase with a novel type of specificity.";
RL   J. Biol. Chem. 273:22466-22470(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RA   Chen J., Bader S., Latif F., Duh F.-M., Lerman M.I., Minna J.D.;
RT   "LUCA2 (HYAL2, lysosomal hyaluronidase) a novel human cDNA with
RT   homology to human PH-20 gene is homozygously deleted in small cell
RT   lung cancer and located in 3p21.3.";
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-18.
RC   TISSUE=Placenta, and Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-18.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-18.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 15-473, AND VARIANT ALA-18.
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   REVIEW.
RX   PubMed=11731268; DOI=10.1016/S0945-053X(01)00170-6;
RA   Lepperdinger G., Mullegger J., Kreil G.;
RT   "Hyal2 -- less active, but more versatile?";
RL   Matrix Biol. 20:509-514(2001).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11296287; DOI=10.1073/pnas.071572898;
RA   Rai S.K., Duh F.-M., Vigdorovich V., Danilkovitch-Miagkova A.,
RA   Lerman M.I., Miller A.D.;
RT   "Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol
RT   (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus,
RT   the envelope protein of which mediates oncogenic transformation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:4443-4448(2001).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH MST1R.
RX   PubMed=12676986; DOI=10.1073/pnas.0837136100;
RA   Danilkovitch-Miagkova A., Duh F.-M., Kuzmin I., Angeloni D.,
RA   Liu S.-L., Miller A.D., Lerman M.I.;
RT   "Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and
RT   mediates transformation of epithelial cells by jaagsiekte sheep
RT   retrovirus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4580-4585(2003).
CC   -!- FUNCTION: Hydrolyzes high molecular weight hyaluronic acid to
CC       produce an intermediate-sized product which is further hydrolyzed
CC       by sperm hyaluronidase to give small oligosaccharides. Displays
CC       very low levels of activity. Associates with and negatively
CC       regulates MST1R. {ECO:0000269|PubMed:11296287,
CC       ECO:0000269|PubMed:12676986, ECO:0000269|PubMed:9712871}.
CC   -!- CATALYTIC ACTIVITY: Random hydrolysis of (1->4)-linkages between
CC       N-acetyl-beta-D-glucosamine and D-glucuronate residues in
CC       hyaluronate.
CC   -!- SUBUNIT: Interacts with MST1R. {ECO:0000269|PubMed:12676986}.
CC   -!- INTERACTION:
CC       Q13643:FHL3; NbExp=3; IntAct=EBI-2806068, EBI-741101;
CC       Q9BYR7:KRTAP3-2; NbExp=3; IntAct=EBI-2806068, EBI-751260;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11296287};
CC       Lipid-anchor, GPI-anchor {ECO:0000269|PubMed:11296287}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. No expression detected in
CC       adult brain. {ECO:0000269|PubMed:9712871}.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 56 family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 EGF-like domain. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be lysosomal. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC28656.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HYAL2ID40904ch3p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ000099; CAA03924.1; -; mRNA.
DR   EMBL; U09577; AAC62823.1; -; mRNA.
DR   EMBL; AK092449; BAG52554.1; -; mRNA.
DR   EMBL; AK127945; BAG54602.1; -; mRNA.
DR   EMBL; AC002455; AAB67045.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW65092.1; -; Genomic_DNA.
DR   EMBL; BC000692; AAH00692.1; -; mRNA.
DR   EMBL; AF070608; AAC28656.1; ALT_INIT; mRNA.
DR   CCDS; CCDS2818.1; -.
DR   RefSeq; NP_003764.3; NM_003773.4.
DR   RefSeq; NP_149348.2; NM_033158.4.
DR   RefSeq; XP_005265581.1; XM_005265524.1.
DR   RefSeq; XP_005265582.1; XM_005265525.1.
DR   UniGene; Hs.76873; -.
DR   ProteinModelPortal; Q12891; -.
DR   SMR; Q12891; 29-439.
DR   BioGrid; 114239; 14.
DR   IntAct; Q12891; 6.
DR   STRING; 9606.ENSP00000350387; -.
DR   CAZy; GH56; Glycoside Hydrolase Family 56.
DR   BioMuta; HYAL2; -.
DR   DMDM; 311033483; -.
DR   MaxQB; Q12891; -.
DR   PaxDb; Q12891; -.
DR   PRIDE; Q12891; -.
DR   DNASU; 8692; -.
DR   Ensembl; ENST00000357750; ENSP00000350387; ENSG00000068001.
DR   Ensembl; ENST00000395139; ENSP00000378571; ENSG00000068001.
DR   Ensembl; ENST00000442581; ENSP00000406657; ENSG00000068001.
DR   Ensembl; ENST00000447092; ENSP00000401853; ENSG00000068001.
DR   GeneID; 8692; -.
DR   KEGG; hsa:8692; -.
DR   UCSC; uc003czv.3; human.
DR   CTD; 8692; -.
DR   GeneCards; HYAL2; -.
DR   H-InvDB; HIX0003314; -.
DR   HGNC; HGNC:5321; HYAL2.
DR   HPA; HPA036436; -.
DR   MIM; 603551; gene.
DR   neXtProt; NX_Q12891; -.
DR   PharmGKB; PA29572; -.
DR   eggNOG; ENOG410IECJ; Eukaryota.
DR   eggNOG; ENOG410XPZT; LUCA.
DR   GeneTree; ENSGT00550000074476; -.
DR   HOGENOM; HOG000015133; -.
DR   HOVERGEN; HBG052053; -.
DR   InParanoid; Q12891; -.
DR   KO; K01197; -.
DR   OMA; WGGEQCQ; -.
DR   PhylomeDB; Q12891; -.
DR   TreeFam; TF321598; -.
DR   BioCyc; MetaCyc:HS00926-MONOMER; -.
DR   BRENDA; 3.2.1.35; 2681.
DR   BRENDA; 4.2.2.1; 2681.
DR   Reactome; R-HSA-2160916; Hyaluronan uptake and degradation.
DR   SignaLink; Q12891; -.
DR   ChiTaRS; HYAL2; human.
DR   GeneWiki; HYAL2; -.
DR   GenomeRNAi; 8692; -.
DR   NextBio; 32597; -.
DR   PRO; PR:Q12891; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; Q12891; -.
DR   CleanEx; HS_HYAL2; -.
DR   ExpressionAtlas; Q12891; baseline and differential.
DR   Genevisible; Q12891; HS.
DR   GO; GO:0031362; C:anchored component of external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0046658; C:anchored component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; NAS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; ISS:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; ISS:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0005540; F:hyaluronic acid binding; IDA:UniProtKB.
DR   GO; GO:0033906; F:hyaluronoglucuronidase activity; IDA:UniProtKB.
DR   GO; GO:0004415; F:hyalurononglucosaminidase activity; IDA:UniProtKB.
DR   GO; GO:0030294; F:receptor signaling protein tyrosine kinase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0050431; F:transforming growth factor beta binding; ISS:BHF-UCL.
DR   GO; GO:0001618; F:virus receptor activity; IDA:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0051216; P:cartilage development; IEP:UniProtKB.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IEA:Ensembl.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; IDA:UniProtKB.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; IDA:UniProtKB.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0030214; P:hyaluronan catabolic process; IDA:UniProtKB.
DR   GO; GO:0030212; P:hyaluronan metabolic process; TAS:Reactome.
DR   GO; GO:0001822; P:kidney development; ISS:UniProtKB.
DR   GO; GO:0042117; P:monocyte activation; IDA:UniProtKB.
DR   GO; GO:0010259; P:multicellular organismal aging; IEA:Ensembl.
DR   GO; GO:0060586; P:multicellular organismal iron ion homeostasis; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0010764; P:negative regulation of fibroblast migration; IDA:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IDA:UniProtKB.
DR   GO; GO:2000778; P:positive regulation of interleukin-6 secretion; IDA:UniProtKB.
DR   GO; GO:2000484; P:positive regulation of interleukin-8 secretion; IDA:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0035810; P:positive regulation of urine volume; ISS:UniProtKB.
DR   GO; GO:0070295; P:renal water absorption; ISS:UniProtKB.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0000302; P:response to reactive oxygen species; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IDA:UniProtKB.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0019087; P:transformation of host cell by virus; IDA:UniProtKB.
DR   GO; GO:0046718; P:viral entry into host cell; ISS:UniProtKB.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR018155; Hyaluronidase.
DR   PANTHER; PTHR11769; PTHR11769; 1.
DR   Pfam; PF01630; Glyco_hydro_56; 1.
DR   PIRSF; PIRSF038193; Hyaluronidase; 1.
DR   PRINTS; PR00846; GLHYDRLASE56.
DR   SMART; SM00181; EGF; 1.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond; EGF-like domain;
KW   Glycoprotein; Glycosidase; GPI-anchor; Hydrolase; Lipoprotein;
KW   Membrane; Polymorphism; Receptor; Reference proteome; Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    448       Hyaluronidase-2.
FT                                /FTId=PRO_0000012099.
FT   PROPEP      449    473       Removed in mature form. {ECO:0000255}.
FT                                /FTId=PRO_0000012100.
FT   DOMAIN      361    439       EGF-like.
FT   ACT_SITE    135    135       Proton donor. {ECO:0000250}.
FT   LIPID       448    448       GPI-anchor amidated glycine.
FT                                {ECO:0000255}.
FT   CARBOHYD     74     74       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    357    357       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     47    340       {ECO:0000250}.
FT   DISULFID    211    227       {ECO:0000250}.
FT   DISULFID    365    376       {ECO:0000250}.
FT   DISULFID    370    427       {ECO:0000250}.
FT   DISULFID    429    438       {ECO:0000250}.
FT   VARIANT      18     18       S -> A (in dbSNP:rs709210).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9712871,
FT                                ECO:0000269|Ref.5, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_028170.
FT   VARIANT     418    418       I -> L (in dbSNP:rs35455589).
FT                                /FTId=VAR_061193.
FT   CONFLICT    261    262       SR -> AL (in Ref. 1; CAA03924).
FT                                {ECO:0000305}.
FT   CONFLICT    301    302       RL -> C (in Ref. 1; CAA03924).
FT                                {ECO:0000305}.
FT   CONFLICT    375    375       Missing (in Ref. 1; CAA03924).
FT                                {ECO:0000305}.
FT   CONFLICT    378    379       RR -> PG (in Ref. 1; CAA03924).
FT                                {ECO:0000305}.
FT   CONFLICT    450    450       S -> N (in Ref. 1; CAA03924).
FT                                {ECO:0000305}.
SQ   SEQUENCE   473 AA;  53860 MW;  A8302738478BFE61 CRC64;
     MRAGPGPTVT LALVLAVSWA MELKPTAPPI FTGRPFVVAW DVPTQDCGPR LKVPLDLNAF
     DVQASPNEGF VNQNITIFYR DRLGLYPRFD SAGRSVHGGV PQNVSLWAHR KMLQKRVEHY
     IRTQESAGLA VIDWEDWRPV WVRNWQDKDV YRRLSRQLVA SRHPDWPPDR IVKQAQYEFE
     FAAQQFMLET LRYVKAVRPR HLWGFYLFPD CYNHDYVQNW ESYTGRCPDV EVARNDQLAW
     LWAESTALFP SVYLDETLAS SRHGRNFVSF RVQEALRVAR THHANHALPV YVFTRPTYSR
     RLTGLSEMDL ISTIGESAAL GAAGVILWGD AGYTTSTETC QYLKDYLTRL LVPYVVNVSW
     ATQYCSRAQC HGHGRCVRRN PSASTFLHLS TNSFRLVPGH APGEPQLRPV GELSWADIDH
     LQTHFRCQCY LGWSGEQCQW DHRQAAGGAS EAWAGSHLTS LLALAALAFT WTL
//
ID   ITB1_RAT                Reviewed;         799 AA.
AC   P49134; A2RRT8;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   20-JAN-2016, entry version 149.
DE   RecName: Full=Integrin beta-1;
DE   AltName: Full=Beta oligodendroglia;
DE            Short=Beta OL;
DE   AltName: Full=Fibronectin receptor subunit beta;
DE   AltName: Full=VLA-4 subunit beta;
DE   AltName: CD_antigen=CD29;
DE   Flags: Precursor;
GN   Name=Itgb1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Oligodendrocyte;
RX   PubMed=7541764; DOI=10.1016/0378-1119(94)00911-B;
RA   Malek-Hedayat S., Rome L.H.;
RT   "Cloning and sequence of the cDNA encoding the rat oligodendrocyte
RT   integrin beta 1 subunit.";
RL   Gene 158:287-290(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-
CC       1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-
CC       1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated
CC       sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-
CC       3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-
CC       10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for
CC       fibronectin. Alpha-4/beta-1 recognizes one or more domains within
CC       the alternatively spliced CS-1 and CS-5 regions of fibronectin.
CC       Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin
CC       alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1
CC       are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor
CC       for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1. Integrin
CC       alpha-9/beta-1 is a receptor for VCAM1, cytotactin and
CC       osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in
CC       cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin,
CC       thrombospondin and CSPG4. Integrin alpha-3/beta-1 provides a
CC       docking site for FAP (seprase) at invadopodia plasma membranes in
CC       a collagen-dependent manner and hence may participate in the
CC       adhesion, formation of invadopodia and matrix degradation
CC       processes, promoting cell invasion. Alpha-3/beta-1 may mediate
CC       with LGALS3 the stimulation by CSPG4 of endothelial cells
CC       migration. Integrin alpha-V/beta-1 is a receptor for vitronectin.
CC       Beta-1 integrins recognize the sequence R-G-D in a wide array of
CC       ligands. When associated with alpha-7/beta-1 integrin, regulates
CC       cell adhesion and laminin matrix deposition. Involved in promoting
CC       endothelial cell motility and angiogenesis. Involved in osteoblast
CC       compaction through the fibronectin fibrillogenesis cell-mediated
CC       matrix assembly process and the formation of mineralized bone
CC       nodules. May be involved in up-regulation of the activity of
CC       kinases such as PKC via binding to KRT1. Together with KRT1 and
CC       GNB2L1, serves as a platform for SRC activation or inactivation.
CC       Plays a mechanistic adhesive role during telophase, required for
CC       the successful completion of cytokinesis.
CC       {ECO:0000250|UniProtKB:P05556}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. Beta-1
CC       associates with either alpha-1, alpha-2, alpha-3, alpha-4, alpha-
CC       5, alpha-6, alpha-7, alpha-8, alpha-9, alpha-10, alpha-11 or
CC       alpha-V. Binds LGALS3BP and NMRK2, when associated with alpha-7,
CC       but not with alpha-5. Interacts with FLNA, FLNB, FLNC and RANBP9.
CC       Interacts with KRT1 in the presence of GNB2L1 and SRC. Interacts
CC       with AMICA1; integrin alpha-4/beta-1 may regulate leukocyte to
CC       endothelial cells adhesion by controlling AMICA1 homodimerization.
CC       Interacts with RAB21. Interacts (via the cytoplasmic region) with
CC       RAB25 (via the hypervariable C-terminal region). Interacts with
CC       FGR and HCK. Interacts with MYO10. Interacts with DAB2. Interacts
CC       with ITGB1BP1 (via C-terminal region); the interaction is a
CC       prerequisite for focal adhesion disassembly. Interacts with
CC       FERMT2; the interaction is inhibited in presence of ITGB1BP1.
CC       Interacts with TLN1; the interaction is prevented by competitive
CC       binding of ITGB1BP1. Interacts with ACAP1; required for ITGB1
CC       recycling. Interacts with ASAP3. Interacts with seprase FAP
CC       (seprase); the interaction occurs at the cell surface of
CC       invadopodia membrane in a collagen-dependent manner. Interacts
CC       with EMP2; the interaction may be direct or indirect and ITGB1 has
CC       an heterodimer form (By similarity). ITGA5:ITGB1 interacts with
CC       NOV (By similarity). {ECO:0000250|UniProtKB:P05556,
CC       ECO:0000250|UniProtKB:P09055}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:P05556}; Single-pass type I membrane
CC       protein {ECO:0000255}. Cell projection, invadopodium membrane
CC       {ECO:0000250|UniProtKB:P05556}; Single-pass type I membrane
CC       protein {ECO:0000255}. Cell projection, ruffle membrane
CC       {ECO:0000250|UniProtKB:P05556}; Single-pass type I membrane
CC       protein {ECO:0000255}. Recycling endosome {ECO:0000250}.
CC       Melanosome {ECO:0000250}. Cell projection, lamellipodium
CC       {ECO:0000250}. Cell projection, ruffle {ECO:0000250}.
CC       Note=Enriched preferentially at invadopodia, cell membrane
CC       protrusions that correspond to sites of cell invasion, in a
CC       collagen-dependent manner. Localized at plasma and ruffle
CC       membranes in a collagen-independent manner. Colocalizes with
CC       ITGB1BP1 and metastatic suppressor protein NME2 at the edge or
CC       peripheral ruffles and lamellipodia during the early stages of
CC       cell spreading on fibronectin or collagen. Translocates from
CC       peripheral focal adhesions to fibrillar adhesions in an ITGB1BP1-
CC       dependent manner. {ECO:0000250|UniProtKB:P05556}.
CC   -!- PTM: The cysteine residues are involved in intrachain disulfide
CC       bonds. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the integrin beta chain family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 VWFA domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI31846.1; Type=Frameshift; Positions=442, 443, 447; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U12309; AAA86669.1; -; mRNA.
DR   EMBL; BC131845; AAI31846.1; ALT_FRAME; mRNA.
DR   PIR; JC4126; JC4126.
DR   RefSeq; NP_058718.2; NM_017022.2.
DR   UniGene; Rn.25733; -.
DR   ProteinModelPortal; P49134; -.
DR   SMR; P49134; 722-798.
DR   BioGrid; 246668; 6.
DR   IntAct; P49134; 4.
DR   MINT; MINT-122445; -.
DR   STRING; 10116.ENSRNOP00000014785; -.
DR   iPTMnet; P49134; -.
DR   PhosphoSite; P49134; -.
DR   PaxDb; P49134; -.
DR   PRIDE; P49134; -.
DR   GeneID; 24511; -.
DR   KEGG; rno:24511; -.
DR   UCSC; RGD:2927; rat.
DR   CTD; 3688; -.
DR   RGD; 2927; Itgb1.
DR   eggNOG; KOG1226; Eukaryota.
DR   eggNOG; ENOG410XP60; LUCA.
DR   HOGENOM; HOG000252936; -.
DR   HOVERGEN; HBG006190; -.
DR   InParanoid; P49134; -.
DR   KO; K05719; -.
DR   OrthoDB; EOG7T7GSB; -.
DR   PhylomeDB; P49134; -.
DR   TreeFam; TF105392; -.
DR   NextBio; 603533; -.
DR   PRO; PR:P49134; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0001669; C:acrosomal vesicle; IDA:RGD.
DR   GO; GO:0005912; C:adherens junction; IDA:RGD.
DR   GO; GO:0005604; C:basement membrane; IDA:RGD.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0005911; C:cell-cell junction; IDA:RGD.
DR   GO; GO:0005925; C:focal adhesion; IDA:RGD.
DR   GO; GO:0030056; C:hemidesmosome; IDA:RGD.
DR   GO; GO:0034667; C:integrin alpha3-beta1 complex; IDA:RGD.
DR   GO; GO:0034679; C:integrin alpha9-beta1 complex; IDA:RGD.
DR   GO; GO:0008305; C:integrin complex; IDA:RGD.
DR   GO; GO:0071438; C:invadopodium membrane; ISS:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:RGD.
DR   GO; GO:0045121; C:membrane raft; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0055037; C:recycling endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0003779; F:actin binding; IDA:RGD.
DR   GO; GO:0051393; F:alpha-actinin binding; IDA:RGD.
DR   GO; GO:0005518; F:collagen binding; IDA:RGD.
DR   GO; GO:0001968; F:fibronectin binding; IDA:RGD.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:RGD.
DR   GO; GO:0005178; F:integrin binding; IMP:RGD.
DR   GO; GO:0019900; F:kinase binding; IPI:RGD.
DR   GO; GO:0043236; F:laminin binding; IDA:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042277; F:peptide binding; IDA:RGD.
DR   GO; GO:0002020; F:protease binding; IPI:RGD.
DR   GO; GO:0032403; F:protein complex binding; IPI:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; IMP:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0004872; F:receptor activity; IEA:InterPro.
DR   GO; GO:0005102; F:receptor binding; IPI:RGD.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IMP:RGD.
DR   GO; GO:0007155; P:cell adhesion; IDA:RGD.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:InterPro.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:RGD.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IEP:RGD.
DR   GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; ISS:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEP:RGD.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:RGD.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEP:RGD.
DR   GO; GO:0031345; P:negative regulation of cell projection organization; IMP:RGD.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:RGD.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IMP:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:RGD.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IMP:RGD.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IMP:RGD.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:RGD.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:RGD.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:RGD.
DR   GO; GO:0032594; P:protein transport within lipid bilayer; IMP:RGD.
DR   GO; GO:0031623; P:receptor internalization; ISS:UniProtKB.
DR   GO; GO:0010710; P:regulation of collagen catabolic process; ISS:UniProtKB.
DR   GO; GO:0008277; P:regulation of G-protein coupled receptor protein signaling pathway; IMP:RGD.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0034698; P:response to gonadotropin; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0071559; P:response to transforming growth factor beta; IEP:RGD.
DR   GO; GO:0001894; P:tissue homeostasis; IMP:RGD.
DR   Gene3D; 1.20.5.630; -; 1.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR027071; Integrin_beta-1.
DR   InterPro; IPR015812; Integrin_bsu.
DR   InterPro; IPR014836; Integrin_bsu_cyt_dom.
DR   InterPro; IPR002369; Integrin_bsu_N.
DR   InterPro; IPR012896; Integrin_bsu_tail.
DR   InterPro; IPR032695; Integrin_dom.
DR   InterPro; IPR016201; Plexin-like_fold.
DR   InterPro; IPR002035; VWF_A.
DR   PANTHER; PTHR10082; PTHR10082; 1.
DR   PANTHER; PTHR10082:SF28; PTHR10082:SF28; 1.
DR   Pfam; PF07974; EGF_2; 1.
DR   Pfam; PF08725; Integrin_b_cyt; 1.
DR   Pfam; PF07965; Integrin_B_tail; 1.
DR   Pfam; PF00362; Integrin_beta; 1.
DR   PIRSF; PIRSF002512; Integrin_B; 1.
DR   PRINTS; PR01186; INTEGRINB.
DR   SMART; SM00187; INB; 1.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF103575; SSF103575; 1.
DR   SUPFAM; SSF53300; SSF53300; 1.
DR   SUPFAM; SSF69179; SSF69179; 1.
DR   SUPFAM; SSF69687; SSF69687; 1.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS00243; INTEGRIN_BETA; 3.
PE   2: Evidence at transcript level;
KW   Acetylation; Cell adhesion; Cell junction; Cell membrane;
KW   Cell projection; Complete proteome; Disulfide bond; Endosome;
KW   Glycoprotein; Integrin; Magnesium; Membrane; Metal-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     20       {ECO:0000250}.
FT   CHAIN        21    798       Integrin beta-1.
FT                                /FTId=PRO_0000016336.
FT   TOPO_DOM     21    729       Extracellular. {ECO:0000255}.
FT   TRANSMEM    730    752       Helical. {ECO:0000255}.
FT   TOPO_DOM    753    799       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      140    378       VWFA.
FT   REPEAT      467    516       I.
FT   REPEAT      517    560       II.
FT   REPEAT      561    599       III.
FT   REPEAT      600    636       IV.
FT   REGION      467    636       Cysteine-rich tandem repeats.
FT   REGION      763    768       Signal for sorting from recycling
FT                                endosomes; interaction with ACAP1.
FT                                {ECO:0000250}.
FT   REGION      786    793       Interaction with ITGB1BP1. {ECO:0000250}.
FT   METAL       152    152       Magnesium. {ECO:0000250}.
FT   METAL       154    154       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       156    156       Calcium 1. {ECO:0000250}.
FT   METAL       157    157       Calcium 1. {ECO:0000250}.
FT   METAL       189    189       Calcium 2. {ECO:0000250}.
FT   METAL       244    244       Calcium 2. {ECO:0000250}.
FT   METAL       246    246       Calcium 2. {ECO:0000250}.
FT   METAL       248    248       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       249    249       Calcium 2. {ECO:0000250}.
FT   METAL       249    249       Magnesium. {ECO:0000250}.
FT   MOD_RES     778    778       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P05556}.
FT   MOD_RES     784    784       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P09055}.
FT   MOD_RES     786    786       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P05556}.
FT   MOD_RES     790    790       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P05556}.
FT   MOD_RES     795    795       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P05556}.
FT   CARBOHYD     50     50       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     94     94       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     97     97       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    212    212       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    269    269       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    363    363       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    482    482       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    521    521       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    585    585       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    670    670       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     27     45       {ECO:0000250}.
FT   DISULFID     35    465       {ECO:0000250}.
FT   DISULFID     38     75       {ECO:0000250}.
FT   DISULFID     48     64       {ECO:0000250}.
FT   DISULFID    207    213       {ECO:0000250}.
FT   DISULFID    261    301       {ECO:0000250}.
FT   DISULFID    401    415       {ECO:0000250}.
FT   DISULFID    435    463       {ECO:0000250}.
FT   DISULFID    467    692       {ECO:0000250}.
FT   DISULFID    478    490       {ECO:0000250}.
FT   DISULFID    487    526       {ECO:0000250}.
FT   DISULFID    492    501       {ECO:0000250}.
FT   DISULFID    503    517       {ECO:0000250}.
FT   DISULFID    532    537       {ECO:0000250}.
FT   DISULFID    534    569       {ECO:0000250}.
FT   DISULFID    539    554       {ECO:0000250}.
FT   DISULFID    556    561       {ECO:0000250}.
FT   DISULFID    575    580       {ECO:0000250}.
FT   DISULFID    577    608       {ECO:0000250}.
FT   DISULFID    582    591       {ECO:0000250}.
FT   DISULFID    593    600       {ECO:0000250}.
FT   DISULFID    614    619       {ECO:0000250}.
FT   DISULFID    616    662       {ECO:0000250}.
FT   DISULFID    621    631       {ECO:0000250}.
FT   DISULFID    634    637       {ECO:0000250}.
FT   DISULFID    641    650       {ECO:0000250}.
FT   DISULFID    647    724       {ECO:0000250}.
FT   DISULFID    666    700       {ECO:0000250}.
FT   CONFLICT     76     76       H -> Q (in Ref. 2; AAI31846).
FT                                {ECO:0000305}.
FT   CONFLICT    711    711       K -> N (in Ref. 2; AAI31846).
FT                                {ECO:0000305}.
SQ   SEQUENCE   799 AA;  88495 MW;  F4475202EB8A3EA6 CRC64;
     MNLQLVFWIG LISLICSVFG QTDKNRCLKA NAKSCGECIQ AGPNCGWCTN TTFLQEGMPT
     SARCDDLEAL KKKGCHPSDI ENPRGSQTIK KNKNVTNRSK GMAEKLRPED ITQIQPQQLL
     LKLRSGEPQK FTLKFKRAED YPIDLYYLMD LSYSMKDDLE NVKSLGTDLM NEMRRITSDF
     RIGFGSFVEK TVMPYISTTP AKLRNPCTSE QNCTSPFSYK NVLSLTDRGE FFNELVGQQR
     ISGNLDSPEG GFDAIMQVAV CGSLIGWRNV TRLLVFSTDA GFHFAGDGKL GGIVLPNDGQ
     CHLENNVYTM SHYYDYPSIA HLVQKLSENN IQTIFAVTEE FQPVYKELKN LIPKSAVGTL
     SGNSSNVIQL IIDAYNSLSS EVILENSKLP DGVTINYKSY CKNGVNGTGE NGRKCSNISI
     GDEVQFEISI TANKCPNKES ENQLKLNPLG FTEEVEVVLQ FICKCNCQSH GIPASPKCHE
     GNGTFECGAC RCNEGRVGRH CECSTDEVNS EDMDAYCRKE NSSEICSNNG ECVCGQCVCR
     KRENTNEIYS GKFCECDNFN CDRSNGLICG GNGVCRCRVC ECYPNYTGSA CDCSLDTVPC
     VATNGQICNG RGICECGACK CTDPKFQGPT CETCQTCLGV CAEHKECVQC RAFNKGEKKD
     TCAQECSHFN LTKVESREKL PQPVQVDPVT HCKEKDIDDC WFYFTYSVNS KGEAHVHVVE
     TPDCPTGPDI IPIVAGVVAG IVLIGLALLL IWKLLMIIHD RREFAKFEKE KMNAKWDTGE
     NPIYKSAVTT VVNPKYEGK
//
ID   B2MG_HUMAN              Reviewed;         119 AA.
AC   P61769; P01884; Q540F8; Q6IAT8; Q9UCK0; Q9UD48; Q9UDF4;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 146.
DE   RecName: Full=Beta-2-microglobulin;
DE   Contains:
DE     RecName: Full=Beta-2-microglobulin form pI 5.3;
DE   Flags: Precursor;
GN   Name=B2M; ORFNames=CDABP0092, HDCMA22P;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3312414;
RA   Guessow D., Rein R., Ginjaar I., Hochstenbach F., Seemann G.,
RA   Kottman A., Ploegh H.L.;
RT   "The human beta 2-microglobulin gene. Primary structure and definition
RT   of the transcriptional unit.";
RL   J. Immunol. 139:3132-3138(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Peripheral blood;
RX   PubMed=16108498;
RA   He X.H., Xu L.H., Liu Y., Zeng Y.Y.;
RT   "Cloning of human beta-microglobulin gene and its high expression in
RT   Escherichia coli.";
RL   Sheng Wu Gong Cheng Xue Bao 20:99-103(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cervix carcinoma;
RA   Matsumoto K., Minamitani T.;
RT   "Human mRNA for beta 2-microglobulin.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Tan J., Ong R., Hibberd M.L., Seielstad M.;
RT   "Genetic variation in immune response genes.";
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Dendritic cell;
RA   Zhao Z., Huang X., Li N., Zhu X., Cao X.;
RT   "A novel gene from human dendritic cell.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Leukemia;
RA   Zhou J., Yu W., Tang H., Mei G., Tsang Y.T.M., Bouck J., Gibbs R.A.,
RA   Margolin J.F.;
RT   "Pediatric leukemia cDNA sequencing project.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Retina, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-21.
RX   PubMed=11894933;
RA   Rosa F., Berissi H., Weissenbach J., Maroteaux L., Fellous M.,
RA   Revel M.;
RT   "The beta-2-microglobulin mRNA in human Daudi cells has a mutated
RT   initiation codon but is still inducible by interferon.";
RL   EMBO J. 2:239-243(1983).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 10-119.
RX   PubMed=6171820; DOI=10.1073/pnas.78.11.6613;
RA   Suggs S.V., Wallace R.B., Hirose T., Kawashima E.H., Itakura K.;
RT   "Use of synthetic oligonucleotides as hybridization probes: isolation
RT   of cloned cDNA sequences for human beta 2-microglobulin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:6613-6617(1981).
RN   [13]
RP   PROTEIN SEQUENCE OF 21-119.
RX   PubMed=4586824; DOI=10.1021/bi00748a001;
RA   Cunningham B.A., Wang J.L., Berggard I., Peterson P.A.;
RT   "The complete amino acid sequence of beta 2-microglobulin.";
RL   Biochemistry 12:4811-4822(1973).
RN   [14]
RP   PROTEIN SEQUENCE OF 21-119, SUBUNIT, AND INVOLVEMENT IN AMYLOIDOSIS.
RX   PubMed=3532124; DOI=10.1073/pnas.83.20.7908;
RA   Gorevic P.D., Munoz P.C., Casey T.T., DiRaimondo C.R., Stone W.J.,
RA   Prelli F.C., Rodrigues M.M., Poulik M.D., Frangione B.;
RT   "Polymerization of intact beta 2-microglobulin in tissue causes
RT   amyloidosis in patients on chronic hemodialysis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7908-7912(1986).
RN   [15]
RP   PROTEIN SEQUENCE OF 21-41.
RC   TISSUE=Plasma;
RX   PubMed=8084451;
RA   Haag-Weber M., Mai B., Hoerl W.H.;
RT   "Isolation of a granulocyte inhibitory protein from uraemic patients
RT   with homology of beta 2-microglobulin.";
RL   Nephrol. Dial. Transplant. 9:382-388(1994).
RN   [16]
RP   PROTEIN SEQUENCE OF 21-40, AND SUBCELLULAR LOCATION.
RX   PubMed=1336137;
RA   Argiles A., Derancourt J., Jauregui-Adell J., Mion C., Demaille J.G.;
RT   "Biochemical characterization of serum and urinary beta 2
RT   microglobulin in end-stage renal disease patients.";
RL   Nephrol. Dial. Transplant. 7:1106-1110(1992).
RN   [17]
RP   PROTEIN SEQUENCE OF 21-30, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Tear;
RX   PubMed=25946035; DOI=10.1021/acs.jproteome.5b00179;
RA   Azkargorta M., Soria J., Ojeda C., Guzman F., Acera A., Iloro I.,
RA   Suarez T., Elortza F.;
RT   "Human basal tear peptidome characterization by CID, HCD, and ETD
RT   followed by in silico and in vitro analyses for antimicrobial peptide
RT   identification.";
RL   J. Proteome Res. 14:2649-2658(2015).
RN   [18]
RP   PROTEIN SEQUENCE OF 22-119, SUBCELLULAR LOCATION, AND PYROGLUTAMATE
RP   FORMATION AT GLN-22 (FORM PI 5.3).
RC   TISSUE=Urine;
RX   PubMed=7554280; DOI=10.1016/0009-8981(95)06039-G;
RA   Momoi T., Suzuki M., Titani K., Hisanaga S., Ogawa H., Saito A.;
RT   "Amino acid sequence of a modified beta 2-microglobulin in renal
RT   failure patient urine and long-term dialysis patient blood.";
RL   Clin. Chim. Acta 236:135-144(1995).
RN   [19]
RP   INVOLVEMENT IN AMYLOIDOSIS, GLYCATION AT ILE-21; LYS-39; LYS-61;
RP   LYS-68; LYS-78; LYS-111 AND LYS-114, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=7918443; DOI=10.1021/bi00206a026;
RA   Miyata T., Inagi R., Wada Y., Ueda Y., Iida Y., Takahashi M.,
RA   Taniguchi N., Maeda K.;
RT   "Glycation of human beta 2-microglobulin in patients with
RT   hemodialysis-associated amyloidosis: identification of the glycated
RT   sites.";
RL   Biochemistry 33:12215-12221(1994).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS).
RX   PubMed=3309677; DOI=10.1038/329506a0;
RA   Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L.,
RA   Wiley D.C.;
RT   "Structure of the human class I histocompatibility antigen, HLA-A2.";
RL   Nature 329:506-512(1987).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX   PubMed=2038058; DOI=10.1016/0022-2836(91)90567-P;
RA   Saper M.A., Bjorkman P.J., Wiley D.C.;
RT   "Refined structure of the human histocompatibility antigen HLA-A2 at
RT   2.6-A resolution.";
RL   J. Mol. Biol. 219:277-319(1991).
RN   [25]
RP   STRUCTURE BY NMR.
RX   PubMed=1390678; DOI=10.1021/bi00152a030;
RA   Okon M., Bray P., Vucelic D.;
RT   "1H NMR assignments and secondary structure of human beta 2-
RT   microglobulin in solution.";
RL   Biochemistry 31:8906-8915(1992).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=7862664; DOI=10.1073/pnas.92.4.1218;
RA   Collins E.J., Garboczi D.N., Karpusas M.N., Wiley D.C.;
RT   "The three-dimensional structure of a class I major histocompatibility
RT   complex molecule missing the alpha 3 domain of the heavy chain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:1218-1221(1995).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=8624812; DOI=10.1016/S1074-7613(00)80430-6;
RA   Smith K.J., Reid S.W., Harlos K., McMichael A.J., Stuart D.I.,
RA   Bell J.I., Jones E.Y.;
RT   "Bound water structure and polymorphic amino acids act together to
RT   allow the binding of different peptides to MHC class I HLA-B53.";
RL   Immunity 4:215-228(1996).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-119, AND DISULFIDE BOND.
RX   PubMed=12119416; DOI=10.1073/pnas.152337399;
RA   Trinh C.H., Smith D.P., Kalverda A.P., Phillips S.E., Radford S.E.;
RT   "Crystal structure of monomeric human beta-2-microglobulin reveals
RT   clues to its amyloidogenic properties.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:9771-9776(2002).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 21-119 OF HLA-A/B2M
RP   HETERODIMER IN COMPLEX WITH TRAC AND TRBC1, AND DISULFIDE BOND.
RX   PubMed=12796775; DOI=10.1038/ni942;
RA   Stewart-Jones G.B.E., McMichael A.J., Bell J.I., Stuart D.I.,
RA   Jones E.Y.;
RT   "A structural basis for immunodominant human T cell receptor
RT   recognition.";
RL   Nat. Immunol. 4:657-663(2003).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 21-119, AMYLOID FORMATION,
RP   AND DISULFIDE BOND.
RX   PubMed=16901902; DOI=10.1074/jbc.M605358200;
RA   Kihara M., Chatani E., Iwata K., Yamamoto K., Matsuura T.,
RA   Nakagawa A., Naiki H., Goto Y.;
RT   "Conformation of amyloid fibrils of beta2-microglobulin probed by
RT   tryptophan mutagenesis.";
RL   J. Biol. Chem. 281:31061-31069(2006).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 21-119, AND DISULFIDE BOND.
RX   PubMed=16491088; DOI=10.1038/nsmb1068;
RA   Eakin C.M., Berman A.J., Miranker A.D.;
RT   "A native to amyloidogenic transition regulated by a backbone
RT   trigger.";
RL   Nat. Struct. Mol. Biol. 13:202-208(2006).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.13 ANGSTROMS) OF 21-119, AND DISULFIDE BOND.
RX   PubMed=17646174; DOI=10.1093/jb/mvm148;
RA   Iwata K., Matsuura T., Sakurai K., Nakagawa A., Goto Y.;
RT   "High-resolution crystal structure of beta2-microglobulin formed at pH
RT   7.0.";
RL   J. Biochem. 142:413-419(2007).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-119, MUTAGENESIS OF
RP   ASP-79, AND DISULFIDE BOND.
RX   PubMed=18835253; DOI=10.1016/j.bbrc.2008.09.108;
RA   Ricagno S., Colombo M., de Rosa M., Sangiovanni E., Giorgetti S.,
RA   Raimondi S., Bellotti V., Bolognesi M.;
RT   "DE loop mutations affect beta2-microglobulin stability and amyloid
RT   aggregation.";
RL   Biochem. Biophys. Res. Commun. 377:146-150(2008).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-119, MUTAGENESIS OF
RP   TRP-80, AND DISULFIDE BOND.
RX   PubMed=18395224; DOI=10.1016/j.jmb.2008.03.002;
RA   Esposito G., Ricagno S., Corazza A., Rennella E., Guemral D.,
RA   Mimmi M.C., Betto E., Pucillo C.E., Fogolari F., Viglino P.,
RA   Raimondi S., Giorgetti S., Bolognesi B., Merlini G., Stoppini M.,
RA   Bolognesi M., Bellotti V.;
RT   "The controlling roles of Trp60 and Trp95 in beta2-microglobulin
RT   function, folding and amyloid aggregation properties.";
RL   J. Mol. Biol. 378:887-897(2008).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-119, MUTAGENESIS OF
RP   TRP-80, AND DISULFIDE BOND.
RX   PubMed=19284997; DOI=10.1016/j.bbrc.2009.01.116;
RA   Ricagno S., Raimondi S., Giorgetti S., Bellotti V., Bolognesi M.;
RT   "Human beta-2 microglobulin W60V mutant structure: Implications for
RT   stability and amyloid aggregation.";
RL   Biochem. Biophys. Res. Commun. 380:543-547(2009).
RN   [36]
RP   VARIANT IMD43 PRO-11, AND CHARACTERIZATION OF VARIANT IMD43 PRO-11.
RX   PubMed=16549777; DOI=10.1073/pnas.0600548103;
RA   Wani M.A., Haynes L.D., Kim J., Bronson C.L., Chaudhury C.,
RA   Mohanty S., Waldmann T.A., Robinson J.M., Anderson C.L.;
RT   "Familial hypercatabolic hypoproteinemia caused by deficiency of the
RT   neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5084-5089(2006).
CC   -!- FUNCTION: Component of the class I major histocompatibility
CC       complex (MHC). Involved in the presentation of peptide antigens to
CC       the immune system.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain. Beta-2-
CC       microglobulin is the beta-chain of major histocompatibility
CC       complex class I molecules. Polymers of beta 2-microglobulin can be
CC       found in tissues from patients on long-term hemodialysis.
CC       {ECO:0000269|PubMed:12796775, ECO:0000269|PubMed:3532124}.
CC   -!- INTERACTION:
CC       Self; NbExp=9; IntAct=EBI-714718, EBI-714718;
CC       P06126:CD1A; NbExp=2; IntAct=EBI-714718, EBI-1036766;
CC       P29016:CD1B; NbExp=3; IntAct=EBI-714718, EBI-1033762;
CC       Q30201:HFE; NbExp=5; IntAct=EBI-714718, EBI-1028850;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:1336137,
CC       ECO:0000269|PubMed:7554280}. Note=Detected in serum and urine.
CC   -!- PTM: Glycation of Ile-21 is observed in long-term hemodialysis
CC       patients.
CC   -!- DISEASE: Immunodeficiency 43 (IMD43) [MIM:241600]: A disorder
CC       characterized by marked reduction in serum concentrations of
CC       immunoglobulins and albumin, and hypoproteinemia due to
CC       hypercatabolism. Patients may suffer from recurrent respiratory
CC       tract infections and severe skin disease.
CC       {ECO:0000269|PubMed:16549777}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Beta-2-microglobulin may adopt the fibrillar
CC       configuration of amyloid in certain pathologic states. The
CC       capacity to assemble into amyloid fibrils is concentration
CC       dependent. Persistently high beta(2)-microglobulin serum levels
CC       lead to amyloidosis in patients on long-term hemodialysis.
CC       {ECO:0000269|PubMed:7918443}.
CC   -!- SIMILARITY: Belongs to the beta-2-microglobulin family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 Ig-like C1-type (immunoglobulin-like)
CC       domain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Beta-2-microglobulin entry;
CC       URL="https://en.wikipedia.org/wiki/Beta-2-microglobulin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M17987; AAA51811.1; -; Genomic_DNA.
DR   EMBL; M17986; AAA51811.1; JOINED; Genomic_DNA.
DR   EMBL; AY187687; AAO20842.1; -; mRNA.
DR   EMBL; AB021288; BAA35182.1; -; mRNA.
DR   EMBL; DQ217933; ABB01003.1; -; Genomic_DNA.
DR   EMBL; AF072097; AAD48083.1; -; mRNA.
DR   EMBL; AY007153; AAG02006.1; -; mRNA.
DR   EMBL; CR457066; CAG33347.1; -; mRNA.
DR   EMBL; AK315776; BAG38125.1; -; mRNA.
DR   EMBL; CH471082; EAW77277.1; -; Genomic_DNA.
DR   EMBL; BC032589; AAH32589.1; -; mRNA.
DR   EMBL; BC064910; AAH64910.1; -; mRNA.
DR   EMBL; V00567; CAA23830.1; -; mRNA.
DR   CCDS; CCDS10113.1; -.
DR   PIR; A90976; MGHUB2.
DR   RefSeq; NP_004039.1; NM_004048.2.
DR   UniGene; Hs.534255; -.
DR   PDB; 1A1M; X-ray; 2.30 A; B=21-119.
DR   PDB; 1A1N; X-ray; 2.00 A; B=21-119.
DR   PDB; 1A1O; X-ray; 2.30 A; B=21-119.
DR   PDB; 1A6Z; X-ray; 2.60 A; B/D=21-119.
DR   PDB; 1A9B; X-ray; 3.20 A; B/E=21-119.
DR   PDB; 1A9E; X-ray; 2.50 A; B=21-119.
DR   PDB; 1AGB; X-ray; 2.20 A; B=21-119.
DR   PDB; 1AGC; X-ray; 2.10 A; B=21-119.
DR   PDB; 1AGD; X-ray; 2.05 A; B=21-119.
DR   PDB; 1AGE; X-ray; 2.30 A; B=21-119.
DR   PDB; 1AGF; X-ray; 2.20 A; B=21-119.
DR   PDB; 1AKJ; X-ray; 2.65 A; B=21-119.
DR   PDB; 1AO7; X-ray; 2.60 A; B=21-119.
DR   PDB; 1B0G; X-ray; 2.50 A; B/E=21-119.
DR   PDB; 1B0R; X-ray; 2.90 A; B=21-119.
DR   PDB; 1BD2; X-ray; 2.50 A; B=21-119.
DR   PDB; 1C16; X-ray; 3.10 A; B/D/F/H=21-119.
DR   PDB; 1CE6; X-ray; 2.90 A; B=21-119.
DR   PDB; 1CG9; X-ray; 2.70 A; B=21-119.
DR   PDB; 1DE4; X-ray; 2.80 A; B/E/H=21-119.
DR   PDB; 1DUY; X-ray; 2.15 A; B/E=21-119.
DR   PDB; 1DUZ; X-ray; 1.80 A; B/E=21-119.
DR   PDB; 1E27; X-ray; 2.20 A; B=21-119.
DR   PDB; 1E28; X-ray; 3.00 A; B=21-119.
DR   PDB; 1EEY; X-ray; 2.25 A; B/E=21-119.
DR   PDB; 1EEZ; X-ray; 2.30 A; B/E=21-119.
DR   PDB; 1EFX; X-ray; 3.00 A; B=21-119.
DR   PDB; 1EXU; X-ray; 2.70 A; B=21-119.
DR   PDB; 1GZP; X-ray; 2.80 A; B=21-119.
DR   PDB; 1GZQ; X-ray; 2.26 A; B=21-119.
DR   PDB; 1HHG; X-ray; 2.60 A; B/E=21-119.
DR   PDB; 1HHH; X-ray; 3.00 A; B=21-119.
DR   PDB; 1HHI; X-ray; 2.50 A; B/E=21-119.
DR   PDB; 1HHJ; X-ray; 2.50 A; B/E=21-119.
DR   PDB; 1HHK; X-ray; 2.50 A; B/E=21-119.
DR   PDB; 1HLA; X-ray; 3.50 A; M=21-117.
DR   PDB; 1HSA; X-ray; 2.10 A; B/E=21-119.
DR   PDB; 1HSB; X-ray; 1.90 A; B=21-119.
DR   PDB; 1I1F; X-ray; 2.80 A; B/E=21-119.
DR   PDB; 1I1Y; X-ray; 2.20 A; B/E=21-119.
DR   PDB; 1I4F; X-ray; 1.40 A; B=21-119.
DR   PDB; 1I7R; X-ray; 2.20 A; B/E=21-119.
DR   PDB; 1I7T; X-ray; 2.80 A; B/E=21-119.
DR   PDB; 1I7U; X-ray; 1.80 A; B/E=21-119.
DR   PDB; 1IM3; X-ray; 2.20 A; B/F/J/N=21-119.
DR   PDB; 1IM9; X-ray; 2.80 A; B/F=21-119.
DR   PDB; 1JF1; X-ray; 1.85 A; B=21-119.
DR   PDB; 1JGD; X-ray; 1.90 A; B=21-119.
DR   PDB; 1JGE; X-ray; 2.10 A; B=21-119.
DR   PDB; 1JHT; X-ray; 2.15 A; B=21-119.
DR   PDB; 1JNJ; NMR; -; A=21-119.
DR   PDB; 1K5N; X-ray; 1.09 A; B=21-119.
DR   PDB; 1KPR; X-ray; 2.80 A; B/D=21-119.
DR   PDB; 1KTL; X-ray; 3.10 A; B/D=21-119.
DR   PDB; 1LDS; X-ray; 1.80 A; A=21-119.
DR   PDB; 1LP9; X-ray; 2.00 A; B/I=21-119.
DR   PDB; 1M05; X-ray; 1.90 A; B/D=21-119.
DR   PDB; 1M6O; X-ray; 1.60 A; B=21-119.
DR   PDB; 1MHE; X-ray; 2.85 A; B/D=21-119.
DR   PDB; 1MI5; X-ray; 2.50 A; B=21-119.
DR   PDB; 1N2R; X-ray; 1.70 A; B=21-119.
DR   PDB; 1OF2; X-ray; 2.20 A; B=21-119.
DR   PDB; 1OGA; X-ray; 1.40 A; B=21-119.
DR   PDB; 1OGT; X-ray; 1.47 A; B=21-119.
DR   PDB; 1ONQ; X-ray; 2.15 A; B/D=21-119.
DR   PDB; 1P7Q; X-ray; 3.40 A; B=21-119.
DR   PDB; 1PY4; X-ray; 2.90 A; A/B/C/D=21-119.
DR   PDB; 1Q94; X-ray; 2.40 A; B/E=21-119.
DR   PDB; 1QEW; X-ray; 2.20 A; B=21-119.
DR   PDB; 1QLF; X-ray; 2.65 A; B=21-119.
DR   PDB; 1QQD; X-ray; 2.70 A; B=21-118.
DR   PDB; 1QR1; X-ray; 2.40 A; B/E=20-119.
DR   PDB; 1QRN; X-ray; 2.80 A; B=21-119.
DR   PDB; 1QSE; X-ray; 2.80 A; B=20-119.
DR   PDB; 1QSF; X-ray; 2.80 A; B=20-119.
DR   PDB; 1QVO; X-ray; 2.22 A; B/E=21-119.
DR   PDB; 1R3H; X-ray; 2.50 A; B/D/F/H=21-119.
DR   PDB; 1S8D; X-ray; 2.20 A; B=21-119.
DR   PDB; 1S9W; X-ray; 2.20 A; B=21-119.
DR   PDB; 1S9X; X-ray; 2.50 A; B=21-119.
DR   PDB; 1S9Y; X-ray; 2.30 A; B=21-119.
DR   PDB; 1SYS; X-ray; 2.40 A; B=21-119.
DR   PDB; 1SYV; X-ray; 1.70 A; B=21-119.
DR   PDB; 1T1W; X-ray; 2.20 A; B=21-119.
DR   PDB; 1T1X; X-ray; 2.20 A; B=21-119.
DR   PDB; 1T1Y; X-ray; 2.00 A; B=21-119.
DR   PDB; 1T1Z; X-ray; 1.90 A; B=21-119.
DR   PDB; 1T20; X-ray; 2.20 A; B=21-119.
DR   PDB; 1T21; X-ray; 2.19 A; B=21-119.
DR   PDB; 1T22; X-ray; 2.20 A; B=21-119.
DR   PDB; 1TMC; X-ray; 2.30 A; B=21-119.
DR   PDB; 1TVB; X-ray; 1.80 A; B/E=21-119.
DR   PDB; 1TVH; X-ray; 1.80 A; B/E=21-119.
DR   PDB; 1UQS; X-ray; 3.10 A; B=21-119.
DR   PDB; 1UR7; Model; -; B=21-119.
DR   PDB; 1UXS; X-ray; 1.55 A; B=21-119.
DR   PDB; 1UXW; X-ray; 1.71 A; B=21-119.
DR   PDB; 1VGK; X-ray; 2.06 A; B=21-119.
DR   PDB; 1W0V; X-ray; 2.27 A; B=21-119.
DR   PDB; 1W0W; X-ray; 2.10 A; B=21-119.
DR   PDB; 1W72; X-ray; 2.15 A; B/E=21-119.
DR   PDB; 1X7Q; X-ray; 1.45 A; B=21-119.
DR   PDB; 1XH3; X-ray; 1.48 A; B=21-119.
DR   PDB; 1XR8; X-ray; 2.30 A; B=21-119.
DR   PDB; 1XR9; X-ray; 1.79 A; B=21-119.
DR   PDB; 1XZ0; X-ray; 2.80 A; B/D=21-119.
DR   PDB; 1YDP; X-ray; 1.90 A; B=21-119.
DR   PDB; 1YPZ; X-ray; 3.40 A; B/D=21-119.
DR   PDB; 1ZHK; X-ray; 1.60 A; B=21-119.
DR   PDB; 1ZHL; X-ray; 1.50 A; B=21-119.
DR   PDB; 1ZS8; X-ray; 3.00 A; B/D/F/H/J=21-119.
DR   PDB; 1ZSD; X-ray; 1.70 A; B=21-119.
DR   PDB; 1ZT4; X-ray; 3.00 A; B/D=21-119.
DR   PDB; 1ZVS; X-ray; 2.80 A; B/E=21-119.
DR   PDB; 2A83; X-ray; 1.40 A; B=21-119.
DR   PDB; 2AK4; X-ray; 2.50 A; B/G/L/R=21-119.
DR   PDB; 2AV1; X-ray; 1.95 A; B/E=21-119.
DR   PDB; 2AV7; X-ray; 2.05 A; B/E=21-119.
DR   PDB; 2AXF; X-ray; 1.80 A; B=21-119.
DR   PDB; 2AXG; X-ray; 2.00 A; B=21-119.
DR   PDB; 2BCK; X-ray; 2.80 A; B/E=21-119.
DR   PDB; 2BNQ; X-ray; 1.70 A; B=21-119.
DR   PDB; 2BNR; X-ray; 1.90 A; B=21-119.
DR   PDB; 2BSR; X-ray; 2.30 A; B=21-119.
DR   PDB; 2BSS; X-ray; 2.00 A; B=21-119.
DR   PDB; 2BST; X-ray; 2.10 A; B=21-119.
DR   PDB; 2BVO; X-ray; 1.65 A; B=21-119.
DR   PDB; 2BVP; X-ray; 1.35 A; B=21-119.
DR   PDB; 2BVQ; X-ray; 2.00 A; B=21-119.
DR   PDB; 2C7U; X-ray; 2.38 A; B/E=21-119.
DR   PDB; 2CII; X-ray; 2.55 A; B=21-119.
DR   PDB; 2CIK; X-ray; 1.75 A; B=21-119.
DR   PDB; 2CLR; X-ray; 2.00 A; B/E=21-119.
DR   PDB; 2D31; X-ray; 3.20 A; B/E=21-119.
DR   PDB; 2D4D; X-ray; 2.10 A; A=21-119.
DR   PDB; 2D4F; X-ray; 1.70 A; A=21-119.
DR   PDB; 2DYP; X-ray; 2.50 A; B=21-119.
DR   PDB; 2E8D; NMR; -; A/B/C/D=40-61.
DR   PDB; 2ESV; X-ray; 2.60 A; B=21-119.
DR   PDB; 2F53; X-ray; 2.10 A; B=21-119.
DR   PDB; 2F54; X-ray; 2.70 A; B/G=21-119.
DR   PDB; 2F74; X-ray; 2.70 A; B/E=21-119.
DR   PDB; 2F8O; X-ray; 1.70 A; A/B=21-119.
DR   PDB; 2FYY; X-ray; 1.50 A; B=21-119.
DR   PDB; 2FZ3; X-ray; 1.90 A; B=21-119.
DR   PDB; 2GIT; X-ray; 1.70 A; B/E=21-119.
DR   PDB; 2GJ6; X-ray; 2.56 A; B=21-119.
DR   PDB; 2GT9; X-ray; 1.75 A; B/E=21-119.
DR   PDB; 2GTW; X-ray; 1.55 A; B/E=21-119.
DR   PDB; 2GTZ; X-ray; 1.70 A; B/E=21-119.
DR   PDB; 2GUO; X-ray; 1.90 A; B/E=21-119.
DR   PDB; 2H26; X-ray; 1.80 A; B=21-119.
DR   PDB; 2H6P; X-ray; 1.90 A; B=21-119.
DR   PDB; 2HJK; X-ray; 1.85 A; B=21-119.
DR   PDB; 2HJL; X-ray; 1.50 A; B=21-119.
DR   PDB; 2HLA; X-ray; 2.60 A; B=21-119.
DR   PDB; 2HN7; X-ray; 1.60 A; B=21-119.
DR   PDB; 2J8U; X-ray; 2.88 A; B/I=21-119.
DR   PDB; 2JCC; X-ray; 2.50 A; B/I=21-119.
DR   PDB; 2NW3; X-ray; 1.70 A; B=21-119.
DR   PDB; 2NX5; X-ray; 2.70 A; B/G/L/R=21-119.
DR   PDB; 2P5E; X-ray; 1.89 A; B=21-119.
DR   PDB; 2P5W; X-ray; 2.20 A; B=21-119.
DR   PDB; 2PO6; X-ray; 3.20 A; B/F=21-119.
DR   PDB; 2PYE; X-ray; 2.30 A; B=21-119.
DR   PDB; 2RFX; X-ray; 2.50 A; B=21-119.
DR   PDB; 2UWE; X-ray; 2.40 A; B/I=21-119.
DR   PDB; 2V2W; X-ray; 1.60 A; B/E=21-119.
DR   PDB; 2V2X; X-ray; 1.60 A; B/E=21-119.
DR   PDB; 2VB5; NMR; -; A=21-119.
DR   PDB; 2VLJ; X-ray; 2.40 A; B=21-119.
DR   PDB; 2VLK; X-ray; 2.50 A; B=21-119.
DR   PDB; 2VLL; X-ray; 1.60 A; B/E=21-119.
DR   PDB; 2VLR; X-ray; 2.30 A; B/G=21-119.
DR   PDB; 2X4N; X-ray; 2.34 A; B/E=21-119.
DR   PDB; 2X4O; X-ray; 2.30 A; B/E=21-119.
DR   PDB; 2X4P; X-ray; 2.30 A; B/E=21-119.
DR   PDB; 2X4Q; X-ray; 1.90 A; B/E=21-119.
DR   PDB; 2X4R; X-ray; 2.30 A; B/E=21-119.
DR   PDB; 2X4S; X-ray; 2.55 A; B/E=21-119.
DR   PDB; 2X4T; X-ray; 2.30 A; B/E=21-119.
DR   PDB; 2X4U; X-ray; 2.10 A; B/E=21-119.
DR   PDB; 2X70; X-ray; 2.00 A; B/E=21-119.
DR   PDB; 2X89; X-ray; 2.16 A; D/E/F/G=27-119.
DR   PDB; 2XKS; NMR; -; A=21-119.
DR   PDB; 2XKU; NMR; -; A=27-119.
DR   PDB; 2XPG; X-ray; 2.60 A; B=22-118.
DR   PDB; 2YPK; X-ray; 1.95 A; B=21-119.
DR   PDB; 2YPL; X-ray; 2.40 A; B=21-119.
DR   PDB; 2YXF; X-ray; 1.13 A; A=21-119.
DR   PDB; 2Z9T; X-ray; 1.80 A; A=21-119.
DR   PDB; 3AM8; X-ray; 2.80 A; C/D=21-119.
DR   PDB; 3B3I; X-ray; 1.86 A; B=21-119.
DR   PDB; 3B6S; X-ray; 1.80 A; B=21-119.
DR   PDB; 3BGM; X-ray; 1.60 A; B=21-119.
DR   PDB; 3BH8; X-ray; 1.65 A; B=21-119.
DR   PDB; 3BH9; X-ray; 1.70 A; B=21-119.
DR   PDB; 3BHB; X-ray; 2.20 A; B=22-119.
DR   PDB; 3BO8; X-ray; 1.80 A; B=21-119.
DR   PDB; 3BP4; X-ray; 1.85 A; B=21-119.
DR   PDB; 3BP7; X-ray; 1.80 A; B=21-119.
DR   PDB; 3BVN; X-ray; 2.55 A; B/E=21-119.
DR   PDB; 3BW9; X-ray; 1.75 A; B=21-119.
DR   PDB; 3BWA; X-ray; 1.30 A; B=21-119.
DR   PDB; 3BXN; X-ray; 1.86 A; B=21-119.
DR   PDB; 3BZE; X-ray; 2.50 A; B/D/F/H=21-119.
DR   PDB; 3BZF; X-ray; 2.50 A; B/D=23-119.
DR   PDB; 3C9N; X-ray; 1.87 A; B=21-119.
DR   PDB; 3CDG; X-ray; 3.40 A; B/D=21-119.
DR   PDB; 3CII; X-ray; 4.41 A; B/E=21-119.
DR   PDB; 3CIQ; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L=21-119.
DR   PDB; 3CZF; X-ray; 1.20 A; B=21-119.
DR   PDB; 3D18; X-ray; 1.74 A; B=21-119.
DR   PDB; 3D25; X-ray; 1.30 A; B=22-119.
DR   PDB; 3D2U; X-ray; 2.21 A; B/F=21-119.
DR   PDB; 3D39; X-ray; 2.81 A; B=21-119.
DR   PDB; 3D3V; X-ray; 2.80 A; B=21-119.
DR   PDB; 3DBX; X-ray; 2.00 A; B=21-119.
DR   PDB; 3DHJ; X-ray; 2.00 A; A=21-119.
DR   PDB; 3DHM; X-ray; 1.80 A; A=21-119.
DR   PDB; 3DTX; X-ray; 2.10 A; B=21-119.
DR   PDB; 3DX6; X-ray; 1.70 A; B=21-119.
DR   PDB; 3DX7; X-ray; 1.60 A; B=21-119.
DR   PDB; 3DX8; X-ray; 2.10 A; B=21-119.
DR   PDB; 3DXA; X-ray; 3.50 A; B/G/L=21-119.
DR   PDB; 3EKC; X-ray; 1.80 A; A=21-119.
DR   PDB; 3FFC; X-ray; 2.80 A; B/G=21-119.
DR   PDB; 3FQN; X-ray; 1.65 A; B=22-119.
DR   PDB; 3FQR; X-ray; 1.70 A; B=22-119.
DR   PDB; 3FQT; X-ray; 1.80 A; B=22-119.
DR   PDB; 3FQU; X-ray; 1.80 A; B=22-119.
DR   PDB; 3FQW; X-ray; 1.93 A; B=22-119.
DR   PDB; 3FQX; X-ray; 1.70 A; B=22-119.
DR   PDB; 3FT2; X-ray; 1.80 A; B=21-119.
DR   PDB; 3FT3; X-ray; 1.95 A; B=21-119.
DR   PDB; 3FT4; X-ray; 1.90 A; B=21-119.
DR   PDB; 3GIV; X-ray; 2.00 A; B/E=21-119.
DR   PDB; 3GJF; X-ray; 1.90 A; B/E=21-119.
DR   PDB; 3GSN; X-ray; 2.80 A; L=21-119.
DR   PDB; 3GSO; X-ray; 1.60 A; B=21-119.
DR   PDB; 3GSQ; X-ray; 2.12 A; B=21-119.
DR   PDB; 3GSR; X-ray; 1.95 A; B=21-119.
DR   PDB; 3GSU; X-ray; 1.80 A; B=21-119.
DR   PDB; 3GSV; X-ray; 1.90 A; B=21-119.
DR   PDB; 3GSW; X-ray; 1.81 A; B=21-119.
DR   PDB; 3GSX; X-ray; 2.10 A; B=21-119.
DR   PDB; 3H7B; X-ray; 1.88 A; B/E=21-119.
DR   PDB; 3H9H; X-ray; 2.00 A; B/E=21-119.
DR   PDB; 3H9S; X-ray; 2.70 A; B=21-119.
DR   PDB; 3HAE; X-ray; 2.90 A; B/E/K/Q=21-119.
DR   PDB; 3HCV; X-ray; 1.95 A; B=21-119.
DR   PDB; 3HG1; X-ray; 3.00 A; B=21-119.
DR   PDB; 3HLA; X-ray; 2.60 A; B=21-119.
DR   PDB; 3HPJ; X-ray; 2.00 A; B/E=21-119.
DR   PDB; 3HUJ; X-ray; 2.50 A; B/D=21-119.
DR   PDB; 3I6G; X-ray; 2.20 A; B/E=21-119.
DR   PDB; 3I6K; X-ray; 2.80 A; B/F=21-119.
DR   PDB; 3I6L; X-ray; 2.40 A; E=21-119.
DR   PDB; 3IB4; X-ray; 1.25 A; A=21-119.
DR   PDB; 3IXA; X-ray; 2.10 A; B/E=21-119.
DR   PDB; 3JTS; X-ray; 2.80 A; B/E/H=1-119.
DR   PDB; 3KLA; X-ray; 1.65 A; B/E=21-119.
DR   PDB; 3KPL; X-ray; 1.96 A; B=21-119.
DR   PDB; 3KPM; X-ray; 1.60 A; B=21-119.
DR   PDB; 3KPN; X-ray; 2.00 A; B=21-119.
DR   PDB; 3KPO; X-ray; 2.30 A; B=21-119.
DR   PDB; 3KPP; X-ray; 1.90 A; B=21-119.
DR   PDB; 3KPQ; X-ray; 1.84 A; B=21-119.
DR   PDB; 3KPR; X-ray; 2.60 A; B/G=21-119.
DR   PDB; 3KPS; X-ray; 2.70 A; B=21-119.
DR   PDB; 3KWW; X-ray; 2.18 A; B=21-119.
DR   PDB; 3KXF; X-ray; 3.10 A; B/F/J/L=21-119.
DR   PDB; 3KYN; X-ray; 2.40 A; B=21-119.
DR   PDB; 3KYO; X-ray; 1.70 A; B/D=21-119.
DR   PDB; 3L3D; X-ray; 1.80 A; B=21-119.
DR   PDB; 3L3G; X-ray; 2.10 A; B=21-119.
DR   PDB; 3L3I; X-ray; 1.70 A; B=21-119.
DR   PDB; 3L3J; X-ray; 2.40 A; B=21-119.
DR   PDB; 3L3K; X-ray; 2.60 A; B=21-119.
DR   PDB; 3LKN; X-ray; 2.00 A; B=21-119.
DR   PDB; 3LKO; X-ray; 1.80 A; B=21-119.
DR   PDB; 3LKP; X-ray; 1.80 A; B=21-119.
DR   PDB; 3LKQ; X-ray; 1.80 A; B=21-119.
DR   PDB; 3LKR; X-ray; 2.00 A; B=21-119.
DR   PDB; 3LKS; X-ray; 1.90 A; B=21-119.
DR   PDB; 3LN4; X-ray; 1.30 A; B=21-119.
DR   PDB; 3LN5; X-ray; 1.90 A; B=21-119.
DR   PDB; 3LOW; X-ray; 2.30 A; A/B=21-119.
DR   PDB; 3LOZ; X-ray; 1.80 A; A/B/C/D=74-79.
DR   PDB; 3LV3; X-ray; 1.94 A; B=21-119.
DR   PDB; 3M17; X-ray; 2.60 A; B/D/F/H=21-119.
DR   PDB; 3M1B; X-ray; 3.10 A; B/D/F/H=21-119.
DR   PDB; 3MGO; X-ray; 2.30 A; B/E/H/K=21-119.
DR   PDB; 3MGT; X-ray; 2.20 A; B/E/H/K=21-119.
DR   PDB; 3MR9; X-ray; 1.93 A; B=21-119.
DR   PDB; 3MRB; X-ray; 1.40 A; B=21-119.
DR   PDB; 3MRC; X-ray; 1.80 A; B=21-119.
DR   PDB; 3MRD; X-ray; 1.70 A; B=21-119.
DR   PDB; 3MRE; X-ray; 1.10 A; B=21-119.
DR   PDB; 3MRF; X-ray; 2.30 A; B=21-119.
DR   PDB; 3MRG; X-ray; 1.30 A; B=21-119.
DR   PDB; 3MRH; X-ray; 2.40 A; B=21-119.
DR   PDB; 3MRI; X-ray; 2.10 A; B=21-119.
DR   PDB; 3MRJ; X-ray; 1.87 A; B=21-119.
DR   PDB; 3MRK; X-ray; 1.40 A; B=21-119.
DR   PDB; 3MRL; X-ray; 2.41 A; B=21-119.
DR   PDB; 3MRM; X-ray; 1.90 A; B=21-119.
DR   PDB; 3MRN; X-ray; 2.30 A; B=21-119.
DR   PDB; 3MRO; X-ray; 2.35 A; B=21-119.
DR   PDB; 3MRP; X-ray; 2.10 A; B=21-119.
DR   PDB; 3MRQ; X-ray; 2.20 A; B=21-119.
DR   PDB; 3MRR; X-ray; 1.60 A; B=21-119.
DR   PDB; 3MV7; X-ray; 2.00 A; B=21-119.
DR   PDB; 3MV8; X-ray; 2.10 A; B=21-119.
DR   PDB; 3MV9; X-ray; 2.70 A; B=21-119.
DR   PDB; 3MYJ; X-ray; 1.89 A; B/E=21-119.
DR   PDB; 3MYZ; X-ray; 1.60 A; A/B=21-119.
DR   PDB; 3MZT; X-ray; 2.70 A; A/B/C/D/E/F=21-119.
DR   PDB; 3NA4; X-ray; 1.90 A; A=21-119.
DR   PDB; 3NFN; X-ray; 2.39 A; B=21-119.
DR   PDB; 3O3A; X-ray; 1.80 A; B/E=21-119.
DR   PDB; 3O3B; X-ray; 1.90 A; B/E=21-119.
DR   PDB; 3O3D; X-ray; 1.70 A; B/E=21-119.
DR   PDB; 3O3E; X-ray; 1.85 A; B/E=21-119.
DR   PDB; 3O4L; X-ray; 2.54 A; B=21-119.
DR   PDB; 3OV6; X-ray; 2.50 A; A=21-119.
DR   PDB; 3OX8; X-ray; 2.16 A; B/E=21-119.
DR   PDB; 3OXR; X-ray; 1.70 A; B=21-119.
DR   PDB; 3OXS; X-ray; 1.75 A; B=21-119.
DR   PDB; 3PWJ; X-ray; 1.70 A; B/E=21-119.
DR   PDB; 3PWL; X-ray; 1.65 A; B/E=21-119.
DR   PDB; 3PWN; X-ray; 1.60 A; B/E=21-119.
DR   PDB; 3PWP; X-ray; 2.69 A; B=21-119.
DR   PDB; 3QDA; X-ray; 1.57 A; A=21-119.
DR   PDB; 3QDG; X-ray; 2.69 A; B=21-119.
DR   PDB; 3QDJ; X-ray; 2.30 A; B=21-119.
DR   PDB; 3QDM; X-ray; 2.80 A; B=21-119.
DR   PDB; 3QEQ; X-ray; 2.59 A; B=21-119.
DR   PDB; 3QFD; X-ray; 1.68 A; B/E=21-119.
DR   PDB; 3QFJ; X-ray; 2.29 A; B=21-119.
DR   PDB; 3QZW; X-ray; 2.80 A; B/E=21-119.
DR   PDB; 3REW; X-ray; 1.90 A; B/E=21-119.
DR   PDB; 3RL1; X-ray; 2.00 A; B=21-119.
DR   PDB; 3RL2; X-ray; 2.39 A; B=21-119.
DR   PDB; 3RWJ; X-ray; 2.70 A; B=21-119.
DR   PDB; 3S6C; X-ray; 2.90 A; A=21-119.
DR   PDB; 3SDX; X-ray; 3.12 A; B/D=21-119.
DR   PDB; 3SJV; X-ray; 3.10 A; B/G/L/Q=21-119.
DR   PDB; 3SKM; X-ray; 1.80 A; B=21-119.
DR   PDB; 3SKO; X-ray; 1.60 A; B=21-119.
DR   PDB; 3SPV; X-ray; 1.30 A; B=21-119.
DR   PDB; 3T8X; X-ray; 1.90 A; B/D=21-119.
DR   PDB; 3TID; X-ray; 1.65 A; B=21-119.
DR   PDB; 3TIE; X-ray; 2.25 A; B/E=21-119.
DR   PDB; 3TLR; X-ray; 2.45 A; A/B/C/D=21-119.
DR   PDB; 3TM6; X-ray; 2.70 A; A/B/C/D/E/F/G/H=21-119.
DR   PDB; 3TO2; X-ray; 2.60 A; B=21-119.
DR   PDB; 3TZV; X-ray; 3.06 A; D=21-119.
DR   PDB; 3U0P; X-ray; 2.80 A; B/D/F=21-119.
DR   PDB; 3UPR; X-ray; 2.00 A; B/D=21-119.
DR   PDB; 3UTQ; X-ray; 1.67 A; B=21-119.
DR   PDB; 3UTS; X-ray; 2.71 A; B/G=21-119.
DR   PDB; 3UTT; X-ray; 2.60 A; B/G=21-119.
DR   PDB; 3V5D; X-ray; 2.00 A; B/E=21-119.
DR   PDB; 3V5H; X-ray; 1.63 A; B/E=21-119.
DR   PDB; 3V5K; X-ray; 2.31 A; B/E=21-119.
DR   PDB; 3VCL; X-ray; 1.70 A; B=21-119.
DR   PDB; 3VFM; X-ray; 1.90 A; B=21-119.
DR   PDB; 3VFN; X-ray; 1.50 A; B=21-119.
DR   PDB; 3VFO; X-ray; 1.70 A; B=21-119.
DR   PDB; 3VFP; X-ray; 1.85 A; B=21-119.
DR   PDB; 3VFR; X-ray; 1.85 A; B=21-119.
DR   PDB; 3VFS; X-ray; 1.85 A; B=21-119.
DR   PDB; 3VFT; X-ray; 1.95 A; B=21-119.
DR   PDB; 3VFU; X-ray; 1.65 A; B=21-119.
DR   PDB; 3VFV; X-ray; 1.55 A; B=21-119.
DR   PDB; 3VFW; X-ray; 2.30 A; B=21-119.
DR   PDB; 3VH8; X-ray; 1.80 A; B/E=21-119.
DR   PDB; 3VRI; X-ray; 1.60 A; B=21-119.
DR   PDB; 3VRJ; X-ray; 1.90 A; B=21-119.
DR   PDB; 3VWJ; X-ray; 3.09 A; B=21-119.
DR   PDB; 3VWK; X-ray; 2.94 A; B=21-119.
DR   PDB; 3VXM; X-ray; 2.50 A; B=21-119.
DR   PDB; 3VXN; X-ray; 1.95 A; B=21-119.
DR   PDB; 3VXO; X-ray; 2.61 A; B/E=21-119.
DR   PDB; 3VXP; X-ray; 2.50 A; B/E=21-119.
DR   PDB; 3VXR; X-ray; 2.40 A; B=21-119.
DR   PDB; 3VXS; X-ray; 1.80 A; B=21-119.
DR   PDB; 3VXU; X-ray; 2.70 A; B/G=21-119.
DR   PDB; 3W0W; X-ray; 2.60 A; B=21-119.
DR   PDB; 3W39; X-ray; 3.10 A; B/E=21-119.
DR   PDB; 3WL9; X-ray; 1.66 A; B=21-119.
DR   PDB; 3WLB; X-ray; 2.00 A; B=21-119.
DR   PDB; 3WUW; X-ray; 2.00 A; B=22-119.
DR   PDB; 3X11; X-ray; 2.15 A; B=21-119.
DR   PDB; 3X12; X-ray; 1.80 A; B=21-119.
DR   PDB; 3X13; X-ray; 1.80 A; B=21-119.
DR   PDB; 3X14; X-ray; 2.00 A; B=21-119.
DR   PDB; 4BEO; X-ray; 2.43 A; B/D=21-119.
DR   PDB; 4E0K; X-ray; 0.97 A; A/B/C/D=78-83.
DR   PDB; 4E0L; X-ray; 1.70 A; A/B/C/D=82-89.
DR   PDB; 4E5X; X-ray; 1.95 A; B/E=21-119.
DR   PDB; 4EN3; X-ray; 2.57 A; D=21-119.
DR   PDB; 4EUP; X-ray; 2.88 A; B/E=21-119.
DR   PDB; 4EUQ; X-ray; 2.69 A; B/E=21-119.
DR   PDB; 4F7M; X-ray; 2.40 A; B/E=21-119.
DR   PDB; 4F7P; X-ray; 1.90 A; B=21-119.
DR   PDB; 4F7T; X-ray; 1.70 A; B/E=21-119.
DR   PDB; 4FTV; X-ray; 2.74 A; B=21-119.
DR   PDB; 4FXL; X-ray; 1.40 A; A=21-119.
DR   PDB; 4G8G; X-ray; 2.40 A; B=21-119.
DR   PDB; 4G8I; X-ray; 1.60 A; B=21-119.
DR   PDB; 4G9D; X-ray; 1.60 A; B=21-119.
DR   PDB; 4G9F; X-ray; 1.90 A; B=21-119.
DR   PDB; 4GKN; X-ray; 2.75 A; B/E=21-119.
DR   PDB; 4GKS; X-ray; 2.35 A; B/E=21-119.
DR   PDB; 4GUP; X-ray; 3.20 A; B/D=21-119.
DR   PDB; 4HKJ; X-ray; 3.00 A; B/F/J/N=21-119.
DR   PDB; 4HWZ; X-ray; 2.40 A; B=21-119.
DR   PDB; 4HX1; X-ray; 1.80 A; B=21-119.
DR   PDB; 4I48; X-ray; 2.80 A; B=21-119.
DR   PDB; 4I4W; X-ray; 1.77 A; B=21-119.
DR   PDB; 4JFD; X-ray; 2.46 A; B=21-119.
DR   PDB; 4JFE; X-ray; 2.70 A; B=21-119.
DR   PDB; 4JFF; X-ray; 2.43 A; B=21-119.
DR   PDB; 4JFO; X-ray; 2.11 A; B/E=21-119.
DR   PDB; 4JFP; X-ray; 1.91 A; B/E=21-119.
DR   PDB; 4JFQ; X-ray; 1.90 A; B/E=21-119.
DR   PDB; 4JQV; X-ray; 1.50 A; C=21-119.
DR   PDB; 4JQX; X-ray; 1.90 A; C=21-119.
DR   PDB; 4JRX; X-ray; 2.30 A; B=21-119.
DR   PDB; 4JRY; X-ray; 2.80 A; B=21-119.
DR   PDB; 4K71; X-ray; 2.40 A; C/F=21-119.
DR   PDB; 4K7F; X-ray; 2.00 A; B/E=21-119.
DR   PDB; 4KDT; X-ray; 2.60 A; C/D=21-119.
DR   PDB; 4L29; X-ray; 3.09 A; B/D/F/H/J/L/N/P/R/T/V/X/Z/b=21-119.
DR   PDB; 4L3C; X-ray; 2.64 A; B/D/F/H/J/L/N/P/R/T/V/X/Z/b=21-119.
DR   PDB; 4L3E; X-ray; 2.56 A; B=21-119.
DR   PDB; 4L4T; X-ray; 2.00 A; B/F=21-119.
DR   PDB; 4L4V; X-ray; 1.90 A; B/F=21-119.
DR   PDB; 4LCW; X-ray; 2.40 A; B/F=21-119.
DR   PDB; 4LCY; X-ray; 1.60 A; B/H=21-119.
DR   PDB; 4LHU; X-ray; 2.87 A; B=21-119.
DR   PDB; 4LNR; X-ray; 2.00 A; B=21-119.
DR   PDB; 4M8V; X-ray; 1.95 A; A/B=21-119.
DR   PDB; 4MJ5; X-ray; 2.40 A; B=21-119.
DR   PDB; 4MJ6; X-ray; 2.57 A; B=21-119.
DR   PDB; 4MJI; X-ray; 2.99 A; B/G=21-119.
DR   PDB; 4MNQ; X-ray; 2.74 A; B=21-119.
DR   PDB; 4N0F; X-ray; 3.02 A; B/F/I/L=21-119.
DR   PDB; 4N0U; X-ray; 3.80 A; B=21-119.
DR   PDB; 4N8V; X-ray; 2.50 A; B/E=21-119.
DR   PDB; 4NNX; X-ray; 2.10 A; B=21-119.
DR   PDB; 4NNY; X-ray; 1.90 A; B=21-119.
DR   PDB; 4NO0; X-ray; 2.70 A; B=21-119.
DR   PDB; 4NO2; X-ray; 2.00 A; B=21-119.
DR   PDB; 4NO3; X-ray; 1.70 A; B=21-119.
DR   PDB; 4NO5; X-ray; 2.10 A; B=22-119.
DR   PDB; 4NQC; X-ray; 2.50 A; B/F=21-119.
DR   PDB; 4NQD; X-ray; 2.20 A; B/F=21-119.
DR   PDB; 4NQE; X-ray; 2.10 A; B/F=21-119.
DR   PDB; 4NQV; X-ray; 2.39 A; B/D/F/H/J/L=21-119.
DR   PDB; 4NQX; X-ray; 2.00 A; B/D/F/H/J/L=21-119.
DR   PDB; 4NT6; X-ray; 1.84 A; B=21-118.
DR   PDB; 4O2C; X-ray; 1.80 A; B=21-119.
DR   PDB; 4O2E; X-ray; 1.98 A; B/E=21-119.
DR   PDB; 4O2F; X-ray; 1.90 A; B/E=21-119.
DR   PDB; 4ONO; X-ray; 2.70 A; A=21-119.
DR   PDB; 4PJ5; X-ray; 2.00 A; B/F=21-119.
DR   PDB; 4PJ7; X-ray; 2.50 A; B/D=21-119.
DR   PDB; 4PJ8; X-ray; 3.30 A; B=21-119.
DR   PDB; 4PJ9; X-ray; 2.00 A; B=21-119.
DR   PDB; 4PJA; X-ray; 2.68 A; B/D=21-119.
DR   PDB; 4PJB; X-ray; 2.85 A; B/D=21-119.
DR   PDB; 4PJC; X-ray; 2.50 A; B/D=21-119.
DR   PDB; 4PJD; X-ray; 2.78 A; B/D=21-119.
DR   PDB; 4PJE; X-ray; 1.95 A; B/D=21-119.
DR   PDB; 4PJF; X-ray; 2.45 A; B/D=21-119.
DR   PDB; 4PJG; X-ray; 2.40 A; B/D=21-119.
DR   PDB; 4PJH; X-ray; 2.00 A; B/D=21-119.
DR   PDB; 4PJI; X-ray; 2.50 A; B/D=21-119.
DR   PDB; 4PJX; X-ray; 2.25 A; B/D=21-119.
DR   PDB; 4PR5; X-ray; 1.80 A; B=21-119.
DR   PDB; 4PRA; X-ray; 1.85 A; B=21-119.
DR   PDB; 4PRB; X-ray; 1.75 A; B=21-119.
DR   PDB; 4PRD; X-ray; 1.75 A; B=21-119.
DR   PDB; 4PRE; X-ray; 1.65 A; B=21-119.
DR   PDB; 4PRH; X-ray; 2.50 A; B=23-119.
DR   PDB; 4PRI; X-ray; 2.40 A; B=21-119.
DR   PDB; 4PRN; X-ray; 1.65 A; B=21-119.
DR   PDB; 4PRP; X-ray; 2.50 A; B=21-119.
DR   PDB; 4QOK; X-ray; 3.00 A; B=21-119.
DR   PDB; 4QRP; X-ray; 2.90 A; B/G=21-119.
DR   PDB; 4QRQ; X-ray; 1.70 A; B=21-119.
DR   PDB; 4QRR; X-ray; 3.00 A; B=21-119.
DR   PDB; 4QRS; X-ray; 1.40 A; B=22-119.
DR   PDB; 4QRT; X-ray; 1.40 A; B=21-119.
DR   PDB; 4QRU; X-ray; 1.60 A; B=21-119.
DR   PDB; 4R9H; X-ray; 1.90 A; A/B/C/D=21-119.
DR   PDB; 4RA3; X-ray; 2.80 A; A/B/C/D=21-119.
DR   PDB; 4RAH; X-ray; 1.40 A; A=21-119.
DR   PDB; 4RMQ; X-ray; 1.46 A; A=21-119.
DR   PDB; 4RMR; X-ray; 1.53 A; A=21-119.
DR   PDB; 4RMS; X-ray; 1.70 A; A=21-119.
DR   PDB; 4RMT; X-ray; 1.24 A; A=21-117.
DR   PDB; 4RMU; X-ray; 1.40 A; A=21-119.
DR   PDB; 4RMV; X-ray; 1.46 A; A=21-119.
DR   PDB; 4RMW; X-ray; 1.40 A; A=21-119.
DR   PDB; 4U1H; X-ray; 1.59 A; B=21-119.
DR   PDB; 4U1I; X-ray; 1.92 A; B=21-119.
DR   PDB; 4U1J; X-ray; 1.38 A; B=21-119.
DR   PDB; 4U1K; X-ray; 2.09 A; B/E=21-119.
DR   PDB; 4U1L; X-ray; 2.06 A; B/E=21-119.
DR   PDB; 4U1M; X-ray; 1.18 A; B=21-119.
DR   PDB; 4U1N; X-ray; 1.77 A; B=21-119.
DR   PDB; 4U1S; X-ray; 1.76 A; B=21-119.
DR   PDB; 4U6X; X-ray; 1.68 A; B=21-119.
DR   PDB; 4U6Y; X-ray; 1.47 A; B=21-119.
DR   PDB; 4UQ2; X-ray; 2.43 A; B/D=21-119.
DR   PDB; 4UQ3; X-ray; 2.10 A; B/D=21-119.
DR   PDB; 4WDI; X-ray; 2.31 A; B/E=21-119.
DR   PDB; 4WJ5; X-ray; 1.65 A; B/E=21-119.
DR   PDB; 4WO4; X-ray; 2.50 A; B=21-119.
DR   PDB; 4WU5; X-ray; 2.40 A; B/E=21-119.
DR   PDB; 4WU7; X-ray; 2.30 A; B/E=21-119.
DR   PDB; 4WUU; X-ray; 3.05 A; B=21-119.
DR   PDB; 4X6C; X-ray; 2.80 A; B/D=21-119.
DR   PDB; 4X6D; X-ray; 2.98 A; B/D=21-119.
DR   PDB; 4X6E; X-ray; 2.10 A; B=21-119.
DR   PDB; 4X6F; X-ray; 1.91 A; B=21-119.
DR   PDB; 4XXC; X-ray; 1.43 A; C=21-119.
DR   PDB; 4Z76; X-ray; 1.88 A; B/E=21-119.
DR   PDB; 4Z77; X-ray; 1.85 A; B/E=21-119.
DR   PDB; 4Z78; X-ray; 2.30 A; B/E/H=21-119.
DR   PDB; 5BXF; X-ray; 2.85 A; B/D=1-119.
DR   PDB; 5D2L; X-ray; 3.51 A; B/D/H/N=21-119.
DR   PDB; 5D2N; X-ray; 2.10 A; B/L=21-119.
DR   PDB; 5DEF; X-ray; 1.60 A; B=21-119.
DR   PDB; 5DEG; X-ray; 1.83 A; B=21-119.
DR   PDBsum; 1A1M; -.
DR   PDBsum; 1A1N; -.
DR   PDBsum; 1A1O; -.
DR   PDBsum; 1A6Z; -.
DR   PDBsum; 1A9B; -.
DR   PDBsum; 1A9E; -.
DR   PDBsum; 1AGB; -.
DR   PDBsum; 1AGC; -.
DR   PDBsum; 1AGD; -.
DR   PDBsum; 1AGE; -.
DR   PDBsum; 1AGF; -.
DR   PDBsum; 1AKJ; -.
DR   PDBsum; 1AO7; -.
DR   PDBsum; 1B0G; -.
DR   PDBsum; 1B0R; -.
DR   PDBsum; 1BD2; -.
DR   PDBsum; 1C16; -.
DR   PDBsum; 1CE6; -.
DR   PDBsum; 1CG9; -.
DR   PDBsum; 1DE4; -.
DR   PDBsum; 1DUY; -.
DR   PDBsum; 1DUZ; -.
DR   PDBsum; 1E27; -.
DR   PDBsum; 1E28; -.
DR   PDBsum; 1EEY; -.
DR   PDBsum; 1EEZ; -.
DR   PDBsum; 1EFX; -.
DR   PDBsum; 1EXU; -.
DR   PDBsum; 1GZP; -.
DR   PDBsum; 1GZQ; -.
DR   PDBsum; 1HHG; -.
DR   PDBsum; 1HHH; -.
DR   PDBsum; 1HHI; -.
DR   PDBsum; 1HHJ; -.
DR   PDBsum; 1HHK; -.
DR   PDBsum; 1HLA; -.
DR   PDBsum; 1HSA; -.
DR   PDBsum; 1HSB; -.
DR   PDBsum; 1I1F; -.
DR   PDBsum; 1I1Y; -.
DR   PDBsum; 1I4F; -.
DR   PDBsum; 1I7R; -.
DR   PDBsum; 1I7T; -.
DR   PDBsum; 1I7U; -.
DR   PDBsum; 1IM3; -.
DR   PDBsum; 1IM9; -.
DR   PDBsum; 1JF1; -.
DR   PDBsum; 1JGD; -.
DR   PDBsum; 1JGE; -.
DR   PDBsum; 1JHT; -.
DR   PDBsum; 1JNJ; -.
DR   PDBsum; 1K5N; -.
DR   PDBsum; 1KPR; -.
DR   PDBsum; 1KTL; -.
DR   PDBsum; 1LDS; -.
DR   PDBsum; 1LP9; -.
DR   PDBsum; 1M05; -.
DR   PDBsum; 1M6O; -.
DR   PDBsum; 1MHE; -.
DR   PDBsum; 1MI5; -.
DR   PDBsum; 1N2R; -.
DR   PDBsum; 1OF2; -.
DR   PDBsum; 1OGA; -.
DR   PDBsum; 1OGT; -.
DR   PDBsum; 1ONQ; -.
DR   PDBsum; 1P7Q; -.
DR   PDBsum; 1PY4; -.
DR   PDBsum; 1Q94; -.
DR   PDBsum; 1QEW; -.
DR   PDBsum; 1QLF; -.
DR   PDBsum; 1QQD; -.
DR   PDBsum; 1QR1; -.
DR   PDBsum; 1QRN; -.
DR   PDBsum; 1QSE; -.
DR   PDBsum; 1QSF; -.
DR   PDBsum; 1QVO; -.
DR   PDBsum; 1R3H; -.
DR   PDBsum; 1S8D; -.
DR   PDBsum; 1S9W; -.
DR   PDBsum; 1S9X; -.
DR   PDBsum; 1S9Y; -.
DR   PDBsum; 1SYS; -.
DR   PDBsum; 1SYV; -.
DR   PDBsum; 1T1W; -.
DR   PDBsum; 1T1X; -.
DR   PDBsum; 1T1Y; -.
DR   PDBsum; 1T1Z; -.
DR   PDBsum; 1T20; -.
DR   PDBsum; 1T21; -.
DR   PDBsum; 1T22; -.
DR   PDBsum; 1TMC; -.
DR   PDBsum; 1TVB; -.
DR   PDBsum; 1TVH; -.
DR   PDBsum; 1UQS; -.
DR   PDBsum; 1UR7; -.
DR   PDBsum; 1UXS; -.
DR   PDBsum; 1UXW; -.
DR   PDBsum; 1VGK; -.
DR   PDBsum; 1W0V; -.
DR   PDBsum; 1W0W; -.
DR   PDBsum; 1W72; -.
DR   PDBsum; 1X7Q; -.
DR   PDBsum; 1XH3; -.
DR   PDBsum; 1XR8; -.
DR   PDBsum; 1XR9; -.
DR   PDBsum; 1XZ0; -.
DR   PDBsum; 1YDP; -.
DR   PDBsum; 1YPZ; -.
DR   PDBsum; 1ZHK; -.
DR   PDBsum; 1ZHL; -.
DR   PDBsum; 1ZS8; -.
DR   PDBsum; 1ZSD; -.
DR   PDBsum; 1ZT4; -.
DR   PDBsum; 1ZVS; -.
DR   PDBsum; 2A83; -.
DR   PDBsum; 2AK4; -.
DR   PDBsum; 2AV1; -.
DR   PDBsum; 2AV7; -.
DR   PDBsum; 2AXF; -.
DR   PDBsum; 2AXG; -.
DR   PDBsum; 2BCK; -.
DR   PDBsum; 2BNQ; -.
DR   PDBsum; 2BNR; -.
DR   PDBsum; 2BSR; -.
DR   PDBsum; 2BSS; -.
DR   PDBsum; 2BST; -.
DR   PDBsum; 2BVO; -.
DR   PDBsum; 2BVP; -.
DR   PDBsum; 2BVQ; -.
DR   PDBsum; 2C7U; -.
DR   PDBsum; 2CII; -.
DR   PDBsum; 2CIK; -.
DR   PDBsum; 2CLR; -.
DR   PDBsum; 2D31; -.
DR   PDBsum; 2D4D; -.
DR   PDBsum; 2D4F; -.
DR   PDBsum; 2DYP; -.
DR   PDBsum; 2E8D; -.
DR   PDBsum; 2ESV; -.
DR   PDBsum; 2F53; -.
DR   PDBsum; 2F54; -.
DR   PDBsum; 2F74; -.
DR   PDBsum; 2F8O; -.
DR   PDBsum; 2FYY; -.
DR   PDBsum; 2FZ3; -.
DR   PDBsum; 2GIT; -.
DR   PDBsum; 2GJ6; -.
DR   PDBsum; 2GT9; -.
DR   PDBsum; 2GTW; -.
DR   PDBsum; 2GTZ; -.
DR   PDBsum; 2GUO; -.
DR   PDBsum; 2H26; -.
DR   PDBsum; 2H6P; -.
DR   PDBsum; 2HJK; -.
DR   PDBsum; 2HJL; -.
DR   PDBsum; 2HLA; -.
DR   PDBsum; 2HN7; -.
DR   PDBsum; 2J8U; -.
DR   PDBsum; 2JCC; -.
DR   PDBsum; 2NW3; -.
DR   PDBsum; 2NX5; -.
DR   PDBsum; 2P5E; -.
DR   PDBsum; 2P5W; -.
DR   PDBsum; 2PO6; -.
DR   PDBsum; 2PYE; -.
DR   PDBsum; 2RFX; -.
DR   PDBsum; 2UWE; -.
DR   PDBsum; 2V2W; -.
DR   PDBsum; 2V2X; -.
DR   PDBsum; 2VB5; -.
DR   PDBsum; 2VLJ; -.
DR   PDBsum; 2VLK; -.
DR   PDBsum; 2VLL; -.
DR   PDBsum; 2VLR; -.
DR   PDBsum; 2X4N; -.
DR   PDBsum; 2X4O; -.
DR   PDBsum; 2X4P; -.
DR   PDBsum; 2X4Q; -.
DR   PDBsum; 2X4R; -.
DR   PDBsum; 2X4S; -.
DR   PDBsum; 2X4T; -.
DR   PDBsum; 2X4U; -.
DR   PDBsum; 2X70; -.
DR   PDBsum; 2X89; -.
DR   PDBsum; 2XKS; -.
DR   PDBsum; 2XKU; -.
DR   PDBsum; 2XPG; -.
DR   PDBsum; 2YPK; -.
DR   PDBsum; 2YPL; -.
DR   PDBsum; 2YXF; -.
DR   PDBsum; 2Z9T; -.
DR   PDBsum; 3AM8; -.
DR   PDBsum; 3B3I; -.
DR   PDBsum; 3B6S; -.
DR   PDBsum; 3BGM; -.
DR   PDBsum; 3BH8; -.
DR   PDBsum; 3BH9; -.
DR   PDBsum; 3BHB; -.
DR   PDBsum; 3BO8; -.
DR   PDBsum; 3BP4; -.
DR   PDBsum; 3BP7; -.
DR   PDBsum; 3BVN; -.
DR   PDBsum; 3BW9; -.
DR   PDBsum; 3BWA; -.
DR   PDBsum; 3BXN; -.
DR   PDBsum; 3BZE; -.
DR   PDBsum; 3BZF; -.
DR   PDBsum; 3C9N; -.
DR   PDBsum; 3CDG; -.
DR   PDBsum; 3CII; -.
DR   PDBsum; 3CIQ; -.
DR   PDBsum; 3CZF; -.
DR   PDBsum; 3D18; -.
DR   PDBsum; 3D25; -.
DR   PDBsum; 3D2U; -.
DR   PDBsum; 3D39; -.
DR   PDBsum; 3D3V; -.
DR   PDBsum; 3DBX; -.
DR   PDBsum; 3DHJ; -.
DR   PDBsum; 3DHM; -.
DR   PDBsum; 3DTX; -.
DR   PDBsum; 3DX6; -.
DR   PDBsum; 3DX7; -.
DR   PDBsum; 3DX8; -.
DR   PDBsum; 3DXA; -.
DR   PDBsum; 3EKC; -.
DR   PDBsum; 3FFC; -.
DR   PDBsum; 3FQN; -.
DR   PDBsum; 3FQR; -.
DR   PDBsum; 3FQT; -.
DR   PDBsum; 3FQU; -.
DR   PDBsum; 3FQW; -.
DR   PDBsum; 3FQX; -.
DR   PDBsum; 3FT2; -.
DR   PDBsum; 3FT3; -.
DR   PDBsum; 3FT4; -.
DR   PDBsum; 3GIV; -.
DR   PDBsum; 3GJF; -.
DR   PDBsum; 3GSN; -.
DR   PDBsum; 3GSO; -.
DR   PDBsum; 3GSQ; -.
DR   PDBsum; 3GSR; -.
DR   PDBsum; 3GSU; -.
DR   PDBsum; 3GSV; -.
DR   PDBsum; 3GSW; -.
DR   PDBsum; 3GSX; -.
DR   PDBsum; 3H7B; -.
DR   PDBsum; 3H9H; -.
DR   PDBsum; 3H9S; -.
DR   PDBsum; 3HAE; -.
DR   PDBsum; 3HCV; -.
DR   PDBsum; 3HG1; -.
DR   PDBsum; 3HLA; -.
DR   PDBsum; 3HPJ; -.
DR   PDBsum; 3HUJ; -.
DR   PDBsum; 3I6G; -.
DR   PDBsum; 3I6K; -.
DR   PDBsum; 3I6L; -.
DR   PDBsum; 3IB4; -.
DR   PDBsum; 3IXA; -.
DR   PDBsum; 3JTS; -.
DR   PDBsum; 3KLA; -.
DR   PDBsum; 3KPL; -.
DR   PDBsum; 3KPM; -.
DR   PDBsum; 3KPN; -.
DR   PDBsum; 3KPO; -.
DR   PDBsum; 3KPP; -.
DR   PDBsum; 3KPQ; -.
DR   PDBsum; 3KPR; -.
DR   PDBsum; 3KPS; -.
DR   PDBsum; 3KWW; -.
DR   PDBsum; 3KXF; -.
DR   PDBsum; 3KYN; -.
DR   PDBsum; 3KYO; -.
DR   PDBsum; 3L3D; -.
DR   PDBsum; 3L3G; -.
DR   PDBsum; 3L3I; -.
DR   PDBsum; 3L3J; -.
DR   PDBsum; 3L3K; -.
DR   PDBsum; 3LKN; -.
DR   PDBsum; 3LKO; -.
DR   PDBsum; 3LKP; -.
DR   PDBsum; 3LKQ; -.
DR   PDBsum; 3LKR; -.
DR   PDBsum; 3LKS; -.
DR   PDBsum; 3LN4; -.
DR   PDBsum; 3LN5; -.
DR   PDBsum; 3LOW; -.
DR   PDBsum; 3LOZ; -.
DR   PDBsum; 3LV3; -.
DR   PDBsum; 3M17; -.
DR   PDBsum; 3M1B; -.
DR   PDBsum; 3MGO; -.
DR   PDBsum; 3MGT; -.
DR   PDBsum; 3MR9; -.
DR   PDBsum; 3MRB; -.
DR   PDBsum; 3MRC; -.
DR   PDBsum; 3MRD; -.
DR   PDBsum; 3MRE; -.
DR   PDBsum; 3MRF; -.
DR   PDBsum; 3MRG; -.
DR   PDBsum; 3MRH; -.
DR   PDBsum; 3MRI; -.
DR   PDBsum; 3MRJ; -.
DR   PDBsum; 3MRK; -.
DR   PDBsum; 3MRL; -.
DR   PDBsum; 3MRM; -.
DR   PDBsum; 3MRN; -.
DR   PDBsum; 3MRO; -.
DR   PDBsum; 3MRP; -.
DR   PDBsum; 3MRQ; -.
DR   PDBsum; 3MRR; -.
DR   PDBsum; 3MV7; -.
DR   PDBsum; 3MV8; -.
DR   PDBsum; 3MV9; -.
DR   PDBsum; 3MYJ; -.
DR   PDBsum; 3MYZ; -.
DR   PDBsum; 3MZT; -.
DR   PDBsum; 3NA4; -.
DR   PDBsum; 3NFN; -.
DR   PDBsum; 3O3A; -.
DR   PDBsum; 3O3B; -.
DR   PDBsum; 3O3D; -.
DR   PDBsum; 3O3E; -.
DR   PDBsum; 3O4L; -.
DR   PDBsum; 3OV6; -.
DR   PDBsum; 3OX8; -.
DR   PDBsum; 3OXR; -.
DR   PDBsum; 3OXS; -.
DR   PDBsum; 3PWJ; -.
DR   PDBsum; 3PWL; -.
DR   PDBsum; 3PWN; -.
DR   PDBsum; 3PWP; -.
DR   PDBsum; 3QDA; -.
DR   PDBsum; 3QDG; -.
DR   PDBsum; 3QDJ; -.
DR   PDBsum; 3QDM; -.
DR   PDBsum; 3QEQ; -.
DR   PDBsum; 3QFD; -.
DR   PDBsum; 3QFJ; -.
DR   PDBsum; 3QZW; -.
DR   PDBsum; 3REW; -.
DR   PDBsum; 3RL1; -.
DR   PDBsum; 3RL2; -.
DR   PDBsum; 3RWJ; -.
DR   PDBsum; 3S6C; -.
DR   PDBsum; 3SDX; -.
DR   PDBsum; 3SJV; -.
DR   PDBsum; 3SKM; -.
DR   PDBsum; 3SKO; -.
DR   PDBsum; 3SPV; -.
DR   PDBsum; 3T8X; -.
DR   PDBsum; 3TID; -.
DR   PDBsum; 3TIE; -.
DR   PDBsum; 3TLR; -.
DR   PDBsum; 3TM6; -.
DR   PDBsum; 3TO2; -.
DR   PDBsum; 3TZV; -.
DR   PDBsum; 3U0P; -.
DR   PDBsum; 3UPR; -.
DR   PDBsum; 3UTQ; -.
DR   PDBsum; 3UTS; -.
DR   PDBsum; 3UTT; -.
DR   PDBsum; 3V5D; -.
DR   PDBsum; 3V5H; -.
DR   PDBsum; 3V5K; -.
DR   PDBsum; 3VCL; -.
DR   PDBsum; 3VFM; -.
DR   PDBsum; 3VFN; -.
DR   PDBsum; 3VFO; -.
DR   PDBsum; 3VFP; -.
DR   PDBsum; 3VFR; -.
DR   PDBsum; 3VFS; -.
DR   PDBsum; 3VFT; -.
DR   PDBsum; 3VFU; -.
DR   PDBsum; 3VFV; -.
DR   PDBsum; 3VFW; -.
DR   PDBsum; 3VH8; -.
DR   PDBsum; 3VRI; -.
DR   PDBsum; 3VRJ; -.
DR   PDBsum; 3VWJ; -.
DR   PDBsum; 3VWK; -.
DR   PDBsum; 3VXM; -.
DR   PDBsum; 3VXN; -.
DR   PDBsum; 3VXO; -.
DR   PDBsum; 3VXP; -.
DR   PDBsum; 3VXR; -.
DR   PDBsum; 3VXS; -.
DR   PDBsum; 3VXU; -.
DR   PDBsum; 3W0W; -.
DR   PDBsum; 3W39; -.
DR   PDBsum; 3WL9; -.
DR   PDBsum; 3WLB; -.
DR   PDBsum; 3WUW; -.
DR   PDBsum; 3X11; -.
DR   PDBsum; 3X12; -.
DR   PDBsum; 3X13; -.
DR   PDBsum; 3X14; -.
DR   PDBsum; 4BEO; -.
DR   PDBsum; 4E0K; -.
DR   PDBsum; 4E0L; -.
DR   PDBsum; 4E5X; -.
DR   PDBsum; 4EN3; -.
DR   PDBsum; 4EUP; -.
DR   PDBsum; 4EUQ; -.
DR   PDBsum; 4F7M; -.
DR   PDBsum; 4F7P; -.
DR   PDBsum; 4F7T; -.
DR   PDBsum; 4FTV; -.
DR   PDBsum; 4FXL; -.
DR   PDBsum; 4G8G; -.
DR   PDBsum; 4G8I; -.
DR   PDBsum; 4G9D; -.
DR   PDBsum; 4G9F; -.
DR   PDBsum; 4GKN; -.
DR   PDBsum; 4GKS; -.
DR   PDBsum; 4GUP; -.
DR   PDBsum; 4HKJ; -.
DR   PDBsum; 4HWZ; -.
DR   PDBsum; 4HX1; -.
DR   PDBsum; 4I48; -.
DR   PDBsum; 4I4W; -.
DR   PDBsum; 4JFD; -.
DR   PDBsum; 4JFE; -.
DR   PDBsum; 4JFF; -.
DR   PDBsum; 4JFO; -.
DR   PDBsum; 4JFP; -.
DR   PDBsum; 4JFQ; -.
DR   PDBsum; 4JQV; -.
DR   PDBsum; 4JQX; -.
DR   PDBsum; 4JRX; -.
DR   PDBsum; 4JRY; -.
DR   PDBsum; 4K71; -.
DR   PDBsum; 4K7F; -.
DR   PDBsum; 4KDT; -.
DR   PDBsum; 4L29; -.
DR   PDBsum; 4L3C; -.
DR   PDBsum; 4L3E; -.
DR   PDBsum; 4L4T; -.
DR   PDBsum; 4L4V; -.
DR   PDBsum; 4LCW; -.
DR   PDBsum; 4LCY; -.
DR   PDBsum; 4LHU; -.
DR   PDBsum; 4LNR; -.
DR   PDBsum; 4M8V; -.
DR   PDBsum; 4MJ5; -.
DR   PDBsum; 4MJ6; -.
DR   PDBsum; 4MJI; -.
DR   PDBsum; 4MNQ; -.
DR   PDBsum; 4N0F; -.
DR   PDBsum; 4N0U; -.
DR   PDBsum; 4N8V; -.
DR   PDBsum; 4NNX; -.
DR   PDBsum; 4NNY; -.
DR   PDBsum; 4NO0; -.
DR   PDBsum; 4NO2; -.
DR   PDBsum; 4NO3; -.
DR   PDBsum; 4NO5; -.
DR   PDBsum; 4NQC; -.
DR   PDBsum; 4NQD; -.
DR   PDBsum; 4NQE; -.
DR   PDBsum; 4NQV; -.
DR   PDBsum; 4NQX; -.
DR   PDBsum; 4NT6; -.
DR   PDBsum; 4O2C; -.
DR   PDBsum; 4O2E; -.
DR   PDBsum; 4O2F; -.
DR   PDBsum; 4ONO; -.
DR   PDBsum; 4PJ5; -.
DR   PDBsum; 4PJ7; -.
DR   PDBsum; 4PJ8; -.
DR   PDBsum; 4PJ9; -.
DR   PDBsum; 4PJA; -.
DR   PDBsum; 4PJB; -.
DR   PDBsum; 4PJC; -.
DR   PDBsum; 4PJD; -.
DR   PDBsum; 4PJE; -.
DR   PDBsum; 4PJF; -.
DR   PDBsum; 4PJG; -.
DR   PDBsum; 4PJH; -.
DR   PDBsum; 4PJI; -.
DR   PDBsum; 4PJX; -.
DR   PDBsum; 4PR5; -.
DR   PDBsum; 4PRA; -.
DR   PDBsum; 4PRB; -.
DR   PDBsum; 4PRD; -.
DR   PDBsum; 4PRE; -.
DR   PDBsum; 4PRH; -.
DR   PDBsum; 4PRI; -.
DR   PDBsum; 4PRN; -.
DR   PDBsum; 4PRP; -.
DR   PDBsum; 4QOK; -.
DR   PDBsum; 4QRP; -.
DR   PDBsum; 4QRQ; -.
DR   PDBsum; 4QRR; -.
DR   PDBsum; 4QRS; -.
DR   PDBsum; 4QRT; -.
DR   PDBsum; 4QRU; -.
DR   PDBsum; 4R9H; -.
DR   PDBsum; 4RA3; -.
DR   PDBsum; 4RAH; -.
DR   PDBsum; 4RMQ; -.
DR   PDBsum; 4RMR; -.
DR   PDBsum; 4RMS; -.
DR   PDBsum; 4RMT; -.
DR   PDBsum; 4RMU; -.
DR   PDBsum; 4RMV; -.
DR   PDBsum; 4RMW; -.
DR   PDBsum; 4U1H; -.
DR   PDBsum; 4U1I; -.
DR   PDBsum; 4U1J; -.
DR   PDBsum; 4U1K; -.
DR   PDBsum; 4U1L; -.
DR   PDBsum; 4U1M; -.
DR   PDBsum; 4U1N; -.
DR   PDBsum; 4U1S; -.
DR   PDBsum; 4U6X; -.
DR   PDBsum; 4U6Y; -.
DR   PDBsum; 4UQ2; -.
DR   PDBsum; 4UQ3; -.
DR   PDBsum; 4WDI; -.
DR   PDBsum; 4WJ5; -.
DR   PDBsum; 4WO4; -.
DR   PDBsum; 4WU5; -.
DR   PDBsum; 4WU7; -.
DR   PDBsum; 4WUU; -.
DR   PDBsum; 4X6C; -.
DR   PDBsum; 4X6D; -.
DR   PDBsum; 4X6E; -.
DR   PDBsum; 4X6F; -.
DR   PDBsum; 4XXC; -.
DR   PDBsum; 4Z76; -.
DR   PDBsum; 4Z77; -.
DR   PDBsum; 4Z78; -.
DR   PDBsum; 5BXF; -.
DR   PDBsum; 5D2L; -.
DR   PDBsum; 5D2N; -.
DR   PDBsum; 5DEF; -.
DR   PDBsum; 5DEG; -.
DR   ProteinModelPortal; P61769; -.
DR   SMR; P61769; 21-119.
DR   BioGrid; 107044; 39.
DR   DIP; DIP-6055N; -.
DR   IntAct; P61769; 72.
DR   MINT; MINT-85778; -.
DR   STRING; 9606.ENSP00000452780; -.
DR   BindingDB; P61769; -.
DR   DrugBank; DB00254; Doxycycline.
DR   iPTMnet; P61769; -.
DR   PhosphoSite; P61769; -.
DR   BioMuta; B2M; -.
DR   DMDM; 48428791; -.
DR   DOSAC-COBS-2DPAGE; P61769; -.
DR   OGP; P61769; -.
DR   SWISS-2DPAGE; P61769; -.
DR   MaxQB; P61769; -.
DR   PaxDb; P61769; -.
DR   PeptideAtlas; P61769; -.
DR   PRIDE; P61769; -.
DR   DNASU; 567; -.
DR   Ensembl; ENST00000558401; ENSP00000452780; ENSG00000166710.
DR   Ensembl; ENST00000559916; ENSP00000453350; ENSG00000166710.
DR   Ensembl; ENST00000561424; ENSP00000453191; ENSG00000166710.
DR   Ensembl; ENST00000617605; ENSP00000481426; ENSG00000273686.
DR   Ensembl; ENST00000631573; ENSP00000488548; ENSG00000273686.
DR   Ensembl; ENST00000631728; ENSP00000488321; ENSG00000273686.
DR   GeneID; 567; -.
DR   KEGG; hsa:567; -.
DR   UCSC; uc001zuc.3; human.
DR   CTD; 567; -.
DR   GeneCards; B2M; -.
DR   HGNC; HGNC:914; B2M.
DR   HPA; CAB002572; -.
DR   HPA; HPA006361; -.
DR   MalaCards; B2M; -.
DR   MIM; 109700; gene.
DR   MIM; 241600; phenotype.
DR   neXtProt; NX_P61769; -.
DR   Orphanet; 314652; Autosomal dominant beta2-microglobulinic amyloidosis.
DR   PharmGKB; PA25207; -.
DR   eggNOG; ENOG410J15A; Eukaryota.
DR   eggNOG; ENOG410YTDG; LUCA.
DR   GeneTree; ENSGT00690000102227; -.
DR   HOVERGEN; HBG006197; -.
DR   InParanoid; P61769; -.
DR   KO; K08055; -.
DR   OMA; ITIDLLC; -.
DR   OrthoDB; EOG7RFTKJ; -.
DR   PhylomeDB; P61769; -.
DR   TreeFam; TF334167; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-1236977; Endosomal/Vacuolar pathway.
DR   Reactome; R-HSA-164940; Nef mediated downregulation of MHC class I complex cell surface expression.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-2172127; DAP12 interactions.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   ChiTaRS; B2M; human.
DR   EvolutionaryTrace; P61769; -.
DR   GeneWiki; Beta-2_microglobulin; -.
DR   GenomeRNAi; 567; -.
DR   NextBio; 2313; -.
DR   PRO; PR:P61769; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; P61769; -.
DR   CleanEx; HS_B2M; -.
DR   ExpressionAtlas; P61769; baseline and differential.
DR   Genevisible; P61769; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0031905; C:early endosome lumen; TAS:Reactome.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0042612; C:MHC class I protein complex; IEA:UniProtKB-KW.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0019885; P:antigen processing and presentation of endogenous peptide antigen via MHC class I; IGI:BHF-UCL.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002480; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent; TAS:Reactome.
DR   GO; GO:0002481; P:antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent; IEA:Ensembl.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071281; P:cellular response to iron ion; IGI:BHF-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0055072; P:iron ion homeostasis; IC:BHF-UCL.
DR   GO; GO:1900121; P:negative regulation of receptor binding; IDA:BHF-UCL.
DR   GO; GO:1904434; P:positive regulation of ferrous iron binding; IGI:BHF-UCL.
DR   GO; GO:1903991; P:positive regulation of ferrous iron import into cell; IGI:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IGI:BHF-UCL.
DR   GO; GO:1900122; P:positive regulation of receptor binding; IGI:BHF-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; IGI:BHF-UCL.
DR   GO; GO:0002726; P:positive regulation of T cell cytokine production; IDA:BHF-UCL.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:1904437; P:positive regulation of transferrin receptor binding; IGI:BHF-UCL.
DR   GO; GO:0042026; P:protein refolding; IEA:Ensembl.
DR   GO; GO:0050690; P:regulation of defense response to virus by virus; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0003254; P:regulation of membrane depolarization; IDA:UniProtKB.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0001895; P:retina homeostasis; IEP:UniProtKB.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR015707; B2Microglobulin.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   PANTHER; PTHR19944:SF62; PTHR19944:SF62; 1.
DR   Pfam; PF07654; C1-set; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyloid; Amyloidosis; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycation; Glycoprotein; Immunity; Immunoglobulin domain; MHC I;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:1336137,
FT                                ECO:0000269|PubMed:25946035,
FT                                ECO:0000269|PubMed:3532124,
FT                                ECO:0000269|PubMed:4586824,
FT                                ECO:0000269|PubMed:8084451}.
FT   CHAIN        21    119       Beta-2-microglobulin.
FT                                /FTId=PRO_0000018779.
FT   CHAIN        22    119       Beta-2-microglobulin form pI 5.3.
FT                                /FTId=PRO_0000018780.
FT   DOMAIN       25    113       Ig-like C1-type.
FT   MOD_RES      22     22       Pyrrolidone carboxylic acid; in form pI
FT                                5.3. {ECO:0000269|PubMed:7554280}.
FT   CARBOHYD     21     21       N-linked (Glc) (glycation); in
FT                                hemodialysis-associated amyloidosis.
FT   CARBOHYD     39     39       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD     61     61       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD     68     68       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD     78     78       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    111    111       N-linked (Glc) (glycation); in vitro.
FT   CARBOHYD    114    114       N-linked (Glc) (glycation); in vitro.
FT   DISULFID     45    100       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:12119416,
FT                                ECO:0000269|PubMed:12796775,
FT                                ECO:0000269|PubMed:16491088,
FT                                ECO:0000269|PubMed:16901902,
FT                                ECO:0000269|PubMed:17646174,
FT                                ECO:0000269|PubMed:18395224,
FT                                ECO:0000269|PubMed:18835253,
FT                                ECO:0000269|PubMed:19284997}.
FT   VARIANT      11     11       A -> P (in IMD43; lower levels of B2M,
FT                                MHC class I and FCGRT proteins).
FT                                {ECO:0000269|PubMed:16549777}.
FT                                /FTId=VAR_030660.
FT   MUTAGEN      79     79       D->P: Increases tendency towards amyloid
FT                                formation. {ECO:0000269|PubMed:18835253}.
FT   MUTAGEN      80     80       W->G: Decreases tendency towards amyloid
FT                                formation. {ECO:0000269|PubMed:18395224,
FT                                ECO:0000269|PubMed:19284997}.
FT   MUTAGEN      80     80       W->V: Increases tendency towards amyloid
FT                                formation. {ECO:0000269|PubMed:18395224,
FT                                ECO:0000269|PubMed:19284997}.
FT   CONFLICT     20     20       A -> G (in Ref. 1; AAA51811).
FT                                {ECO:0000305}.
FT   CONFLICT     52     52       P -> Q (in Ref. 1; AAA51811).
FT                                {ECO:0000305}.
FT   CONFLICT    119    119       M -> I (in Ref. 7; CAG33347).
FT                                {ECO:0000305}.
FT   STRAND       26     33       {ECO:0000244|PDB:1K5N}.
FT   HELIX        35     37       {ECO:0000244|PDB:2YXF}.
FT   STRAND       41     53       {ECO:0000244|PDB:1K5N}.
FT   STRAND       56     61       {ECO:0000244|PDB:1K5N}.
FT   STRAND       64     66       {ECO:0000244|PDB:3LOW}.
FT   STRAND       71     78       {ECO:0000244|PDB:2YXF}.
FT   STRAND       79     82       {ECO:0000244|PDB:4E0K}.
FT   STRAND       86     90       {ECO:0000244|PDB:1CE6}.
FT   TURN         93     95       {ECO:0000244|PDB:4RMW}.
FT   STRAND       98    103       {ECO:0000244|PDB:1K5N}.
FT   STRAND      107    109       {ECO:0000244|PDB:3MYZ}.
FT   STRAND      111    114       {ECO:0000244|PDB:1K5N}.
FT   HELIX       117    119       {ECO:0000244|PDB:3OV6}.
SQ   SEQUENCE   119 AA;  13715 MW;  AFD2DBEF07DCEF27 CRC64;
     MSRSVALAVL ALLSLSGLEA IQRTPKIQVY SRHPAENGKS NFLNCYVSGF HPSDIEVDLL
     KNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDM
//
ID   NLGN1_RAT               Reviewed;         843 AA.
AC   Q62765;
DT   23-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   17-FEB-2016, entry version 133.
DE   RecName: Full=Neuroligin-1;
DE   AltName: Full=Neuroligin I;
DE   Flags: Precursor;
GN   Name=Nlgn1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), PARTIAL PROTEIN
RP   SEQUENCE, CHARACTERIZATION, AND INTERACTION WITH NEUREXIN 1-BETA.
RC   TISSUE=Brain;
RX   PubMed=7736595; DOI=10.1016/0092-8674(95)90396-8;
RA   Ichtchenko K., Hata Y., Nguyen T., Ullrich B., Missler M., Moomaw C.,
RA   Suedhof T.C.;
RT   "Neuroligin 1: a splice site-specific ligand for beta-neurexins.";
RL   Cell 81:435-443(1995).
RN   [2]
RP   INTERACTION WITH NEUREXIN 1-BETA, AND FUNCTION.
RX   PubMed=9325340; DOI=10.1074/jbc.272.41.26032;
RA   Nguyen T., Suedhof T.C.;
RT   "Binding properties of neuroligin 1 and neurexin 1beta reveal function
RT   as heterophilic cell adhesion molecules.";
RL   J. Biol. Chem. 272:26032-26039(1997).
RN   [3]
RP   BLOCKAGE OF N-TERMINUS, AND INTERACTION WITH NEUREXIN 1-BETA; NEUREXIN
RP   2-BETA AND NEUREXIN 3-BETA.
RX   PubMed=8576240; DOI=10.1074/jbc.271.5.2676;
RA   Ichtchenko K., Nguyen T., Suedhof T.C.;
RT   "Structures, alternative splicing, and neurexin binding of multiple
RT   neuroligins.";
RL   J. Biol. Chem. 271:2676-2682(1996).
RN   [4]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=9927700; DOI=10.1073/pnas.96.3.1100;
RA   Song J.-Y., Ichtchenko K., Suedhof T.C., Brose N.;
RT   "Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory
RT   synapses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1100-1105(1999).
RN   [5]
RP   INTERACTION WITH AIP1.
RX   PubMed=9694864; DOI=10.1074/jbc.273.33.21105;
RA   Hirao K., Hata Y., Ide N., Takeuchi M., Irie M., Yao I., Deguchi M.,
RA   Toyoda A., Suedhof T.C., Takai Y.;
RT   "A novel multiple PDZ domain-containing molecule interacting with N-
RT   methyl-d-aspartate receptors and neuronal cell adhesion proteins.";
RL   J. Biol. Chem. 273:21105-21110(1998).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=11329178; DOI=10.1002/glia.1050;
RA   Gilbert M., Smith J., Roskams A.J., Auld V.J.;
RT   "Neuroligin 3 is a vertebrate gliotactin expressed in the olfactory
RT   ensheathing glia, a growth-promoting class of macroglia.";
RL   Glia 34:151-164(2001).
RN   [7]
RP   DISULFIDE BONDS, AND GLYCOSYLATION.
RX   PubMed=14769026; DOI=10.1021/bi035278t;
RA   Hoffman R.C., Jennings L.L., Tsigelny I., Comoletti D., Flynn R.E.,
RA   Suedhof T.C., Taylor P.;
RT   "Structural characterization of recombinant soluble rat neuroligin 1:
RT   mapping of secondary structure and glycosylation by mass
RT   spectrometry.";
RL   Biochemistry 43:1496-1506(2004).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15620359; DOI=10.1016/j.cell.2004.11.035;
RA   Graf E.R., Zhang X., Jin S.X., Linhoff M.W., Craig A.M.;
RT   "Neurexins induce differentiation of GABA and glutamate postsynaptic
RT   specializations via neuroligins.";
RL   Cell 119:1013-1026(2004).
RN   [9]
RP   INTERACTION WITH PDZRN3.
RX   PubMed=15458844; DOI=10.1016/j.neuropharm.2004.06.023;
RA   Meyer G., Varoqueaux F., Neeb A., Oschlies M., Brose N.;
RT   "The complexity of PDZ domain-mediated interactions at glutamatergic
RT   synapses: a case study on neuroligin.";
RL   Neuropharmacology 47:724-733(2004).
RN   [10]
RP   TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING.
RX   PubMed=18755801; DOI=10.1210/en.2008-0274;
RA   Suckow A.T., Comoletti D., Waldrop M.A., Mosedale M., Egodage S.,
RA   Taylor P., Chessler S.D.;
RT   "Expression of neurexin, neuroligin, and their cytoplasmic binding
RT   partners in the pancreatic beta-cells and the involvement of
RT   neuroligin in insulin secretion.";
RL   Endocrinology 149:6006-6017(2008).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18434543; DOI=10.1073/pnas.0801383105;
RA   Bolliger M.F., Pei J., Maxeiner S., Boucard A.A., Grishin N.V.,
RA   Sudhof T.C.;
RT   "Unusually rapid evolution of neuroligin-4 in mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:6421-6426(2008).
RN   [12]
RP   INTERACTION WITH NRXN1.
RX   PubMed=18334216; DOI=10.1016/j.str.2007.12.024;
RA   Koehnke J., Jin X., Trbovic N., Katsamba P.S., Brasch J., Ahlsen G.,
RA   Scheiffele P., Honig B., Palmer A.G. III, Shapiro L.;
RT   "Crystal structures of beta-neurexin 1 and beta-neurexin 2 ectodomains
RT   and dynamics of splice insertion sequence 4.";
RL   Structure 16:410-421(2008).
RN   [13]
RP   INTERACTION WITH NRXN1.
RX   PubMed=20624592; DOI=10.1016/j.neuron.2010.06.001;
RA   Koehnke J., Katsamba P.S., Ahlsen G., Bahna F., Vendome J., Honig B.,
RA   Shapiro L., Jin X.;
RT   "Splice form dependence of beta-neurexin/neuroligin binding
RT   interactions.";
RL   Neuron 67:61-74(2010).
RN   [14]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19914352; DOI=10.1016/j.neuroscience.2009.11.016;
RA   Levinson J.N., Li R., Kang R., Moukhles H., El-Husseini A.,
RA   Bamji S.X.;
RT   "Postsynaptic scaffolding molecules modulate the localization of
RT   neuroligins.";
RL   Neuroscience 165:782-793(2010).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 46-638 IN COMPLEX WITH NRXN1,
RP   GLYCOSYLATION AT ASN-109 AND ASN-343, AND DISULFIDE BONDS.
RX   PubMed=18093522; DOI=10.1016/j.neuron.2007.12.002;
RA   Arac D., Boucard A.A., Ozkan E., Strop P., Newell E., Sudhof T.C.,
RA   Brunger A.T.;
RT   "Structures of neuroligin-1 and the neuroligin-1/neurexin-1 beta
RT   complex reveal specific protein-protein and protein-Ca2+
RT   interactions.";
RL   Neuron 56:992-1003(2007).
CC   -!- FUNCTION: Cell surface protein involved in cell-cell-interactions
CC       via its interactions with neurexin family members. Plays a role in
CC       synapse function and synaptic signal transmission, and probably
CC       mediates its effects by recruiting and clustering other synaptic
CC       proteins. May promote the initial formation of synapses, but is
CC       not essential for this. In vitro, triggers the de novo formation
CC       of presynaptic structures. May be involved in specification of
CC       excitatory synapses. Required to maintain wakefulness quality and
CC       normal synchrony of cerebral cortex activity during wakefulness
CC       and sleep (By similarity). {ECO:0000250|UniProtKB:Q99K10,
CC       ECO:0000269|PubMed:15620359, ECO:0000269|PubMed:9325340}.
CC   -!- SUBUNIT: Interacts with NRXN1, NRXN2 and NRXN3. Interacts with
CC       NLGN3. Interacts (via its C-terminus) with DLG4/PSD-95 (via PDZ
CC       domain 3). Interacts with GOPC (By similarity). Interacts with
CC       AIP1 and PDZRN3. {ECO:0000250, ECO:0000269|PubMed:15458844,
CC       ECO:0000269|PubMed:18093522, ECO:0000269|PubMed:18334216,
CC       ECO:0000269|PubMed:20624592, ECO:0000269|PubMed:7736595,
CC       ECO:0000269|PubMed:8576240, ECO:0000269|PubMed:9325340,
CC       ECO:0000269|PubMed:9694864}.
CC   -!- INTERACTION:
CC       Q63373:Nrxn1; NbExp=5; IntAct=EBI-7281118, EBI-1780696;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cell junction, synapse. Cell junction, synapse,
CC       postsynaptic cell membrane, postsynaptic density. Note=Enriched in
CC       synaptic plasma membranes and clustered in synaptic clefts and
CC       postsynaptic densities. Detected at dendritic spines. Colocalized
CC       with DLG4/PSD-95 and GRIN1/NMDAR1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q62765-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q62765-2; Sequence=VSP_007531, VSP_007532;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q62765-3; Sequence=VSP_007532;
CC       Name=4;
CC         IsoId=Q62765-4; Sequence=VSP_007531;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, almost exclusively in
CC       neurons, and spinal chord. Detected in pancreas islet beta cells.
CC       {ECO:0000269|PubMed:11329178, ECO:0000269|PubMed:18755801,
CC       ECO:0000269|PubMed:19914352, ECO:0000269|PubMed:9927700}.
CC   -!- DEVELOPMENTAL STAGE: Expression is low in embryonic brains (E12-
CC       E16) but increases dramatically after birth (postnatal days P0-P3)
CC       and reaches a plateau during the period when most synapses are
CC       formed (P5-P8). {ECO:0000269|PubMed:9927700}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- SIMILARITY: Belongs to the type-B carboxylesterase/lipase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U22952; AAA85720.1; -; mRNA.
DR   RefSeq; NP_446320.1; NM_053868.2. [Q62765-1]
DR   UniGene; Rn.10173; -.
DR   PDB; 3BIW; X-ray; 3.50 A; A/B/C/D=46-638.
DR   PDB; 3BIX; X-ray; 1.80 A; A/B/C/D=46-638.
DR   PDB; 3VKF; X-ray; 3.30 A; A/B=45-638.
DR   PDBsum; 3BIW; -.
DR   PDBsum; 3BIX; -.
DR   PDBsum; 3VKF; -.
DR   ProteinModelPortal; Q62765; -.
DR   SMR; Q62765; 52-631.
DR   BioGrid; 250532; 12.
DR   DIP; DIP-44832N; -.
DR   IntAct; Q62765; 4.
DR   MINT; MINT-1526995; -.
DR   STRING; 10116.ENSRNOP00000049486; -.
DR   ESTHER; ratno-1neur; Neuroligin.
DR   MEROPS; S09.994; -.
DR   UniCarbKB; Q62765; -.
DR   PaxDb; Q62765; -.
DR   PRIDE; Q62765; -.
DR   Ensembl; ENSRNOT00000092660; ENSRNOP00000075793; ENSRNOG00000032576. [Q62765-1]
DR   GeneID; 116647; -.
DR   KEGG; rno:116647; -.
DR   UCSC; RGD:621117; rat. [Q62765-1]
DR   CTD; 22871; -.
DR   RGD; 621117; Nlgn1.
DR   eggNOG; KOG1516; Eukaryota.
DR   eggNOG; COG2272; LUCA.
DR   GeneTree; ENSGT00760000118946; -.
DR   HOGENOM; HOG000231424; -.
DR   HOVERGEN; HBG008839; -.
DR   InParanoid; Q62765; -.
DR   KO; K07378; -.
DR   OMA; KFVELIV; -.
DR   OrthoDB; EOG7RBZ7R; -.
DR   PhylomeDB; Q62765; -.
DR   TreeFam; TF326187; -.
DR   EvolutionaryTrace; Q62765; -.
DR   NextBio; 619391; -.
DR   PRO; PR:Q62765; -.
DR   Proteomes; UP000002494; Unplaced.
DR   ExpressionAtlas; Q62765; baseline.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IDA:BHF-UCL.
DR   GO; GO:0043198; C:dendritic shaft; IDA:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:BHF-UCL.
DR   GO; GO:0060076; C:excitatory synapse; IC:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0032433; C:filopodium tip; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045202; C:synapse; IDA:UniProtKB.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:BHF-UCL.
DR   GO; GO:0042043; F:neurexin family protein binding; ISS:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004872; F:receptor activity; IDA:BHF-UCL.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; IMP:BHF-UCL.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:UniProtKB.
DR   GO; GO:0048789; P:cytoskeletal matrix organization at active zone; IMP:BHF-UCL.
DR   GO; GO:0045184; P:establishment of protein localization; ISS:BHF-UCL.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; ISS:BHF-UCL.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IMP:RGD.
DR   GO; GO:0061002; P:negative regulation of dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; ISS:UniProtKB.
DR   GO; GO:0097115; P:neurexin clustering involved in presynaptic membrane assembly; ISS:BHF-UCL.
DR   GO; GO:0007158; P:neuron cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0045161; P:neuronal ion channel clustering; TAS:UniProtKB.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; IDA:BHF-UCL.
DR   GO; GO:0010841; P:positive regulation of circadian sleep/wake cycle, wakefulness; ISS:UniProtKB.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IDA:BHF-UCL.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IDA:BHF-UCL.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IDA:BHF-UCL.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; IDA:BHF-UCL.
DR   GO; GO:1902474; P:positive regulation of protein localization to synapse; IMP:RGD.
DR   GO; GO:1900029; P:positive regulation of ruffle assembly; IDA:BHF-UCL.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IDA:BHF-UCL.
DR   GO; GO:0032230; P:positive regulation of synaptic transmission, GABAergic; IDA:BHF-UCL.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IDA:BHF-UCL.
DR   GO; GO:2000809; P:positive regulation of synaptic vesicle clustering; IEA:Ensembl.
DR   GO; GO:1900244; P:positive regulation of synaptic vesicle endocytosis; IMP:BHF-UCL.
DR   GO; GO:2000302; P:positive regulation of synaptic vesicle exocytosis; IMP:BHF-UCL.
DR   GO; GO:0097119; P:postsynaptic density protein 95 clustering; IDA:BHF-UCL.
DR   GO; GO:0097104; P:postsynaptic membrane assembly; ISS:BHF-UCL.
DR   GO; GO:0097105; P:presynaptic membrane assembly; IDA:BHF-UCL.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:RGD.
DR   GO; GO:0051260; P:protein homooligomerization; ISS:BHF-UCL.
DR   GO; GO:0035418; P:protein localization to synapse; ISS:BHF-UCL.
DR   GO; GO:0006605; P:protein targeting; IDA:UniProtKB.
DR   GO; GO:0097120; P:receptor localization to synapse; ISS:BHF-UCL.
DR   GO; GO:2000311; P:regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity; IDA:BHF-UCL.
DR   GO; GO:2000310; P:regulation of N-methyl-D-aspartate selective glutamate receptor activity; IDA:BHF-UCL.
DR   GO; GO:0045664; P:regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0002087; P:regulation of respiratory gaseous exchange by neurological system process; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007416; P:synapse assembly; ISS:UniProtKB.
DR   GO; GO:0050808; P:synapse organization; IDA:MGI.
DR   GO; GO:0097091; P:synaptic vesicle clustering; IDA:BHF-UCL.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; IBA:GO_Central.
DR   GO; GO:0016080; P:synaptic vesicle targeting; ISS:UniProtKB.
DR   GO; GO:0048489; P:synaptic vesicle transport; IMP:CACAO.
DR   GO; GO:0072553; P:terminal button organization; IMP:BHF-UCL.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR002018; CarbesteraseB.
DR   InterPro; IPR019819; Carboxylesterase_B_CS.
DR   InterPro; IPR000460; Nlgn.
DR   InterPro; IPR030022; NLGN1.
DR   PANTHER; PTHR11559:SF52; PTHR11559:SF52; 2.
DR   Pfam; PF00135; COesterase; 1.
DR   PRINTS; PR01090; NEUROLIGIN.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   PROSITE; PS00941; CARBOXYLESTERASE_B_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms; Cell adhesion;
KW   Cell junction; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Membrane;
KW   Phosphoprotein; Postsynaptic cell membrane; Reference proteome;
KW   Signal; Synapse; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     45       {ECO:0000255}.
FT   CHAIN        46    843       Neuroligin-1.
FT                                /FTId=PRO_0000008642.
FT   TOPO_DOM     46    697       Extracellular. {ECO:0000255}.
FT   TRANSMEM    698    718       Helical. {ECO:0000255}.
FT   TOPO_DOM    719    843       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES     733    733       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q69ZK9}.
FT   MOD_RES     782    782       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q8BYM5}.
FT   CARBOHYD    109    109       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:18093522}.
FT   CARBOHYD    303    303       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:14769026}.
FT   CARBOHYD    343    343       N-linked (GlcNAc...) (complex).
FT                                {ECO:0000269|PubMed:18093522}.
FT   CARBOHYD    547    547       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14769026}.
FT   CARBOHYD    683    683       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:14769026}.
FT   CARBOHYD    686    686       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:14769026}.
FT   DISULFID    117    153
FT   DISULFID    172    181
FT   DISULFID    342    353
FT   DISULFID    512    546
FT   VAR_SEQ     165    184       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:7736595}.
FT                                /FTId=VSP_007531.
FT   VAR_SEQ     298    306       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:7736595}.
FT                                /FTId=VSP_007532.
FT   STRAND       54     57       {ECO:0000244|PDB:3BIX}.
FT   STRAND       60     63       {ECO:0000244|PDB:3BIX}.
FT   STRAND       65     67       {ECO:0000244|PDB:3BIX}.
FT   STRAND       70     74       {ECO:0000244|PDB:3BIX}.
FT   STRAND       77     84       {ECO:0000244|PDB:3BIX}.
FT   HELIX        91     93       {ECO:0000244|PDB:3BIX}.
FT   STRAND      105    109       {ECO:0000244|PDB:3BIX}.
FT   STRAND      122    124       {ECO:0000244|PDB:3BIX}.
FT   TURN        128    130       {ECO:0000244|PDB:3BIX}.
FT   HELIX       133    136       {ECO:0000244|PDB:3BIX}.
FT   HELIX       139    145       {ECO:0000244|PDB:3BIX}.
FT   STRAND      146    149       {ECO:0000244|PDB:3BIX}.
FT   STRAND      155    161       {ECO:0000244|PDB:3BIX}.
FT   HELIX       169    174       {ECO:0000244|PDB:3VKF}.
FT   HELIX       179    182       {ECO:0000244|PDB:3VKF}.
FT   STRAND      193    198       {ECO:0000244|PDB:3BIX}.
FT   STRAND      202    206       {ECO:0000244|PDB:3BIX}.
FT   HELIX       209    211       {ECO:0000244|PDB:3BIX}.
FT   HELIX       215    221       {ECO:0000244|PDB:3BIX}.
FT   STRAND      224    228       {ECO:0000244|PDB:3BIX}.
FT   HELIX       233    237       {ECO:0000244|PDB:3BIX}.
FT   STRAND      241    244       {ECO:0000244|PDB:3BIX}.
FT   HELIX       249    264       {ECO:0000244|PDB:3BIX}.
FT   HELIX       265    268       {ECO:0000244|PDB:3BIX}.
FT   STRAND      270    280       {ECO:0000244|PDB:3BIX}.
FT   HELIX       282    291       {ECO:0000244|PDB:3BIX}.
FT   HELIX       294    296       {ECO:0000244|PDB:3VKF}.
FT   STRAND      311    316       {ECO:0000244|PDB:3BIX}.
FT   STRAND      319    321       {ECO:0000244|PDB:3BIX}.
FT   HELIX       329    340       {ECO:0000244|PDB:3BIX}.
FT   HELIX       347    354       {ECO:0000244|PDB:3BIX}.
FT   HELIX       359    363       {ECO:0000244|PDB:3BIX}.
FT   STRAND      375    377       {ECO:0000244|PDB:3BIX}.
FT   STRAND      382    385       {ECO:0000244|PDB:3BIX}.
FT   HELIX       389    394       {ECO:0000244|PDB:3BIX}.
FT   STRAND      402    408       {ECO:0000244|PDB:3BIX}.
FT   TURN        409    412       {ECO:0000244|PDB:3BIX}.
FT   HELIX       413    416       {ECO:0000244|PDB:3BIX}.
FT   TURN        417    419       {ECO:0000244|PDB:3BIX}.
FT   HELIX       428    443       {ECO:0000244|PDB:3BIX}.
FT   STRAND      445    448       {ECO:0000244|PDB:3BIX}.
FT   HELIX       452    459       {ECO:0000244|PDB:3BIX}.
FT   HELIX       463    465       {ECO:0000244|PDB:3BIX}.
FT   HELIX       469    484       {ECO:0000244|PDB:3BIX}.
FT   HELIX       486    498       {ECO:0000244|PDB:3BIX}.
FT   STRAND      503    508       {ECO:0000244|PDB:3BIX}.
FT   STRAND      515    517       {ECO:0000244|PDB:3VKF}.
FT   TURN        525    528       {ECO:0000244|PDB:3BIX}.
FT   HELIX       529    532       {ECO:0000244|PDB:3BIX}.
FT   HELIX       535    538       {ECO:0000244|PDB:3BIX}.
FT   STRAND      542    544       {ECO:0000244|PDB:3BIX}.
FT   HELIX       550    569       {ECO:0000244|PDB:3BIX}.
FT   STRAND      574    576       {ECO:0000244|PDB:3BIX}.
FT   HELIX       582    584       {ECO:0000244|PDB:3BIX}.
FT   TURN        589    592       {ECO:0000244|PDB:3BIX}.
FT   TURN        600    602       {ECO:0000244|PDB:3BIX}.
FT   STRAND      604    611       {ECO:0000244|PDB:3BIX}.
FT   STRAND      613    617       {ECO:0000244|PDB:3BIX}.
FT   HELIX       620    627       {ECO:0000244|PDB:3BIX}.
FT   HELIX       629    634       {ECO:0000244|PDB:3BIX}.
SQ   SEQUENCE   843 AA;  94294 MW;  90A18540245B789D CRC64;
     MALPRCMWPN YVWRAMMACV VHRGSGAPLT LCLLGCLLQT FHVLSQKLDD VDPLVTTNFG
     KIRGIKKELN NEILGPVIQF LGVPYAAPPT GEHRFQPPEP PSPWSDIRNA TQFAPVCPQN
     IIDGRLPEVM LPVWFTNNLD VVSSYVQDQS EDCLYLNIYV PTEDVKRISK ECARKPGKKI
     CRKGDIRDSG GPKPVMVYIH GGSYMEGTGN LYDGSVLASY GNVIVITVNY RLGVLGFLST
     GDQAAKGNYG LLDLIQALRW TSENIGFFGG DPLRITVFGS GAGGSCVNLL TLSHYSEGNR
     WSNSTKGLFQ RAIAQSGTAL SSWAVSFQPA KYARILATKV GCNVSDTVEL VECLQKKPYK
     ELVDQDVQPA RYHIAFGPVI DGDVIPDDPQ ILMEQGEFLN YDIMLGVNQG EGLKFVENIV
     DSDDGVSASD FDFAVSNFVD NLYGYPEGKD VLRETIKFMY TDWADRHNPE TRRKTLLALF
     TDHQWVAPAV ATADLHSNFG SPTYFYAFYH HCQTDQVPAW ADAAHGDEVP YVLGIPMIGP
     TELFPCNFSK NDVMLSAVVM TYWTNFAKTG DPNQPVPQDT KFIHTKPNRF EEVAWTRYSQ
     KDQLYLHIGL KPRVKEHYRA NKVNLWLELV PHLHNLNDIS QYTSTTTKVP STDITLRPTR
     KNSTPVTSAF PTAKQDDPKQ QPSPFSVDQR DYSTELSVTI AVGASLLFLN ILAFAALYYK
     KDKRRHDVHR RCSPQRTTTN DLTHAPEEEI MSLQMKHTDL DHECESIHPH EVVLRTACPP
     DYTLAMRRSP DDVPLMTPNT ITMIPNTIPG IQPLHTFNTF TGGQNNTLPH PHPHPHSHST
     TRV
//
ID   SHH_DANRE               Reviewed;         418 AA.
AC   Q92008; O13170; O13171; O13208; O13209; O13245; O13246;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   20-JAN-2016, entry version 150.
DE   RecName: Full=Sonic hedgehog protein A;
DE            Short=SHHA;
DE   AltName: Full=VHH-1;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein A N-product;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein A C-product;
DE   Flags: Precursor;
GN   Name=shha; Synonyms=shh, vhh1;
OS   Danio rerio (Zebrafish) (Brachydanio rerio).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC   Cyprinidae; Danio.
OX   NCBI_TaxID=7955;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Embryo;
RX   PubMed=8124714; DOI=10.1016/0092-8674(94)90514-2;
RA   Roelink H., Augsburger A., Heemskerk J., Korzh V., Norlin S.,
RA   Ruiz i Altaba A., Tanabe Y., Placzek M., Edlund T., Jessell T.M.,
RA   Dodd J.;
RT   "Floor plate and motor neuron induction by vhh-1, a vertebrate homolog
RT   of hedgehog expressed by the notochord.";
RL   Cell 76:761-775(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEOLYTIC PROCESSING, AND AUTOCATALYTIC
RP   CLEAVAGE.
RX   PubMed=7583153; DOI=10.1016/S0960-9822(95)00185-0;
RA   Ekker S.C., Ungar A.R., Greenstein P., von Kessler D.P., Porter J.A.,
RA   Moon R.T., Beachy P.A.;
RT   "Patterning activities of vertebrate hedgehog proteins in the
RT   developing eye and brain.";
RL   Curr. Biol. 5:944-955(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7579523;
RA   Fietz M.J., Concordet J.-P., Barbosa R., Johnson R., Krauss S.,
RA   McMahon A.P., Tabin C., Ingham P.W.;
RT   "The hedgehog gene family in Drosophila and vertebrate development.";
RL   Development Suppl. 120:43-51(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10207136;
RA   Muller F., Chang B., Albert S., Fischer N., Tora L., Strahle U.;
RT   "Intronic enhancers control expression of zebrafish sonic hedgehog in
RT   floor plate and notochord.";
RL   Development 126:2103-2116(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 30-92 AND 113-170.
RC   TISSUE=Muscle;
RX   PubMed=8917540; DOI=10.1073/pnas.93.23.13036;
RA   Zardoya R., Abouheif E., Meyer A.;
RT   "Evolutionary analyses of hedgehog and Hoxd-10 genes in fish species
RT   closely related to the zebrafish.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13036-13041(1996).
CC   -!- FUNCTION: Intercellular signal essential for a variety of
CC       patterning events during development. Signal produced by the
CC       notochord that induces somite patterning, dorso-ventral patterning
CC       of the brain and early patterning of the developing eyes. Displays
CC       floor plate-inducing activity. Binds to the patched (PTC)
CC       receptor, which functions in association with smoothened (SMO), to
CC       activate the transcription of target genes. In the absence of SHH,
CC       PTC represses the constitutive signaling activity of SMO (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: N-product is active as a multimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein A C-product:
CC       Secreted, extracellular space {ECO:0000250}. Note=The C-terminal
CC       peptide diffuses from the cell. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein A N-product: Cell
CC       membrane {ECO:0000250}; Lipid-anchor {ECO:0000250}. Note=The N-
CC       product either remains associated with lipid rafts at the cell
CC       surface, or forms freely diffusible active multimers with its
CC       hydrophobic lipid-modified N- and C-termini buried inside.
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in the ventral midline of the neural
CC       tube and brain. Also found in the notochord and in developing fin
CC       bud. In the developing brain, expression occurs in domains that
CC       include a discrete region in the floor of the diencephalon.
CC   -!- DEVELOPMENTAL STAGE: First detectable in the inner cell layer of
CC       the embryonic shield during gastrulation. By 9.5 hours of
CC       development, expressed in a continuous band that extends from the
CC       tail to the head, the anterior boundary of expression being
CC       positioned in the center of the animal pole anterior to the
CC       presumptive midbrain.
CC   -!- DOMAIN: The sonic hedgehog protein N-product binds calcium and
CC       zinc ions; this stabilizes the protein fold and is essential for
CC       protein-protein interactions mediated by this domain.
CC       {ECO:0000250}.
CC   -!- PTM: The C-terminal domain displays an autoproteolysis activity
CC       and a cholesterol transferase activity. Both activities result in
CC       the cleavage of the full-length protein and covalent attachment of
CC       a cholesterol moiety to the C-terminal of the newly generated N-
CC       terminal fragment (N-product). The N-product is the active species
CC       in both local and long-range signaling, whereas the C-product has
CC       no signaling activity. {ECO:0000269|PubMed:7583153}.
CC   -!- PTM: Cholesterylation is required for N-product targeting to lipid
CC       rafts and multimerization. {ECO:0000250}.
CC   -!- PTM: N-palmitoylation of Cys-24 by HHAT is required for N-product
CC       multimerization and full activity. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the hedgehog family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L27585; AAA20998.1; -; mRNA.
DR   EMBL; U30711; AAC59742.1; -; mRNA.
DR   EMBL; Z35669; CAA84738.1; -; mRNA.
DR   EMBL; AF124382; AAD47913.1; -; Genomic_DNA.
DR   EMBL; U51339; AAB38570.1; -; Genomic_DNA.
DR   EMBL; U51351; AAB38575.1; -; Genomic_DNA.
DR   EMBL; U51357; AAB38588.1; -; Genomic_DNA.
DR   EMBL; U51370; AAB38593.1; -; Genomic_DNA.
DR   PIR; A53193; A53193.
DR   RefSeq; NP_571138.1; NM_131063.3.
DR   UniGene; Dr.115833; -.
DR   UniGene; Dr.36074; -.
DR   ProteinModelPortal; Q92008; -.
DR   SMR; Q92008; 38-194.
DR   STRING; 7955.ENSDARP00000125090; -.
DR   MEROPS; C46.005; -.
DR   PaxDb; Q92008; -.
DR   Ensembl; ENSDART00000149395; ENSDARP00000125090; ENSDARG00000068567.
DR   GeneID; 30269; -.
DR   KEGG; dre:30269; -.
DR   CTD; 30269; -.
DR   ZFIN; ZDB-GENE-980526-166; shha.
DR   eggNOG; KOG3638; Eukaryota.
DR   eggNOG; ENOG410XQA3; LUCA.
DR   GeneTree; ENSGT00390000001117; -.
DR   HOVERGEN; HBG005480; -.
DR   InParanoid; Q92008; -.
DR   KO; K11988; -.
DR   OMA; EHSWAHR; -.
DR   OrthoDB; EOG779NZ5; -.
DR   PhylomeDB; Q92008; -.
DR   TreeFam; TF106458; -.
DR   Reactome; R-DRE-5358346; Hedgehog ligand biogenesis.
DR   Reactome; R-DRE-5362798; Release of Hh-Np from the secreting cell.
DR   Reactome; R-DRE-5632681; Ligand-receptor interactions.
DR   NextBio; 20806716; -.
DR   PRO; PR:Q92008; -.
DR   Proteomes; UP000000437; Chromosome 7.
DR   Bgee; Q92008; -.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008233; F:peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0021984; P:adenohypophysis development; IDA:ZFIN.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:ZFIN.
DR   GO; GO:0007411; P:axon guidance; IMP:ZFIN.
DR   GO; GO:0008015; P:blood circulation; IMP:ZFIN.
DR   GO; GO:0007420; P:brain development; IMP:ZFIN.
DR   GO; GO:0043010; P:camera-type eye development; IDA:ZFIN.
DR   GO; GO:0010002; P:cardioblast differentiation; IMP:ZFIN.
DR   GO; GO:0035143; P:caudal fin morphogenesis; IMP:ZFIN.
DR   GO; GO:0001708; P:cell fate specification; IMP:ZFIN.
DR   GO; GO:0007267; P:cell-cell signaling; IEA:InterPro.
DR   GO; GO:0007417; P:central nervous system development; IMP:ZFIN.
DR   GO; GO:0007368; P:determination of left/right symmetry; IDA:ZFIN.
DR   GO; GO:0021536; P:diencephalon development; IGI:ZFIN.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IMP:ZFIN.
DR   GO; GO:0031076; P:embryonic camera-type eye development; IMP:ZFIN.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; IMP:ZFIN.
DR   GO; GO:0048702; P:embryonic neurocranium morphogenesis; IMP:ZFIN.
DR   GO; GO:0048703; P:embryonic viscerocranium morphogenesis; IMP:ZFIN.
DR   GO; GO:0060956; P:endocardial cell differentiation; IGI:ZFIN.
DR   GO; GO:0031018; P:endocrine pancreas development; IDA:ZFIN.
DR   GO; GO:0042462; P:eye photoreceptor cell development; IMP:ZFIN.
DR   GO; GO:0033504; P:floor plate development; IMP:ZFIN.
DR   GO; GO:0021508; P:floor plate formation; IMP:ZFIN.
DR   GO; GO:0030900; P:forebrain development; IMP:ZFIN.
DR   GO; GO:0010001; P:glial cell differentiation; IMP:ZFIN.
DR   GO; GO:0042063; P:gliogenesis; IMP:ZFIN.
DR   GO; GO:0032835; P:glomerulus development; IMP:ZFIN.
DR   GO; GO:0001947; P:heart looping; IDA:ZFIN.
DR   GO; GO:0030902; P:hindbrain development; IMP:ZFIN.
DR   GO; GO:0048839; P:inner ear development; IGI:ZFIN.
DR   GO; GO:0016539; P:intein-mediated protein splicing; IEA:InterPro.
DR   GO; GO:0042694; P:muscle cell fate specification; IMP:ZFIN.
DR   GO; GO:0007517; P:muscle organ development; IMP:ZFIN.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:ZFIN.
DR   GO; GO:0007399; P:nervous system development; IMP:ZFIN.
DR   GO; GO:0001839; P:neural plate morphogenesis; IMP:ZFIN.
DR   GO; GO:0030182; P:neuron differentiation; IMP:ZFIN.
DR   GO; GO:0048663; P:neuron fate commitment; IGI:ZFIN.
DR   GO; GO:0042476; P:odontogenesis; IMP:ZFIN.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IMP:ZFIN.
DR   GO; GO:0070444; P:oligodendrocyte progenitor proliferation; IMP:ZFIN.
DR   GO; GO:0031016; P:pancreas development; IDA:ZFIN.
DR   GO; GO:0033339; P:pectoral fin development; IMP:ZFIN.
DR   GO; GO:0045494; P:photoreceptor cell maintenance; IMP:ZFIN.
DR   GO; GO:0048618; P:post-embryonic foregut morphogenesis; IMP:ZFIN.
DR   GO; GO:0048793; P:pronephros development; IMP:ZFIN.
DR   GO; GO:2000223; P:regulation of BMP signaling pathway involved in heart jogging; IDA:ZFIN.
DR   GO; GO:0061035; P:regulation of cartilage development; IGI:ZFIN.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:MGI.
DR   GO; GO:0030947; P:regulation of vascular endothelial growth factor receptor signaling pathway; IMP:ZFIN.
DR   GO; GO:0048741; P:skeletal muscle fiber development; IDA:ZFIN.
DR   GO; GO:0007224; P:smoothened signaling pathway; IGI:ZFIN.
DR   GO; GO:0001756; P:somitogenesis; IMP:ZFIN.
DR   GO; GO:0021520; P:spinal cord motor neuron cell fate specification; IMP:ZFIN.
DR   GO; GO:0055002; P:striated muscle cell development; IMP:ZFIN.
DR   GO; GO:0048795; P:swim bladder morphogenesis; IMP:ZFIN.
DR   Gene3D; 2.170.16.10; -; 1.
DR   Gene3D; 3.30.1380.10; -; 1.
DR   InterPro; IPR001657; Hedgehog.
DR   InterPro; IPR028992; Hedgehog/Intein_dom.
DR   InterPro; IPR009045; Hedgehog_sig/DD-Pept_Zn-bd_dom.
DR   InterPro; IPR000320; Hedgehog_signalling_dom.
DR   InterPro; IPR001767; Hint_dom.
DR   InterPro; IPR003586; Hint_dom_C.
DR   InterPro; IPR003587; Hint_dom_N.
DR   InterPro; IPR006141; Intein_N.
DR   Pfam; PF01085; HH_signal; 1.
DR   Pfam; PF01079; Hint; 1.
DR   PIRSF; PIRSF009400; Peptidase_C46; 1.
DR   PRINTS; PR00632; SONICHHOG.
DR   SMART; SM00305; HintC; 1.
DR   SMART; SM00306; HintN; 1.
DR   SUPFAM; SSF51294; SSF51294; 1.
DR   SUPFAM; SSF55166; SSF55166; 1.
DR   PROSITE; PS50817; INTEIN_N_TER; 1.
PE   1: Evidence at protein level;
KW   Autocatalytic cleavage; Calcium; Cell membrane; Complete proteome;
KW   Developmental protein; Hydrolase; Lipoprotein; Membrane;
KW   Metal-binding; Palmitate; Protease; Reference proteome; Secreted;
KW   Signal; Zinc.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    418       Sonic hedgehog protein A.
FT                                /FTId=PRO_0000013226.
FT   CHAIN        24    197       Sonic hedgehog protein A N-product.
FT                                /FTId=PRO_0000013227.
FT   CHAIN       198    418       Sonic hedgehog protein A C-product.
FT                                /FTId=PRO_0000013228.
FT   METAL        89     89       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL        90     90       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL        90     90       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL        95     95       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       125    125       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       126    126       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       126    126       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       129    129       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       131    131       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       140    140       Zinc. {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       147    147       Zinc. {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       182    182       Zinc. {ECO:0000250|UniProtKB:Q15465}.
FT   SITE        197    198       Cleavage; by autolysis.
FT   SITE        243    243       Involved in cholesterol transfer.
FT                                {ECO:0000250}.
FT   SITE        267    267       Involved in auto-cleavage. {ECO:0000250}.
FT   SITE        270    270       Essential for auto-cleavage.
FT                                {ECO:0000250}.
FT   LIPID        24     24       N-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID       197    197       Cholesterol glycine ester. {ECO:0000250}.
SQ   SEQUENCE   418 AA;  46403 MW;  CF000AFFFD2F5795 CRC64;
     MRLLTRVLLV SLLTLSLVVS GLACGPGRGY GRRRHPKKLT PLAYKQFIPN VAEKTLGASG
     RYEGKITRNS ERFKELTPNY NPDIIFKDEE NTGADRLMTQ RCKDKLNSLA ISVMNHWPGV
     KLRVTEGWDE DGHHFEESLH YEGRAVDITT SDRDKSKYGT LSRLAVEAGF DWVYYESKAH
     IHCSVKAENS VAAKSGGCFP GSALVSLQDG GQKAVKDLNP GDKVLAADSA GNLVFSDFIM
     FTDRDSTTRR VFYVIETQEP VEKITLTAAH LLFVLDNSTE DLHTMTAAYA SSVRAGQKVM
     VVDDSGQLKS VIVQRIYTEE QRGSFAPVTA HGTIVVDRIL ASCYAVIEDQ GLAHLAFAPA
     RLYYYVSSFL FPQNSSSRSN ATLQQEGVHW YSRLLYQMGT WLLDSNMLHP LGMSVNSS
//
ID   CATC_HUMAN              Reviewed;         463 AA.
AC   P53634; A8K7V2; B5MDD5; Q2HIY8; Q53G93; Q71E75; Q71E76; Q7M4N9;
AC   Q7Z3G7; Q7Z5U7; Q8WY99; Q8WYA7; Q8WYA8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   17-FEB-2016, entry version 171.
DE   RecName: Full=Dipeptidyl peptidase 1;
DE            EC=3.4.14.1;
DE   AltName: Full=Cathepsin C;
DE   AltName: Full=Cathepsin J;
DE   AltName: Full=Dipeptidyl peptidase I;
DE            Short=DPP-I;
DE            Short=DPPI;
DE   AltName: Full=Dipeptidyl transferase;
DE   Contains:
DE     RecName: Full=Dipeptidyl peptidase 1 exclusion domain chain;
DE     AltName: Full=Dipeptidyl peptidase I exclusion domain chain;
DE   Contains:
DE     RecName: Full=Dipeptidyl peptidase 1 heavy chain;
DE     AltName: Full=Dipeptidyl peptidase I heavy chain;
DE   Contains:
DE     RecName: Full=Dipeptidyl peptidase 1 light chain;
DE     AltName: Full=Dipeptidyl peptidase I light chain;
DE   Flags: Precursor;
GN   Name=CTSC; Synonyms=CPPI;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-153.
RC   TISSUE=Ileum;
RX   PubMed=7649281; DOI=10.1016/0014-5793(95)00777-7;
RA   Paris A., Strukelj B., Pungercar J., Renko M., Dolenc I., Turk V.;
RT   "Molecular cloning and sequence analysis of human preprocathepsin C.";
RL   FEBS Lett. 369:326-330(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], INDUCTION, TISSUE SPECIFICITY, AND
RP   VARIANT THR-153.
RX   PubMed=9092576; DOI=10.1074/jbc.272.15.10260;
RA   Rao N.V., Rao G.V., Hoidal J.R.;
RT   "Human dipeptidyl-peptidase I. Gene characterization, localization,
RT   and expression.";
RL   J. Biol. Chem. 272:10260-10265(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS PLS TYR-236; ARG-286
RP   AND TYR-291, AND VARIANT THR-153.
RC   TISSUE=Blood;
RX   PubMed=11180601;
RX   DOI=10.1002/1098-1004(200102)17:2<152::AID-HUMU10>3.3.CO;2-R;
RA   Allende L.M., Garcia-Perez M.A., Moreno A., Corell A., Carasol M.,
RA   Martinez-Canut P., Arnaiz-Villena A.;
RT   "Cathepsin C gene: first compound heterozygous patient with Papillon-
RT   Lefevre syndrome and a novel symptomless mutation.";
RL   Hum. Mutat. 17:152-153(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-153 AND PLS
RP   HIS-294.
RC   TISSUE=Blood;
RX   PubMed=12809647; DOI=10.1016/S1096-7192(03)00070-2;
RA   Allende L.M., Moreno A., de Unamuno P.;
RT   "A genetic study of cathepsin C gene in two families with Papillon-
RT   Lefevre syndrome.";
RL   Mol. Genet. Metab. 79:146-148(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   THR-153.
RC   TISSUE=Cerebellum, and Rheumatoid arthritic synovial fluid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   THR-153.
RC   TISSUE=Thyroid;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT THR-153.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 25-71; 122-143; 231-235 AND 395-399,
RP   CHARACTERIZATION OF EXCLUSION DOMAIN, AND GLYCOSYLATION.
RX   PubMed=9507095; DOI=10.1016/S0167-4838(97)00173-8;
RA   Cigic B., Krizaj I., Kralj B., Turk V., Pain R.H.;
RT   "Stoichiometry and heterogeneity of the pro-region chain in tetrameric
RT   human cathepsin C.";
RL   Biochim. Biophys. Acta 1382:143-150(1998).
RN   [12]
RP   PROTEIN SEQUENCE OF 25-34; 231-239 AND 395-404, AND CHARACTERIZATION.
RX   PubMed=7665576; DOI=10.1074/jbc.270.37.21626;
RA   Dolenc I., Turk B., Pungercic G., Ritonja A., Turk V.;
RT   "Oligomeric structure and substrate induced inhibition of human
RT   cathepsin C.";
RL   J. Biol. Chem. 270:21626-21631(1995).
RN   [13]
RP   PROTEIN SEQUENCE OF 25-28; 51-61; 114-117 AND 133-139,
RP   CHARACTERIZATION OF EXCLUSION DOMAIN, AND DISULFIDE BONDS.
RX   PubMed=11015218; DOI=10.1021/bi0008837;
RA   Cigic B., Dahl S.W., Pain R.H.;
RT   "The residual pro-part of cathepsin C fulfills the criteria required
RT   for an intramolecular chaperone in folding and stabilizing the human
RT   proenzyme.";
RL   Biochemistry 39:12382-12390(2000).
RN   [14]
RP   PROTEIN SEQUENCE OF 231-290; 310-328 AND 340-383, FUNCTION, ENZYME
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, GLYCOSYLATION, AND
RP   VARIANT THR-153.
RC   TISSUE=Spleen;
RX   PubMed=1586157; DOI=10.1016/0003-9861(92)90519-3;
RA   McGuire M.J., Lipsky P.E., Thiele D.L.;
RT   "Purification and characterization of dipeptidyl peptidase I from
RT   human spleen.";
RL   Arch. Biochem. Biophys. 295:280-288(1992).
RN   [15]
RP   GLYCOSYLATION AT ASN-29; ASN-53; ASN-119 AND ASN-276.
RX   PubMed=19167329; DOI=10.1016/j.cell.2008.11.047;
RA   Ruiz-Canada C., Kelleher D.J., Gilmore R.;
RT   "Cotranslational and posttranslational N-glycosylation of polypeptides
RT   by distinct mammalian OST isoforms.";
RL   Cell 136:272-283(2009).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-53.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 25-143 AND 231-463 IN
RP   COMPLEX WITH CHLORIDE IONS, SUBUNIT, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-29.
RX   PubMed=11726493; DOI=10.1093/emboj/20.23.6570;
RA   Turk D., Janjic V., Stern I., Podobnik M., Lamba D., Dahl S.W.,
RA   Lauritzen C., Pedersen J., Turk V., Turk B.;
RT   "Structure of human dipeptidyl peptidase I (cathepsin C): exclusion
RT   domain added to an endopeptidase framework creates the machine for
RT   activation of granular serine proteases.";
RL   EMBO J. 20:6570-6582(2001).
RN   [21]
RP   VARIANTS PLS PHE-249; LEU-252; PRO-272; SER-301; CYS-339 AND CYS-347.
RX   PubMed=10581027; DOI=10.1038/70525;
RA   Toomes C., James J., Wood A.J., Wu C.L., McCormick D., Lench N.,
RA   Hewitt C., Moynihan L., Roberts E., Woods C.G., Markham A., Wong M.,
RA   Widmer R., Ghaffar K.A., Pemberton M., Hussein I.R., Temtamy S.A.,
RA   Davies R., Read A.P., Sloan P., Dixon M.J., Thakker N.S.;
RT   "Loss-of-function mutations in the cathepsin C gene result in
RT   periodontal disease and palmoplantar keratosis.";
RL   Nat. Genet. 23:421-424(1999).
RN   [22]
RP   VARIANT HMS ARG-286.
RX   PubMed=10662807; DOI=10.1136/jmg.37.2.88;
RA   Hart T.C., Hart P.S., Michalec M.D., Zhang Y., Firatli E.,
RA   Van Dyke T.E., Stabholz A., Zlotogorski A., Shapira L., Soskolne W.A.;
RT   "Haim-Munk syndrome and Papillon-Lefevre syndrome are allelic
RT   mutations in cathepsin C.";
RL   J. Med. Genet. 37:88-94(2000).
RN   [23]
RP   VARIANTS PLS CYS-339 AND CYS-340, AND VARIANT AP1 CYS-347.
RX   PubMed=10662808; DOI=10.1136/jmg.37.2.95;
RA   Hart T.C., Hart P.S., Michalec M.D., Zhang Y., Marazita M.L.,
RA   Cooper M., Yassin O.M., Nusier M., Walker S.;
RT   "Localisation of a gene for prepubertal periodontitis to chromosome
RT   11q14 and identification of a cathepsin C gene mutation.";
RL   J. Med. Genet. 37:95-101(2000).
RN   [24]
RP   VARIANTS PLS 67-TYR--ALA-74 DEL; PRO-272; SER-300; VAL-301; SER-301;
RP   ASN-304; GLY-319; CYS-339; CYS-340 AND GLY-447, AND VARIANT THR-153.
RX   PubMed=11106356; DOI=10.1136/jmg.37.12.927;
RA   Hart P.S., Zhang Y., Firatli E., Uygur C., Lotfazar M., Michalec M.D.,
RA   Marks J.J., Lu X., Coates B.J., Seow W.K., Marshall R., Williams D.,
RA   Reed J.B., Wright J.T., Hart T.C.;
RT   "Identification of cathepsin C mutations in ethnically diverse
RT   Papillon-Lefevre syndrome patients.";
RL   J. Med. Genet. 37:927-932(2000).
RN   [25]
RP   VARIANTS PLS SER-39 AND SER-301, AND VARIANT VAL-453.
RX   PubMed=11180012; DOI=10.1046/j.1523-1747.2001.01244.x;
RA   Nakano A., Nomura K., Nakano H., Ono Y., LaForgia S., Pulkkinen L.,
RA   Hashimoto I., Uitto J.;
RT   "Papillon-Lefevre syndrome: mutations and polymorphisms in the
RT   cathepsin C gene.";
RL   J. Invest. Dermatol. 116:339-343(2001).
RN   [26]
RP   VARIANTS PLS PRO-127; PRO-272; CYS-339 AND CYS-429, AND VARIANTS
RP   THR-153 AND LYS-401.
RX   PubMed=11886537; DOI=10.1046/j.0022-202x.2001.01595.x;
RA   Lefevre C., Blanchet-Bardon C., Jobard F., Bouadjar B., Stalder J.-F.,
RA   Cure S., Hoffmann A., Prud'Homme J.-F., Fischer J.;
RT   "Novel point mutations, deletions, and polymorphisms in the cathepsin
RT   C gene in nine families from Europe and North Africa with Papillon-
RT   Lefevre syndrome.";
RL   J. Invest. Dermatol. 117:1657-1661(2001).
RN   [27]
RP   VARIANTS PLS PRO-272 AND ASP-300.
RX   PubMed=11158173; DOI=10.1136/jmg.38.2.96;
RA   Zhang Y., Lundgren T., Renvert S., Tatakis D.N., Firatli E., Uygur C.,
RA   Hart P.S., Gorry M.C., Marks J.J., Hart T.C.;
RT   "Evidence of a founder effect for four cathepsin C gene mutations in
RT   Papillon-Lefevre syndrome patients.";
RL   J. Med. Genet. 38:96-101(2001).
RN   [28]
RP   VARIANTS PLS ARG-139 AND PRO-272, AND VARIANT THR-153.
RX   PubMed=12112662; DOI=10.1002/humu.9040;
RA   Zhang Y., Hart P.S., Moretti A.J., Bouwsma O.J., Fisher E.M.,
RA   Dudlicek L., Pettenati M.J., Hart T.C.;
RT   "Biochemical and mutational analyses of the cathepsin c gene (CTSC) in
RT   three North American families with Papillon Lefevre syndrome.";
RL   Hum. Mutat. 20:75-75(2002).
RN   [29]
RP   VARIANTS PLS GLU-129; ARG-139; TYR-236; PHE-249; LEU-252; HIS-272;
RP   SER-301; ARG-312; CYS-339; CYS-347 AND GLY-447, VARIANTS AP1 HIS-272
RP   AND CYS-412, AND VARIANT THR-153.
RX   PubMed=14974080; DOI=10.1002/humu.10314;
RA   Hewitt C., McCormick D., Linden G., Turk D., Stern I., Wallace I.,
RA   Southern L., Zhang L., Howard R., Bullon P., Wong M., Widmer R.,
RA   Gaffar K.A., Awawdeh L., Briggs J., Yaghmai R., Jabs E.W., Hoeger P.,
RA   Bleck O., Rudiger S.G., Petersilka G., Battino M., Brett P.,
RA   Hattab F., Al-Hamed M., Sloan P., Toomes C., Dixon M.J., James J.,
RA   Read A.P., Thakker N.S.;
RT   "The role of cathepsin C in Papillon-Lefevre syndrome, prepubertal
RT   periodontitis, and aggressive periodontitis.";
RL   Hum. Mutat. 23:222-228(2004).
RN   [30]
RP   VARIANT PLS ASN-405.
RX   PubMed=15108292; DOI=10.1002/humu.9243;
RA   de Haar S.F., Jansen D.C., Schoenmaker T., De Vree H., Everts V.,
RA   Beertsen W.;
RT   "Loss-of-function mutations in cathepsin C in two families with
RT   Papillon-Lefevre syndrome are associated with deficiency of serine
RT   proteinases in PMNs.";
RL   Hum. Mutat. 23:524-524(2004).
RN   [31]
RP   VARIANT PLS ARG-405.
RX   PubMed=15991336;
RA   de Haar S.F., Mir M., Nguyen M., Kazemi B., Ramezani G.H., Everts V.;
RT   "Gene symbol: CTSC. Disease: Papillon-Lefevre syndrome.";
RL   Hum. Genet. 116:545-545(2005).
RN   [32]
RP   ERRATUM.
RA   de Haar S.F., Mir M., Nguyen M., Kazemi B., Ramezani G.H., Everts V.;
RL   Hum. Genet. 118:533-533(2005).
RN   [33]
RP   VARIANT PLS ASP-300.
RX   PubMed=25799584; DOI=10.1371/journal.pone.0121351;
RA   Erzurumluoglu A.M., Alsaadi M.M., Rodriguez S., Alotaibi T.S.,
RA   Guthrie P.A., Lewis S., Ginwalla A., Gaunt T.R., Alharbi K.K.,
RA   Alsaif F.M., Alsaadi B.M., Day I.N.;
RT   "Proxy molecular diagnosis from whole-exome sequencing reveals
RT   Papillon-Lefevre syndrome caused by a missense mutation in CTSC.";
RL   PLoS ONE 10:E0121351-E0121351(2015).
CC   -!- FUNCTION: Thiol protease. Has dipeptidylpeptidase activity. Active
CC       against a broad range of dipeptide substrates composed of both
CC       polar and hydrophobic amino acids. Proline cannot occupy the P1
CC       position and arginine cannot occupy the P2 position of the
CC       substrate. Can act as both an exopeptidase and endopeptidase.
CC       Activates serine proteases such as elastase, cathepsin G and
CC       granzymes A and B. Can also activate neuraminidase and factor
CC       XIII. {ECO:0000269|PubMed:1586157}.
CC   -!- CATALYTIC ACTIVITY: Release of an N-terminal dipeptide, Xaa-Yaa-|-
CC       Zaa-, except when Xaa is Arg or Lys, or Yaa or Zaa is Pro.
CC   -!- COFACTOR:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC       Note=Binds 1 Cl(-) ion per heavy chain.;
CC   -!- ENZYME REGULATION: Strongly inhibited by the cysteine peptidase
CC       inhibitors mersalyl acid, iodoacetic acid and cystatin. Inhibited
CC       by N-ethylmaleimide, Gly-Phe-diazomethane, TLCK, TPCK and, at low
CC       pH, by dithiodipyridine. Not inhibited by the serine peptidase
CC       inhibitor PMSF, the aminopeptidase inhibitor bestatin, or metal
CC       ion chelators. {ECO:0000269|PubMed:1586157}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         High activity at pH 4.5-6.8. {ECO:0000269|PubMed:1586157};
CC   -!- SUBUNIT: Tetramer of heterotrimers consisting of exclusion domain,
CC       heavy- and light chains. {ECO:0000269|PubMed:11726493,
CC       ECO:0000269|PubMed:1586157}.
CC   -!- INTERACTION:
CC       O76096:CST7; NbExp=2; IntAct=EBI-1047323, EBI-2807448;
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P53634-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P53634-2; Sequence=VSP_039123, VSP_039124;
CC       Name=3;
CC         IsoId=P53634-3; Sequence=VSP_043232, VSP_043233;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in lung, kidney
CC       and placenta. Detected at intermediate levels in colon, small
CC       intestine, spleen and pancreas. {ECO:0000269|PubMed:9092576}.
CC   -!- INDUCTION: Up-regulated in lymphocytes by IL2/interleukin-2.
CC       {ECO:0000269|PubMed:9092576}.
CC   -!- PTM: N-glycosylated. While glycosylation at Asn-53, Asn-119 and
CC       Asn-276 is mediated by STT3A-containing complexes, glycosylation
CC       at Asn-29 is mediated STT3B-containing complexes.
CC       {ECO:0000269|PubMed:11726493, ECO:0000269|PubMed:1586157,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19167329,
CC       ECO:0000269|PubMed:9507095}.
CC   -!- PTM: In approximately 50% of the complexes the exclusion domain is
CC       cleaved at position 58 or 61. The two parts of the exclusion
CC       domain are held together by a disulfide bond.
CC   -!- DISEASE: Papillon-Lefevre syndrome (PLS) [MIM:245000]: An
CC       autosomal recessive disorder characterized by palmoplantar
CC       keratosis and severe periodontitis affecting deciduous and
CC       permanent dentitions and resulting in premature tooth loss. The
CC       palmoplantar keratotic phenotype vary from mild psoriasiform scaly
CC       skin to overt hyperkeratosis. Keratosis also affects other sites
CC       such as elbows and knees. {ECO:0000269|PubMed:10581027,
CC       ECO:0000269|PubMed:10662808, ECO:0000269|PubMed:11106356,
CC       ECO:0000269|PubMed:11158173, ECO:0000269|PubMed:11180012,
CC       ECO:0000269|PubMed:11180601, ECO:0000269|PubMed:11886537,
CC       ECO:0000269|PubMed:12112662, ECO:0000269|PubMed:12809647,
CC       ECO:0000269|PubMed:14974080, ECO:0000269|PubMed:15108292,
CC       ECO:0000269|PubMed:15991336, ECO:0000269|PubMed:25799584}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Haim-Munk syndrome (HMS) [MIM:245010]: An autosomal
CC       recessive disorder characterized by palmoplantar keratosis,
CC       onychogryphosis and periodontitis. Additional features are pes
CC       planus, arachnodactyly, and acroosteolysis.
CC       {ECO:0000269|PubMed:10662807}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Periodontititis, aggressive, 1 (AP1) [MIM:170650]: A
CC       disease characterized by severe and protracted gingival
CC       infections, generalized or localized, leading to tooth loss.
CC       Amounts of microbial deposits are generally inconsistent with the
CC       severity of periodontal tissue destruction and the progression of
CC       attachment and bone loss may be self arresting.
CC       {ECO:0000269|PubMed:10662808, ECO:0000269|PubMed:14974080}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase C1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU10088, ECO:0000255|PROSITE-
CC       ProRule:PRU10089, ECO:0000255|PROSITE-ProRule:PRU10090}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD97897.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=CTSCbase; Note=CTSC mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/CTSCbase/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X87212; CAA60671.1; -; mRNA.
DR   EMBL; U79415; AAC51341.1; -; Genomic_DNA.
DR   EMBL; AF234263; AAL48191.1; -; mRNA.
DR   EMBL; AF234264; AAL48192.1; -; mRNA.
DR   EMBL; AF254757; AAL48195.1; -; mRNA.
DR   EMBL; AF525032; AAQ08887.1; -; mRNA.
DR   EMBL; AF525033; AAQ08888.1; -; mRNA.
DR   EMBL; AK292117; BAF84806.1; -; mRNA.
DR   EMBL; AK311923; BAG34864.1; -; mRNA.
DR   EMBL; AK223038; BAD96758.1; -; mRNA.
DR   EMBL; BX537913; CAD97897.1; ALT_INIT; mRNA.
DR   EMBL; AC011088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471185; EAW59364.1; -; Genomic_DNA.
DR   EMBL; BC054028; AAH54028.1; -; mRNA.
DR   EMBL; BC100891; AAI00892.1; -; mRNA.
DR   EMBL; BC100892; AAI00893.1; -; mRNA.
DR   EMBL; BC100893; AAI00894.1; -; mRNA.
DR   EMBL; BC100894; AAI00895.1; -; mRNA.
DR   EMBL; BC109386; AAI09387.1; -; mRNA.
DR   EMBL; BC110071; AAI10072.1; -; mRNA.
DR   EMBL; BC113850; AAI13851.1; -; mRNA.
DR   EMBL; BC113897; AAI13898.1; -; mRNA.
DR   CCDS; CCDS31654.1; -. [P53634-2]
DR   CCDS; CCDS44693.1; -. [P53634-3]
DR   CCDS; CCDS8282.1; -. [P53634-1]
DR   PIR; S23941; S23941.
DR   PIR; S66504; S66504.
DR   RefSeq; NP_001107645.1; NM_001114173.2. [P53634-3]
DR   RefSeq; NP_001805.3; NM_001814.4.
DR   RefSeq; NP_680475.1; NM_148170.4. [P53634-2]
DR   UniGene; Hs.128065; -.
DR   PDB; 1K3B; X-ray; 2.15 A; A=25-143, B=231-394, C=395-463.
DR   PDB; 2DJF; X-ray; 2.00 A; A=25-143, B=231-394, C=395-463.
DR   PDB; 2DJG; X-ray; 2.05 A; A=25-143, B=231-394, C=395-463.
DR   PDB; 3PDF; X-ray; 1.85 A; A=25-463.
DR   PDB; 4CDC; X-ray; 2.40 A; A/D/G/J=25-143, B/E/H/K=230-394, C/F/I/L=395-463.
DR   PDB; 4CDD; X-ray; 2.35 A; A/D=25-144, B/E=230-394, C/F=395-463.
DR   PDB; 4CDE; X-ray; 2.40 A; A/D=25-143, B/E=230-394, C/F=395-463.
DR   PDB; 4CDF; X-ray; 2.20 A; A/D=25-144, B/E=229-394, C/F=395-463.
DR   PDB; 4OEL; X-ray; 1.40 A; A=25-394, B=395-463.
DR   PDB; 4OEM; X-ray; 1.52 A; A=25-394, B=395-463.
DR   PDBsum; 1K3B; -.
DR   PDBsum; 2DJF; -.
DR   PDBsum; 2DJG; -.
DR   PDBsum; 3PDF; -.
DR   PDBsum; 4CDC; -.
DR   PDBsum; 4CDD; -.
DR   PDBsum; 4CDE; -.
DR   PDBsum; 4CDF; -.
DR   PDBsum; 4OEL; -.
DR   PDBsum; 4OEM; -.
DR   ProteinModelPortal; P53634; -.
DR   SMR; P53634; 25-142, 174-463.
DR   BioGrid; 107502; 10.
DR   IntAct; P53634; 22.
DR   MINT; MINT-4655964; -.
DR   STRING; 9606.ENSP00000227266; -.
DR   BindingDB; P53634; -.
DR   ChEMBL; CHEMBL2252; -.
DR   GuidetoPHARMACOLOGY; 2344; -.
DR   MEROPS; C01.070; -.
DR   PhosphoSite; P53634; -.
DR   SwissPalm; P53634; -.
DR   BioMuta; CTSC; -.
DR   DMDM; 317373330; -.
DR   MaxQB; P53634; -.
DR   PaxDb; P53634; -.
DR   PRIDE; P53634; -.
DR   DNASU; 1075; -.
DR   Ensembl; ENST00000227266; ENSP00000227266; ENSG00000109861. [P53634-1]
DR   Ensembl; ENST00000524463; ENSP00000432541; ENSG00000109861. [P53634-2]
DR   Ensembl; ENST00000529974; ENSP00000433539; ENSG00000109861. [P53634-3]
DR   GeneID; 1075; -.
DR   KEGG; hsa:1075; -.
DR   UCSC; uc001pck.4; human. [P53634-1]
DR   UCSC; uc001pcm.4; human. [P53634-2]
DR   UCSC; uc001pcn.4; human. [P53634-3]
DR   CTD; 1075; -.
DR   GeneCards; CTSC; -.
DR   HGNC; HGNC:2528; CTSC.
DR   HPA; CAB025364; -.
DR   MalaCards; CTSC; -.
DR   MIM; 170650; phenotype.
DR   MIM; 245000; phenotype.
DR   MIM; 245010; phenotype.
DR   MIM; 602365; gene.
DR   neXtProt; NX_P53634; -.
DR   Orphanet; 2342; Haim-Munk syndrome.
DR   Orphanet; 678; Papillon-Lefevre syndrome.
DR   PharmGKB; PA27028; -.
DR   eggNOG; KOG1543; Eukaryota.
DR   eggNOG; COG4870; LUCA.
DR   GeneTree; ENSGT00760000118871; -.
DR   HOGENOM; HOG000127503; -.
DR   HOVERGEN; HBG005248; -.
DR   InParanoid; P53634; -.
DR   KO; K01275; -.
DR   OMA; YDDFLHY; -.
DR   OrthoDB; EOG74R1QK; -.
DR   PhylomeDB; P53634; -.
DR   TreeFam; TF313225; -.
DR   BioCyc; MetaCyc:HS03265-MONOMER; -.
DR   BRENDA; 3.4.14.1; 2681.
DR   Reactome; R-HSA-204005; COPII (Coat Protein 2) Mediated Vesicle Transport.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   Reactome; R-HSA-5694530; Cargo concentration in the ER.
DR   SABIO-RK; P53634; -.
DR   ChiTaRS; CTSC; human.
DR   EvolutionaryTrace; P53634; -.
DR   GeneWiki; Cathepsin_C; -.
DR   GenomeRNAi; 1075; -.
DR   NextBio; 4488; -.
DR   PMAP-CutDB; P53634; -.
DR   PRO; PR:P53634; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P53634; -.
DR   ExpressionAtlas; P53634; baseline and differential.
DR   Genevisible; P53634; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:GOC.
DR   GO; GO:0005764; C:lysosome; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; ISS:BHF-UCL.
DR   GO; GO:0031404; F:chloride ion binding; IEA:Ensembl.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; IDA:UniProtKB.
DR   GO; GO:0016505; F:peptidase activator activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0019902; F:phosphatase binding; ISS:BHF-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0048208; P:COPII vesicle coating; TAS:Reactome.
DR   GO; GO:0006888; P:ER to Golgi vesicle-mediated transport; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:1903052; P:positive regulation of proteolysis involved in cellular protein catabolic process; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0051603; P:proteolysis involved in cellular protein catabolic process; IBA:GO_Central.
DR   GO; GO:0010033; P:response to organic substance; IEA:Ensembl.
DR   GO; GO:0001913; P:T cell mediated cytotoxicity; IEA:Ensembl.
DR   Gene3D; 2.40.128.80; -; 1.
DR   InterPro; IPR014882; CathepsinC_exc.
DR   InterPro; IPR025661; Pept_asp_AS.
DR   InterPro; IPR000169; Pept_cys_AS.
DR   InterPro; IPR025660; Pept_his_AS.
DR   InterPro; IPR013128; Peptidase_C1A.
DR   InterPro; IPR000668; Peptidase_C1A_C.
DR   PANTHER; PTHR12411; PTHR12411; 1.
DR   Pfam; PF08773; CathepsinC_exc; 1.
DR   Pfam; PF00112; Peptidase_C1; 1.
DR   PRINTS; PR00705; PAPAIN.
DR   SMART; SM00645; Pept_C1; 1.
DR   SUPFAM; SSF75001; SSF75001; 1.
DR   PROSITE; PS00640; THIOL_PROTEASE_ASN; 1.
DR   PROSITE; PS00139; THIOL_PROTEASE_CYS; 1.
DR   PROSITE; PS00639; THIOL_PROTEASE_HIS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chloride; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hydrolase; Lysosome; Palmoplantar keratoderma;
KW   Polymorphism; Protease; Reference proteome; Signal; Thiol protease;
KW   Zymogen.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:11015218,
FT                                ECO:0000269|PubMed:7665576,
FT                                ECO:0000269|PubMed:9507095}.
FT   CHAIN        25    134       Dipeptidyl peptidase 1 exclusion domain
FT                                chain.
FT                                /FTId=PRO_0000026338.
FT   PROPEP      135    230       {ECO:0000269|PubMed:1586157,
FT                                ECO:0000269|PubMed:7665576,
FT                                ECO:0000269|PubMed:9507095}.
FT                                /FTId=PRO_0000026339.
FT   CHAIN       231    394       Dipeptidyl peptidase 1 heavy chain.
FT                                /FTId=PRO_0000026340.
FT   CHAIN       395    463       Dipeptidyl peptidase 1 light chain.
FT                                /FTId=PRO_0000026341.
FT   ACT_SITE    258    258
FT   ACT_SITE    405    405
FT   ACT_SITE    427    427
FT   BINDING     302    302       Chloride.
FT   BINDING     304    304       Chloride; via amide nitrogen.
FT   BINDING     347    347       Chloride.
FT   CARBOHYD     29     29       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:11726493,
FT                                ECO:0000269|PubMed:19167329}.
FT   CARBOHYD     53     53       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19167329}.
FT   CARBOHYD    119    119       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19167329}.
FT   CARBOHYD    276    276       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19167329}.
FT   DISULFID     30    118
FT   DISULFID     54    136
FT   DISULFID    255    298
FT   DISULFID    291    331
FT   DISULFID    321    337
FT   VAR_SEQ     107    141       YKEEGSKVTTYCNETMTGWVHDVLGRNWACFTGKK -> DV
FT                                TDFISHLFMQLGTVGIYDLPHLRNKLAMNRRWG (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043232.
FT   VAR_SEQ     107    137       YKEEGSKVTTYCNETMTGWVHDVLGRNWACF -> DVTDFI
FT                                SHLFMQLGTVGIYDLPHLRNKLVIK (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_039123.
FT   VAR_SEQ     138    463       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_039124.
FT   VAR_SEQ     142    463       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043233.
FT   VARIANT      39     39       W -> S (in PLS).
FT                                {ECO:0000269|PubMed:11180012}.
FT                                /FTId=VAR_016933.
FT   VARIANT      67     74       Missing (in PLS).
FT                                {ECO:0000269|PubMed:11106356}.
FT                                /FTId=VAR_019035.
FT   VARIANT     127    127       H -> P (in PLS).
FT                                {ECO:0000269|PubMed:11886537}.
FT                                /FTId=VAR_016934.
FT   VARIANT     129    129       V -> E (in PLS).
FT                                {ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_019036.
FT   VARIANT     139    139       G -> R (in PLS).
FT                                {ECO:0000269|PubMed:12112662,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_019037.
FT   VARIANT     153    153       I -> T (in dbSNP:rs217086).
FT                                {ECO:0000269|PubMed:11106356,
FT                                ECO:0000269|PubMed:11180601,
FT                                ECO:0000269|PubMed:11886537,
FT                                ECO:0000269|PubMed:12112662,
FT                                ECO:0000269|PubMed:12809647,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:14974080,
FT                                ECO:0000269|PubMed:1586157,
FT                                ECO:0000269|PubMed:7649281,
FT                                ECO:0000269|PubMed:9092576,
FT                                ECO:0000269|Ref.6, ECO:0000269|Ref.9}.
FT                                /FTId=VAR_016943.
FT   VARIANT     236    236       D -> Y (in PLS).
FT                                {ECO:0000269|PubMed:11180601,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_019038.
FT   VARIANT     249    249       V -> F (in PLS).
FT                                {ECO:0000269|PubMed:10581027,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_009541.
FT   VARIANT     252    252       Q -> L (in PLS).
FT                                {ECO:0000269|PubMed:10581027,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_009542.
FT   VARIANT     272    272       R -> H (in PLS).
FT                                {ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_019039.
FT   VARIANT     272    272       R -> P (in PLS).
FT                                {ECO:0000269|PubMed:10581027,
FT                                ECO:0000269|PubMed:11106356,
FT                                ECO:0000269|PubMed:11158173,
FT                                ECO:0000269|PubMed:11886537,
FT                                ECO:0000269|PubMed:12112662}.
FT                                /FTId=VAR_009543.
FT   VARIANT     286    286       Q -> R (in HMS and PLS).
FT                                {ECO:0000269|PubMed:10662807,
FT                                ECO:0000269|PubMed:11180601}.
FT                                /FTId=VAR_016935.
FT   VARIANT     291    291       C -> Y (in PLS).
FT                                {ECO:0000269|PubMed:11180601}.
FT                                /FTId=VAR_019040.
FT   VARIANT     294    294       Y -> H (in PLS).
FT                                {ECO:0000269|PubMed:12809647}.
FT                                /FTId=VAR_039686.
FT   VARIANT     300    300       G -> D (in PLS).
FT                                {ECO:0000269|PubMed:11158173,
FT                                ECO:0000269|PubMed:25799584}.
FT                                /FTId=VAR_019041.
FT   VARIANT     300    300       G -> S (in PLS).
FT                                {ECO:0000269|PubMed:11106356}.
FT                                /FTId=VAR_019042.
FT   VARIANT     301    301       G -> S (in PLS).
FT                                {ECO:0000269|PubMed:10581027,
FT                                ECO:0000269|PubMed:11106356,
FT                                ECO:0000269|PubMed:11180012,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_009544.
FT   VARIANT     301    301       G -> V (in PLS).
FT                                {ECO:0000269|PubMed:11106356}.
FT                                /FTId=VAR_019043.
FT   VARIANT     304    304       Y -> N (in PLS).
FT                                {ECO:0000269|PubMed:11106356}.
FT                                /FTId=VAR_019044.
FT   VARIANT     312    312       Q -> R (in PLS).
FT                                {ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_019045.
FT   VARIANT     319    319       E -> G (in PLS).
FT                                {ECO:0000269|PubMed:11106356}.
FT                                /FTId=VAR_019046.
FT   VARIANT     339    339       R -> C (in PLS).
FT                                {ECO:0000269|PubMed:10581027,
FT                                ECO:0000269|PubMed:10662808,
FT                                ECO:0000269|PubMed:11106356,
FT                                ECO:0000269|PubMed:11886537,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_009545.
FT   VARIANT     340    340       Y -> C (in PLS).
FT                                {ECO:0000269|PubMed:10662808,
FT                                ECO:0000269|PubMed:11106356}.
FT                                /FTId=VAR_016944.
FT   VARIANT     347    347       Y -> C (in PLS and AP1).
FT                                {ECO:0000269|PubMed:10581027,
FT                                ECO:0000269|PubMed:10662808,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_009546.
FT   VARIANT     401    401       E -> K. {ECO:0000269|PubMed:11886537}.
FT                                /FTId=VAR_016945.
FT   VARIANT     405    405       H -> N (in PLS).
FT                                {ECO:0000269|PubMed:15108292}.
FT                                /FTId=VAR_027249.
FT   VARIANT     405    405       H -> R (in PLS; dbSNP:rs151269219).
FT                                {ECO:0000269|PubMed:15991336}.
FT                                /FTId=VAR_027250.
FT   VARIANT     412    412       Y -> C (in AP1; dbSNP:rs28937571).
FT                                {ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_019047.
FT   VARIANT     429    429       W -> C (in PLS).
FT                                {ECO:0000269|PubMed:11886537}.
FT                                /FTId=VAR_016936.
FT   VARIANT     447    447       E -> G (in PLS).
FT                                {ECO:0000269|PubMed:11106356,
FT                                ECO:0000269|PubMed:14974080}.
FT                                /FTId=VAR_019048.
FT   VARIANT     453    453       I -> V (rare polymorphism;
FT                                dbSNP:rs3888798).
FT                                {ECO:0000269|PubMed:11180012}.
FT                                /FTId=VAR_016946.
FT   CONFLICT     63     63       K -> I (in Ref. 6; BAD96758).
FT                                {ECO:0000305}.
FT   CONFLICT    237    237       W -> V (in Ref. 14; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    321    321       C -> S (in Ref. 14; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    355    355       C -> M (in Ref. 14; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    366    366       H -> R (in Ref. 14; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    376    378       VYD -> YVY (in Ref. 14; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        32     35       {ECO:0000244|PDB:4OEL}.
FT   STRAND       37     48       {ECO:0000244|PDB:4OEL}.
FT   TURN         49     51       {ECO:0000244|PDB:1K3B}.
FT   HELIX        54     56       {ECO:0000244|PDB:4OEL}.
FT   STRAND       60     69       {ECO:0000244|PDB:4OEL}.
FT   TURN         70     72       {ECO:0000244|PDB:4OEL}.
FT   STRAND       73     75       {ECO:0000244|PDB:4OEL}.
FT   STRAND       81     87       {ECO:0000244|PDB:4OEL}.
FT   TURN         88     90       {ECO:0000244|PDB:4OEL}.
FT   STRAND       91     96       {ECO:0000244|PDB:4OEL}.
FT   STRAND       99    110       {ECO:0000244|PDB:4OEL}.
FT   STRAND      113    121       {ECO:0000244|PDB:4OEL}.
FT   STRAND      123    128       {ECO:0000244|PDB:4OEL}.
FT   STRAND      133    141       {ECO:0000244|PDB:4OEL}.
FT   STRAND      254    256       {ECO:0000244|PDB:2DJF}.
FT   HELIX       258    274       {ECO:0000244|PDB:4OEL}.
FT   TURN        275    277       {ECO:0000244|PDB:4OEL}.
FT   HELIX       285    291       {ECO:0000244|PDB:4OEL}.
FT   HELIX       297    299       {ECO:0000244|PDB:4OEM}.
FT   HELIX       303    306       {ECO:0000244|PDB:4OEL}.
FT   HELIX       309    313       {ECO:0000244|PDB:4OEL}.
FT   HELIX       319    321       {ECO:0000244|PDB:4OEL}.
FT   STRAND      342    347       {ECO:0000244|PDB:4OEL}.
FT   HELIX       357    367       {ECO:0000244|PDB:4OEL}.
FT   STRAND      370    374       {ECO:0000244|PDB:4OEL}.
FT   HELIX       378    382       {ECO:0000244|PDB:4OEL}.
FT   STRAND      385    388       {ECO:0000244|PDB:4OEL}.
FT   STRAND      405    414       {ECO:0000244|PDB:4OEL}.
FT   TURN        416    418       {ECO:0000244|PDB:4OEL}.
FT   STRAND      421    426       {ECO:0000244|PDB:4OEL}.
FT   STRAND      431    433       {ECO:0000244|PDB:2DJG}.
FT   STRAND      438    442       {ECO:0000244|PDB:4OEL}.
FT   TURN        443    446       {ECO:0000244|PDB:4CDE}.
FT   HELIX       447    449       {ECO:0000244|PDB:4OEL}.
FT   STRAND      455    459       {ECO:0000244|PDB:4OEL}.
SQ   SEQUENCE   463 AA;  51854 MW;  4C9C7C24D900CEE6 CRC64;
     MGAGPSLLLA ALLLLLSGDG AVRCDTPANC TYLDLLGTWV FQVGSSGSQR DVNCSVMGPQ
     EKKVVVYLQK LDTAYDDLGN SGHFTIIYNQ GFEIVLNDYK WFAFFKYKEE GSKVTTYCNE
     TMTGWVHDVL GRNWACFTGK KVGTASENVY VNIAHLKNSQ EKYSNRLYKY DHNFVKAINA
     IQKSWTATTY MEYETLTLGD MIRRSGGHSR KIPRPKPAPL TAEIQQKILH LPTSWDWRNV
     HGINFVSPVR NQASCGSCYS FASMGMLEAR IRILTNNSQT PILSPQEVVS CSQYAQGCEG
     GFPYLIAGKY AQDFGLVEEA CFPYTGTDSP CKMKEDCFRY YSSEYHYVGG FYGGCNEALM
     KLELVHHGPM AVAFEVYDDF LHYKKGIYHH TGLRDPFNPF ELTNHAVLLV GYGTDSASGM
     DYWIVKNSWG TGWGENGYFR IRRGTDECAI ESIAVAATPI PKL
//
ID   GRP78_HUMAN             Reviewed;         654 AA.
AC   P11021; B0QZ61; Q2EF78; Q9NPF1; Q9UK02;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2001, sequence version 2.
DT   17-FEB-2016, entry version 188.
DE   RecName: Full=78 kDa glucose-regulated protein;
DE            Short=GRP-78;
DE   AltName: Full=Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78;
DE   AltName: Full=Heat shock 70 kDa protein 5;
DE   AltName: Full=Immunoglobulin heavy chain-binding protein;
DE            Short=BiP;
DE   Flags: Precursor;
GN   Name=HSPA5; Synonyms=GRP78;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2840249; DOI=10.1089/dna.1988.7.275;
RA   Ting J., Lee A.S.;
RT   "Human gene encoding the 78,000-dalton glucose-regulated protein and
RT   its pseudogene: structure, conservation, and regulation.";
RL   DNA 7:275-286(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cervix carcinoma;
RA   Chao C.C.K.;
RL   Submitted (DEC-1995) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fibroblast;
RA   Hansen J.J., Nielsen M.N., Jorgensen M.M., Gregersen N., Bolund L.;
RT   "Grp78 is involved in the quality control of the LDL-receptor.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Bermudez-Fajardo A., Llewellyn D.H., Campbell A.K., Errington R.R.;
RT   "Sequence differences between human grp78/BiP isolated from HeLa cells
RT   and previously reported human sequences.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT HIS-543.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-25.
RX   PubMed=1480470; DOI=10.1093/nar/20.24.6481;
RA   Chao C.C.K., Lin-Chao S.;
RT   "A direct-repeat sequence of the human BiP gene is required for
RT   A23187-mediated inducibility and an inducible nuclear factor
RT   binding.";
RL   Nucleic Acids Res. 20:6481-6485(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-650, AND DISEASE.
RC   TISSUE=Articular cartilage;
RX   PubMed=11160188; DOI=10.4049/jimmunol.166.3.1492;
RA   Corrigall V.M., Bodman-Smith M.D., Fife M.S., Canas B., Myers L.K.,
RA   Wooley P., Soh C., Staines N.A., Pappin D.J.C., Berlo S.E.,
RA   van Eden W., van Der Zee R., Lanchbury J.S., Panayi G.S.;
RT   "The human endoplasmic reticulum molecular chaperone BiP is an
RT   autoantigen for rheumatoid arthritis and prevents the induction of
RT   experimental arthritis.";
RL   J. Immunol. 166:1492-1498(2001).
RN   [11]
RP   PROTEIN SEQUENCE OF 22-38.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=9150946; DOI=10.1002/elps.1150180342;
RA   Rasmussen R.K., Ji H., Eddes J.S., Moritz R.L., Reid G.E.,
RA   Simpson R.J., Dorow D.S.;
RT   "Two-dimensional electrophoretic analysis of human breast carcinoma
RT   proteins: mapping of proteins that bind to the SH3 domain of mixed
RT   lineage kinase MLK2.";
RL   Electrophoresis 18:588-598(1997).
RN   [12]
RP   PROTEIN SEQUENCE OF 19-39, AND FUNCTION.
RX   PubMed=2294010; DOI=10.1210/endo-126-1-672;
RA   Dana R.C., Welch W.J., Deftos L.J.;
RT   "Heat shock proteins bind calcitonin.";
RL   Endocrinology 126:672-674(1990).
RN   [13]
RP   PROTEIN SEQUENCE OF 19-40.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [14]
RP   PROTEIN SEQUENCE OF 61-74; 82-96; 102-113; 124-152; 164-181; 186-214;
RP   307-336; 353-367; 448-464; 475-492; 563-573; 602-617 AND 622-654, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [15]
RP   PROTEIN SEQUENCE OF 582-596, INTERACTION WITH METTL23, METHYLATION AT
RP   LYS-585, MUTAGENESIS OF LYS-585, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=23349634; DOI=10.1371/journal.pgen.1003210;
RA   Cloutier P., Lavallee-Adam M., Faubert D., Blanchette M., Coulombe B.;
RT   "A newly uncovered group of distantly related lysine
RT   methyltransferases preferentially interact with molecular chaperones
RT   to regulate their activity.";
RL   PLoS Genet. 9:E1003210-E1003210(2013).
RN   [16]
RP   COMPONENT OF A CHAPERONE COMPLEX.
RX   PubMed=12475965; DOI=10.1091/mbc.E02-05-0311;
RA   Meunier L., Usherwood Y.-K., Chung K.T., Hendershot L.M.;
RT   "A subset of chaperones and folding enzymes form multiprotein
RT   complexes in endoplasmic reticulum to bind nascent proteins.";
RL   Mol. Biol. Cell 13:4456-4469(2002).
RN   [17]
RP   INTERACTION WITH TRIM21.
RX   PubMed=12699405; DOI=10.1046/j.1365-2249.2003.02153.x;
RA   Purcell A.W., Todd A., Kinoshita G., Lynch T.A., Keech C.L.,
RA   Gething M.J., Gordon T.P.;
RT   "Association of stress proteins with autoantigens: a possible
RT   mechanism for triggering autoimmunity?";
RL   Clin. Exp. Immunol. 132:193-200(2003).
RN   [18]
RP   INTERACTION WITH DNAJC10.
RX   PubMed=12411443; DOI=10.1074/jbc.M206995200;
RA   Cunnea P.M., Miranda-Vizuete A., Bertoli G., Simmen T.,
RA   Damdimopoulos A.E., Hermann S., Leinonen S., Huikko M.P.,
RA   Gustafsson J.-A., Sitia R., Spyrou G.;
RT   "ERdj5, an endoplasmic reticulum (ER)-resident protein containing DnaJ
RT   and thioredoxin domains, is expressed in secretory cells or following
RT   ER stress.";
RL   J. Biol. Chem. 278:1059-1066(2003).
RN   [19]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K.,
RA   Valencia J., Muller J., Vieira W.D., Watabe H., Shabanowitz J.,
RA   Hearing V.J., Hunt D.F., Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [20]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [21]
RP   INTERACTION WITH ERLEC1; OS9; SEL1L AND SYVN1.
RX   PubMed=18502753; DOI=10.1074/jbc.M709336200;
RA   Hosokawa N., Wada I., Nagasawa K., Moriyama T., Okawa K., Nagata K.;
RT   "Human XTP3-B forms an endoplasmic reticulum quality control scaffold
RT   with the HRD1-SEL1L ubiquitin ligase complex and BiP.";
RL   J. Biol. Chem. 283:20914-20924(2008).
RN   [22]
RP   INTERACTION WITH ERLEC1; OS9; SEL1L AND SYVN1.
RX   PubMed=18264092; DOI=10.1038/ncb1689;
RA   Christianson J.C., Shaler T.A., Tyler R.E., Kopito R.R.;
RT   "OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L
RT   ubiquitin ligase complex for ERAD.";
RL   Nat. Cell Biol. 10:272-282(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-518, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [26]
RP   METHYLATION AT LYS-585, AND MUTAGENESIS OF LYS-585.
RX   PubMed=23921388; DOI=10.1074/jbc.M113.483248;
RA   Jakobsson M.E., Moen A., Bousset L., Egge-Jacobsen W., Kernstock S.,
RA   Melki R., Falnes P.O.;
RT   "Identification and characterization of a novel human
RT   methyltransferase modulating Hsp70 function through lysine
RT   methylation.";
RL   J. Biol. Chem. 288:27752-27763(2013).
RN   [27]
RP   FUNCTION, INTERACTION WITH CEMIP, AND SUBCELLULAR LOCATION.
RX   PubMed=23990668; DOI=10.1093/jnci/djt224;
RA   Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P.,
RA   Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.;
RT   "Unraveling the role of KIAA1199, a novel endoplasmic reticulum
RT   protein, in cancer cell migration.";
RL   J. Natl. Cancer Inst. 105:1402-1416(2013).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH DNAJC10.
RX   PubMed=23769672; DOI=10.1016/j.molcel.2013.05.014;
RA   Oka O.B., Pringle M.A., Schopp I.M., Braakman I., Bulleid N.J.;
RT   "ERdj5 is the ER reductase that catalyzes the removal of non-native
RT   disulfides and correct folding of the LDL receptor.";
RL   Mol. Cell 50:793-804(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-518, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-352, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [31]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-352, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 26-410.
RX   PubMed=20072699; DOI=10.1371/journal.pone.0008625;
RA   Wisniewska M., Karlberg T., Lehtio L., Johansson I., Kotenyova T.,
RA   Moche M., Schuler H.;
RT   "Crystal structures of the ATPase domains of four human Hsp70
RT   isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and
RT   HSPA5/BiP/GRP78.";
RL   PLoS ONE 5:E8625-E8625(2010).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 26-407 IN COMPLEXES WITH ATP
RP   ANALOG.
RX   PubMed=21526763; DOI=10.1021/jm101625x;
RA   Macias A.T., Williamson D.S., Allen N., Borgognoni J., Clay A.,
RA   Daniels Z., Dokurno P., Drysdale M.J., Francis G.L., Graham C.J.,
RA   Howes R., Matassova N., Murray J.B., Parsons R., Shaw T.,
RA   Surgenor A.E., Terry L., Wang Y., Wood M., Massey A.J.;
RT   "Adenosine-derived inhibitors of 78 kDa glucose regulated protein
RT   (Grp78) ATPase: insights into isoform selectivity.";
RL   J. Med. Chem. 54:4034-4041(2011).
CC   -!- FUNCTION: Probably plays a role in facilitating the assembly of
CC       multimeric protein complexes inside the endoplasmic reticulum.
CC       Involved in the correct folding of proteins and degradation of
CC       misfolded proteins via its interaction with DNAJC10, probably to
CC       facilitate the release of DNAJC10 from its substrate.
CC       {ECO:0000269|PubMed:2294010, ECO:0000269|PubMed:23769672,
CC       ECO:0000269|PubMed:23990668}.
CC   -!- SUBUNIT: Interacts with DNAJC1 (via J domain) (By similarity).
CC       Component of an EIF2 complex at least composed of CELF1/CUGBP1,
CC       CALR, CALR3, EIF2S1, EIF2S2, HSP90B1 and HSPA5. Part of a large
CC       chaperone multiprotein complex comprising DNAJB11, HSP90B1, HSPA5,
CC       HYOU, PDIA2, PDIA4, PDIA6, PPIB, SDF2L1, UGT1A1 and very small
CC       amounts of ERP29, but not, or at very low levels, CALR nor CANX.
CC       Interacts with TMEM132A and TRIM21. May form a complex with
CC       ERLEC1, OS9, SEL1L and SYVN1. Interacts with DNAJC10 and MX1.
CC       Interacts with METTL23. Interacts with CEMIP; the interaction
CC       induces calcium leakage from the endoplamic reticulum and cell
CC       migration. {ECO:0000250, ECO:0000269|PubMed:12411443,
CC       ECO:0000269|PubMed:12699405, ECO:0000269|PubMed:18264092,
CC       ECO:0000269|PubMed:18502753, ECO:0000269|PubMed:23349634,
CC       ECO:0000269|PubMed:23769672, ECO:0000269|PubMed:23990668}.
CC   -!- INTERACTION:
CC       Q6T424:-; NbExp=3; IntAct=EBI-354921, EBI-7888150;
CC       P31749:AKT1; NbExp=2; IntAct=EBI-354921, EBI-296087;
CC       Q6E0U4:DMKN; NbExp=3; IntAct=EBI-354921, EBI-7943171;
CC       Q9UBS4:DNAJB11; NbExp=3; IntAct=EBI-354921, EBI-713113;
CC       Q91YW3:Dnajc3 (xeno); NbExp=2; IntAct=EBI-354921, EBI-8381770;
CC       Q96IZ0:PAWR; NbExp=8; IntAct=EBI-354921, EBI-595869;
CC       Q62627:Pawr (xeno); NbExp=4; IntAct=EBI-354921, EBI-1187240;
CC       P04049:RAF1; NbExp=4; IntAct=EBI-354921, EBI-365996;
CC       P61619:SEC61A1; NbExp=3; IntAct=EBI-354921, EBI-358919;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum lumen. Melanosome.
CC       Cytoplasm {ECO:0000250}. Note=Identified by mass spectrometry in
CC       melanosome fractions from stage I to stage IV.
CC   -!- DISEASE: Note=Autoantigen in rheumatoid arthritis.
CC       {ECO:0000269|PubMed:11160188}.
CC   -!- SIMILARITY: Belongs to the heat shock protein 70 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/hspa5/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HSPA5ID40876ch9q33.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M19645; AAA52614.1; -; Genomic_DNA.
DR   EMBL; X87949; CAA61201.1; -; mRNA.
DR   EMBL; AJ271729; CAB71335.1; -; mRNA.
DR   EMBL; AF216292; AAF42836.1; -; mRNA.
DR   EMBL; DQ385847; ABD04090.1; -; Genomic_DNA.
DR   EMBL; AL354710; CAQ08732.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87620.1; -; Genomic_DNA.
DR   EMBL; BC020235; AAH20235.1; -; mRNA.
DR   EMBL; X59969; CAA42595.1; -; Genomic_DNA.
DR   EMBL; AF188611; AAF13605.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS6863.1; -.
DR   PIR; A29821; A29821.
DR   RefSeq; NP_005338.1; NM_005347.4.
DR   UniGene; Hs.743241; -.
DR   PDB; 3IUC; X-ray; 2.40 A; A/C=26-410.
DR   PDB; 3LDL; X-ray; 2.30 A; A/B=26-407.
DR   PDB; 3LDN; X-ray; 2.20 A; A/B=26-407.
DR   PDB; 3LDO; X-ray; 1.95 A; A/B=26-407.
DR   PDB; 3LDP; X-ray; 2.20 A; A/B=26-407.
DR   PDB; 5E85; X-ray; 2.57 A; A=418-637.
DR   PDB; 5E86; X-ray; 2.68 A; A=418-637.
DR   PDBsum; 3IUC; -.
DR   PDBsum; 3LDL; -.
DR   PDBsum; 3LDN; -.
DR   PDBsum; 3LDO; -.
DR   PDBsum; 3LDP; -.
DR   PDBsum; 5E85; -.
DR   PDBsum; 5E86; -.
DR   ProteinModelPortal; P11021; -.
DR   SMR; P11021; 26-635.
DR   BioGrid; 109541; 364.
DR   DIP; DIP-33189N; -.
DR   IntAct; P11021; 171.
DR   MINT; MINT-1135308; -.
DR   STRING; 9606.ENSP00000324173; -.
DR   ChEMBL; CHEMBL1781865; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00025; Antihemophilic Factor (Recombinant).
DR   iPTMnet; P11021; -.
DR   PhosphoSite; P11021; -.
DR   SwissPalm; P11021; -.
DR   BioMuta; HSPA5; -.
DR   DMDM; 14916999; -.
DR   DOSAC-COBS-2DPAGE; P11021; -.
DR   OGP; P11021; -.
DR   REPRODUCTION-2DPAGE; P11021; -.
DR   SWISS-2DPAGE; P11021; -.
DR   UCD-2DPAGE; P11021; -.
DR   PaxDb; P11021; -.
DR   PRIDE; P11021; -.
DR   DNASU; 3309; -.
DR   Ensembl; ENST00000324460; ENSP00000324173; ENSG00000044574.
DR   GeneID; 3309; -.
DR   KEGG; hsa:3309; -.
DR   UCSC; uc004bpn.3; human.
DR   CTD; 3309; -.
DR   GeneCards; HSPA5; -.
DR   HGNC; HGNC:5238; HSPA5.
DR   HPA; CAB005221; -.
DR   HPA; HPA038845; -.
DR   HPA; HPA038846; -.
DR   MIM; 138120; gene.
DR   neXtProt; NX_P11021; -.
DR   PharmGKB; PA29504; -.
DR   eggNOG; KOG0101; Eukaryota.
DR   eggNOG; COG0443; LUCA.
DR   HOGENOM; HOG000228135; -.
DR   HOVERGEN; HBG051845; -.
DR   InParanoid; P11021; -.
DR   KO; K09490; -.
DR   OMA; NQDTEPE; -.
DR   OrthoDB; EOG780RKX; -.
DR   PhylomeDB; P11021; -.
DR   TreeFam; TF105044; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-381033; ATF6-alpha activates chaperones.
DR   Reactome; R-HSA-381042; PERK regulates gene expression.
DR   Reactome; R-HSA-381070; IRE1alpha activates chaperones.
DR   Reactome; R-HSA-381183; ATF6-alpha activates chaperone genes.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   ChiTaRS; HSPA5; human.
DR   EvolutionaryTrace; P11021; -.
DR   GeneWiki; Binding_immunoglobulin_protein; -.
DR   GenomeRNAi; 3309; -.
DR   NextBio; 13123; -.
DR   PRO; PR:P11021; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; P11021; -.
DR   CleanEx; HS_HSPA5; -.
DR   ExpressionAtlas; P11021; baseline and differential.
DR   Genevisible; P11021; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IMP:UniProtKB.
DR   GO; GO:0034663; C:endoplasmic reticulum chaperone complex; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IDA:BHF-UCL.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATPase activity; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; TAS:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; TAS:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0051787; F:misfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0043022; F:ribosome binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:UniProtKB.
DR   GO; GO:0006987; P:activation of signaling protein activity involved in unfolded protein response; IEA:Ensembl.
DR   GO; GO:0036500; P:ATF6-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071236; P:cellular response to antibiotic; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEA:Ensembl.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEA:Ensembl.
DR   GO; GO:0021680; P:cerebellar Purkinje cell layer development; IEA:Ensembl.
DR   GO; GO:0021589; P:cerebellum structural organization; IEA:Ensembl.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; TAS:BHF-UCL.
DR   GO; GO:0006983; P:ER overload response; IEA:Ensembl.
DR   GO; GO:0030433; P:ER-associated ubiquitin-dependent protein catabolic process; TAS:BHF-UCL.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0035437; P:maintenance of protein localization in endoplasmic reticulum; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0090074; P:negative regulation of protein homodimerization activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0036499; P:PERK-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0034975; P:protein folding in endoplasmic reticulum; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903891; P:regulation of ATF6-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903894; P:regulation of IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903897; P:regulation of PERK-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0060904; P:regulation of protein folding in endoplasmic reticulum; TAS:BHF-UCL.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProtKB.
DR   GO; GO:1901998; P:toxin transport; IEA:Ensembl.
DR   Gene3D; 1.20.1270.10; -; 1.
DR   Gene3D; 2.60.34.10; -; 1.
DR   InterPro; IPR018181; Heat_shock_70_CS.
DR   InterPro; IPR029048; HSP70_C.
DR   InterPro; IPR029047; HSP70_peptide-bd.
DR   InterPro; IPR013126; Hsp_70_fam.
DR   Pfam; PF00012; HSP70; 1.
DR   PRINTS; PR00301; HEATSHOCK70.
DR   SUPFAM; SSF100920; SSF100920; 1.
DR   SUPFAM; SSF100934; SSF100934; 1.
DR   PROSITE; PS00014; ER_TARGET; 1.
DR   PROSITE; PS00297; HSP70_1; 1.
DR   PROSITE; PS00329; HSP70_2; 1.
DR   PROSITE; PS01036; HSP70_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Endoplasmic reticulum; Isopeptide bond;
KW   Methylation; Nitration; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Signal; Ubl conjugation.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:2294010,
FT                                ECO:0000269|PubMed:9150948}.
FT   CHAIN        19    654       78 kDa glucose-regulated protein.
FT                                /FTId=PRO_0000013566.
FT   NP_BIND      36     39       ATP.
FT   NP_BIND     227    229       ATP.
FT   NP_BIND     293    300       ATP.
FT   NP_BIND     364    367       ATP.
FT   MOTIF       651    654       Prevents secretion from ER.
FT   BINDING      96     96       ATP.
FT   MOD_RES      86     86       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06761}.
FT   MOD_RES     125    125       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   MOD_RES     160    160       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   MOD_RES     213    213       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   MOD_RES     271    271       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P0DMV8}.
FT   MOD_RES     326    326       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   MOD_RES     353    353       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   MOD_RES     447    447       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   MOD_RES     518    518       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     585    585       N6,N6,N6-trimethyllysine; by METTL21A; in
FT                                vitro. {ECO:0000269|PubMed:23349634,
FT                                ECO:0000269|PubMed:23921388}.
FT   MOD_RES     643    643       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   MOD_RES     648    648       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P20029}.
FT   CROSSLNK    352    352       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297}.
FT   VARIANT     543    543       N -> H (in dbSNP:rs35356639).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_025815.
FT   MUTAGEN     585    585       K->R: Complete loss of in vitro
FT                                methylation by METTL21A.
FT                                {ECO:0000269|PubMed:23349634,
FT                                ECO:0000269|PubMed:23921388}.
FT   CONFLICT    297    297       Missing (in Ref. 1; AAA52614 and 2;
FT                                CAA61201). {ECO:0000305}.
FT   CONFLICT    418    418       D -> H (in Ref. 1; AAA52614 and 2;
FT                                CAA61201). {ECO:0000305}.
FT   CONFLICT    439    439       R -> S (in Ref. 1; AAA52614 and 2;
FT                                CAA61201). {ECO:0000305}.
FT   CONFLICT    447    447       K -> N (in Ref. 1; AAA52614 and 2;
FT                                CAA61201). {ECO:0000305}.
FT   STRAND       31     34       {ECO:0000244|PDB:3LDO}.
FT   STRAND       37     46       {ECO:0000244|PDB:3LDO}.
FT   STRAND       49     52       {ECO:0000244|PDB:3LDO}.
FT   STRAND       60     63       {ECO:0000244|PDB:3LDO}.
FT   STRAND       66     68       {ECO:0000244|PDB:3LDO}.
FT   STRAND       74     76       {ECO:0000244|PDB:3LDO}.
FT   HELIX        78     82       {ECO:0000244|PDB:3LDO}.
FT   HELIX        84     86       {ECO:0000244|PDB:3LDN}.
FT   HELIX        88     90       {ECO:0000244|PDB:3LDO}.
FT   STRAND       91     93       {ECO:0000244|PDB:3IUC}.
FT   HELIX        95     97       {ECO:0000244|PDB:3LDO}.
FT   TURN         98    100       {ECO:0000244|PDB:3LDO}.
FT   HELIX       106    114       {ECO:0000244|PDB:3LDO}.
FT   STRAND      116    122       {ECO:0000244|PDB:3LDO}.
FT   STRAND      125    131       {ECO:0000244|PDB:3LDO}.
FT   STRAND      137    140       {ECO:0000244|PDB:3LDO}.
FT   HELIX       142    161       {ECO:0000244|PDB:3LDO}.
FT   STRAND      167    172       {ECO:0000244|PDB:3LDO}.
FT   HELIX       178    190       {ECO:0000244|PDB:3LDO}.
FT   STRAND      194    200       {ECO:0000244|PDB:3LDO}.
FT   HELIX       201    208       {ECO:0000244|PDB:3LDO}.
FT   HELIX       211    213       {ECO:0000244|PDB:3LDO}.
FT   STRAND      215    225       {ECO:0000244|PDB:3LDO}.
FT   STRAND      230    238       {ECO:0000244|PDB:3LDO}.
FT   STRAND      241    250       {ECO:0000244|PDB:3LDO}.
FT   HELIX       255    273       {ECO:0000244|PDB:3LDO}.
FT   HELIX       278    280       {ECO:0000244|PDB:3LDO}.
FT   HELIX       282    298       {ECO:0000244|PDB:3LDO}.
FT   TURN        299    301       {ECO:0000244|PDB:3LDO}.
FT   STRAND      302    313       {ECO:0000244|PDB:3LDO}.
FT   STRAND      316    323       {ECO:0000244|PDB:3LDO}.
FT   HELIX       324    336       {ECO:0000244|PDB:3LDO}.
FT   HELIX       339    348       {ECO:0000244|PDB:3LDO}.
FT   HELIX       353    355       {ECO:0000244|PDB:3LDO}.
FT   STRAND      358    363       {ECO:0000244|PDB:3LDO}.
FT   HELIX       364    367       {ECO:0000244|PDB:3LDO}.
FT   HELIX       369    378       {ECO:0000244|PDB:3LDO}.
FT   TURN        379    381       {ECO:0000244|PDB:3LDO}.
FT   TURN        390    392       {ECO:0000244|PDB:3LDO}.
FT   HELIX       393    406       {ECO:0000244|PDB:3LDO}.
SQ   SEQUENCE   654 AA;  72333 MW;  59B7D8D85BC32A00 CRC64;
     MKLSLVAAML LLLSAARAEE EDKKEDVGTV VGIDLGTTYS CVGVFKNGRV EIIANDQGNR
     ITPSYVAFTP EGERLIGDAA KNQLTSNPEN TVFDAKRLIG RTWNDPSVQQ DIKFLPFKVV
     EKKTKPYIQV DIGGGQTKTF APEEISAMVL TKMKETAEAY LGKKVTHAVV TVPAYFNDAQ
     RQATKDAGTI AGLNVMRIIN EPTAAAIAYG LDKREGEKNI LVFDLGGGTF DVSLLTIDNG
     VFEVVATNGD THLGGEDFDQ RVMEHFIKLY KKKTGKDVRK DNRAVQKLRR EVEKAKRALS
     SQHQARIEIE SFYEGEDFSE TLTRAKFEEL NMDLFRSTMK PVQKVLEDSD LKKSDIDEIV
     LVGGSTRIPK IQQLVKEFFN GKEPSRGINP DEAVAYGAAV QAGVLSGDQD TGDLVLLDVC
     PLTLGIETVG GVMTKLIPRN TVVPTKKSQI FSTASDNQPT VTIKVYEGER PLTKDNHLLG
     TFDLTGIPPA PRGVPQIEVT FEIDVNGILR VTAEDKGTGN KNKITITNDQ NRLTPEEIER
     MVNDAEKFAE EDKKLKERID TRNELESYAY SLKNQIGDKE KLGGKLSSED KETMEKAVEE
     KIEWLESHQD ADIEDFKAKK KELEEIVQPI ISKLYGSAGP PPTGEEDTAE KDEL
//
ID   HPSE_HUMAN              Reviewed;         543 AA.
AC   Q9Y251; A9JIG7; C7F7I3; C7F7I4; E9PCA9; E9PGR1; Q53GE5; Q9UL39;
DT   11-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   17-FEB-2016, entry version 139.
DE   RecName: Full=Heparanase;
DE            EC=3.2.1.166;
DE   AltName: Full=Endo-glucoronidase;
DE   AltName: Full=Heparanase-1;
DE            Short=Hpa1;
DE   Contains:
DE     RecName: Full=Heparanase 8 kDa subunit;
DE   Contains:
DE     RecName: Full=Heparanase 50 kDa subunit;
DE   Flags: Precursor;
GN   Name=HPSE; Synonyms=HEP, HPA, HPA1, HPR1, HPSE1, HSE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ARG-307, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=10405343; DOI=10.1006/bbrc.1999.0962;
RA   Kussie P.H., Hulmes J.D., Ludwig D.L., Patel S., Navarro E.C.,
RA   Seddon A.P., Giorgio N.A., Bohlen P.;
RT   "Cloning and functional expression of a human heparanase gene.";
RL   Biochem. Biophys. Res. Commun. 261:183-187(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BIOPHYSICOCHEMICAL PROPERTIES,
RP   PROTEIN SEQUENCE OF 158-168; 326-337 AND 447-491, AND VARIANT ARG-307.
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=10446189; DOI=10.1074/jbc.274.34.24153;
RA   Toyoshima M., Nakajima M.;
RT   "Human heparanase. Purification, characterization, cloning, and
RT   expression.";
RL   J. Biol. Chem. 274:24153-24160(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), GLYCOSYLATION, PROTEOLYTIC
RP   PROCESSING, AND VARIANT ARG-307.
RX   PubMed=10395325; DOI=10.1038/10518;
RA   Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R.,
RA   Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I.,
RA   Spector L., Pecker I.;
RT   "Mammalian heparanase: gene cloning, expression and function in tumor
RT   progression and metastasis.";
RL   Nat. Med. 5:793-802(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, PROTEIN
RP   SEQUENCE OF 158-174; 263-272; 326-337; 433-436; 438-443; 466-468 AND
RP   478-483, AND VARIANT ARG-307.
RC   TISSUE=Placenta;
RX   PubMed=10395326; DOI=10.1038/10525;
RA   Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J.,
RA   Parish C.R.;
RT   "Cloning of mammalian heparanase, an important enzyme in tumor
RT   invasion and metastasis.";
RL   Nat. Med. 5:803-809(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BIOPHYSICOCHEMICAL PROPERTIES,
RP   TISSUE SPECIFICITY, AND VARIANT ARG-307.
RC   TISSUE=Placenta;
RX   PubMed=10764835; DOI=10.1093/glycob/10.5.467;
RA   Dempsey L.A., Plummer T.B., Coombes S.L., Platt J.L.;
RT   "Heparanase expression in invasive trophoblasts and acute vascular
RT   damage.";
RL   Glycobiology 10:467-475(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RX   PubMed=11547900; DOI=10.1023/A:1011375624902;
RA   Zcharia E., Metzger S., Chajek-Shaul T., Friedmann Y., Pappo O.,
RA   Aviv A., Elkin M., Pecker I., Peretz T., Vlodavsky I.;
RT   "Molecular properties and involvement of heparanase in cancer
RT   progression and mammary gland morphogenesis.";
RL   J. Mammary Gland Biol. Neoplasia 6:311-322(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 36-41 AND
RP   158-163, SUBUNIT, GLYCOSYLATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Placenta;
RX   PubMed=12713442; DOI=10.1042/BJ20030318;
RA   McKenzie E., Young K., Hircock M., Bennett J., Bhaman M., Felix R.,
RA   Turner P., Stamps A., McMillan D., Saville G., Ng S., Mason S.,
RA   Snell D., Schofield D., Gong H., Townsend R., Gallagher J., Page M.,
RA   Parekh R., Stubberfield C.;
RT   "Biochemical characterization of the active heterodimer form of human
RT   heparanase (Hpa1) protein expressed in insect cells.";
RL   Biochem. J. 373:423-435(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ALTERNATIVE SPLICING, AND
RP   VARIANT ARG-307.
RC   TISSUE=Kidney;
RX   PubMed=17208203; DOI=10.1016/j.bbrc.2006.12.189;
RA   Nasser N.J., Avivi A., Shushy M., Vlodavsky I., Nevo E.;
RT   "Cloning, expression, and characterization of an alternatively spliced
RT   variant of human heparanase.";
RL   Biochem. Biophys. Res. Commun. 354:33-38(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-307.
RA   Pinhal M.A., Semedo P.;
RT   "Cloned heparanase from MCF-7 cells.";
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), AND VARIANT ARG-307.
RA   Jin S., Yu L., Gong F.;
RT   "Two new transcript variants of Homo sapiens heparanase (HPSE).";
RL   Submitted (JUN-2009) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-307.
RC   TISSUE=Small intestine;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-307.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   MUTAGENESIS OF GLU-225; GLU-343 AND ASP-367.
RX   PubMed=11123890; DOI=10.1021/bi002080p;
RA   Hulett M.D., Hornby J.R., Ohms S.J., Zuegg J., Freeman C.,
RA   Gready J.E., Parish C.R.;
RT   "Identification of active-site residues of the pro-metastatic
RT   endoglycosidase heparanase.";
RL   Biochemistry 39:15659-15667(2000).
RN   [15]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND INTERACTION WITH
RP   SDC1.
RX   PubMed=12441129; DOI=10.1006/excr.2002.5651;
RA   Goldshmidt O., Nadav L., Aingorn H., Irit C., Feinstein N., Ilan N.,
RA   Zamir E., Geiger B., Vlodavsky I., Katz B.Z.;
RT   "Human heparanase is localized within lysosomes in a stable form.";
RL   Exp. Cell Res. 281:50-62(2002).
RN   [16]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=12213822; DOI=10.1074/jbc.M206510200;
RA   Okada Y., Yamada S., Toyoshima M., Dong J., Nakajima M., Sugahara K.;
RT   "Structural recognition by recombinant human heparanase that plays
RT   critical roles in tumor metastasis. Hierarchical sulfate groups with
RT   different effects and the essential target disulfated trisaccharide
RT   sequence.";
RL   J. Biol. Chem. 277:42488-42495(2002).
RN   [17]
RP   PROTEOLYTIC PROCESSING, ENZYME ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=11973358;
RA   Nadav L., Eldor A., Yacoby-Zeevi O., Zamir E., Pecker I., Ilan N.,
RA   Geiger B., Vlodavsky I., Katz B.Z.;
RT   "Activation, processing and trafficking of extracellular heparanase by
RT   primary human fibroblasts.";
RL   J. Cell Sci. 115:2179-2187(2002).
RN   [18]
RP   HETERODIMERIZATION, AND ENZYME ACTIVITY.
RX   PubMed=12927802; DOI=10.1016/S0006-291X(03)01478-5;
RA   Levy-Adam F., Miao H.Q., Heinrikson R.L., Vlodavsky I., Ilan N.;
RT   "Heterodimer formation is essential for heparanase enzymatic
RT   activity.";
RL   Biochem. Biophys. Res. Commun. 308:885-891(2003).
RN   [19]
RP   FUNCTION, AND MUTAGENESIS OF GLU-225.
RX   PubMed=12773484; DOI=10.1096/fj.02-0773com;
RA   Goldshmidt O., Zcharia E., Cohen M., Aingorn H., Cohen I., Nadav L.,
RA   Katz B.Z., Geiger B., Vlodavsky I.;
RT   "Heparanase mediates cell adhesion independent of its enzymatic
RT   activity.";
RL   FASEB J. 17:1015-1025(2003).
RN   [20]
RP   GLYCOSYLATION AT ASN-162; ASN-178; ASN-200; ASN-217; ASN-238 AND
RP   ASN-459, AND MUTAGENESIS OF ASN-162; ASN-178; ASN-200; ASN-217;
RP   ASN-238 AND ASN-459.
RX   PubMed=14573609; DOI=10.1074/jbc.M300541200;
RA   Simizu S., Ishida K., Wierzba M.K., Osada H.;
RT   "Secretion of heparanase protein is regulated by glycosylation in
RT   human tumor cell lines.";
RL   J. Biol. Chem. 279:2697-2703(2004).
RN   [21]
RP   FUNCTION.
RX   PubMed=15044433; DOI=10.1074/jbc.M400554200;
RA   Gingis-Velitski S., Zetser A., Flugelman M.Y., Vlodavsky I., Ilan N.;
RT   "Heparanase induces endothelial cell migration via protein kinase
RT   B/Akt activation.";
RL   J. Biol. Chem. 279:23536-23541(2004).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15292202; DOI=10.1074/jbc.M402131200;
RA   Gingis-Velitski S., Zetser A., Kaplan V., Ben-Zaken O., Cohen E.,
RA   Levy-Adam F., Bashenko Y., Flugelman M.Y., Vlodavsky I., Ilan N.;
RT   "Heparanase uptake is mediated by cell membrane heparan sulfate
RT   proteoglycans.";
RL   J. Biol. Chem. 279:44084-44092(2004).
RN   [23]
RP   PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION.
RX   PubMed=15126626; DOI=10.1242/jcs.01068;
RA   Zetser A., Levy-Adam F., Kaplan V., Gingis-Velitski S., Bashenko Y.,
RA   Schubert S., Flugelman M.Y., Vlodavsky I., Ilan N.;
RT   "Processing and activation of latent heparanase occurs in lysosomes.";
RL   J. Cell Sci. 117:2249-2258(2004).
RN   [24]
RP   BIOPHYSICOCHEMICAL PROPERTIES, PROTEOLYTIC PROCESSING, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15848168; DOI=10.1016/j.febslet.2005.03.030;
RA   Cohen E., Atzmon R., Vlodavsky I., Ilan N.;
RT   "Heparanase processing by lysosomal/endosomal protein preparation.";
RL   FEBS Lett. 579:2334-2338(2005).
RN   [25]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF
RP   TYR-156.
RX   PubMed=15659389; DOI=10.1074/jbc.M413370200;
RA   Abboud-Jarrous G., Rangini-Guetta Z., Aingorn H., Atzmon R.,
RA   Elgavish S., Peretz T., Vlodavsky I.;
RT   "Site-directed mutagenesis, proteolytic cleavage, and activation of
RT   human proheparanase.";
RL   J. Biol. Chem. 280:13568-13575(2005).
RN   [26]
RP   HEPARIN/HS-BINDING DOMAINS, AND MUTAGENESIS OF LYS-158 AND LYS-161.
RX   PubMed=15760902; DOI=10.1074/jbc.M414546200;
RA   Levy-Adam F., Abboud-Jarrous G., Guerrini M., Beccati D.,
RA   Vlodavsky I., Ilan N.;
RT   "Identification and characterization of heparin/heparan sulfate
RT   binding domains of the endoglycosidase heparanase.";
RL   J. Biol. Chem. 280:20457-20466(2005).
RN   [27]
RP   FUNCTION.
RX   PubMed=16452201; DOI=10.1158/0008-5472.CAN-05-1811;
RA   Zetser A., Bashenko Y., Edovitsky E., Levy-Adam F., Vlodavsky I.,
RA   Ilan N.;
RT   "Heparanase induces vascular endothelial growth factor expression:
RT   correlation with p38 phosphorylation levels and Src activation.";
RL   Cancer Res. 66:1455-1463(2006).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-217.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [29]
RP   TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=18557927; DOI=10.1111/j.1600-0625.2008.00739.x;
RA   Malgouries S., Donovan M., Thibaut S., Bernard B.A.;
RT   "Heparanase 1: a key participant of inner root sheath differentiation
RT   program and hair follicle homeostasis.";
RL   Exp. Dermatol. 17:1017-1023(2008).
RN   [30]
RP   FUNCTION.
RX   PubMed=18798279; DOI=10.1002/ijc.23898;
RA   Cohen-Kaplan V., Naroditsky I., Zetser A., Ilan N., Vlodavsky I.,
RA   Doweck I.;
RT   "Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.";
RL   Int. J. Cancer 123:2566-2573(2008).
RN   [31]
RP   FUNCTION OF THE C-TERMINAL DOMAIN, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF VAL-414; LYS-417; PRO-525; PHE-527; SER-528; TYR-529;
RP   PHE-531; VAL-533; ILE-534; ARG-535; ASN-536; ALA-537; LYS-538;
RP   VAL-539; ALA-540; ALA-541 AND CYS-542.
RX   PubMed=19244131; DOI=10.1158/0008-5472.CAN-08-1837;
RA   Fux L., Feibish N., Cohen-Kaplan V., Gingis-Velitski S., Feld S.,
RA   Geffen C., Vlodavsky I., Ilan N.;
RT   "Structure-function approach identifies a COOH-terminal domain that
RT   mediates heparanase signaling.";
RL   Cancer Res. 69:1758-1767(2009).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-217 AND ASN-238.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [33]
RP   FUNCTION.
RX   PubMed=20097882; DOI=10.1182/blood-2009-07-234757;
RA   Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K.,
RA   Rapraeger A.C., Sanderson R.D.;
RT   "Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes
RT   endothelial invasion and angiogenesis.";
RL   Blood 115:2449-2457(2010).
RN   [34]
RP   INTERACTION WITH TF, AND ENZYME ACTIVITY.
RX   PubMed=20634491; DOI=10.3324/haematol.2010.023713;
RA   Nadir Y., Brenner B., Fux L., Shafat I., Attias J., Vlodavsky I.;
RT   "Heparanase enhances the generation of activated factor X in the
RT   presence of tissue factor and activated factor VII.";
RL   Haematologica 95:1927-1934(2010).
RN   [35]
RP   INTERACTION WITH HRG, ENZYME ACTIVITY, AND FUNCTION.
RX   PubMed=20561914; DOI=10.1016/j.biocel.2010.05.008;
RA   Poon I.K., Yee D.Y., Jones A.L., Wood R.J., Davis D.S., Freeman C.,
RA   Parish C.R., Hulett M.D.;
RT   "Histidine-rich glycoprotein binds heparanase and regulates its
RT   enzymatic activity and cell surface interactions.";
RL   Int. J. Biochem. Cell Biol. 42:1507-1516(2010).
RN   [36]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=20181948; DOI=10.1074/jbc.M110.104166;
RA   Peterson S.B., Liu J.;
RT   "Unraveling the specificity of heparanase utilizing synthetic
RT   substrates.";
RL   J. Biol. Chem. 285:14504-14513(2010).
RN   [37]
RP   INTERACTION WITH HPSE2.
RX   PubMed=20576607; DOI=10.1074/jbc.M110.116384;
RA   Levy-Adam F., Feld S., Cohen-Kaplan V., Shteingauz A., Gross M.,
RA   Arvatz G., Naroditsky I., Ilan N., Doweck I., Vlodavsky I.;
RT   "Heparanase 2 interacts with heparan sulfate with high affinity and
RT   inhibits heparanase activity.";
RL   J. Biol. Chem. 285:28010-28019(2010).
RN   [38]
RP   FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=20309870; DOI=10.1002/jor.21138;
RA   Smith P.N., Freeman C., Yu D., Chen M., Gatenby P.A., Parish C.R.,
RA   Li R.W.;
RT   "Heparanase in primary human osteoblasts.";
RL   J. Orthop. Res. 28:1315-1322(2010).
RN   [39]
RP   FUNCTION.
RX   PubMed=21131364; DOI=10.1074/jbc.M110.183277;
RA   Ramani V.C., Yang Y., Ren Y., Nan L., Sanderson R.D.;
RT   "Heparanase plays a dual role in driving hepatocyte growth factor
RT   (HGF) signaling by enhancing HGF expression and activity.";
RL   J. Biol. Chem. 286:6490-6499(2011).
RN   [40]
RP   VARIANT SER-260.
RX   PubMed=15334672;
RA   Chen X.P., Liu Y.B., Rui J., Peng S.Y., Peng C.H., Zhou Z.Y.,
RA   Shi L.H., Shen H.W., Xu B.;
RT   "Heparanase mRNA expression and point mutation in hepatocellular
RT   carcinoma.";
RL   World J. Gastroenterol. 10:2795-2799(2004).
CC   -!- FUNCTION: Endoglycosidase that cleaves heparan sulfate
CC       proteoglycans (HSPGs) into heparan sulfate side chains and core
CC       proteoglycans. Participates in extracellular matrix (ECM)
CC       degradation and remodeling. Selectively cleaves the linkage
CC       between a glucuronic acid unit and an N-sulfo glucosamine unit
CC       carrying either a 3-O-sulfo or a 6-O-sulfo group. Can also cleave
CC       the linkage between a glucuronic acid unit and an N-sulfo
CC       glucosamine unit carrying a 2-O-sulfo group, but not linkages
CC       between a glucuronic acid unit and a 2-O-sulfated iduronic acid
CC       moiety. It is essentially inactive at neutral pH but becomes
CC       active under acidic conditions such as during tumor invasion and
CC       in inflammatory processes. Facilitates cell migration associated
CC       with metastasis, wound healing and inflammation. Enhances shedding
CC       of syndecans, and increases endothelial invasion and angiogenesis
CC       in myelomas. Acts as procoagulant by increasing the generation of
CC       activation factor X in the presence of tissue factor and
CC       activation factor VII. Increases cell adhesion to the extacellular
CC       matrix (ECM), independent of its enzymatic activity. Induces
CC       AKT1/PKB phosphorylation via lipid rafts increasing cell mobility
CC       and invasion. Heparin increases this AKT1/PKB activation.
CC       Regulates osteogenesis. Enhances angiogenesis through up-
CC       regulation of SRC-mediated activation of VEGF. Implicated in hair
CC       follicle inner root sheath differentiation and hair homeostasis.
CC       {ECO:0000269|PubMed:12213822, ECO:0000269|PubMed:12773484,
CC       ECO:0000269|PubMed:15044433, ECO:0000269|PubMed:16452201,
CC       ECO:0000269|PubMed:18557927, ECO:0000269|PubMed:18798279,
CC       ECO:0000269|PubMed:19244131, ECO:0000269|PubMed:20097882,
CC       ECO:0000269|PubMed:20181948, ECO:0000269|PubMed:20309870,
CC       ECO:0000269|PubMed:20561914, ECO:0000269|PubMed:21131364}.
CC   -!- CATALYTIC ACTIVITY: Endohydrolysis of (1->4)-beta-D-glycosidic
CC       bonds of heparan sulfate chains in heparan sulfate proteoglycan.
CC       {ECO:0000269|PubMed:11973358, ECO:0000269|PubMed:12213822,
CC       ECO:0000269|PubMed:12927802, ECO:0000269|PubMed:20181948,
CC       ECO:0000269|PubMed:20561914, ECO:0000269|PubMed:20634491}.
CC   -!- ENZYME REGULATION: Inhibited by EDTA, laminarin sulfate and, to a
CC       lower extent, by heparin and sulfamin and activated by calcium and
CC       magnesium. {ECO:0000250}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 4-6. {ECO:0000269|PubMed:10446189,
CC         ECO:0000269|PubMed:10764835, ECO:0000269|PubMed:12713442,
CC         ECO:0000269|PubMed:15848168};
CC   -!- SUBUNIT: Heterodimer; heterodimer formation between the 8 kDa and
CC       the 50 kDa subunits is required for enzyme activity. Interacts
CC       with TF; the interaction, inhibited by heparin, enhances the
CC       generation of activated factor X and activates coagulation.
CC       Interacts with HRG; the interaction is enhanced at acidic pH,
CC       partially inhibits binding of HPSE to cell surface receptors and
CC       modulates its enzymatic activity. Interacts with SDC1; the
CC       interaction enhances the shedding of SDC1. Interacts with HPSE2.
CC       {ECO:0000269|PubMed:12441129, ECO:0000269|PubMed:12713442,
CC       ECO:0000269|PubMed:20561914, ECO:0000269|PubMed:20576607,
CC       ECO:0000269|PubMed:20634491}.
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane; Peripheral membrane
CC       protein. Secreted. Nucleus. Note=Proheparanase is secreted via
CC       vesicles of the Golgi. Interacts with cell membrane heparan
CC       sulfate proteoglycans (HSPGs). Endocytosed and accumulates in
CC       endosomes. Transferred to lysosomes where it is proteolytically
CC       cleaved to produce the active enzyme. Under certain stimuli,
CC       transferred to the cell surface. Associates with lipid rafts.
CC       Colocalizes with SDC1 in endosomal/lysosomal vesicles. Accumulates
CC       in perinuclear lysosomal vesicles. Heparin retains proheparanase
CC       in the extracellular medium (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9Y251-1; Sequence=Displayed;
CC       Name=2; Synonyms=55 kDa, splice 5;
CC         IsoId=Q9Y251-2; Sequence=VSP_044537;
CC         Note=Escapes proteolytic cleavage, devoid of HS degradation
CC         activity.;
CC       Name=3; Synonyms=ex9-10del;
CC         IsoId=Q9Y251-3; Sequence=VSP_044664;
CC       Name=4; Synonyms=ex10del;
CC         IsoId=Q9Y251-4; Sequence=VSP_053730, VSP_053731;
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta and spleen and
CC       weakly expressed in lymph node, thymus, peripheral blood
CC       leukocytes, bone marrow, endothelial cells, fetal liver and tumor
CC       tissues. Also expressed in hair follicles, specifically in both
CC       Henle's and Huxley's layers of inner the root sheath (IRS) at
CC       anagen phase. {ECO:0000269|PubMed:10395326,
CC       ECO:0000269|PubMed:10405343, ECO:0000269|PubMed:10764835,
CC       ECO:0000269|PubMed:18557927, ECO:0000269|PubMed:20309870}.
CC   -!- PTM: Proteolytically processed. The cleavage of the 65 kDa form
CC       leads to the generation of a linker peptide, and 8 kDa and 50 kDa
CC       products. The active form, the 8/50 kDa heterodimer, is resistant
CC       to degradation. Complete removal of the linker peptide appears to
CC       be a prerequisite to the complete activation of the enzyme.
CC       {ECO:0000269|PubMed:10395325, ECO:0000269|PubMed:11973358,
CC       ECO:0000269|PubMed:12441129, ECO:0000269|PubMed:15126626,
CC       ECO:0000269|PubMed:15659389, ECO:0000269|PubMed:15848168}.
CC   -!- PTM: N-glycosylated. Glycosylation of the 50 kDa subunit appears
CC       to be essential for its solubility. {ECO:0000269|PubMed:10395325,
CC       ECO:0000269|PubMed:12713442, ECO:0000269|PubMed:14573609,
CC       ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:19159218}.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 79 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF152376; AAD45669.1; -; mRNA.
DR   EMBL; AF155510; AAD54941.1; -; mRNA.
DR   EMBL; AF144325; AAD41342.1; -; mRNA.
DR   EMBL; AF165154; AAD45379.1; -; mRNA.
DR   EMBL; AF084467; AAD54516.1; -; mRNA.
DR   EMBL; AM419200; CAL91960.1; -; mRNA.
DR   EMBL; AY948074; AAX47106.1; -; mRNA.
DR   EMBL; GQ337901; ACT98237.1; -; mRNA.
DR   EMBL; GQ337902; ACT98238.1; -; mRNA.
DR   EMBL; AK222986; BAD96706.1; -; mRNA.
DR   EMBL; AC114781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC051321; AAH51321.1; -; mRNA.
DR   CCDS; CCDS3602.1; -. [Q9Y251-1]
DR   CCDS; CCDS54774.1; -. [Q9Y251-3]
DR   CCDS; CCDS56337.1; -. [Q9Y251-2]
DR   RefSeq; NP_001092010.1; NM_001098540.2. [Q9Y251-1]
DR   RefSeq; NP_001159970.1; NM_001166498.2. [Q9Y251-3]
DR   RefSeq; NP_001186759.1; NM_001199830.1. [Q9Y251-2]
DR   RefSeq; NP_006656.2; NM_006665.5. [Q9Y251-1]
DR   UniGene; Hs.44227; -.
DR   PDB; 5E8M; X-ray; 1.75 A; A=158-543, B=36-109.
DR   PDB; 5E97; X-ray; 1.63 A; A=158-543, B=36-109.
DR   PDB; 5E98; X-ray; 1.63 A; A=158-543, B=36-109.
DR   PDB; 5E9B; X-ray; 1.88 A; A=158-543, B=36-109.
DR   PDB; 5E9C; X-ray; 1.73 A; A=158-543, B=36-109.
DR   PDBsum; 5E8M; -.
DR   PDBsum; 5E97; -.
DR   PDBsum; 5E98; -.
DR   PDBsum; 5E9B; -.
DR   PDBsum; 5E9C; -.
DR   ProteinModelPortal; Q9Y251; -.
DR   BioGrid; 116066; 4.
DR   IntAct; Q9Y251; 7.
DR   STRING; 9606.ENSP00000308107; -.
DR   BindingDB; Q9Y251; -.
DR   ChEMBL; CHEMBL3921; -.
DR   DrugBank; DB06779; Dalteparin.
DR   DrugBank; DB01109; Heparin.
DR   CAZy; GH79; Glycoside Hydrolase Family 79.
DR   iPTMnet; Q9Y251; -.
DR   PhosphoSite; Q9Y251; -.
DR   BioMuta; HPSE; -.
DR   DMDM; 296434532; -.
DR   MaxQB; Q9Y251; -.
DR   PaxDb; Q9Y251; -.
DR   PRIDE; Q9Y251; -.
DR   DNASU; 10855; -.
DR   Ensembl; ENST00000311412; ENSP00000308107; ENSG00000173083. [Q9Y251-1]
DR   Ensembl; ENST00000405413; ENSP00000384262; ENSG00000173083. [Q9Y251-1]
DR   Ensembl; ENST00000509906; ENSP00000421038; ENSG00000173083. [Q9Y251-4]
DR   Ensembl; ENST00000512196; ENSP00000423265; ENSG00000173083. [Q9Y251-3]
DR   Ensembl; ENST00000513463; ENSP00000421365; ENSG00000173083. [Q9Y251-2]
DR   GeneID; 10855; -.
DR   KEGG; hsa:10855; -.
DR   UCSC; uc003hoj.4; human. [Q9Y251-1]
DR   CTD; 10855; -.
DR   GeneCards; HPSE; -.
DR   HGNC; HGNC:5164; HPSE.
DR   HPA; CAB009813; -.
DR   HPA; HPA055344; -.
DR   MIM; 604724; gene.
DR   neXtProt; NX_Q9Y251; -.
DR   PharmGKB; PA29435; -.
DR   eggNOG; ENOG410IHNV; Eukaryota.
DR   eggNOG; ENOG410YDJW; LUCA.
DR   GeneTree; ENSGT00390000004874; -.
DR   HOGENOM; HOG000007256; -.
DR   HOVERGEN; HBG081606; -.
DR   InParanoid; Q9Y251; -.
DR   KO; K07964; -.
DR   OMA; XPRYKEG; -.
DR   OrthoDB; EOG7BZVRW; -.
DR   PhylomeDB; Q9Y251; -.
DR   TreeFam; TF328999; -.
DR   BioCyc; MetaCyc:ENSG00000173083-MONOMER; -.
DR   BRENDA; 3.2.1.166; 2681.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   GeneWiki; Heparanase; -.
DR   GenomeRNAi; 10855; -.
DR   NextBio; 35483544; -.
DR   PRO; PR:Q9Y251; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; Q9Y251; -.
DR   CleanEx; HS_HPSE; -.
DR   ExpressionAtlas; Q9Y251; baseline and differential.
DR   Genevisible; Q9Y251; HS.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004566; F:beta-glucuronidase activity; TAS:ProtInc.
DR   GO; GO:0030305; F:heparanase activity; IDA:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:UniProtKB.
DR   GO; GO:0045545; F:syndecan binding; IDA:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0030200; P:heparan sulfate proteoglycan catabolic process; IDA:UniProtKB.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IDA:UniProtKB.
DR   GO; GO:0051798; P:positive regulation of hair follicle development; IEA:Ensembl.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IDA:UniProtKB.
DR   GO; GO:0006029; P:proteoglycan metabolic process; TAS:ProtInc.
DR   GO; GO:0051797; P:regulation of hair follicle development; IDA:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0061042; P:vascular wound healing; IEA:Ensembl.
DR   Gene3D; 3.20.20.80; -; 1.
DR   InterPro; IPR005199; Glyco_hydro_79.
DR   InterPro; IPR013781; Glyco_hydro_catalytic_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR14363; PTHR14363; 2.
DR   Pfam; PF03662; Glyco_hydro_79n; 1.
DR   SUPFAM; SSF51445; SSF51445; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Complete proteome; Direct protein sequencing; Glycoprotein; Hydrolase;
KW   Lysosome; Magnesium; Membrane; Nucleus; Polymorphism;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     35       {ECO:0000269|PubMed:12713442}.
FT   CHAIN        36    109       Heparanase 8 kDa subunit.
FT                                /FTId=PRO_0000042260.
FT   PROPEP      110    157       Linker peptide.
FT                                {ECO:0000269|PubMed:10395326,
FT                                ECO:0000269|PubMed:10446189,
FT                                ECO:0000269|PubMed:12713442}.
FT                                /FTId=PRO_0000042261.
FT   CHAIN       158    543       Heparanase 50 kDa subunit.
FT                                /FTId=PRO_0000042262.
FT   REGION      158    162       Heparin/HS-binding.
FT   REGION      270    280       Heparin/HS-binding.
FT   REGION      527    543       Required for transferring proheparanase
FT                                to the Golgi apparatus, secretion and
FT                                subsequent enzyme activity and for
FT                                enhancement of PKB/AKT1 phosphorylation.
FT   ACT_SITE    225    225       Proton donor. {ECO:0000255}.
FT   ACT_SITE    343    343       Nucleophile. {ECO:0000255}.
FT   CARBOHYD    162    162       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14573609}.
FT   CARBOHYD    178    178       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14573609}.
FT   CARBOHYD    200    200       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14573609}.
FT   CARBOHYD    217    217       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14573609,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    238    238       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14573609,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    459    459       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14573609}.
FT   VAR_SEQ     167    225       RSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLL
FT                                LDYCSSKGYNISWELGNE -> K (in isoform 2).
FT                                {ECO:0000303|PubMed:17208203}.
FT                                /FTId=VSP_044537.
FT   VAR_SEQ     329    402       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_044664.
FT   VAR_SEQ     365    380       WLDKLGLSARMGIEVV -> IIGYLFCSRNWWAPRC (in
FT                                isoform 4). {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_053730.
FT   VAR_SEQ     381    543       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_053731.
FT   VARIANT     260    260       N -> S (in some hepatocellular
FT                                carcinoma).
FT                                {ECO:0000269|PubMed:15334672}.
FT                                /FTId=VAR_023600.
FT   VARIANT     307    307       K -> R (in dbSNP:rs11099592).
FT                                {ECO:0000269|PubMed:10395325,
FT                                ECO:0000269|PubMed:10395326,
FT                                ECO:0000269|PubMed:10405343,
FT                                ECO:0000269|PubMed:10446189,
FT                                ECO:0000269|PubMed:10764835,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17208203,
FT                                ECO:0000269|Ref.10, ECO:0000269|Ref.11,
FT                                ECO:0000269|Ref.9}.
FT                                /FTId=VAR_068907.
FT   MUTAGEN     156    156       Y->A,E: Alteration of the correct
FT                                processing of heparanase which results in
FT                                the cleavage at an upstream site in the
FT                                linker peptide and no activation of
FT                                proheparanase.
FT                                {ECO:0000269|PubMed:15659389}.
FT   MUTAGEN     156    156       Y->V: Normal processing.
FT                                {ECO:0000269|PubMed:15659389}.
FT   MUTAGEN     158    158       K->A: No association with GS-modified
FT                                heparin; when associated with K-158.
FT                                {ECO:0000269|PubMed:15760902}.
FT   MUTAGEN     161    161       K->A: Two-fold increase in the level of
FT                                secretion upon addition of GS-modified
FT                                heparin. No association with GS-modified
FT                                heparin; when associated with K-161.
FT                                {ECO:0000269|PubMed:15760902}.
FT   MUTAGEN     162    162       N->Q: Faster electrophoretic migration
FT                                typical of a size reduction and important
FT                                decrease of secretion. Larger size
FT                                reduction; when associated with Q-178; Q-
FT                                200; Q-217; Q-238 and Q-459.
FT                                {ECO:0000269|PubMed:14573609}.
FT   MUTAGEN     178    178       N->Q: Faster electrophoretic migration
FT                                typical of a size reduction and important
FT                                decrease of secretion. Larger size
FT                                reduction; when associated with Q-162; Q-
FT                                200; Q-217; Q-238 and Q-459.
FT                                {ECO:0000269|PubMed:14573609}.
FT   MUTAGEN     200    200       N->Q: Faster electrophoretic migration
FT                                typical of a size reduction and partial
FT                                decrease in secretion. Larger size
FT                                reduction; when associated with Q-162; Q-
FT                                178; Q-217; Q-238 and Q-459.
FT                                {ECO:0000269|PubMed:14573609}.
FT   MUTAGEN     217    217       N->Q: Faster electrophoretic migration
FT                                typical of a size reduction and partial
FT                                decrease in secretion. Larger size
FT                                reduction; when associated with Q-162; Q-
FT                                178; Q-200; Q-238 and Q-459.
FT                                {ECO:0000269|PubMed:14573609}.
FT   MUTAGEN     225    225       E->A: Loss of heparanase activity. No
FT                                effect on HPSE-mediated cell adhesion.
FT                                {ECO:0000269|PubMed:11123890,
FT                                ECO:0000269|PubMed:12773484}.
FT   MUTAGEN     238    238       N->Q: Faster electrophoretic migration
FT                                typical of a size reduction. Larger size
FT                                reduction and important decrease of
FT                                secretion; when associated with Q-162; Q-
FT                                178; Q-200; Q-217 and Q-459.
FT                                {ECO:0000269|PubMed:14573609}.
FT   MUTAGEN     343    343       E->A: Loss of heparanase activity.
FT                                {ECO:0000269|PubMed:11123890}.
FT   MUTAGEN     367    367       D->A: Strong decrease in heparanase
FT                                activity. {ECO:0000269|PubMed:11123890}.
FT   MUTAGEN     378    378       E->A: No reduction in heparanase
FT                                activity.
FT   MUTAGEN     396    396       E->A: No reduction in heparanase
FT                                activity.
FT   MUTAGEN     414    414       V->K: Abolishes processing, secretion and
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     417    417       K->E: No effect on processing nor
FT                                secretion. No enzyme activity detected.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     459    459       N->Q: Faster electrophoretic migration
FT                                typical of a size reduction. Larger size
FT                                reduction and important decrease of
FT                                secretion; when associated with Q-162; Q-
FT                                178; Q-200; Q-217 and Q-238.
FT                                {ECO:0000269|PubMed:14573609}.
FT   MUTAGEN     525    525       P->G: No effect on processing nor
FT                                secretion. No enzyme activity detected.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     527    527       F->R: No effect on processing nor
FT                                secretion. No enzyme activity detected.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     528    528       S->K: No effect on processing nor
FT                                secretion. No enzyme activity detected.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     529    529       Y->A: No effect on processing nor
FT                                secretion. No enzyme activity detected.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     531    531       F->R: Abolishes processing, secretion and
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     533    533       V->R: Abolishes processing, secretion and
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     534    534       I->D: Abolishes processing, secretion and
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     535    535       R->A: No effect on processing, secretion
FT                                nor enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     536    536       N->A: No effect on processing, secretion
FT                                nor enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     537    537       A->K: Abolishes processing, secretion and
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     538    538       K->A: No effect on processing, secretion
FT                                nor enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     539    539       V->A: No effect on processing, secretion
FT                                nor enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     540    540       A->K: No effect on processing, secretion
FT                                nor enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     541    541       A->K: No effect on processing, secretion
FT                                nor enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   MUTAGEN     542    542       C->A: Abolishes processing, secretion and
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:19244131}.
FT   CONFLICT     13     13       L -> LL (in Ref. 5; AAD54516).
FT                                {ECO:0000305}.
FT   CONFLICT     36     36       Q -> QQ (in Ref. 5; AAD54516).
FT                                {ECO:0000305}.
FT   CONFLICT    291    291       D -> G (in Ref. 11; BAD96706).
FT                                {ECO:0000305}.
FT   STRAND       38     44       {ECO:0000244|PDB:5E97}.
FT   STRAND       49     51       {ECO:0000244|PDB:5E97}.
FT   STRAND       57     62       {ECO:0000244|PDB:5E97}.
FT   HELIX        63     67       {ECO:0000244|PDB:5E97}.
FT   HELIX        71     76       {ECO:0000244|PDB:5E97}.
FT   HELIX        78     86       {ECO:0000244|PDB:5E97}.
FT   STRAND       89     96       {ECO:0000244|PDB:5E97}.
FT   HELIX        97    101       {ECO:0000244|PDB:5E97}.
FT   STRAND      102    104       {ECO:0000244|PDB:5E97}.
FT   STRAND      163    165       {ECO:0000244|PDB:5E97}.
FT   HELIX       167    180       {ECO:0000244|PDB:5E97}.
FT   STRAND      182    188       {ECO:0000244|PDB:5E97}.
FT   HELIX       202    213       {ECO:0000244|PDB:5E97}.
FT   STRAND      219    222       {ECO:0000244|PDB:5E97}.
FT   HELIX       226    228       {ECO:0000244|PDB:5E97}.
FT   HELIX       229    233       {ECO:0000244|PDB:5E97}.
FT   HELIX       239    254       {ECO:0000244|PDB:5E97}.
FT   STRAND      256    258       {ECO:0000244|PDB:5E97}.
FT   STRAND      263    268       {ECO:0000244|PDB:5E97}.
FT   HELIX       273    286       {ECO:0000244|PDB:5E97}.
FT   HELIX       287    289       {ECO:0000244|PDB:5E97}.
FT   STRAND      291    301       {ECO:0000244|PDB:5E97}.
FT   TURN        302    304       {ECO:0000244|PDB:5E97}.
FT   HELIX       307    310       {ECO:0000244|PDB:5E97}.
FT   HELIX       313    316       {ECO:0000244|PDB:5E97}.
FT   HELIX       318    331       {ECO:0000244|PDB:5E97}.
FT   STRAND      338    348       {ECO:0000244|PDB:5E97}.
FT   TURN        353    357       {ECO:0000244|PDB:5E97}.
FT   HELIX       359    361       {ECO:0000244|PDB:5E97}.
FT   HELIX       362    375       {ECO:0000244|PDB:5E97}.
FT   STRAND      379    383       {ECO:0000244|PDB:5E97}.
FT   STRAND      385    390       {ECO:0000244|PDB:5E97}.
FT   HELIX       402    413       {ECO:0000244|PDB:5E97}.
FT   STRAND      414    418       {ECO:0000244|PDB:5E97}.
FT   STRAND      420    423       {ECO:0000244|PDB:5E97}.
FT   STRAND      429    438       {ECO:0000244|PDB:5E97}.
FT   STRAND      450    456       {ECO:0000244|PDB:5E97}.
FT   STRAND      458    460       {ECO:0000244|PDB:5E97}.
FT   STRAND      462    465       {ECO:0000244|PDB:5E97}.
FT   STRAND      475    482       {ECO:0000244|PDB:5E97}.
FT   STRAND      484    486       {ECO:0000244|PDB:5E97}.
FT   HELIX       487    489       {ECO:0000244|PDB:5E97}.
FT   STRAND      493    495       {ECO:0000244|PDB:5E97}.
FT   STRAND      522    524       {ECO:0000244|PDB:5E97}.
FT   STRAND      528    534       {ECO:0000244|PDB:5E97}.
FT   HELIX       540    542       {ECO:0000244|PDB:5E97}.
SQ   SEQUENCE   543 AA;  61149 MW;  A990F5AFD639CA1A CRC64;
     MLLRSKPALP PPLMLLLLGP LGPLSPGALP RPAQAQDVVD LDFFTQEPLH LVSPSFLSVT
     IDANLATDPR FLILLGSPKL RTLARGLSPA YLRFGGTKTD FLIFDPKKES TFEERSYWQS
     QVNQDICKYG SIPPDVEEKL RLEWPYQEQL LLREHYQKKF KNSTYSRSSV DVLYTFANCS
     GLDLIFGLNA LLRTADLQWN SSNAQLLLDY CSSKGYNISW ELGNEPNSFL KKADIFINGS
     QLGEDFIQLH KLLRKSTFKN AKLYGPDVGQ PRRKTAKMLK SFLKAGGEVI DSVTWHHYYL
     NGRTATKEDF LNPDVLDIFI SSVQKVFQVV ESTRPGKKVW LGETSSAYGG GAPLLSDTFA
     AGFMWLDKLG LSARMGIEVV MRQVFFGAGN YHLVDENFDP LPDYWLSLLF KKLVGTKVLM
     ASVQGSKRRK LRVYLHCTNT DNPRYKEGDL TLYAINLHNV TKYLRLPYPF SNKQVDKYLL
     RPLGPHGLLS KSVQLNGLTL KMVDDQTLPP LMEKPLRPGS SLGLPAFSYS FFVIRNAKVA
     ACI
//
ID   IL6_MOUSE               Reviewed;         211 AA.
AC   P08505; Q3UCQ0; Q8BN26;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   20-JAN-2016, entry version 156.
DE   RecName: Full=Interleukin-6;
DE            Short=IL-6;
DE   AltName: Full=B-cell hybridoma growth factor;
DE   AltName: Full=Interleukin HP-1;
DE   Flags: Precursor;
GN   Name=Il6; Synonyms=Il-6;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2965020; DOI=10.1002/eji.1830180202;
RA   van Snick J., Cayphas S., Szikora J.-P., Renauld J.-C., van Roost E.,
RA   Boon T., Simpson R.J.;
RT   "cDNA cloning of murine interleukin-HP1: homology with human
RT   interleukin 6.";
RL   Eur. J. Immunol. 18:193-197(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3263439;
RA   Tanabe O., Akira S., Kamiya T., Wong G.G., Hirano T., Kishimoto T.;
RT   "Genomic structure of the murine IL-6 gene. High degree conservation
RT   of potential regulatory sequences between mouse and human.";
RL   J. Immunol. 141:3875-3881(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3262872; DOI=10.1073/pnas.85.19.7099;
RA   Chiu C.P., Moulds C., Coffman R.L., Rennick D., Lee F.;
RT   "Multiple biological activities are expressed by a mouse interleukin 6
RT   cDNA clone isolated from bone marrow stromal cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7099-7103(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ;
RX   PubMed=2243807; DOI=10.1093/nar/18.21.6455;
RA   Grenett H.E., Fuentes N.L., Fuller G.M.;
RT   "Cloning and sequence analysis of the cDNA for murine interleukin-6.";
RL   Nucleic Acids Res. 18:6455-6455(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Macrophage;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.
RC   STRAIN=BALB/cJ;
RX   PubMed=2106569; DOI=10.1084/jem.171.3.965;
RA   Blankenstein T., Qin Z., Li W., Diamantstein T.;
RT   "DNA rearrangement and constitutive expression of the interleukin 6
RT   gene in a mouse plasmacytoma.";
RL   J. Exp. Med. 171:965-970(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-211.
RC   STRAIN=C57BL/6J;
RX   PubMed=2563387;
RA   Mock B.A., Nordan R.P., Justice M.J., Kozak C., Jenkins N.A.,
RA   Copeland N.G., Clark S.C., Wong G.G., Rudikoff S.;
RT   "The murine Il-6 gene maps to the proximal region of chromosome 5.";
RL   J. Immunol. 142:1372-1376(1989).
RN   [8]
RP   PROTEIN SEQUENCE OF 25-45.
RX   PubMed=2948184; DOI=10.1073/pnas.83.24.9679;
RA   van Snick J., Cayphas S., Vink A., Uyttenhove C., Coulie P.G.,
RA   Rubira M.R., Simpson R.J.;
RT   "Purification and NH2-terminal amino acid sequence of a T-cell-derived
RT   lymphokine with growth factor activity for B-cell hybridomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:9679-9683(1986).
RN   [9]
RP   PROTEIN SEQUENCE OF 25-211.
RX   PubMed=3262059; DOI=10.1111/j.1432-1033.1988.tb14267.x;
RA   Simpson R.J., Moritz R.L., Rubira M.R., van Snick J.;
RT   "Murine hybridoma/plasmacytoma growth factor. Complete amino-acid
RT   sequence and relation to human interleukin-6.";
RL   Eur. J. Biochem. 176:187-197(1988).
RN   [10]
RP   PROTEIN SEQUENCE OF 66-75; 78-84 AND 128-148.
RX   PubMed=2302197; DOI=10.1016/0006-291X(90)91922-F;
RA   Jahnen W., Ward L.D., Reid G.E., Moritz R.L., Simpson R.J.;
RT   "Internal amino acid sequencing of proteins by in situ cyanogen
RT   bromide cleavage in polyacrylamide gels.";
RL   Biochem. Biophys. Res. Commun. 166:139-145(1990).
RN   [11]
RP   DISULFIDE BONDS.
RX   PubMed=3264160; DOI=10.1016/S0006-291X(88)80056-1;
RA   Simpson R.J., Moritz R.L., van Roost E., van Snick J.;
RT   "Characterization of a recombinant murine interleukin-6: assignment of
RT   disulphide bonds.";
RL   Biochem. Biophys. Res. Commun. 157:364-372(1988).
RN   [12]
RP   FUNCTION IN TH17 DIFFERENTIATION, AND DISRUPTION PHENOTYPE.
RX   PubMed=16990136; DOI=10.1016/j.cell.2006.07.035;
RA   Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A.,
RA   Lafaille J.J., Cua D.J., Littman D.R.;
RT   "The orphan nuclear receptor RORgammat directs the differentiation
RT   program of proinflammatory IL-17+ T helper cells.";
RL   Cell 126:1121-1133(2006).
CC   -!- FUNCTION: Cytokine with a wide variety of biological functions. It
CC       is a potent inducer of the acute phase response. Plays an
CC       essential role in the final differentiation of B-cells into Ig-
CC       secreting cells Involved in lymphocyte and monocyte
CC       differentiation. Acts on B-cells, T-cells, hepatocytes,
CC       hematopoietic progenitor cells and cells of the CNS. Required for
CC       the generation of T(H)17 cells. Also acts as a myokine. It is
CC       discharged into the bloodstream after muscle contraction and acts
CC       to increase the breakdown of fats and to improve insulin
CC       resistance. It induces myeloma and plasmacytoma growth and induces
CC       nerve cells differentiation. {ECO:0000269|PubMed:16990136}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- DISRUPTION PHENOTYPE: Animals have normal T-cell numbers in the
CC       lamina propria but the T(H)17 cells are reduced by about 10-fold.
CC       {ECO:0000269|PubMed:16990136}.
CC   -!- SIMILARITY: Belongs to the IL-6 superfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06203; CAA29560.1; -; mRNA.
DR   EMBL; M20572; AAA39302.1; -; Genomic_DNA.
DR   EMBL; J03783; AAA39301.1; -; mRNA.
DR   EMBL; X54542; CAA38411.1; -; mRNA.
DR   EMBL; AK150440; BAE29562.1; -; mRNA.
DR   EMBL; X51457; CAA35824.1; -; Genomic_DNA.
DR   EMBL; M24221; AAA68814.1; -; Genomic_DNA.
DR   CCDS; CCDS19153.1; -.
DR   PIR; A30531; ICMS6.
DR   RefSeq; NP_001300983.1; NM_001314054.1.
DR   RefSeq; NP_112445.1; NM_031168.2.
DR   UniGene; Mm.1019; -.
DR   PDB; 2L3Y; NMR; -; A=27-211.
DR   PDBsum; 2L3Y; -.
DR   ProteinModelPortal; P08505; -.
DR   SMR; P08505; 28-211.
DR   BioGrid; 200641; 2.
DR   IntAct; P08505; 1.
DR   STRING; 10090.ENSMUSP00000026845; -.
DR   PhosphoSite; P08505; -.
DR   MaxQB; P08505; -.
DR   PaxDb; P08505; -.
DR   PRIDE; P08505; -.
DR   Ensembl; ENSMUST00000026845; ENSMUSP00000026845; ENSMUSG00000025746.
DR   GeneID; 16193; -.
DR   KEGG; mmu:16193; -.
DR   UCSC; uc008wuu.1; mouse.
DR   CTD; 3569; -.
DR   MGI; MGI:96559; Il6.
DR   eggNOG; ENOG410IW11; Eukaryota.
DR   eggNOG; ENOG4112BXV; LUCA.
DR   GeneTree; ENSGT00390000000878; -.
DR   HOGENOM; HOG000236330; -.
DR   HOVERGEN; HBG000471; -.
DR   InParanoid; P08505; -.
DR   KO; K05405; -.
DR   OMA; FNQETCL; -.
DR   OrthoDB; EOG7QG453; -.
DR   PhylomeDB; P08505; -.
DR   TreeFam; TF335984; -.
DR   Reactome; R-MMU-1059683; Interleukin-6 signaling.
DR   Reactome; R-MMU-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-MMU-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-MMU-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   EvolutionaryTrace; P08505; -.
DR   NextBio; 289109; -.
DR   PRO; PR:P08505; -.
DR   Proteomes; UP000000589; Chromosome 5.
DR   Bgee; P08505; -.
DR   CleanEx; MM_IL6; -.
DR   ExpressionAtlas; P08505; baseline and differential.
DR   Genevisible; P08505; MM.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; ISO:MGI.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0008083; F:growth factor activity; ISO:MGI.
DR   GO; GO:0005138; F:interleukin-6 receptor binding; IDA:MGI.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IDA:MGI.
DR   GO; GO:0016049; P:cell growth; IEA:Ensembl.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IDA:MGI.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISO:MGI.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:MGI.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:MGI.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:MGI.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISO:MGI.
DR   GO; GO:0042832; P:defense response to protozoan; IMP:MGI.
DR   GO; GO:0051607; P:defense response to virus; ISO:MGI.
DR   GO; GO:0031018; P:endocrine pancreas development; IMP:BHF-UCL.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IDA:MGI.
DR   GO; GO:0070091; P:glucagon secretion; IMP:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IGI:MGI.
DR   GO; GO:0002384; P:hepatic immune response; ISO:MGI.
DR   GO; GO:0006954; P:inflammatory response; ISO:MGI.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IGI:MGI.
DR   GO; GO:0002262; P:myeloid cell homeostasis; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045079; P:negative regulation of chemokine biosynthetic process; IDA:MGI.
DR   GO; GO:0032966; P:negative regulation of collagen biosynthetic process; ISO:MGI.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0050710; P:negative regulation of cytokine secretion; IEA:Ensembl.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; IEA:Ensembl.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IDA:MGI.
DR   GO; GO:0048635; P:negative regulation of muscle organ development; IEA:Ensembl.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; ISO:MGI.
DR   GO; GO:0001781; P:neutrophil apoptotic process; IDA:MGI.
DR   GO; GO:0002675; P:positive regulation of acute inflammatory response; ISO:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0050871; P:positive regulation of B cell activation; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISO:MGI.
DR   GO; GO:0071864; P:positive regulation of cell proliferation in bone marrow; IGI:MGI.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISO:MGI.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:MGI.
DR   GO; GO:0051024; P:positive regulation of immunoglobulin secretion; ISO:MGI.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISO:MGI.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; ISO:MGI.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISO:MGI.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; ISO:MGI.
DR   GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0045727; P:positive regulation of translation; ISO:MGI.
DR   GO; GO:0051971; P:positive regulation of transmission of nerve impulse; IEA:Ensembl.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; ISO:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
DR   GO; GO:0045188; P:regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0010574; P:regulation of vascular endothelial growth factor production; ISO:MGI.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0010996; P:response to auditory stimulus; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; ISO:MGI.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IDA:MGI.
DR   GO; GO:0001878; P:response to yeast; IEA:Ensembl.
DR   GO; GO:0042110; P:T cell activation; IGI:MGI.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; IMP:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 1.20.1250.10; -; 1.
DR   InterPro; IPR009079; 4_helix_cytokine-like_core.
DR   InterPro; IPR012351; 4_helix_cytokine_core.
DR   InterPro; IPR003574; IL-6.
DR   InterPro; IPR030474; IL-6/GCSF/MGF.
DR   InterPro; IPR030473; IL6/GCSF/MGF_CS.
DR   PANTHER; PTHR11457; PTHR11457; 1.
DR   Pfam; PF00489; IL6; 1.
DR   PIRSF; PIRSF001935; IL6_MGF_GCSF; 1.
DR   PRINTS; PR00433; IL6GCSFMGF.
DR   SMART; SM00126; IL6; 1.
DR   SUPFAM; SSF47266; SSF47266; 1.
DR   PROSITE; PS00254; INTERLEUKIN_6; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Complete proteome; Cytokine;
KW   Direct protein sequencing; Disulfide bond; Growth factor;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:2948184,
FT                                ECO:0000269|PubMed:3262059}.
FT   CHAIN        25    211       Interleukin-6.
FT                                /FTId=PRO_0000015588.
FT   DISULFID     70     76       {ECO:0000269|PubMed:3264160}.
FT   DISULFID     99    109       {ECO:0000269|PubMed:3264160}.
FT   HELIX        48     68       {ECO:0000244|PDB:2L3Y}.
FT   TURN         69     72       {ECO:0000244|PDB:2L3Y}.
FT   HELIX        74     77       {ECO:0000244|PDB:2L3Y}.
FT   TURN         81     83       {ECO:0000244|PDB:2L3Y}.
FT   HELIX        84     86       {ECO:0000244|PDB:2L3Y}.
FT   STRAND      101    103       {ECO:0000244|PDB:2L3Y}.
FT   HELIX       114    129       {ECO:0000244|PDB:2L3Y}.
FT   HELIX       133    160       {ECO:0000244|PDB:2L3Y}.
FT   HELIX       170    176       {ECO:0000244|PDB:2L3Y}.
FT   HELIX       186    209       {ECO:0000244|PDB:2L3Y}.
SQ   SEQUENCE   211 AA;  24384 MW;  BBB47DDA9E86787A CRC64;
     MKFLSARDFH PVAFLGLMLV TTTAFPTSQV RRGDFTEDTT PNRPVYTTSQ VGGLITHVLW
     EIVEMRKELC NGNSDCMNND DALAENNLKL PEIQRNDGCY QTGYNQEICL LKISSGLLEY
     HSYLEYMKNN LKDNKKDKAR VLQRDTETLI HIFNQEVKDL HKIVLPTPIS NALLTDKLES
     QKEWLRTKTI QFILKSLEEF LKVTLRSTRQ T
//
ID   EDN1_RAT                Reviewed;         202 AA.
AC   P22388;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 2.
DT   11-NOV-2015, entry version 122.
DE   RecName: Full=Endothelin-1;
DE            Short=ET-1;
DE   AltName: Full=Preproendothelin-1;
DE            Short=PPET1;
DE   Flags: Precursor;
GN   Name=Edn1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1840483; DOI=10.1016/S0006-291X(05)81197-0;
RA   Sakurai T., Yanagisawa M., Inoue A., Ryan U.S., Kimura S., Mitsui Y.,
RA   Goto K., Masaki T.;
RT   "cDNA cloning, sequence analysis and tissue distribution of rat
RT   preproendothelin-1 mRNA.";
RL   Biochem. Biophys. Res. Commun. 175:44-47(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 51-77.
RC   STRAIN=Wistar; TISSUE=Kidney;
RX   PubMed=2039460;
RA   Nunez D.J.R., Taylor E.A., Oh V.M.S., Schofield J.P., Brown M.J.;
RT   "Endothelin-1 mRNA expression in the rat kidney.";
RL   Biochem. J. 275:817-819(1991).
CC   -!- FUNCTION: Endothelins are endothelium-derived vasoconstrictor
CC       peptides.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the endothelin/sarafotoxin family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M64711; AAA41129.1; -; mRNA.
DR   PIR; JN0125; JN0125.
DR   RefSeq; NP_036680.1; NM_012548.2.
DR   UniGene; Rn.10918; -.
DR   PDB; 3CMH; NMR; -; A=60-73.
DR   PDB; 6CMH; NMR; -; A=53-73.
DR   PDBsum; 3CMH; -.
DR   PDBsum; 6CMH; -.
DR   STRING; 10116.ENSRNOP00000019361; -.
DR   PaxDb; P22388; -.
DR   PRIDE; P22388; -.
DR   Ensembl; ENSRNOT00000019361; ENSRNOP00000019361; ENSRNOG00000014361.
DR   GeneID; 24323; -.
DR   KEGG; rno:24323; -.
DR   UCSC; RGD:2532; rat.
DR   CTD; 1906; -.
DR   RGD; 2532; Edn1.
DR   eggNOG; ENOG410IWVG; Eukaryota.
DR   eggNOG; ENOG4111WED; LUCA.
DR   GeneTree; ENSGT00530000063310; -.
DR   HOGENOM; HOG000231110; -.
DR   HOVERGEN; HBG051441; -.
DR   InParanoid; P22388; -.
DR   KO; K16366; -.
DR   OMA; CASQKDK; -.
DR   OrthoDB; EOG7PS1H7; -.
DR   PhylomeDB; P22388; -.
DR   TreeFam; TF333184; -.
DR   Reactome; R-RNO-375276; Peptide ligand-binding receptors.
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   EvolutionaryTrace; P22388; -.
DR   NextBio; 602983; -.
DR   PRO; PR:P22388; -.
DR   Proteomes; UP000002494; Chromosome 17.
DR   Genevisible; P22388; RN.
DR   GO; GO:0045178; C:basal part of cell; IDA:RGD.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0048237; C:rough endoplasmic reticulum lumen; IDA:RGD.
DR   GO; GO:0033093; C:Weibel-Palade body; IDA:RGD.
DR   GO; GO:0031707; F:endothelin A receptor binding; IMP:RGD.
DR   GO; GO:0031708; F:endothelin B receptor binding; IMP:RGD.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IDA:RGD.
DR   GO; GO:0007589; P:body fluid secretion; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0016049; P:cell growth; IDA:RGD.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0071277; P:cellular response to calcium ion; IEP:RGD.
DR   GO; GO:0035690; P:cellular response to drug; IEP:RGD.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEP:RGD.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEP:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:RGD.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEP:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:RGD.
DR   GO; GO:0071389; P:cellular response to mineralocorticoid stimulus; IEP:RGD.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEP:RGD.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IEA:Ensembl.
DR   GO; GO:0042045; P:epithelial fluid transport; IDA:RGD.
DR   GO; GO:0015758; P:glucose transport; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0001821; P:histamine secretion; IDA:RGD.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048016; P:inositol phosphate-mediated signaling; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:RGD.
DR   GO; GO:0060137; P:maternal process involved in parturition; IEP:RGD.
DR   GO; GO:0051899; P:membrane depolarization; IMP:RGD.
DR   GO; GO:0042474; P:middle ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0010259; P:multicellular organismal aging; IEP:RGD.
DR   GO; GO:0030818; P:negative regulation of cAMP biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032269; P:negative regulation of cellular protein metabolic process; IEA:Ensembl.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IDA:RGD.
DR   GO; GO:0051771; P:negative regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IDA:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0014032; P:neural crest cell development; IEA:Ensembl.
DR   GO; GO:0030185; P:nitric oxide transport; IEA:Ensembl.
DR   GO; GO:0001569; P:patterning of blood vessels; IEA:Ensembl.
DR   GO; GO:0030072; P:peptide hormone secretion; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:0031583; P:phospholipase D-activating G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:RGD.
DR   GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:RGD.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway; IEA:Ensembl.
DR   GO; GO:0010460; P:positive regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0046887; P:positive regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IEA:Ensembl.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IDA:RGD.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; IDA:RGD.
DR   GO; GO:0032308; P:positive regulation of prostaglandin secretion; IDA:RGD.
DR   GO; GO:0060585; P:positive regulation of prostaglandin-endoperoxide synthase activity; IEA:Ensembl.
DR   GO; GO:0010870; P:positive regulation of receptor biosynthetic process; IEA:Ensembl.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0060298; P:positive regulation of sarcomere organization; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IDA:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:RGD.
DR   GO; GO:0035810; P:positive regulation of urine volume; IEA:Ensembl.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042313; P:protein kinase C deactivation; IEA:Ensembl.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:RGD.
DR   GO; GO:0006885; P:regulation of pH; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IDA:RGD.
DR   GO; GO:0003100; P:regulation of systemic arterial blood pressure by endothelin; IEA:Ensembl.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IEA:InterPro.
DR   GO; GO:0007585; P:respiratory gaseous exchange; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0043200; P:response to amino acid; IEP:RGD.
DR   GO; GO:0071548; P:response to dexamethasone; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0044321; P:response to leptin; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0035994; P:response to muscle stretch; IEP:RGD.
DR   GO; GO:0035094; P:response to nicotine; IEP:RGD.
DR   GO; GO:0010193; P:response to ozone; IEP:RGD.
DR   GO; GO:0034696; P:response to prostaglandin F; IEP:RGD.
DR   GO; GO:1902074; P:response to salt; IEP:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0071559; P:response to transforming growth factor beta; IEP:RGD.
DR   GO; GO:0043179; P:rhythmic excitation; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IDA:RGD.
DR   GO; GO:0042554; P:superoxide anion generation; IDA:RGD.
DR   GO; GO:0042310; P:vasoconstriction; IDA:RGD.
DR   GO; GO:0014826; P:vein smooth muscle contraction; IEA:Ensembl.
DR   InterPro; IPR020475; Bibrotoxin/Sarafotoxin-D.
DR   InterPro; IPR019764; Endothelin_toxin_CS.
DR   InterPro; IPR001928; Endothln-like_toxin.
DR   Pfam; PF00322; Endothelin; 1.
DR   PRINTS; PR00365; ENDOTHELIN.
DR   SMART; SM00272; END; 2.
DR   PROSITE; PS00270; ENDOTHELIN; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues; Complete proteome;
KW   Disulfide bond; Reference proteome; Secreted; Signal; Vasoactive;
KW   Vasoconstrictor.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   PROPEP       26     50
FT                                /FTId=PRO_0000008072.
FT   PEPTIDE      53     73       Endothelin-1.
FT                                /FTId=PRO_0000008073.
FT   PROPEP       74    202
FT                                /FTId=PRO_0000008074.
FT   REGION      110    124       Endothelin-like.
FT   SITE         73     74       Cleavage; by KEL. {ECO:0000250}.
FT   DISULFID     53     67       {ECO:0000250}.
FT   DISULFID     55     63       {ECO:0000250}.
FT   HELIX        54     57       {ECO:0000244|PDB:6CMH}.
FT   HELIX        61     69       {ECO:0000244|PDB:3CMH}.
SQ   SEQUENCE   202 AA;  23135 MW;  701886BAFD09AC4B CRC64;
     MDYFPVIFSL LFVAFQGAPE TAVLGAELSP RAEKEVQSPP PSTSWRPRRS KRCSCSSLMD
     KECVYFCHLD IIWVNTPERV VPYGLGSPSR SKRSLKDLLP TKTTDQGNRC QCAHQKDKKC
     WNFCQADKEL RAQSTMQKGV KDFKKGKPCP KLGKKCIYQQ LVEGRKLRRL EAISNSIKTS
     FRVAKLKAEL YRDQKLIHNR AH
//
ID   ZP3_MOUSE               Reviewed;         424 AA.
AC   P10761; Q4FZI2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 4.
DT   20-JAN-2016, entry version 132.
DE   RecName: Full=Zona pellucida sperm-binding protein 3;
DE   AltName: Full=Sperm receptor;
DE   AltName: Full=Zona pellucida glycoprotein 3;
DE            Short=Zp-3;
DE   AltName: Full=Zona pellucida protein C;
DE   Contains:
DE     RecName: Full=Processed zona pellucida sperm-binding protein 3;
DE   Flags: Precursor;
GN   Name=Zp3; Synonyms=Zp-3, Zpc;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3378665; DOI=10.1016/0012-1606(88)90315-6;
RA   Ringuette M.J., Chamberlin M.E., Baur A.W., Sobieski D.A., Dean J.;
RT   "Molecular analysis of cDNA coding for ZP3, a sperm binding protein of
RT   the mouse zona pellucida.";
RL   Dev. Biol. 127:287-295(1988).
RN   [2]
RP   SEQUENCE REVISION TO 387.
RA   Dean J.;
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=CD-1; TISSUE=Liver;
RX   PubMed=2541416; DOI=10.1093/nar/17.7.2861;
RA   Kinloch R.A., Wassarman P.M.;
RT   "Nucleotide sequence of the gene encoding zona pellucida glycoprotein
RT   ZP3 -- the mouse sperm receptor.";
RL   Nucleic Acids Res. 17:2861-2863(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2842770; DOI=10.1073/pnas.85.17.6409;
RA   Kinloch R.A., Roller R.J., Fimiani C.M., Wassarman D.A.,
RA   Wassarman P.M.;
RT   "Primary structure of the mouse sperm receptor polypeptide determined
RT   by genomic cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6409-6413(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 49-63; 197-204; 219-233 AND 261-275.
RC   STRAIN=CD-1;
RX   PubMed=1330788; DOI=10.1016/0012-1606(92)90070-W;
RA   Rosiere T.K., Wassarman P.M.;
RT   "Identification of a region of mouse zona pellucida glycoprotein mZP3
RT   that possesses sperm receptor activity.";
RL   Dev. Biol. 154:309-317(1992).
RN   [7]
RP   PROTEIN SEQUENCE OF C-TERMINUS, PYROGLUTAMATE FORMATION AT GLN-23,
RP   DISULFIDE BOND FORMATION AT 78-CYS--CYS-98; 216-CYS--CYS-283 AND
RP   240-CYS--CYS-301, GLYCOSYLATION AT ASN-146; ASN-273; ASN-304; ASN-327
RP   AND ASN-330, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12799386; DOI=10.1074/jbc.M304026200;
RA   Boja E.S., Hoodbhoy T., Fales H.M., Dean J.;
RT   "Structural characterization of native mouse zona pellucida proteins
RT   using mass spectrometry.";
RL   J. Biol. Chem. 278:34189-34202(2003).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 42-143, IDENTIFICATION BY
RP   MASS SPECTROMETRY, MUTAGENESIS OF TYR-111, SUBCELLULAR LOCATION, AND
RP   DISULFIDE BONDS.
RX   PubMed=19052627; DOI=10.1038/nature07599;
RA   Monne M., Han L., Schwend T., Burendahl S., Jovine L.;
RT   "Crystal structure of the ZP-N domain of ZP3 reveals the core fold of
RT   animal egg coats.";
RL   Nature 456:653-657(2008).
CC   -!- FUNCTION: The mammalian zona pellucida, which mediates species-
CC       specific sperm binding, induction of the acrosome reaction and
CC       prevents post-fertilization polyspermy, is composed of three to
CC       four glycoproteins, ZP1, ZP2, ZP3, and ZP4. ZP3 is essential for
CC       sperm binding and zona matrix formation.
CC   -!- SUBUNIT: Polymers of ZP2 and ZP3 organized into long filaments
CC       cross-linked by ZP1 homodimers.
CC   -!- SUBCELLULAR LOCATION: Processed zona pellucida sperm-binding
CC       protein 3: Secreted, extracellular space, extracellular matrix
CC       {ECO:0000269|PubMed:19052627}. Note=The glycoproteinaceous
CC       translucent extracellular matrix that surrounds the mammalian
CC       oocyte is called zona pellucida. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19052627};
CC       Single-pass type I membrane protein {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Oocytes.
CC   -!- DEVELOPMENTAL STAGE: Expressed during the 2-week growth phase of
CC       oogenesis, prior to ovulation.
CC   -!- DOMAIN: The ZP domain is involved in the polymerization of the ZP
CC       proteins to form the zona pellucida.
CC   -!- PTM: Proteolytically cleaved before the transmembrane segment to
CC       yield the secreted ectodomain incorporated in the zona pellucida.
CC   -!- PTM: O-glycosylated; removal of O-linked glycans may play an
CC       important role in the post-fertilization block to polyspermy.
CC       {ECO:0000269|PubMed:12799386}.
CC   -!- PTM: Cys-320, Cys-322, Cys-323 and Cys-328 are involved in two
CC       additional disulfide bonds.
CC   -!- SIMILARITY: Belongs to the ZP domain family. ZPC subfamily.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 ZP domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00375}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Molecular chastity -
CC       Issue 93 of April 2008;
CC       URL="http://web.expasy.org/spotlight/back_issues/093";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M20026; AAB18629.1; -; mRNA.
DR   EMBL; X14376; CAA32550.1; -; Genomic_DNA.
DR   EMBL; BC099465; AAH99465.1; -; mRNA.
DR   EMBL; BC100745; AAI00746.1; -; mRNA.
DR   EMBL; BC103583; AAI03584.1; -; mRNA.
DR   EMBL; BC103584; AAI03585.1; -; mRNA.
DR   EMBL; BC103585; AAI03586.1; -; mRNA.
DR   CCDS; CCDS19749.1; -.
DR   PIR; A30334; A30334.
DR   RefSeq; NP_035906.1; NM_011776.1.
DR   UniGene; Mm.1381; -.
DR   PDB; 3D4C; X-ray; 2.90 A; A=42-143.
DR   PDB; 3D4G; X-ray; 2.30 A; A/B/C/D/E/F/G/H=42-143.
DR   PDB; 3EF7; X-ray; 3.10 A; A/B=42-143.
DR   PDBsum; 3D4C; -.
DR   PDBsum; 3D4G; -.
DR   PDBsum; 3EF7; -.
DR   ProteinModelPortal; P10761; -.
DR   SMR; P10761; 42-143.
DR   STRING; 10090.ENSMUSP00000005073; -.
DR   PhosphoSite; P10761; -.
DR   UniCarbKB; P10761; -.
DR   PaxDb; P10761; -.
DR   PRIDE; P10761; -.
DR   Ensembl; ENSMUST00000005073; ENSMUSP00000005073; ENSMUSG00000004948.
DR   GeneID; 22788; -.
DR   KEGG; mmu:22788; -.
DR   UCSC; uc008zzl.1; mouse.
DR   CTD; 7784; -.
DR   MGI; MGI:99215; Zp3.
DR   eggNOG; ENOG410II9V; Eukaryota.
DR   eggNOG; ENOG410YXE1; LUCA.
DR   GeneTree; ENSGT00530000063482; -.
DR   HOGENOM; HOG000220813; -.
DR   HOVERGEN; HBG007985; -.
DR   InParanoid; P10761; -.
DR   OMA; NRRHVTE; -.
DR   OrthoDB; EOG773XG3; -.
DR   PhylomeDB; P10761; -.
DR   TreeFam; TF331369; -.
DR   Reactome; R-MMU-1300644; Interaction With The Zona Pellucida.
DR   EvolutionaryTrace; P10761; -.
DR   NextBio; 303371; -.
DR   PRO; PR:P10761; -.
DR   Proteomes; UP000000589; Chromosome 5.
DR   Bgee; P10761; -.
DR   CleanEx; MM_ZP3; -.
DR   ExpressionAtlas; P10761; baseline and differential.
DR   Genevisible; P10761; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005771; C:multivesicular body; IDA:UniProtKB.
DR   GO; GO:0002081; C:outer acrosomal membrane; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0030141; C:secretory granule; IDA:UniProtKB.
DR   GO; GO:0032190; F:acrosin binding; ISO:MGI.
DR   GO; GO:0030246; F:carbohydrate binding; ISS:UniProtKB.
DR   GO; GO:0005384; F:manganese ion transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IDA:UniProtKB.
DR   GO; GO:0015279; F:store-operated calcium channel activity; ISO:MGI.
DR   GO; GO:0007339; P:binding of sperm to zona pellucida; IMP:UniProtKB.
DR   GO; GO:0001825; P:blastocyst formation; IMP:UniProtKB.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; ISO:MGI.
DR   GO; GO:0035803; P:egg coat formation; IMP:UniProtKB.
DR   GO; GO:0002455; P:humoral immune response mediated by circulating immunoglobulin; IDA:UniProtKB.
DR   GO; GO:0006886; P:intracellular protein transport; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0071421; P:manganese ion transmembrane transport; IDA:GOC.
DR   GO; GO:0006828; P:manganese ion transport; IDA:UniProtKB.
DR   GO; GO:2000360; P:negative regulation of binding of sperm to zona pellucida; ISO:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0048599; P:oocyte development; IMP:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IMP:UniProtKB.
DR   GO; GO:2000368; P:positive regulation of acrosomal vesicle exocytosis; ISS:UniProtKB.
DR   GO; GO:2000344; P:positive regulation of acrosome reaction; IDA:UniProtKB.
DR   GO; GO:2000388; P:positive regulation of antral ovarian follicle growth; IMP:UniProtKB.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; IDA:UniProtKB.
DR   GO; GO:0002922; P:positive regulation of humoral immune response; ISS:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IDA:UniProtKB.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; IDA:UniProtKB.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IDA:UniProtKB.
DR   GO; GO:2000386; P:positive regulation of ovarian follicle development; IDA:UniProtKB.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001809; P:positive regulation of type IV hypersensitivity; IDA:UniProtKB.
DR   GO; GO:0070528; P:protein kinase C signaling; ISS:UniProtKB.
DR   InterPro; IPR001507; ZP_dom.
DR   InterPro; IPR017977; ZP_dom_CS.
DR   Pfam; PF00100; Zona_pellucida; 1.
DR   PRINTS; PR00023; ZPELLUCIDA.
DR   SMART; SM00241; ZP; 1.
DR   PROSITE; PS00682; ZP_1; 1.
DR   PROSITE; PS51034; ZP_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cleavage on pair of basic residues;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Membrane;
KW   Pyrrolidone carboxylic acid; Receptor; Reference proteome; Secreted;
KW   Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:12799386}.
FT   CHAIN        23    351       Zona pellucida sperm-binding protein 3.
FT                                /FTId=PRO_0000041715.
FT   CHAIN        23      ?       Processed zona pellucida sperm-binding
FT                                protein 3.
FT                                /FTId=PRO_0000304572.
FT   PROPEP      352    424       Removed in mature form.
FT                                {ECO:0000269|PubMed:12799386}.
FT                                /FTId=PRO_0000041716.
FT   TOPO_DOM     23    387       Extracellular.
FT   TRANSMEM    388    408       Helical. {ECO:0000255}.
FT   TOPO_DOM    409    424       Cytoplasmic.
FT   DOMAIN       45    308       ZP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00375}.
FT   MOD_RES      23     23       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:12799386}.
FT   CARBOHYD     32     32       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD     34     34       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD     39     39       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD    146    146       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12799386}.
FT   CARBOHYD    155    155       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD    162    162       O-linked (GalNAc...). {ECO:0000305}.
FT   CARBOHYD    273    273       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12799386}.
FT   CARBOHYD    304    304       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12799386}.
FT   CARBOHYD    327    327       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12799386}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12799386}.
FT   DISULFID     46    139       {ECO:0000269|PubMed:19052627}.
FT   DISULFID     78     98       {ECO:0000269|PubMed:12799386}.
FT   DISULFID    216    283       {ECO:0000269|PubMed:12799386}.
FT   DISULFID    240    301       {ECO:0000269|PubMed:12799386}.
FT   MUTAGEN     111    111       Y->C: Reduces protein solubility and
FT                                causes formation of an abnormal disulfide
FT                                bond between C-111 and C-139 in
FT                                approximately half of the molecules.
FT                                {ECO:0000269|PubMed:19052627}.
FT   MUTAGEN     111    111       Y->F: Causes a mild reduction of protein
FT                                solubility.
FT                                {ECO:0000269|PubMed:19052627}.
FT   MUTAGEN     111    111       Y->L,V: Strongly reduces protein
FT                                solubility.
FT                                {ECO:0000269|PubMed:19052627}.
FT   MUTAGEN     111    111       Y->S: Reduces protein solubility.
FT                                {ECO:0000269|PubMed:19052627}.
FT   STRAND       42     46       {ECO:0000244|PDB:3D4G}.
FT   STRAND       48     58       {ECO:0000244|PDB:3D4G}.
FT   STRAND       60     63       {ECO:0000244|PDB:3D4G}.
FT   HELIX        68     70       {ECO:0000244|PDB:3D4G}.
FT   STRAND       71     75       {ECO:0000244|PDB:3D4G}.
FT   STRAND       81     84       {ECO:0000244|PDB:3D4G}.
FT   STRAND       86     94       {ECO:0000244|PDB:3D4G}.
FT   HELIX        95     98       {ECO:0000244|PDB:3D4G}.
FT   STRAND      100    104       {ECO:0000244|PDB:3D4G}.
FT   STRAND      106    117       {ECO:0000244|PDB:3D4G}.
FT   STRAND      133    142       {ECO:0000244|PDB:3D4G}.
SQ   SEQUENCE   424 AA;  46304 MW;  9089903FBD268365 CRC64;
     MASSYFLFLC LLLCGGPELC NSQTLWLLPG GTPTPVGSSS PVKVECLEAE LVVTVSRDLF
     GTGKLVQPGD LTLGSEGCQP RVSVDTDVVR FNAQLHECSS RVQMTKDALV YSTFLLHDPR
     PVSGLSILRT NRVEVPIECR YPRQGNVSSH PIQPTWVPFR ATVSSEEKLA FSLRLMEENW
     NTEKSAPTFH LGEVAHLQAE VQTGSHLPLQ LFVDHCVATP SPLPDPNSSP YHFIVDFHGC
     LVDGLSESFS AFQVPRPRPE TLQFTVDVFH FANSSRNTLY ITCHLKVAPA NQIPDKLNKA
     CSFNKTSQSW LPVEGDADIC DCCSHGNCSN SSSSQFQIHG PRQWSKLVSR NRRHVTDEAD
     VTVGPLIFLG KANDQTVEGW TASAQTSVAL GLGLATVAFL TLAAIVLAVT RKCHSSSYLV
     SLPQ
//
ID   NOTC2_MOUSE             Reviewed;        2470 AA.
AC   O35516; Q06008; Q60941;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   17-FEB-2016, entry version 170.
DE   RecName: Full=Neurogenic locus notch homolog protein 2;
DE            Short=Notch 2;
DE   AltName: Full=Motch B;
DE   Contains:
DE     RecName: Full=Notch 2 extracellular truncation;
DE   Contains:
DE     RecName: Full=Notch 2 intracellular domain;
DE   Flags: Precursor;
GN   Name=Notch2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Thymus;
RA   Hamada Y., Higuchi M., Tsujimoto Y.;
RT   "Complete amino acid sequence and mutliform transcripts encoded by a
RT   single copy of mouse Notch2 gene.";
RL   Submitted (JUL-1994) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 316-1518.
RC   STRAIN=C57BL/6 X CBA; TISSUE=Embryo;
RX   PubMed=8440332; DOI=10.1006/excr.1993.1044;
RA   Lardelli M., Lendahl U.;
RT   "Motch A and Motch B-two mouse Notch homologues coexpressed in a wide
RT   variety of tissues.";
RL   Exp. Cell Res. 204:364-372(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1765-2153.
RX   PubMed=8917536; DOI=10.1073/pnas.93.23.13014;
RA   Milner L.A., Bigas A., Kopan R., Brashem-Stein C., Bernstein I.D.,
RA   Martin D.I.;
RT   "Inhibition of granulocytic differentiation by mNotch1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13014-13019(1996).
RN   [4]
RP   FUNCTION.
RX   PubMed=10393120;
RA   Hamada Y., Kadokawa Y., Okabe M., Ikawa M., Coleman J.R.,
RA   Tsujimoto Y.;
RT   "Mutation in ankyrin repeats of the mouse Notch2 gene induces early
RT   embryonic lethality.";
RL   Development 126:3415-3424(1999).
RN   [5]
RP   DEVELOPMENTAL STAGE, AND ALTERNATIVE SPLICING.
RX   PubMed=7609614; DOI=10.1016/0169-328X(94)00257-F;
RA   Higuchi M., Kiyama H., Hayakawa T., Hamada Y., Tsujimoto Y.;
RT   "Differential expression of Notch1 and Notch2 in developing and adult
RT   mouse brain.";
RL   Brain Res. Mol. Brain Res. 29:263-272(1995).
RN   [6]
RP   PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF MET-1699.
RX   PubMed=11518718; DOI=10.1074/jbc.M107234200;
RA   Saxena M.T., Schroeter E.H., Mumm J.S., Kopan R.;
RT   "Murine notch homologs (N1-4) undergo presenilin-dependent
RT   proteolysis.";
RL   J. Biol. Chem. 276:40268-40273(2001).
RN   [7]
RP   PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF MET-1699.
RX   PubMed=11459941; DOI=10.1073/pnas.161269998;
RA   Mizutani T., Taniguchi Y., Aoki T., Hashimoto N., Honjo T.;
RT   "Conservation of the biochemical mechanisms of signal transduction
RT   among mammalian Notch family members.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9026-9031(2001).
RN   [8]
RP   INTERACTION WITH MAML1.
RX   PubMed=15019995; DOI=10.1016/j.gene.2003.12.007;
RA   Wu L., Kobayashi K., Sun T., Gao P., Liu J., Nakamura M., Weisberg E.,
RA   Mukhopadhyay N.K., Griffin J.D.;
RT   "Cloning and functional characterization of the murine mastermind-like
RT   1 (Maml1) gene.";
RL   Gene 328:153-165(2004).
RN   [9]
RP   INTERACTION WITH HIF1AN.
RX   PubMed=17573339; DOI=10.1074/jbc.M704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by
RT   factor inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [10]
RP   FUNCTION AS POSITIVE REGULATOR OF OSTEOCLASTOGENESIS, AND INTERACTION
RP   WITH RELA.
RX   PubMed=18710934; DOI=10.1128/MCB.00299-08;
RA   Fukushima H., Nakao A., Okamoto F., Shin M., Kajiya H., Sakano S.,
RA   Bigas A., Jimi E., Okabe K.;
RT   "The association of Notch2 and NF-kappaB accelerates RANKL-induced
RT   osteoclastogenesis.";
RL   Mol. Cell. Biol. 28:6402-6412(2008).
RN   [11]
RP   HYDROXYLATION BY HIF1AN.
RX   PubMed=18299578; DOI=10.1073/pnas.0711591105;
RA   Zheng X., Linke S., Dias J.M., Zheng X., Gradin K., Wallis T.P.,
RA   Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L.,
RA   Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J.,
RA   Peet D.J., Lendahl U., Poellinger L.;
RT   "Interaction with factor inhibiting HIF-1 defines an additional mode
RT   of cross-coupling between the Notch and hypoxia signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3368-3373(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1777; SER-1840 AND
RP   SER-1843, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Kidney, and Liver;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [14]
RP   GLYCOSYLATION AT SER-611, AND MUTAGENESIS OF SER-612.
RX   PubMed=21949356; DOI=10.1073/pnas.1109696108;
RA   Takeuchi H., Fernandez-Valdivia R.C., Caswell D.S., Nita-Lazar A.,
RA   Rana N.A., Garner T.P., Weldeghiorghis T.K., Macnaughtan M.A.,
RA   Jafar-Nejad H., Haltiwanger R.S.;
RT   "Rumi functions as both a protein O-glucosyltransferase and a protein
RT   O-xylosyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:16600-16605(2011).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands
CC       Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
CC       Upon ligand activation through the released notch intracellular
CC       domain (NICD) it forms a transcriptional activator complex with
CC       RBPJ/RBPSUH and activates genes of the enhancer of split locus.
CC       Affects the implementation of differentiation, proliferation and
CC       apoptotic programs (By similarity). May play an essential role in
CC       postimplantation development, probably in some aspect of cell
CC       specification and/or differentiation. In collaboration with
CC       RELA/p65 enhances NFATc1 promoter activity and positively
CC       regulates RANKL-induced osteoclast differentiation. Positively
CC       regulates self-renewal of liver cancer cells (By similarity).
CC       {ECO:0000250|UniProtKB:Q04721, ECO:0000269|PubMed:10393120,
CC       ECO:0000269|PubMed:18710934}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-
CC       terminal fragment N(EC) which are probably linked by disulfide
CC       bonds. Interacts with MAML1, MAML2 and MAML3 which act as
CC       transcriptional coactivators for NOTCH2. Interacts with RELA/p65.
CC       Interacts with HIF1AN. Interacts (via ANK repeats) with
CC       C8orf4/TC1, the interaction inhibits the nuclear translocation of
CC       NOTCH2 N2ICD (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q04721, ECO:0000269|PubMed:15019995,
CC       ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:18710934}.
CC   -!- SUBCELLULAR LOCATION: Notch 2 extracellular truncation: Cell
CC       membrane {ECO:0000250|UniProtKB:Q04721}; Single-pass type I
CC       membrane protein {ECO:0000250|UniProtKB:Q04721}.
CC   -!- SUBCELLULAR LOCATION: Notch 2 intracellular domain: Nucleus
CC       {ECO:0000250|UniProtKB:Q04721}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q04721}. Note=Following proteolytical
CC       processing NICD is translocated to the nucleus. Retained at the
CC       cytoplasm by C8orf4/TC1. {ECO:0000250|UniProtKB:Q04721}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O35516-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O35516-2; Sequence=VSP_001405;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, liver, kidney,
CC       neuroepithelia, somites, optic vesicles and branchial arches, but
CC       not heart.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the embryonic ventricular zone,
CC       the postnatal ependymal cells, and the choroid plexus throughout
CC       embryonic and postnatal development. {ECO:0000269|PubMed:7609614}.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form
CC       which is proteolytically cleaved by a furin-like convertase in the
CC       trans-Golgi network before it reaches the plasma membrane to yield
CC       an active, ligand-accessible form. Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by TNF-alpha converting enzyme
CC       (TACE) to yield a membrane-associated intermediate fragment called
CC       notch extracellular truncation (NEXT). This fragment is then
CC       cleaved by presenilin dependent gamma-secretase to release a
CC       notch-derived peptide containing the intracellular domain (NICD)
CC       from the membrane. {ECO:0000269|PubMed:11459941,
CC       ECO:0000269|PubMed:11518718}.
CC   -!- PTM: Hydroxylated by HIF1AN. {ECO:0000269|PubMed:18299578}.
CC   -!- PTM: Can be either O-glucosylated or O-xylosylated at Ser-611 by
CC       POGLUT1.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 6 ANK repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00023}.
CC   -!- SIMILARITY: Contains 35 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 LNR (Lin/Notch) repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00525}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D32210; BAA22094.1; -; mRNA.
DR   EMBL; X68279; CAA48340.1; -; mRNA.
DR   EMBL; U31881; AAC52924.1; -; mRNA.
DR   PIR; A49175; A49175.
DR   RefSeq; NP_035058.2; NM_010928.2.
DR   UniGene; Mm.485843; -.
DR   ProteinModelPortal; O35516; -.
DR   SMR; O35516; 413-531, 1423-1669, 1870-2061.
DR   BioGrid; 201809; 5.
DR   DIP; DIP-6008N; -.
DR   IntAct; O35516; 2.
DR   STRING; 10090.ENSMUSP00000078741; -.
DR   iPTMnet; O35516; -.
DR   PhosphoSite; O35516; -.
DR   MaxQB; O35516; -.
DR   PaxDb; O35516; -.
DR   PRIDE; O35516; -.
DR   GeneID; 18129; -.
DR   KEGG; mmu:18129; -.
DR   CTD; 4853; -.
DR   MGI; MGI:97364; Notch2.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   HOGENOM; HOG000234369; -.
DR   HOVERGEN; HBG052650; -.
DR   InParanoid; O35516; -.
DR   KO; K02599; -.
DR   PhylomeDB; O35516; -.
DR   ChiTaRS; Notch2; mouse.
DR   NextBio; 293360; -.
DR   PRO; PR:O35516; -.
DR   Proteomes; UP000000589; Unplaced.
DR   CleanEx; MM_NOTCH2; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005929; C:cilium; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0051059; F:NF-kappaB binding; IPI:UniProtKB.
DR   GO; GO:0060413; P:atrial septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0046849; P:bone remodeling; ISO:MGI.
DR   GO; GO:0007050; P:cell cycle arrest; ISS:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; TAS:UniProtKB.
DR   GO; GO:0016049; P:cell growth; ISS:UniProtKB.
DR   GO; GO:1990705; P:cholangiocyte proliferation; IMP:MGI.
DR   GO; GO:0061073; P:ciliary body morphogenesis; IMP:MGI.
DR   GO; GO:0042742; P:defense response to bacterium; IMP:MGI.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IGI:MGI.
DR   GO; GO:0072104; P:glomerular capillary formation; IEP:UniProtKB.
DR   GO; GO:0072015; P:glomerular visceral epithelial cell development; IEP:UniProtKB.
DR   GO; GO:0001947; P:heart looping; IGI:BHF-UCL.
DR   GO; GO:0072574; P:hepatocyte proliferation; IMP:MGI.
DR   GO; GO:0006959; P:humoral immune response; IGI:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IGI:MGI.
DR   GO; GO:0072602; P:interleukin-4 secretion; IGI:MGI.
DR   GO; GO:0035622; P:intrahepatic bile duct development; IMP:MGI.
DR   GO; GO:0070986; P:left/right axis specification; IGI:BHF-UCL.
DR   GO; GO:0001889; P:liver development; IMP:MGI.
DR   GO; GO:0072576; P:liver morphogenesis; IMP:MGI.
DR   GO; GO:0002315; P:marginal zone B cell differentiation; IMP:UniProtKB.
DR   GO; GO:0002011; P:morphogenesis of an epithelial sheet; IMP:MGI.
DR   GO; GO:0035264; P:multicellular organism growth; IMP:MGI.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IMP:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0007219; P:Notch signaling pathway; ISS:UniProtKB.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:UniProtKB.
DR   GO; GO:0060674; P:placenta blood vessel development; IMP:MGI.
DR   GO; GO:0001890; P:placenta development; IMP:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IGI:MGI.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IMP:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IDA:UniProtKB.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0072014; P:proximal tubule development; IEP:UniProtKB.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; ISO:MGI.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; IDA:UniProtKB.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR022336; Notch_2.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 25.
DR   Pfam; PF07645; EGF_CA; 5.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01985; NOTCH2.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00181; EGF; 12.
DR   SMART; SM00179; EGF_CA; 23.
DR   SMART; SM00004; NL; 3.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 5.
DR   SUPFAM; SSF90193; SSF90193; 2.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 33.
DR   PROSITE; PS01186; EGF_2; 27.
DR   PROSITE; PS50026; EGF_3; 35.
DR   PROSITE; PS01187; EGF_CA; 22.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; ANK repeat; Cell membrane;
KW   Complete proteome; Cytoplasm; Developmental protein; Differentiation;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Membrane;
KW   Notch signaling pathway; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transcription;
KW   Transcription regulation; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26   2470       Neurogenic locus notch homolog protein 2.
FT                                /FTId=PRO_0000007686.
FT   CHAIN      1666   2470       Notch 2 extracellular truncation.
FT                                /FTId=PRO_0000007687.
FT   CHAIN      1697   2470       Notch 2 intracellular domain.
FT                                /FTId=PRO_0000007688.
FT   TOPO_DOM     26   1677       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1678   1698       Helical. {ECO:0000255}.
FT   TOPO_DOM   1699   2470       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       26     63       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       64    102       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      105    143       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      144    180       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      182    219       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      221    256       EGF-like 6; incomplete.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      258    294       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      296    334       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      336    372       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      373    411       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      413    452       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      454    490       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      492    528       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      530    566       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      568    603       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      605    641       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      643    678       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      680    716       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      718    753       EGF-like 19. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      755    791       EGF-like 20; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      793    829       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      831    869       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      871    907       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      909    945       EGF-like 24; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      947    983       EGF-like 25; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      985   1021       EGF-like 26; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1023   1059       EGF-like 27; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1061   1097       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1099   1145       EGF-like 29. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1147   1183       EGF-like 30; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1185   1221       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1223   1260       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1262   1300       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1302   1345       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1372   1410       EGF-like 35. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1423   1463       LNR 1.
FT   REPEAT     1464   1500       LNR 2.
FT   REPEAT     1501   1542       LNR 3.
FT   REPEAT     1825   1869       ANK 1.
FT   REPEAT     1874   1903       ANK 2.
FT   REPEAT     1907   1937       ANK 3.
FT   REPEAT     1941   1970       ANK 4.
FT   REPEAT     1974   2003       ANK 5.
FT   REPEAT     2007   2036       ANK 6.
FT   REGION     1423   1677       Negative regulatory region (NRR).
FT                                {ECO:0000250}.
FT   COMPBIAS   1645   1648       Poly-Ala.
FT   COMPBIAS   1992   1995       Poly-Leu.
FT   COMPBIAS   2183   2189       Poly-Ala.
FT   COMPBIAS   2425   2428       Poly-Ser.
FT   COMPBIAS   2445   2450       Poly-Gly.
FT   SITE        612    612       Essential for O-xylosylation.
FT   MOD_RES    1715   1715       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q04721}.
FT   MOD_RES    1777   1777       Phosphoserine.
FT                                {ECO:0000244|PubMed:19144319}.
FT   MOD_RES    1800   1800       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q04721}.
FT   MOD_RES    1802   1802       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q04721}.
FT   MOD_RES    1806   1806       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q04721}.
FT   MOD_RES    1840   1840       Phosphoserine.
FT                                {ECO:0000244|PubMed:19144319}.
FT   MOD_RES    1843   1843       Phosphoserine.
FT                                {ECO:0000244|PubMed:19144319}.
FT   MOD_RES    2068   2068       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q04721}.
FT   MOD_RES    2076   2076       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QW30}.
FT   MOD_RES    2079   2079       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q04721}.
FT   MOD_RES    2095   2095       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q04721}.
FT   CARBOHYD     46     46       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    155    155       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    611    611       O-linked (Glc...); alternate.
FT                                {ECO:0000269|PubMed:21949356}.
FT   CARBOHYD    611    611       O-linked (Xyl...); alternate.
FT                                {ECO:0000269|PubMed:21949356}.
FT   CARBOHYD    731    731       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1100   1100       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1463   1463       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     28     41       {ECO:0000250}.
FT   DISULFID     35     51       {ECO:0000250}.
FT   DISULFID     53     62       {ECO:0000250}.
FT   DISULFID     68     79       {ECO:0000250}.
FT   DISULFID     73     90       {ECO:0000250}.
FT   DISULFID     92    101       {ECO:0000250}.
FT   DISULFID    109    121       {ECO:0000250}.
FT   DISULFID    115    131       {ECO:0000250}.
FT   DISULFID    133    142       {ECO:0000250}.
FT   DISULFID    148    159       {ECO:0000250}.
FT   DISULFID    153    168       {ECO:0000250}.
FT   DISULFID    170    179       {ECO:0000250}.
FT   DISULFID    186    198       {ECO:0000250}.
FT   DISULFID    192    207       {ECO:0000250}.
FT   DISULFID    209    218       {ECO:0000250}.
FT   DISULFID    228    244       {ECO:0000250}.
FT   DISULFID    246    255       {ECO:0000250}.
FT   DISULFID    262    273       {ECO:0000250}.
FT   DISULFID    267    282       {ECO:0000250}.
FT   DISULFID    284    293       {ECO:0000250}.
FT   DISULFID    300    313       {ECO:0000250}.
FT   DISULFID    307    322       {ECO:0000250}.
FT   DISULFID    324    333       {ECO:0000250}.
FT   DISULFID    340    351       {ECO:0000250}.
FT   DISULFID    345    360       {ECO:0000250}.
FT   DISULFID    362    371       {ECO:0000250}.
FT   DISULFID    377    388       {ECO:0000250}.
FT   DISULFID    382    399       {ECO:0000250}.
FT   DISULFID    401    410       {ECO:0000250}.
FT   DISULFID    417    431       {ECO:0000250}.
FT   DISULFID    425    440       {ECO:0000250}.
FT   DISULFID    442    451       {ECO:0000250}.
FT   DISULFID    458    469       {ECO:0000250}.
FT   DISULFID    463    478       {ECO:0000250}.
FT   DISULFID    480    489       {ECO:0000250}.
FT   DISULFID    496    507       {ECO:0000250}.
FT   DISULFID    501    516       {ECO:0000250}.
FT   DISULFID    518    527       {ECO:0000250}.
FT   DISULFID    534    545       {ECO:0000250}.
FT   DISULFID    539    554       {ECO:0000250}.
FT   DISULFID    556    565       {ECO:0000250}.
FT   DISULFID    572    582       {ECO:0000250}.
FT   DISULFID    577    591       {ECO:0000250}.
FT   DISULFID    593    602       {ECO:0000250}.
FT   DISULFID    609    620       {ECO:0000250}.
FT   DISULFID    614    629       {ECO:0000250}.
FT   DISULFID    631    640       {ECO:0000250}.
FT   DISULFID    647    657       {ECO:0000250}.
FT   DISULFID    652    666       {ECO:0000250}.
FT   DISULFID    668    677       {ECO:0000250}.
FT   DISULFID    684    695       {ECO:0000250}.
FT   DISULFID    689    704       {ECO:0000250}.
FT   DISULFID    706    715       {ECO:0000250}.
FT   DISULFID    722    732       {ECO:0000250}.
FT   DISULFID    727    741       {ECO:0000250}.
FT   DISULFID    743    752       {ECO:0000250}.
FT   DISULFID    759    770       {ECO:0000250}.
FT   DISULFID    764    779       {ECO:0000250}.
FT   DISULFID    781    790       {ECO:0000250}.
FT   DISULFID    797    808       {ECO:0000250}.
FT   DISULFID    802    817       {ECO:0000250}.
FT   DISULFID    819    828       {ECO:0000250}.
FT   DISULFID    835    846       {ECO:0000250}.
FT   DISULFID    840    857       {ECO:0000250}.
FT   DISULFID    859    868       {ECO:0000250}.
FT   DISULFID    875    886       {ECO:0000250}.
FT   DISULFID    880    895       {ECO:0000250}.
FT   DISULFID    897    906       {ECO:0000250}.
FT   DISULFID    913    924       {ECO:0000250}.
FT   DISULFID    918    933       {ECO:0000250}.
FT   DISULFID    935    944       {ECO:0000250}.
FT   DISULFID    951    962       {ECO:0000250}.
FT   DISULFID    956    971       {ECO:0000250}.
FT   DISULFID    973    982       {ECO:0000250}.
FT   DISULFID    989   1000       {ECO:0000250}.
FT   DISULFID    994   1009       {ECO:0000250}.
FT   DISULFID   1011   1020       {ECO:0000250}.
FT   DISULFID   1027   1038       {ECO:0000250}.
FT   DISULFID   1032   1047       {ECO:0000250}.
FT   DISULFID   1049   1058       {ECO:0000250}.
FT   DISULFID   1065   1076       {ECO:0000250}.
FT   DISULFID   1070   1085       {ECO:0000250}.
FT   DISULFID   1087   1096       {ECO:0000250}.
FT   DISULFID   1103   1124       {ECO:0000250}.
FT   DISULFID   1118   1133       {ECO:0000250}.
FT   DISULFID   1135   1144       {ECO:0000250}.
FT   DISULFID   1151   1162       {ECO:0000250}.
FT   DISULFID   1156   1171       {ECO:0000250}.
FT   DISULFID   1173   1182       {ECO:0000250}.
FT   DISULFID   1189   1200       {ECO:0000250}.
FT   DISULFID   1194   1209       {ECO:0000250}.
FT   DISULFID   1211   1220       {ECO:0000250}.
FT   DISULFID   1227   1239       {ECO:0000250}.
FT   DISULFID   1233   1248       {ECO:0000250}.
FT   DISULFID   1250   1259       {ECO:0000250}.
FT   DISULFID   1266   1279       {ECO:0000250}.
FT   DISULFID   1271   1288       {ECO:0000250}.
FT   DISULFID   1290   1299       {ECO:0000250}.
FT   DISULFID   1306   1317       {ECO:0000250}.
FT   DISULFID   1311   1329       {ECO:0000250}.
FT   DISULFID   1331   1344       {ECO:0000250}.
FT   DISULFID   1376   1387       {ECO:0000250}.
FT   DISULFID   1381   1398       {ECO:0000250}.
FT   DISULFID   1400   1409       {ECO:0000250}.
FT   DISULFID   1423   1446       {ECO:0000250}.
FT   DISULFID   1428   1441       {ECO:0000250}.
FT   DISULFID   1437   1453       {ECO:0000250}.
FT   DISULFID   1464   1487       {ECO:0000250}.
FT   DISULFID   1470   1482       {ECO:0000250}.
FT   DISULFID   1478   1494       {ECO:0000250}.
FT   DISULFID   1501   1525       {ECO:0000250}.
FT   DISULFID   1507   1520       {ECO:0000250}.
FT   DISULFID   1516   1532       {ECO:0000250}.
FT   DISULFID   1632   1639       {ECO:0000250}.
FT   VAR_SEQ    1302   1508       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_001405.
FT   MUTAGEN     612    612       S->A: No effect on O-glycosylation by
FT                                POGLUT1. Loss of O-xylosylation.
FT                                {ECO:0000269|PubMed:21949356}.
FT   MUTAGEN    1699   1699       M->L: No effect on NICD processing.
FT                                {ECO:0000269|PubMed:11459941,
FT                                ECO:0000269|PubMed:11518718}.
FT   MUTAGEN    1699   1699       M->V: Decreased NICD processing.
FT                                {ECO:0000269|PubMed:11459941,
FT                                ECO:0000269|PubMed:11518718}.
FT   CONFLICT   1340   1340       L -> C (in Ref. 2; CAA48340).
FT                                {ECO:0000305}.
FT   CONFLICT   1798   1798       S -> R (in Ref. 3; AAC52924).
FT                                {ECO:0000305}.
FT   CONFLICT   1901   1901       R -> A (in Ref. 3; AAC52924).
FT                                {ECO:0000305}.
FT   CONFLICT   1918   1918       G -> A (in Ref. 3; AAC52924).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2470 AA;  265327 MW;  B55A31B35242716D CRC64;
     MPDLRPAALR ALLWLWLCGA GPAHALQCRG GQEPCVNEGT CVTYHNGTGF CRCPEGFLGE
     YCQHRDPCEK NRCQNGGTCV PQGMLGKATC RCAPGFTGED CQYSTSHPCF VSRPCQNGGT
     CHMLSRDTYE CTCQVGFTGK QCQWTDACLS HPCENGSTCT SVASQFSCKC PAGLTGQKCE
     ADINECDIPG RCQHGGTCLN LPGSYRCQCG QGFTGQHCDS PYVRGLPCVN GGTCRQTGDF
     TLECNCLPGF EGSTCERNID DCPNHKCQNG GVCVDGVNTY NCRCPPQWTG QFCTEDVDEC
     LLQPNACQNG GTCTNRNGGY GCVCVNGWSG DDCSENIDDC AYASCTPGST CIDRVASFSC
     LCPEGKAGLL CHLDDACISN PCHKGALCDT NPLNGQYICT CPQGYKGADC TEDVDECAMA
     NSNPCEHAGK CVNTDGAFHC ECLKGYAGPR CEMDINECHS DPCQNDATCL DKIGGFTCLC
     MPGFKGVHCE LEVNECQSNP CVNNGQCVDK VNRFQCLCPP GFTGPVCQID IDDCSSTPCL
     NGAKCIDHPN GYECQCATGF TGILCDENID NCDPDPCHHG QCQDGIDSYT CICNPGYMGA
     ICSDQIDECY SSPCLNDGRC IDLVNGYQCN CQPGTSGLNC EINFDDCASN PCMHGVCVDG
     INRYSCVCSP GFTGQRCNID IDECASNPCR KGATCINDVN GFRCICPEGP HHPSCYSQVN
     ECLSNPCIHG NCTGGLSGYK CLCDAGWVGV NCEVDKNECL SNPCQNGGTC NNLVNGYRCT
     CKKGFKGYNC QVNIDECASN PCLNQGTCFD DVSGYTCHCM LPYTGKNCQT VLAPCSPNPC
     ENAAVCKEAP NFESFSCLCA PGWQGKRCTV DVDECISKPC MNNGVCHNTQ GSYVCECPPG
     FSGMDCEEDI NDCLANPCQN GGSCVDHVNT FSCQCHPGFI GDKCQTDMNE CLSEPCKNGG
     TCSDYVNSYT CTCPAGFHGV HCENNIDECT ESSCFNGGTC VDGINSFSCL CPVGFTGPFC
     LHDINECSSN PCLNAGTCVD GLGTYRCICP LGYTGKNCQT LVNLCSRSPC KNKGTCVQEK
     ARPHCLCPPG WDGAYCDVLN VSCKAAALQK GVPVEHLCQH SGICINAGNT HHCQCPLGYT
     GSYCEEQLDE CASNPCQHGA TCNDFIGGYR CECVPGYQGV NCEYEVDECQ NQPCQNGGTC
     IDLVNHFKCS CPPGTRGLLC EENIDECAGG PHCLNGGQCV DRIGGYTCRC LPGFAGERCE
     GDINECLSNP CSSEGSLDCV QLKNNYNCIC RSAFTGRHCE TFLDVCPQKP CLNGGTCAVA
     SNMPDGFICR CPPGFSGARL QSSCGQVKCR RGEQCIHTDS GPRCFCLNPK DCESGCASNP
     CQHGGTCYPQ RQPPHYSCRC PPSFGGSHCE LYTAPTSTPP ATCQSQYCAD KARDGICDEA
     CNSHACQWDG GDCSLTMEDP WANCTSTLRC WEYINNQCDE QCNTAECLFD NFECQRNSKT
     CKYDKYCADH FKDNHCDQGC NSEECGWDGL DCASDQPENL AEGTLIIVVL LPPEQLLQDS
     RSFLRALGTL LHTNLRIKQD SQGALMVYPY FGEKSAAMKK QKMTRRSLPE EQEQEQEVIG
     SKIFLEIDNR QCVQDSDQCF KNTDAAAALL ASHAIQGTLS YPLVSVFSEL ESPRNAQLLY
     LLAVAVVIIL FFILLGVIMA KRKQAWLPLA AGRFTLRRDS SNHKRREPVG QDAVGLKNLS
     VQVSEANLIG SGTSEHWVDD EGPQPKKAKA EDEALLSEDD PIDRRPWTQQ HLEAADISHT
     PSLALTPPQA EQEVDVLDVN VRGPDGCTPL MLASLRGGSS DLSDEDEDAE DSSANIITDL
     VYQGASLQAQ TDRTGEMALH LAARYSRADA AKRLLDAGAD RNAQDNMGRC PLHAAVAGDA
     QGVFQILIRN RVTDLDARMN DGTTPLILAA RLAVEGMVAE LINCQADVNA VDDHGKSALH
     WAAAVNNVEA TLLLLKNGAN RDMQDNKEET PLFLAAREGS YEAAKILLDH FANRDITDHM
     DRLPRDVARD RMHHDIVRLL DEYNVTPSPP GTVLTSALSP VLCGPNRSFL SLKHTPMGKK
     ARRPNTKSTM PTSLPNLAKE AKDAKGSRRK KCLNEKVQLS ESSVTLSPVD SLESPHTYVS
     DATSSPMITS PGILQASPTP LLAAAAPAAP VHTQHALSFS NLHDMQPLAP GASTVLPSVS
     QLLSHHHIAP PGSSSAGSLG RLHPVPVPAD WMNRVEMNET QYSEMFGMVL APAEGAHPGI
     AAPQSRPPEG KHMSTQREPL PPIVTFQLIP KRSIAQAAGA PQTQSSCPPA VAGPLPSMYQ
     IPEMPRLPSV AFPPTMMPQQ EGQVAQTIVP TYHPFPASVG KYPTPPSQHS YASSNAAERT
     PSHGGHLQGE HPYLTPSPES PDQWSSSSPH SASDWSDVTT SPTPGGGGGG QRGPGTHMSE
     PPHSNMQVYA
//
ID   PDGFA_HUMAN             Reviewed;         211 AA.
AC   P04085; B5BU73;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   17-FEB-2016, entry version 169.
DE   RecName: Full=Platelet-derived growth factor subunit A;
DE            Short=PDGF subunit A;
DE   AltName: Full=PDGF-1;
DE   AltName: Full=Platelet-derived growth factor A chain;
DE   AltName: Full=Platelet-derived growth factor alpha polypeptide;
DE   Flags: Precursor;
GN   Name=PDGFA; Synonyms=PDGF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3422746; DOI=10.1073/pnas.85.5.1492;
RA   Bonthron D.T., Morton C.C., Orkin S.H., Collins T.;
RT   "Platelet-derived growth factor A chain: gene structure, chromosomal
RT   location, and basis for alternative mRNA splicing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1492-1496(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2832727;
RA   Rorsman F., Bywater M., Knott T.J., Scott J., Betsholtz C.;
RT   "Structural characterization of the human platelet-derived growth
RT   factor A-chain cDNA and gene: alternative exon usage predicts two
RT   different precursor proteins.";
RL   Mol. Cell. Biol. 8:571-577(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3754619; DOI=10.1038/320695a0;
RA   Betsholtz C., Johnsson A., Heldin C.H., Westermark B., Lind P.,
RA   Urdea M.S., Eddy R., Shows T.B., Philpott K., Mellor A.L., Knott T.J.,
RA   Scott J.;
RT   "cDNA sequence and chromosomal localization of human platelet-derived
RT   growth factor A-chain and its expression in tumour cell lines.";
RL   Nature 320:695-699(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3666150; DOI=10.1016/0014-5793(87)80297-1;
RA   Hoppe J., Schumacher L., Eichner W., Weich H.A.;
RT   "The long 3'-untranslated regions of the PDGF-A and -B mRNAs are only
RT   distantly related.";
RL   FEBS Lett. 223:243-246(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-53.
RX   PubMed=8486521;
RA   Takimoto Y., Li W.Y., Wang Z.Y., Tong B.D., Deuel T.F.;
RT   "Nucleotide sequence of the 5' region of the human platelet-derived
RT   growth factor A-chain gene.";
RL   Hiroshima J. Med. Sci. 42:47-52(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 152-211.
RX   PubMed=1612586; DOI=10.1016/0888-7543(92)90240-S;
RA   Bonthron D., Collins T., Grzeschik K.H., van Roy N., Speleman F.;
RT   "Platelet-derived growth factor A chain: confirmation of localization
RT   of PDGFA to chromosome 7p22 and description of an unusual
RT   minisatellite.";
RL   Genomics 13:257-263(1992).
RN   [9]
RP   ALTERNATIVE SPLICING.
RX   PubMed=3614363; DOI=10.1038/328619a0;
RA   Tong B.D., Auer D.E., Jaye M., Kaplow J.M., Ricca G., McConathy E.,
RA   Drohan W., Deuel T.F.;
RT   "cDNA clones reveal differences between human glial and endothelial
RT   cell platelet-derived growth factor A-chains.";
RL   Nature 328:619-621(1987).
RN   [10]
RP   ALTERNATIVE SPLICING.
RX   PubMed=3614364; DOI=10.1038/328621a0;
RA   Collins T., Bonthron D.T., Orkin S.H.;
RT   "Alternative RNA splicing affects function of encoded platelet-derived
RT   growth factor A chain.";
RL   Nature 328:621-624(1987).
RN   [11]
RP   INTERCHAIN DISULFIDE BONDS.
RX   PubMed=1317862;
RA   Andersson M., Oestman A., Baeckstroem G., Hellman U.,
RA   George-Nascimento C., Westermark B., Heldin C.-H.;
RT   "Assignment of interchain disulfide bonds in platelet-derived growth
RT   factor (PDGF) and evidence for agonist activity of monomeric PDGF.";
RL   J. Biol. Chem. 267:11260-11266(1992).
RN   [12]
RP   INTERACTION WITH CSPG4.
RX   PubMed=10358027; DOI=10.1074/jbc.274.24.16831;
RA   Goretzki L., Burg M.A., Grako K.A., Stallcup W.B.;
RT   "High-affinity binding of basic fibroblast growth factor and platelet-
RT   derived growth factor-AA to the core protein of the NG2
RT   proteoglycan.";
RL   J. Biol. Chem. 274:16831-16837(1999).
RN   [13]
RP   REVIEW ON FUNCTION IN DEVELOPMENT AND DISEASE.
RX   PubMed=18483217; DOI=10.1101/gad.1653708;
RA   Andrae J., Gallini R., Betsholtz C.;
RT   "Role of platelet-derived growth factors in physiology and medicine.";
RL   Genes Dev. 22:1276-1312(2008).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 21-181, AND DISULFIDE BONDS.
RX   PubMed=20534510; DOI=10.1073/pnas.1000806107;
RA   Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.;
RT   "Structures of a platelet-derived growth factor/propeptide complex and
RT   a platelet-derived growth factor/receptor complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010).
CC   -!- FUNCTION: Growth factor that plays an essential role in the
CC       regulation of embryonic development, cell proliferation, cell
CC       migration, survival and chemotaxis. Potent mitogen for cells of
CC       mesenchymal origin. Required for normal lung alveolar septum
CC       formation during embryogenesis, normal development of the
CC       gastrointestinal tract, normal development of Leydig cells and
CC       spermatogenesis. Required for normal oligodendrocyte development
CC       and normal myelination in the spinal cord and cerebellum. Plays an
CC       important role in wound healing. Signaling is modulated by the
CC       formation of heterodimers with PDGFB (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer; antiparallel disulfide-linked dimer.
CC       Heterodimer with PDGFB; antiparallel disulfide-linked dimer. The
CC       PDGFA homodimer interacts with PDGFRA homodimers, and with
CC       heterodimers formed by PDGFRA and PDGFRB. The heterodimer composed
CC       of PDGFA and PDGFB interacts with PDGFRA homodimers, and with
CC       heterodimers formed by PDGFRA and PDGFRB. Interacts with CSPG4.
CC       {ECO:0000269|PubMed:10358027, ECO:0000269|PubMed:20534510}.
CC   -!- INTERACTION:
CC       P16234:PDGFRA; NbExp=6; IntAct=EBI-2881386, EBI-2861522;
CC   -!- SUBCELLULAR LOCATION: Secreted. Note=Released by platelets upon
CC       wounding.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P04085-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P04085-2; Sequence=VSP_004602, VSP_004603;
CC   -!- DOMAIN: The long form contains a basic insert which acts as a cell
CC       retention signal.
CC   -!- SIMILARITY: Belongs to the PDGF/VEGF growth factor family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=R&D Systems' cytokine mini-reviews: PDGF;
CC       URL="http://www.rndsystems.com/molecule_detail.aspx?m=1967";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03795; CAA27421.1; -; mRNA.
DR   EMBL; X06374; CAA29677.1; -; mRNA.
DR   EMBL; M20494; AAA60045.1; -; Genomic_DNA.
DR   EMBL; M20488; AAA60045.1; JOINED; Genomic_DNA.
DR   EMBL; M20489; AAA60045.1; JOINED; Genomic_DNA.
DR   EMBL; M20490; AAA60045.1; JOINED; Genomic_DNA.
DR   EMBL; M20491; AAA60045.1; JOINED; Genomic_DNA.
DR   EMBL; M20492; AAA60045.1; JOINED; Genomic_DNA.
DR   EMBL; M20493; AAA60045.1; JOINED; Genomic_DNA.
DR   EMBL; M19988; AAA60046.1; -; Genomic_DNA.
DR   EMBL; M21571; AAA60046.1; JOINED; Genomic_DNA.
DR   EMBL; M19984; AAA60046.1; JOINED; Genomic_DNA.
DR   EMBL; M19985; AAA60046.1; JOINED; Genomic_DNA.
DR   EMBL; M19986; AAA60046.1; JOINED; Genomic_DNA.
DR   EMBL; M19987; AAA60046.1; JOINED; Genomic_DNA.
DR   EMBL; M19989; AAA60047.1; -; Genomic_DNA.
DR   EMBL; M21571; AAA60047.1; JOINED; Genomic_DNA.
DR   EMBL; M19984; AAA60047.1; JOINED; Genomic_DNA.
DR   EMBL; M19985; AAA60047.1; JOINED; Genomic_DNA.
DR   EMBL; M19986; AAA60047.1; JOINED; Genomic_DNA.
DR   EMBL; M19987; AAA60047.1; JOINED; Genomic_DNA.
DR   EMBL; AB451309; BAG70123.1; -; mRNA.
DR   EMBL; AB451439; BAG70253.1; -; mRNA.
DR   EMBL; AC147651; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S62078; AAB26566.1; -; Genomic_DNA.
DR   CCDS; CCDS34578.1; -. [P04085-1]
DR   CCDS; CCDS47524.1; -. [P04085-2]
DR   PIR; A28964; PFHUG1.
DR   PIR; B28964; B28964.
DR   RefSeq; NP_002598.4; NM_002607.5. [P04085-1]
DR   RefSeq; NP_148983.1; NM_033023.4. [P04085-2]
DR   UniGene; Hs.535898; -.
DR   PDB; 3MJK; X-ray; 2.40 A; A/B/E/F/X/Y=21-181.
DR   PDBsum; 3MJK; -.
DR   ProteinModelPortal; P04085; -.
DR   SMR; P04085; 23-182.
DR   BioGrid; 111180; 11.
DR   DIP; DIP-5735N; -.
DR   IntAct; P04085; 3.
DR   STRING; 9606.ENSP00000346508; -.
DR   BindingDB; P04085; -.
DR   ChEMBL; CHEMBL3137294; -.
DR   PhosphoSite; P04085; -.
DR   BioMuta; PDGFA; -.
DR   PaxDb; P04085; -.
DR   PRIDE; P04085; -.
DR   DNASU; 5154; -.
DR   Ensembl; ENST00000354513; ENSP00000346508; ENSG00000197461. [P04085-1]
DR   Ensembl; ENST00000402802; ENSP00000383889; ENSG00000197461. [P04085-2]
DR   GeneID; 5154; -.
DR   KEGG; hsa:5154; -.
DR   UCSC; uc003sir.3; human. [P04085-1]
DR   UCSC; uc003sis.3; human. [P04085-2]
DR   CTD; 5154; -.
DR   GeneCards; PDGFA; -.
DR   H-InvDB; HIX0167622; -.
DR   HGNC; HGNC:8799; PDGFA.
DR   HPA; CAB005579; -.
DR   MIM; 173430; gene.
DR   neXtProt; NX_P04085; -.
DR   PharmGKB; PA33144; -.
DR   eggNOG; ENOG410IEXJ; Eukaryota.
DR   eggNOG; ENOG4111GMH; LUCA.
DR   GeneTree; ENSGT00510000046755; -.
DR   HOGENOM; HOG000286027; -.
DR   HOVERGEN; HBG053546; -.
DR   InParanoid; P04085; -.
DR   KO; K04359; -.
DR   OMA; HASKHAP; -.
DR   OrthoDB; EOG78H3VV; -.
DR   PhylomeDB; P04085; -.
DR   TreeFam; TF319554; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P04085; -.
DR   EvolutionaryTrace; P04085; -.
DR   GeneWiki; PDGFA; -.
DR   GenomeRNAi; 5154; -.
DR   NextBio; 19930; -.
DR   PRO; PR:P04085; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; P04085; -.
DR   CleanEx; HS_PDGFA; -.
DR   ExpressionAtlas; P04085; baseline and differential.
DR   Genevisible; P04085; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005902; C:microvillus; ISS:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005518; F:collagen binding; IDA:MGI.
DR   GO; GO:0008083; F:growth factor activity; IDA:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0001775; P:cell activation; TAS:BHF-UCL.
DR   GO; GO:0030031; P:cell projection assembly; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:1990401; P:embryonic lung development; ISS:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001942; P:hair follicle development; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048286; P:lung alveolus development; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0050919; P:negative chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0010512; P:negative regulation of phosphatidylinositol biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:BHF-UCL.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0009887; P:organ morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051781; P:positive regulation of cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB.
DR   GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; TAS:BHF-UCL.
DR   GO; GO:0060683; P:regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling; ISS:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0014910; P:regulation of smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010035; P:response to inorganic substance; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IDA:BHF-UCL.
DR   GO; GO:0043588; P:skin development; ISS:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; TAS:BHF-UCL.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR023581; PD_growth_factor_CS.
DR   InterPro; IPR000072; PDGF/VEGF_dom.
DR   InterPro; IPR006782; PDGF_N.
DR   Pfam; PF00341; PDGF; 1.
DR   Pfam; PF04692; PDGF_N; 1.
DR   SMART; SM00141; PDGF; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00249; PDGF_1; 1.
DR   PROSITE; PS50278; PDGF_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Developmental protein; Disulfide bond; Glycoprotein; Growth factor;
KW   Mitogen; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     20
FT   PROPEP       21     86       Removed in mature form.
FT                                /FTId=PRO_0000023356.
FT   CHAIN        87    211       Platelet-derived growth factor subunit A.
FT                                /FTId=PRO_0000023357.
FT   REGION      158    162       Receptor binding site. {ECO:0000255}.
FT   CARBOHYD    134    134       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     96    140       {ECO:0000269|PubMed:20534510}.
FT   DISULFID    123    123       Interchain.
FT                                {ECO:0000269|PubMed:20534510}.
FT   DISULFID    129    177       {ECO:0000269|PubMed:20534510}.
FT   DISULFID    132    132       Interchain.
FT                                {ECO:0000269|PubMed:20534510}.
FT   DISULFID    133    179       {ECO:0000269|PubMed:20534510}.
FT   VAR_SEQ     194    196       GRP -> DVR (in isoform Short).
FT                                {ECO:0000303|PubMed:19054851}.
FT                                /FTId=VSP_004602.
FT   VAR_SEQ     197    211       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:19054851}.
FT                                /FTId=VSP_004603.
FT   CONFLICT     64     66       RAH -> TRD (in Ref. 2; AAA60045).
FT                                {ECO:0000305}.
FT   HELIX        27     34       {ECO:0000244|PDB:3MJK}.
FT   HELIX        41     47       {ECO:0000244|PDB:3MJK}.
FT   STRAND       96    104       {ECO:0000244|PDB:3MJK}.
FT   HELIX       107    109       {ECO:0000244|PDB:3MJK}.
FT   STRAND      118    130       {ECO:0000244|PDB:3MJK}.
FT   STRAND      134    181       {ECO:0000244|PDB:3MJK}.
SQ   SEQUENCE   211 AA;  24043 MW;  48633DDE558EFA43 CRC64;
     MRTLACLLLL GCGYLAHVLA EEAEIPREVI ERLARSQIHS IRDLQRLLEI DSVGSEDSLD
     TSLRAHGVHA TKHVPEKRPL PIRRKRSIEE AVPAVCKTRT VIYEIPRSQV DPTSANFLIW
     PPCVEVKRCT GCCNTSSVKC QPSRVHHRSV KVAKVEYVRK KPKLKEVQVR LEEHLECACA
     TTSLNPDYRE EDTGRPRESG KKRKRKRLKP T
//
ID   BMR1A_MOUSE             Reviewed;         532 AA.
AC   P36895;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   20-JAN-2016, entry version 162.
DE   RecName: Full=Bone morphogenetic protein receptor type-1A;
DE            Short=BMP type-1A receptor;
DE            Short=BMPR-1A;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 3;
DE            Short=ALK-3;
DE   AltName: Full=BMP-2/BMP-4 receptor;
DE   AltName: Full=Serine/threonine-protein kinase receptor R5;
DE            Short=SKR5;
DE   AltName: CD_antigen=CD292;
DE   Flags: Precursor;
GN   Name=Bmpr1a; Synonyms=Acvrlk3, Bmpr;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=SWR/J; TISSUE=Embryo;
RX   PubMed=7750489; DOI=10.1210/endo.136.6.7750489;
RA   Dewulf N., Verschueren K., Lonnoy O., Moren A., Grimsby S.,
RA   Spiegle K., Miyazono K., Huylebroeck D., ten Dijke P.;
RT   "Distinct spatial and temporal expression patterns of two type I
RT   receptors for bone morphogenetic proteins during mouse
RT   embryogenesis.";
RL   Endocrinology 136:2652-2663(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7937936; DOI=10.1073/pnas.91.22.10255;
RA   Suzuki A., Thies R.S., Yamaji N., Song J.J., Wozney J., Murakami K.,
RA   Kung H.;
RT   "A truncated bone morphogenetic protein receptor affects dorsal-
RT   ventral patterning in the early Xenopus embryo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:10255-10259(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8065329; DOI=10.1128/MCB.14.9.5961;
RA   Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P.,
RA   Correa P.E., Olson C.A., Pecquet A.L., Ventura F., Grant R.A.,
RA   Chen G., Wrana J.L., Massague J., Rosenbaum J.S.;
RT   "Characterization and cloning of a receptor for BMP-2 and BMP-4 from
RT   NIH 3T3 cells.";
RL   Mol. Cell. Biol. 14:5961-5974(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Retina;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=24098149; DOI=10.1371/journal.pgen.1003846;
RA   Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C.,
RA   Nickel J., Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T.,
RA   Mundlos S., Doelken S.C., Seemann P.;
RT   "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2.";
RL   PLoS Genet. 9:E1003846-E1003846(2013).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for BMP-2 and BMP-4.
CC       Positively regulates chondrocyte differentiation through GDF5
CC       interaction (PubMed:24098149). {ECO:0000269|PubMed:24098149}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with low affinity with GDF5; positively
CC       regulates chondrocyte differentiation.
CC       {ECO:0000250|UniProtKB:P36894}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 GS domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00585}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z23154; CAA80678.1; -; mRNA.
DR   EMBL; D16250; BAA03769.1; -; mRNA.
DR   EMBL; U04672; AAA21514.1; -; mRNA.
DR   EMBL; BC042611; AAH42611.1; -; mRNA.
DR   CCDS; CCDS26938.1; -.
DR   PIR; A56238; A56238.
DR   RefSeq; NP_033888.2; NM_009758.4.
DR   RefSeq; XP_006518532.1; XM_006518469.2.
DR   RefSeq; XP_006518533.1; XM_006518470.2.
DR   UniGene; Mm.237825; -.
DR   ProteinModelPortal; P36895; -.
DR   SMR; P36895; 55-143, 204-530.
DR   BioGrid; 198371; 4.
DR   DIP; DIP-5796N; -.
DR   IntAct; P36895; 137.
DR   STRING; 10090.ENSMUSP00000035900; -.
DR   BindingDB; P36895; -.
DR   iPTMnet; P36895; -.
DR   PhosphoSite; P36895; -.
DR   MaxQB; P36895; -.
DR   PaxDb; P36895; -.
DR   PRIDE; P36895; -.
DR   Ensembl; ENSMUST00000049005; ENSMUSP00000035900; ENSMUSG00000021796.
DR   GeneID; 12166; -.
DR   KEGG; mmu:12166; -.
DR   UCSC; uc007taw.1; mouse.
DR   CTD; 657; -.
DR   MGI; MGI:1338938; Bmpr1a.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P36895; -.
DR   KO; K04673; -.
DR   OMA; KHYCKSM; -.
DR   OrthoDB; EOG7Q8CN3; -.
DR   PhylomeDB; P36895; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 3474.
DR   Reactome; R-MMU-201451; Signaling by BMP.
DR   NextBio; 280531; -.
DR   PRO; PR:P36895; -.
DR   Proteomes; UP000000589; Chromosome 14.
DR   Bgee; P36895; -.
DR   CleanEx; MM_BMPR1A; -.
DR   ExpressionAtlas; P36895; baseline and differential.
DR   Genevisible; P36895; MM.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0005524; F:ATP binding; ISO:MGI.
DR   GO; GO:0001948; F:glycoprotein binding; ISO:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISO:MGI.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0046332; F:SMAD binding; ISO:MGI.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:MGI.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:MGI.
DR   GO; GO:0051216; P:cartilage development; IMP:MGI.
DR   GO; GO:0030154; P:cell differentiation; IGI:MGI.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; ISO:MGI.
DR   GO; GO:0002062; P:chondrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0048589; P:developmental growth; IMP:MGI.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IMP:MGI.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IGI:MGI.
DR   GO; GO:0007398; P:ectoderm development; IMP:MGI.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IGI:MGI.
DR   GO; GO:0048598; P:embryonic morphogenesis; IMP:MGI.
DR   GO; GO:0048568; P:embryonic organ development; IMP:MGI.
DR   GO; GO:0003272; P:endocardial cushion formation; IMP:MGI.
DR   GO; GO:0007492; P:endoderm development; IMP:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0060914; P:heart formation; IMP:MGI.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:MGI.
DR   GO; GO:0035137; P:hindlimb morphogenesis; IMP:MGI.
DR   GO; GO:0006955; P:immune response; ISO:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0048368; P:lateral mesoderm development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0048382; P:mesendoderm development; IMP:MGI.
DR   GO; GO:0001707; P:mesoderm formation; IMP:MGI.
DR   GO; GO:0001880; P:Mullerian duct regression; IMP:MGI.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IMP:MGI.
DR   GO; GO:0007399; P:nervous system development; IMP:MGI.
DR   GO; GO:0014032; P:neural crest cell development; IMP:MGI.
DR   GO; GO:0021998; P:neural plate mediolateral regionalization; IMP:MGI.
DR   GO; GO:0060896; P:neural plate pattern specification; IMP:MGI.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR   GO; GO:0060021; P:palate development; IMP:MGI.
DR   GO; GO:0048339; P:paraxial mesoderm development; IMP:MGI.
DR   GO; GO:0048352; P:paraxial mesoderm structural organization; IMP:MGI.
DR   GO; GO:0007389; P:pattern specification process; IMP:MGI.
DR   GO; GO:0021983; P:pituitary gland development; IMP:MGI.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISO:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISO:MGI.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISO:MGI.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; ISO:MGI.
DR   GO; GO:2000772; P:regulation of cellular senescence; IGI:MGI.
DR   GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IGI:MGI.
DR   GO; GO:0001756; P:somitogenesis; IMP:MGI.
DR   GO; GO:0019827; P:stem cell population maintenance; IMP:MGI.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Complete proteome; Disulfide bond; Glycoprotein; Kinase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Receptor; Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    532       Bone morphogenetic protein receptor type-
FT                                1A.
FT                                /FTId=PRO_0000024411.
FT   TOPO_DOM     24    152       Extracellular. {ECO:0000255}.
FT   TRANSMEM    153    176       Helical. {ECO:0000255}.
FT   TOPO_DOM    177    532       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      204    233       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      234    525       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     240    248       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      107    109       Mediates specificity for BMP ligand.
FT                                {ECO:0000250}.
FT   ACT_SITE    362    362       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     261    261       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   CARBOHYD     73     73       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     61     82       {ECO:0000250|UniProtKB:P36894}.
FT   DISULFID     63     67       {ECO:0000250|UniProtKB:P36894}.
FT   DISULFID     76    100       {ECO:0000250|UniProtKB:P36894}.
FT   DISULFID    110    124       {ECO:0000250|UniProtKB:P36894}.
FT   DISULFID    125    130       {ECO:0000250|UniProtKB:P36894}.
SQ   SEQUENCE   532 AA;  60063 MW;  70CC83CFB07CE9D5 CRC64;
     MTQLYTYIRL LGACLFIISH VQGQNLDSML HGTGMKSDLD QKKPENGVTL APEDTLPFLK
     CYCSGHCPDD AINNTCITNG HCFAIIEEDD QGETTLTSGC MKYEGSDFQC KDSPKAQLRR
     TIECCRTNLC NQYLQPTLPP VVIGPFFDGS IRWLVVLISM AVCIVAMIIF SSCFCYKHYC
     KSISSRGRYN RDLEQDEAFI PVGESLKDLI DQSQSSGSGS GLPLLVQRTI AKQIQMVRQV
     GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG
     SWTQLYLITD YHENGSLYDF LKCATLDTRA LLKLAYSAAC GLCHLHTEIY GTQGKPAIAH
     RDLKSKNILI KKNGSCCIAD LGLAVKFNSD TNEVDIPLNT RVGTKRYMAP EVLDESLNKN
     HFQPYIMADI YSFGLIIWEM ARRCITGGIV EEYQLPYYNM VPSDPSYEDM REVVCVKRLR
     PIVSNRWNSD ECLRAVLKLM SECWAHNPAS RLTALRIKKT LAKMVESQDV KI
//
ID   LEP_MOUSE               Reviewed;         167 AA.
AC   P41160;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   17-FEB-2016, entry version 139.
DE   RecName: Full=Leptin;
DE   AltName: Full=Obesity factor;
DE   Flags: Precursor;
GN   Name=Lep; Synonyms=Ob;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7984236; DOI=10.1038/372425a0;
RA   Zhang Y., Proenca P., Maffei M., Barone M., Leopold L., Friedman J.M.;
RT   "Positional cloning of the mouse obese gene and its human homologue.";
RL   Nature 372:425-432(1994).
RN   [2]
RP   ERRATUM.
RA   Zhang Y., Proenca P., Maffei M., Barone M., Leopold L., Friedman J.M.;
RL   Nature 374:479-479(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RA   Chehab F.F., Lim M.E.;
RL   Submitted (MAR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=8589726; DOI=10.1038/ng0396-318;
RA   Chehab F.F., Lim M.E., Lu R.;
RT   "Correction of the sterility defect in homozygous obese female mice by
RT   treatment with the human recombinant leptin.";
RL   Nat. Genet. 12:318-320(1996).
RN   [5]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=9732873; DOI=10.1038/29795;
RA   Lord G.M., Matarese G., Howard J.K., Baker R.J., Bloom S.R.,
RA   Lechler R.I.;
RT   "Leptin modulates the T-cell immune response and reverses starvation-
RT   induced immunosuppression.";
RL   Nature 394:897-901(1998).
RN   [6]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=10660043; DOI=10.1016/S0092-8674(00)81558-5;
RA   Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T.,
RA   Shen J., Vinson C., Rueger J.M., Karsenty G.;
RT   "Leptin inhibits bone formation through a hypothalamic relay: a
RT   central control of bone mass.";
RL   Cell 100:197-207(2000).
RN   [7]
RP   FUNCTION.
RX   PubMed=11373681; DOI=10.1038/35078085;
RA   Cowley M.A., Smart J.L., Rubinstein M., Cerdan M.G., Diano S.,
RA   Horvath T.L., Cone R.D., Low M.J.;
RT   "Leptin activates anorexigenic POMC neurons through a neural network
RT   in the arcuate nucleus.";
RL   Nature 411:480-484(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=12594516; DOI=10.1038/nature01388;
RA   Bates S.H., Stearns W.H., Dundon T.A., Schubert M., Tso A.W., Wang Y.,
RA   Banks A.S., Lavery H.J., Haq A.K., Maratos-Flier E., Neel B.G.,
RA   Schwartz M.W., Myers M.G. Jr.;
RT   "STAT3 signalling is required for leptin regulation of energy balance
RT   but not reproduction.";
RL   Nature 421:856-859(2003).
RN   [9]
RP   REVIEW OF FUNCTION IN IMMUNITY.
RX   PubMed=15122202; DOI=10.1038/nri1350;
RA   La Cava A., Matarese G.;
RT   "The weight of leptin in immunity.";
RL   Nat. Rev. Immunol. 4:371-379(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=15899045; DOI=10.1186/ar1708;
RA   Otero M., Lago R., Lago F., Reino J.J., Gualillo O.;
RT   "signaling pathway involved in nitric oxide synthase type II
RT   activation in chondrocytes: synergistic effect of leptin with
RT   interleukin-1.";
RL   Arthritis Res. Ther. 7:R581-R591(2005).
RN   [11]
RP   FUNCTION.
RX   PubMed=16825198; DOI=10.1074/jbc.M601991200;
RA   Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C.,
RA   Styer A.K., Sullivan B.T., Sakamoto H., Olawaiye A., Serikawa T.,
RA   Lynch M.P., Rueda B.R.;
RT   "Leptin signaling promotes the growth of mammary tumors and increases
RT   the expression of vascular endothelial growth factor (VEGF) and its
RT   receptor type two (VEGF-R2).";
RL   J. Biol. Chem. 281:26320-26328(2006).
RN   [12]
RP   FUNCTION.
RX   PubMed=20620997; DOI=10.1016/j.cmet.2010.05.010;
RA   Ramadori G., Fujikawa T., Fukuda M., Anderson J., Morgan D.A.,
RA   Mostoslavsky R., Stuart R.C., Perello M., Vianna C.R., Nillni E.A.,
RA   Rahmouni K., Coppari R.;
RT   "SIRT1 deacetylase in POMC neurons is required for homeostatic
RT   defenses against diet-induced obesity.";
RL   Cell Metab. 12:78-87(2010).
RN   [13]
RP   REVIEW OF FUNCTION.
RX   PubMed=25232147; DOI=10.1530/JOE-14-0404;
RA   Allison M.B., Myers M.G. Jr.;
RT   "20 years of leptin: connecting leptin signaling to biological
RT   function.";
RL   J. Endocrinol. 223:T25-T35(2014).
RN   [14]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=25060689; DOI=10.1016/j.metabol.2014.06.010;
RA   Cassano S., Pucino V., La Rocca C., Procaccini C., De Rosa V.,
RA   Marone G., Matarese G.;
RT   "Leptin modulates autophagy in human CD4+CD25- conventional T cells.";
RL   Metabolism 63:1272-1279(2014).
RN   [15]
RP   FUNCTION.
RX   PubMed=25383904; DOI=10.1038/nn.3861;
RA   Flak J.N., Patterson C.M., Garfield A.S., D'Agostino G., Goforth P.B.,
RA   Sutton A.K., Malec P.A., Wong J.M., Germani M., Jones J.C., Rajala M.,
RA   Satin L., Rhodes C.J., Olson D.P., Kennedy R.T., Heisler L.K.,
RA   Myers M.G. Jr.;
RT   "Leptin-inhibited PBN neurons enhance responses to hypoglycemia in
RT   negative energy balance.";
RL   Nat. Neurosci. 17:1744-1750(2014).
CC   -!- FUNCTION: Key player in the regulation of energy balance and body
CC       weight control. Once released into the circulation, has central
CC       and peripheral effects by binding LEPR, found in many tissues,
CC       which results in the activation of several major signaling
CC       pathways (PubMed:15899045, PubMed:16825198, PubMed:11373681,
CC       PubMed:12594516, PubMed:20620997). In the hypothalamus, acts as an
CC       appetite-regulating factor that induces a decrease in food intake
CC       and an increase in energy consumption by inducing anorexinogenic
CC       factors and suppressing orexigenic neuropeptides, also regulates
CC       bone mass and secretion of hypothalamo-pituitary-adrenal hormones.
CC       In the periphery, increases basal metabolism, influences
CC       reproductive function, regulates pancreatic beta-cell function and
CC       insulin secretion, is pro-angiogenic for endothelial cell and
CC       affects innate and adaptive immunity (By similarity)
CC       (PubMed:8589726, PubMed:10660043, PubMed:25383904,
CC       PubMed:25060689, PubMed:9732873, PubMed:12594516). In the arcuate
CC       nucleus of the hypothalamus, activates by depolarization POMC
CC       neurons inducing FOS and SOCS3 expression to release anorexigenic
CC       peptides and inhibits by hyperpolarization NPY neurons inducing
CC       SOCS3 with a consequent reduction on release of orexigenic
CC       peptides (By similarity) (PubMed:20620997, PubMed:11373681). In
CC       addition to its known satiety inducing effect, has a modulatory
CC       role in nutrient absorption. In the intestine, reduces glucose
CC       absorption by enterocytes by activating PKC and leading to a
CC       sequential activation of p38, PI3K and ERK signaling pathways
CC       which exerts an inhibitory effect on glucose absorption. Acts as a
CC       growth factor on certain tissues, through the activation of
CC       different signaling pathways increases expression of genes
CC       involved in cell cycle regulation such as CCND1, via JAK2-STAT3
CC       pathway, or VEGFA, via MAPK1/3 and PI3K-AKT1 pathways (By
CC       similarity) (PubMed:16825198, PubMed:20620997). May also play an
CC       apoptotic role via JAK2-STAT3 pathway and up-regulation of BIRC5
CC       expression (By similarity). Pro-angiogenic, has mitogenic activity
CC       on vascular endothelial cells and plays a role in matrix
CC       remodeling by regulating the expression of matrix
CC       metalloproteinases (MMPs) and tissue inhibitors of
CC       metalloproteinases (TIMPs) (PubMed:16825198). In innate immunity,
CC       modulates the activity and function of neutrophils by increasing
CC       chemotaxis and the secretion of oxygen radicals. Increases
CC       phagocytosis by macrophages and enhances secretion of pro-
CC       inflammatory mediators. Increases cytotoxic ability of NK cells
CC       (Probable). Plays a pro-inflammatory role, in synergy with IL1B,
CC       by inducing NOS2 wich promotes the production of IL6, IL8 and
CC       Prostaglandin E2, through a signaling pathway that involves JAK2,
CC       PI3K, MAP2K1/MEK1 and MAPK14/p38 (PubMed:15899045). In adaptive
CC       immunity, promotes the switch of memory T-cells towards T helper-1
CC       cell immune responses (By similarity). Increases CD4(+)CD25(-) T
CC       cells proliferation and reduces autophagy during TCR (T cell
CC       receptor) stimulation, through MTOR signaling pathway activation
CC       and BCL2 up-regulation (PubMed:25060689).
CC       {ECO:0000250|UniProtKB:P41159, ECO:0000250|UniProtKB:P41160,
CC       ECO:0000250|UniProtKB:P50596, ECO:0000269|PubMed:10660043,
CC       ECO:0000269|PubMed:11373681, ECO:0000269|PubMed:12594516,
CC       ECO:0000269|PubMed:15899045, ECO:0000269|PubMed:16825198,
CC       ECO:0000269|PubMed:20620997, ECO:0000269|PubMed:25060689,
CC       ECO:0000269|PubMed:25383904, ECO:0000269|PubMed:8589726,
CC       ECO:0000269|PubMed:9732873, ECO:0000305|PubMed:15122202,
CC       ECO:0000305|PubMed:25232147}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305|PubMed:25232147}.
CC   -!- DISEASE: Note=Defects in Lep are the cause of profound obesity and
CC       type II diabetes.
CC   -!- DISRUPTION PHENOTYPE: Mutants are severely obese and sterile
CC       (PubMed:8589726). Animals have an increased bone formation leading
CC       to high bone mass (PubMed:10660043). Have impaired T-cell
CC       immunity, Th2 responses are favoured in mutants (PubMed:9732873).
CC       CD4(+)CD25(-) T cells of mutant mice show high levels of autophagy
CC       (PubMed:25060689). {ECO:0000269|PubMed:10660043,
CC       ECO:0000269|PubMed:25060689, ECO:0000269|PubMed:8589726,
CC       ECO:0000269|PubMed:9732873}.
CC   -!- SIMILARITY: Belongs to the leptin family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U18812; AAA64564.1; -; mRNA.
DR   EMBL; U22421; AAA64213.1; -; Genomic_DNA.
DR   CCDS; CCDS19955.1; -.
DR   PIR; S50863; LTMS.
DR   RefSeq; NP_032519.1; NM_008493.3.
DR   UniGene; Mm.277072; -.
DR   ProteinModelPortal; P41160; -.
DR   SMR; P41160; 24-167.
DR   BioGrid; 201138; 4.
DR   DIP; DIP-60999N; -.
DR   STRING; 10090.ENSMUSP00000067046; -.
DR   PhosphoSite; P41160; -.
DR   PaxDb; P41160; -.
DR   PRIDE; P41160; -.
DR   Ensembl; ENSMUST00000069789; ENSMUSP00000067046; ENSMUSG00000059201.
DR   GeneID; 16846; -.
DR   KEGG; mmu:16846; -.
DR   UCSC; uc009bcv.1; mouse.
DR   CTD; 3952; -.
DR   MGI; MGI:104663; Lep.
DR   eggNOG; ENOG410IVT0; Eukaryota.
DR   eggNOG; ENOG410Y7NT; LUCA.
DR   HOGENOM; HOG000252923; -.
DR   HOVERGEN; HBG007860; -.
DR   InParanoid; P41160; -.
DR   KO; K05424; -.
DR   OMA; INDISHT; -.
DR   OrthoDB; EOG77Q4Z3; -.
DR   PhylomeDB; P41160; -.
DR   TreeFam; TF105086; -.
DR   Reactome; R-MMU-2586551; Signaling by Leptin.
DR   Reactome; R-MMU-2586552; Signaling by Leptin.
DR   Reactome; R-MMU-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1).
DR   Reactome; R-MMU-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   NextBio; 290772; -.
DR   PRO; PR:P41160; -.
DR   Proteomes; UP000000589; Chromosome 6.
DR   Bgee; P41160; -.
DR   CleanEx; MM_LEP; -.
DR   ExpressionAtlas; P41160; baseline and differential.
DR   Genevisible; P41160; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0008083; F:growth factor activity; IDA:MGI.
DR   GO; GO:1990051; P:activation of protein kinase C activity; ISS:UniProtKB.
DR   GO; GO:0060612; P:adipose tissue development; IGI:MGI.
DR   GO; GO:0008343; P:adult feeding behavior; IDA:HGNC.
DR   GO; GO:0008206; P:bile acid metabolic process; IDA:MGI.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; IEA:Ensembl.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; IEA:Ensembl.
DR   GO; GO:0071298; P:cellular response to L-ascorbic acid; IEA:Ensembl.
DR   GO; GO:0044320; P:cellular response to leptin stimulus; ISS:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0021954; P:central nervous system neuron development; IMP:MGI.
DR   GO; GO:0008203; P:cholesterol metabolic process; IGI:MGI.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0042755; P:eating behavior; IGI:MGI.
DR   GO; GO:0006112; P:energy reserve metabolic process; IEA:Ensembl.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IGI:MGI.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IGI:MGI.
DR   GO; GO:0006006; P:glucose metabolic process; IMP:MGI.
DR   GO; GO:0006114; P:glycerol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042445; P:hormone metabolic process; IMP:MGI.
DR   GO; GO:0030073; P:insulin secretion; IGI:MGI.
DR   GO; GO:0050892; P:intestinal absorption; ISS:UniProtKB.
DR   GO; GO:0033210; P:leptin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; IEA:Ensembl.
DR   GO; GO:0006629; P:lipid metabolic process; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0032099; P:negative regulation of appetite; IDA:HGNC.
DR   GO; GO:0038108; P:negative regulation of appetite by leptin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0061037; P:negative regulation of cartilage development; IEA:Ensembl.
DR   GO; GO:0070093; P:negative regulation of glucagon secretion; IDA:BHF-UCL.
DR   GO; GO:0046325; P:negative regulation of glucose import; ISS:UniProtKB.
DR   GO; GO:2000486; P:negative regulation of glutamine transport; IEA:Ensembl.
DR   GO; GO:0010888; P:negative regulation of lipid storage; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0001542; P:ovulation from ovarian follicle; IEA:Ensembl.
DR   GO; GO:0001890; P:placenta development; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:0048639; P:positive regulation of developmental growth; ISO:MGI.
DR   GO; GO:1904651; P:positive regulation of fat cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl.
DR   GO; GO:2000491; P:positive regulation of hepatic stellate cell activation; IEA:Ensembl.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043270; P:positive regulation of ion transport; IEA:Ensembl.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; IDA:UniProtKB.
DR   GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IDA:MGI.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0035360; P:positive regulation of peroxisome proliferator activated receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:2000366; P:positive regulation of STAT protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0090335; P:regulation of brown fat cell differentiation; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0045598; P:regulation of fat cell differentiation; IGI:MGI.
DR   GO; GO:0006111; P:regulation of gluconeogenesis; IMP:MGI.
DR   GO; GO:0050796; P:regulation of insulin secretion; IMP:MGI.
DR   GO; GO:0030300; P:regulation of intestinal cholesterol absorption; IDA:MGI.
DR   GO; GO:0060587; P:regulation of lipoprotein lipid oxidation; IEA:Ensembl.
DR   GO; GO:0019222; P:regulation of metabolic process; IMP:MGI.
DR   GO; GO:1900180; P:regulation of protein localization to nucleus; IMP:MGI.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050810; P:regulation of steroid biosynthetic process; IMP:MGI.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0002021; P:response to dietary excess; IMP:MGI.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IMP:MGI.
DR   GO; GO:0033197; P:response to vitamin E; IEA:Ensembl.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:BHF-UCL.
DR   Gene3D; 1.20.1250.10; -; 1.
DR   InterPro; IPR009079; 4_helix_cytokine-like_core.
DR   InterPro; IPR012351; 4_helix_cytokine_core.
DR   InterPro; IPR000065; Leptin.
DR   PANTHER; PTHR11724; PTHR11724; 1.
DR   Pfam; PF02024; Leptin; 1.
DR   PIRSF; PIRSF001837; Leptin; 1.
DR   PRINTS; PR00495; LEPTIN.
DR   ProDom; PD005698; Leptin; 1.
DR   SUPFAM; SSF47266; SSF47266; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Diabetes mellitus; Disulfide bond; Obesity;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    167       Leptin.
FT                                /FTId=PRO_0000017687.
FT   DISULFID    117    167       {ECO:0000250}.
FT   VARIANT      49     49       Missing (in 30% the clones).
SQ   SEQUENCE   167 AA;  18709 MW;  D6783E6C76FD7116 CRC64;
     MCWRPLCRFL WLWSYLSYVQ AVPIQKVQDD TKTLIKTIVT RINDISHTQS VSAKQRVTGL
     DFIPGLHPIL SLSKMDQTLA VYQQVLTSLP SQNVLQIAND LENLRDLLHL LAFSKSCSLP
     QTSGLQKPES LDGVLEASLY STEVVALSRL QGSLQDILQQ LDVSPEC
//
ID   WNT1_MOUSE              Reviewed;         370 AA.
AC   P04426;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   17-FEB-2016, entry version 148.
DE   RecName: Full=Proto-oncogene Wnt-1;
DE   AltName: Full=Proto-oncogene Int-1;
DE   Flags: Precursor;
GN   Name=Wnt1; Synonyms=Int-1, Wnt-1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=C3H/HeJ;
RX   PubMed=6091914; DOI=10.1016/0092-8674(84)90209-5;
RA   Ooyen A.V., Nusse R.;
RT   "Structure and nucleotide sequence of the putative mammary oncogene
RT   int-1; proviral insertions leave the protein-encoding domain intact.";
RL   Cell 39:233-240(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3018519;
RA   Fung Y.-K.T., Shackleford G.M., Brown A.M.C., Sanders G.S.,
RA   Varmus H.E.;
RT   "Nucleotide sequence and expression in vitro of cDNA derived from mRNA
RT   of int-1, a provirally activated mouse mammary oncogene.";
RL   Mol. Cell. Biol. 5:3337-3344(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=2279700; DOI=10.1101/gad.4.12b.2319;
RA   Gavin B.J., McMahon J.A., McMahon A.P.;
RT   "Expression of multiple novel Wnt-1/int-1-related genes during fetal
RT   and adult mouse development.";
RL   Genes Dev. 4:2319-2332(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Czech II;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   POSSIBLE FUNCTION.
RX   PubMed=2202907; DOI=10.1038/346847a0;
RA   Thomas K.R., Capecchi M.R.;
RT   "Targeted disruption of the murine int-1 proto-oncogene resulting in
RT   severe abnormalities in midbrain and cerebellar development.";
RL   Nature 346:847-850(1990).
RN   [6]
RP   DEVELOPMENTAL STAGE.
RC   STRAIN=CBA/CaJ; TISSUE=Embryo;
RX   PubMed=3594565; DOI=10.1016/0092-8674(87)90664-7;
RA   Wilkinson D.G., Bailes J.A., McMahon A.P.;
RT   "Expression of the proto-oncogene int-1 is restricted to specific
RT   neural cells in the developing mouse embryo.";
RL   Cell 50:79-88(1987).
RN   [7]
RP   TISSUE SPECIFICITY.
RC   STRAIN=ICR;
RX   PubMed=3594566; DOI=10.1016/0092-8674(87)90665-9;
RA   Shackleford G.M., Varmus H.E.;
RT   "Expression of the proto-oncogene int-1 is restricted to postmeiotic
RT   male germ cells and the neural tube of mid-gestational embryos.";
RL   Cell 50:89-95(1987).
RN   [8]
RP   INTERACTION WITH PORCN.
RX   PubMed=10866835; DOI=10.1046/j.1432-1033.2000.01478.x;
RA   Tanaka K., Okabayashi H., Asashima M., Perrimon N., Kadowaki T.;
RT   "The evolutionarily conserved porcupine gene family is involved in the
RT   processing of the Wnt family.";
RL   Eur. J. Biochem. 267:4300-4311(2000).
RN   [9]
RP   FUNCTION.
RX   PubMed=15454084; DOI=10.1016/j.cell.2004.09.019;
RA   Lu W., Yamamoto V., Ortega B., Baltimore D.;
RT   "Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite
RT   outgrowth.";
RL   Cell 119:97-108(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=16116452; DOI=10.1038/nn1520;
RA   Liu Y., Shi J., Lu C.C., Wang Z.B., Lyuksyutova A.I., Song X.J.,
RA   Zou Y.;
RT   "Ryk-mediated Wnt repulsion regulates posterior-directed growth of
RT   corticospinal tract.";
RL   Nat. Neurosci. 8:1151-1159(2005).
RN   [11]
RP   INTERACTION WITH RSPO1; RSPO2 AND RSPO3.
RX   PubMed=16543246; DOI=10.1074/jbc.M508324200;
RA   Nam J.-S., Turcotte T.J., Smith P.F., Choi S., Yoon J.K.;
RT   "Mouse cristin/R-spondin family proteins are novel ligands for the
RT   Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene
RT   expression.";
RL   J. Biol. Chem. 281:13247-13257(2006).
RN   [12]
RP   INTERACTION WITH WLS.
RX   PubMed=19841259; DOI=10.1073/pnas.0904894106;
RA   Fu J., Jiang M., Mirando A.J., Yu H.-M., Hsu W.;
RT   "Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for
RT   embryonic axis formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:18598-18603(2009).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=23499309; DOI=10.1016/j.ajhg.2013.02.010;
RA   Keupp K., Beleggia F., Kayserili H., Barnes A.M., Steiner M.,
RA   Semler O., Fischer B., Yigit G., Janda C.Y., Becker J., Breer S.,
RA   Altunoglu U., Gruenhagen J., Krawitz P., Hecht J., Schinke T.,
RA   Makareeva E., Lausch E., Cankaya T., Caparros-Martin J.A.,
RA   Lapunzina P., Temtamy S., Aglan M., Zabel B., Eysel P., Koerber F.,
RA   Leikin S., Garcia K.C., Netzer C., Schoenau E., Ruiz-Perez V.L.,
RA   Mundlos S., Amling M., Kornak U., Marini J., Wollnik B.;
RT   "Mutations in WNT1 cause different forms of bone fragility.";
RL   Am. J. Hum. Genet. 92:565-574(2013).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=23656646; DOI=10.1056/NEJMoa1215458;
RA   Laine C.M., Joeng K.S., Campeau P.M., Kiviranta R., Tarkkonen K.,
RA   Grover M., Lu J.T., Pekkinen M., Wessman M., Heino T.J.,
RA   Nieminen-Pihala V., Aronen M., Laine T., Kroeger H., Cole W.G.,
RA   Lehesjoki A.E., Nevarez L., Krakow D., Curry C.J., Cohn D.H.,
RA   Gibbs R.A., Lee B.H., Maekitie O.;
RT   "WNT1 mutations in early-onset osteoporosis and osteogenesis
RT   imperfecta.";
RL   N. Engl. J. Med. 368:1809-1816(2013).
CC   -!- FUNCTION: Ligand for members of the frizzled family of seven
CC       transmembrane receptors. In some developmental processes, is also
CC       a ligand for the coreceptor RYK, thus triggering Wnt signaling.
CC       Probable developmental protein. May be a signaling molecule
CC       important in CNS development. Is likely to signal over only few
CC       cell diameters. Proeminent role in the induction of the
CC       mesencephalon and cerebellum. May play a crucial role in the
CC       morphogenesis of the neural tube and/or the early stages of CNS
CC       development. Has a role in osteoblast function and bone
CC       development (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:15454084, ECO:0000269|PubMed:16116452}.
CC   -!- SUBUNIT: Interacts with PORCN. Interacts with RSPO1, RSPO2 and
CC       RSPO3. Interacts with WLS. {ECO:0000269|PubMed:10866835,
CC       ECO:0000269|PubMed:16543246, ECO:0000269|PubMed:19841259}.
CC   -!- INTERACTION:
CC       O35082:Kl; NbExp=2; IntAct=EBI-1570911, EBI-1570828;
CC       O75581:LRP6 (xeno); NbExp=2; IntAct=EBI-1570911, EBI-910915;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- TISSUE SPECIFICITY: Testis and mid-gestational embryos. In the
CC       testis, detected only in postmeiotic germ cells undergoing
CC       differentiation from round spermatids into mature spermatozoa. In
CC       the embryos, expression is restricted to the developing CNS in
CC       regions of the neural tube other than the telencephalon. Expressed
CC       in osteoblast; expression levels increase with advancing
CC       osteoblast differentiation. Expressed in the brain, femur, spleen,
CC       and hematopoietic bone marrow. {ECO:0000269|PubMed:23499309,
CC       ECO:0000269|PubMed:23656646, ECO:0000269|PubMed:3594566}.
CC   -!- DEVELOPMENTAL STAGE: Accumulates throughout the neural plate at
CC       the anterior head folds of the 9 day embryo but only at its
CC       lateral tips in more posterior regions. Following neural tube
CC       closure, expression is restricted to specific regions of the
CC       dorsal wall of the brain ventricles and spinal cord, the ventral
CC       wall of the midbrain and the diencephalon, and the lateral walls
CC       of the neuroepithelium at the midbrain-hindbrain junction.
CC       {ECO:0000269|PubMed:3594565}.
CC   -!- PTM: Palmitoleylation is required for efficient binding to
CC       frizzled receptors. Palmitoleylation is necessary for proper
CC       trafficking to cell surface (By similarity). Depalmitoleylated by
CC       NOTUM, leading to inhibit Wnt signaling pathway (By similarity).
CC       {ECO:0000250|UniProtKB:P56704, ECO:0000250|UniProtKB:Q91029}.
CC   -!- MISCELLANEOUS: Many mouse mammary tumors induced by mouse mammary
CC       tumor virus (MMTV) contain a provirus integrated into a host cell
CC       region which has been named INT-1 (now Wnt1).
CC       {ECO:0000269|PubMed:6091914}.
CC   -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}.
CC   -!- CAUTION: A palmitoylation site was proposed at Cys-93, but it was
CC       later shown that this cysteine is engaged in a disulfide bond.
CC       {ECO:0000250|UniProtKB:P04628}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K02593; AAA39321.1; -; Genomic_DNA.
DR   EMBL; M11943; AAA39322.1; -; mRNA.
DR   EMBL; BC005449; AAH05449.1; -; mRNA.
DR   CCDS; CCDS27807.1; -.
DR   PIR; A23447; TVMST1.
DR   RefSeq; NP_067254.1; NM_021279.4.
DR   RefSeq; XP_006520953.1; XM_006520890.2.
DR   UniGene; Mm.1123; -.
DR   ProteinModelPortal; P04426; -.
DR   SMR; P04426; 85-299.
DR   BioGrid; 204567; 9.
DR   DIP; DIP-39896N; -.
DR   IntAct; P04426; 2.
DR   STRING; 10090.ENSMUSP00000023734; -.
DR   PhosphoSite; P04426; -.
DR   PaxDb; P04426; -.
DR   PRIDE; P04426; -.
DR   Ensembl; ENSMUST00000023734; ENSMUSP00000023734; ENSMUSG00000022997.
DR   GeneID; 22408; -.
DR   KEGG; mmu:22408; -.
DR   UCSC; uc007xnx.1; mouse.
DR   CTD; 7471; -.
DR   MGI; MGI:98953; Wnt1.
DR   eggNOG; KOG3913; Eukaryota.
DR   eggNOG; ENOG410XQZ1; LUCA.
DR   HOGENOM; HOG000039528; -.
DR   HOVERGEN; HBG001595; -.
DR   InParanoid; P04426; -.
DR   KO; K03209; -.
DR   OMA; NNSGRWW; -.
DR   OrthoDB; EOG7C8GJ8; -.
DR   PhylomeDB; P04426; -.
DR   TreeFam; TF105310; -.
DR   Reactome; R-MMU-3238698; WNT ligand biogenesis and trafficking.
DR   Reactome; R-MMU-4086400; PCP/CE pathway.
DR   Reactome; R-MMU-442533; Transcriptional Regulation of Adipocyte Differentiation in 3T3-L1 Pre-adipocytes.
DR   Reactome; R-MMU-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   NextBio; 302801; -.
DR   PRO; PR:P04426; -.
DR   Proteomes; UP000000589; Chromosome 15.
DR   Bgee; P04426; -.
DR   CleanEx; MM_WNT1; -.
DR   ExpressionAtlas; P04426; baseline.
DR   Genevisible; P04426; MM.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0005109; F:frizzled binding; IBA:GO_Central.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; TAS:MGI.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; ISO:MGI.
DR   GO; GO:0030509; P:BMP signaling pathway; ISO:MGI.
DR   GO; GO:0060348; P:bone development; ISS:UniProtKB.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IGI:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0044336; P:canonical Wnt signaling pathway involved in negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0033278; P:cell proliferation in midbrain; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:BHF-UCL.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0021551; P:central nervous system morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0021549; P:cerebellum development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0021588; P:cerebellum formation; IMP:BHF-UCL.
DR   GO; GO:0021536; P:diencephalon development; IGI:MGI.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000578; P:embryonic axis specification; IMP:BHF-UCL.
DR   GO; GO:1990403; P:embryonic brain development; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0021797; P:forebrain anterior/posterior pattern specification; IGI:MGI.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; IDA:MGI.
DR   GO; GO:0070365; P:hepatocyte differentiation; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IGI:MGI.
DR   GO; GO:0022037; P:metencephalon development; IMP:MGI.
DR   GO; GO:0030901; P:midbrain development; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030917; P:midbrain-hindbrain boundary development; IMP:MGI.
DR   GO; GO:0022004; P:midbrain-hindbrain boundary maturation during brain development; IMP:MGI.
DR   GO; GO:0007520; P:myoblast fusion; IDA:MGI.
DR   GO; GO:0014902; P:myotube differentiation; IGI:MGI.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; ISO:MGI.
DR   GO; GO:0090344; P:negative regulation of cell aging; ISO:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:AgBase.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; ISO:MGI.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; ISO:MGI.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IMP:BHF-UCL.
DR   GO; GO:2000059; P:negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:MGI.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:MGI.
DR   GO; GO:0022008; P:neurogenesis; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0048666; P:neuron development; IEA:Ensembl.
DR   GO; GO:0048663; P:neuron fate commitment; IMP:MGI.
DR   GO; GO:0048664; P:neuron fate determination; IMP:MGI.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:MGI.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0061184; P:positive regulation of dermatome development; ISO:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISO:MGI.
DR   GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; ISO:MGI.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISO:MGI.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:MGI.
DR   GO; GO:0042770; P:signal transduction in response to DNA damage; ISO:MGI.
DR   GO; GO:0060061; P:Spemann organizer formation; IMP:BHF-UCL.
DR   GO; GO:0021527; P:spinal cord association neuron differentiation; IGI:MGI.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IDA:MGI.
DR   GO; GO:0030579; P:ubiquitin-dependent SMAD protein catabolic process; IDA:MGI.
DR   GO; GO:0016055; P:Wnt signaling pathway; IDA:ParkinsonsUK-UCL.
DR   InterPro; IPR005817; Wnt.
DR   InterPro; IPR009139; Wnt1.
DR   InterPro; IPR018161; Wnt_CS.
DR   PANTHER; PTHR12027; PTHR12027; 1.
DR   Pfam; PF00110; wnt; 1.
DR   PRINTS; PR01841; WNT1PROTEIN.
DR   PRINTS; PR01349; WNTPROTEIN.
DR   SMART; SM00097; WNT1; 1.
DR   PROSITE; PS00246; WNT1; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Lipoprotein; Proto-oncogene;
KW   Reference proteome; Secreted; Signal; Wnt signaling pathway.
FT   SIGNAL        1     27       {ECO:0000255}.
FT   CHAIN        28    370       Proto-oncogene Wnt-1.
FT                                /FTId=PRO_0000041406.
FT   LIPID       224    224       O-palmitoleyl serine; by PORCN.
FT                                {ECO:0000250|UniProtKB:Q91029}.
FT   CARBOHYD     29     29       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    316    316       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    346    346       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    359    359       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     93    104       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    143    151       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    153    170       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    218    232       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    220    227       {ECO:0000250}.
FT   DISULFID    315    330       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    345    360       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    347    357       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    352    353       {ECO:0000250|UniProtKB:P28026}.
SQ   SEQUENCE   370 AA;  41086 MW;  02EEB23109231A40 CRC64;
     MGLWALLPSW VSTTLLLALT ALPAALAANS SGRWWGIVNI ASSTNLLTDS KSLQLVLEPS
     LQLLSRKQRR LIRQNPGILH SVSGGLQSAV RECKWQFRNR RWNCPTAPGP HLFGKIVNRG
     CRETAFIFAI TSAGVTHSVA RSCSEGSIES CTCDYRRRGP GGPDWHWGGC SDNIDFGRLF
     GREFVDSGEK GRDLRFLMNL HNNEAGRTTV FSEMRQECKC HGMSGSCTVR TCWMRLPTLR
     AVGDVLRDRF DGASRVLYGN RGSNRASRAE LLRLEPEDPA HKPPSPHDLV YFEKSPNFCT
     YSGRLGTAGT AGRACNSSSP ALDGCELLCC GRGHRTRTQR VTERCNCTFH WCCHVSCRNC
     THTRVLHECL
//
ID   SHH_RAT                 Reviewed;         437 AA.
AC   Q63673;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   20-JAN-2016, entry version 142.
DE   RecName: Full=Sonic hedgehog protein;
DE            Short=SHH;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein N-product;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein C-product;
DE   Flags: Precursor;
GN   Name=Shh; Synonyms=Vhh-1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Embryonic floor plate;
RX   PubMed=8124714; DOI=10.1016/0092-8674(94)90514-2;
RA   Roelink H., Augsburger A., Heemskerk J., Korzh V., Norlin S.,
RA   Ruiz i Altaba A., Tanabe Y., Placzek M., Edlund T., Jessell T.M.,
RA   Dodd J.;
RT   "Floor plate and motor neuron induction by vhh-1, a vertebrate homolog
RT   of hedgehog expressed by the notochord.";
RL   Cell 76:761-775(1994).
RN   [2]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=11395778; DOI=10.1038/35079648;
RA   Zeng X., Goetz J.A., Suber L.M., Scott W.J. Jr., Schreiner C.M.,
RA   Robbins D.J.;
RT   "A freely diffusible form of Sonic hedgehog mediates long-range
RT   signalling.";
RL   Nature 411:716-720(2001).
CC   -!- FUNCTION: Intercellular signal essential for a variety of
CC       patterning events during development: signal produced by the
CC       notochord that induces ventral cell fate in the neural tube and
CC       somites, and the polarizing signal for patterning of the anterior-
CC       posterior axis of the developing limb bud. Displays both floor
CC       plate- and motor neuron-inducing activity. The threshold
CC       concentration of N-product required for motor neuron induction is
CC       5-fold lower than that required for floor plate induction.
CC       Activates the transcription of target genes by interacting with
CC       its receptor PTCH1 to prevent normal inhibition by PTCH1 on the
CC       constitutive signaling activity of SMO (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with HHATL/GUP1 which negatively regulates
CC       HHAT-mediated palmitoylation of the SHH N-terminus. Interacts with
CC       BOC and CDON. Interacts with HHIP (By similarity). N-product is
CC       active as a multimer. {ECO:0000250, ECO:0000269|PubMed:11395778}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein C-product: Secreted,
CC       extracellular space {ECO:0000250|UniProtKB:Q62226}. Note=The C-
CC       terminal peptide diffuses from the cell.
CC       {ECO:0000250|UniProtKB:Q62226}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein N-product: Cell
CC       membrane {ECO:0000250|UniProtKB:Q62226}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:Q62226}. Note=The N-product either remains
CC       associated with lipid rafts at the cell surface, or forms freely
CC       diffusible active multimers with its hydrophobic lipid-modified N-
CC       and C-termini buried inside (PubMed:11395778).
CC   -!- TISSUE SPECIFICITY: Expressed in the node, notochord, floor plate,
CC       and posterior limb bud mesenchyme.
CC   -!- DOMAIN: The sonic hedgehog protein N-product binds calcium and
CC       zinc ions; this stabilizes the protein fold and is essential for
CC       protein-protein interactions mediated by this domain.
CC       {ECO:0000250}.
CC   -!- PTM: The C-terminal domain displays an autoproteolysis activity
CC       and a cholesterol transferase activity. Both activities result in
CC       the cleavage of the full-length protein and covalent attachment of
CC       a cholesterol moiety to the C-terminal of the newly generated N-
CC       terminal fragment (N-product). The N-product is the active species
CC       in both local and long-range signaling, whereas the C-product has
CC       no signaling activity.
CC   -!- PTM: Cholesterylation is required for N-product targeting to lipid
CC       rafts and multimerization. {ECO:0000250}.
CC   -!- PTM: N-palmitoylation of Cys-25 by HHAT is required for N-product
CC       multimerization and full activity. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the hedgehog family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L27340; AAA20999.1; -; mRNA.
DR   PIR; B53193; B53193.
DR   RefSeq; NP_058917.1; NM_017221.1.
DR   UniGene; Rn.10432; -.
DR   ProteinModelPortal; Q63673; -.
DR   SMR; Q63673; 39-195.
DR   STRING; 10116.ENSRNOP00000008497; -.
DR   MEROPS; C46.002; -.
DR   PaxDb; Q63673; -.
DR   PRIDE; Q63673; -.
DR   GeneID; 29499; -.
DR   KEGG; rno:29499; -.
DR   CTD; 6469; -.
DR   RGD; 3673; Shh.
DR   eggNOG; KOG3638; Eukaryota.
DR   eggNOG; ENOG410XQA3; LUCA.
DR   HOGENOM; HOG000233428; -.
DR   HOVERGEN; HBG005480; -.
DR   InParanoid; Q63673; -.
DR   KO; K11988; -.
DR   PhylomeDB; Q63673; -.
DR   NextBio; 609396; -.
DR   PRO; PR:Q63673; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:RGD.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:RGD.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030133; C:transport vesicle; IDA:RGD.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0043237; F:laminin-1 binding; ISS:UniProtKB.
DR   GO; GO:0008233; F:peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0005102; F:receptor binding; TAS:RGD.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0008209; P:androgen metabolic process; ISS:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISS:UniProtKB.
DR   GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; ISS:UniProtKB.
DR   GO; GO:0048468; P:cell development; ISS:UniProtKB.
DR   GO; GO:0001708; P:cell fate specification; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB.
DR   GO; GO:0007417; P:central nervous system development; ISS:UniProtKB.
DR   GO; GO:0021930; P:cerebellar granule cell precursor proliferation; ISS:UniProtKB.
DR   GO; GO:0007502; P:digestive tract mesoderm development; IDA:RGD.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; ISS:UniProtKB.
DR   GO; GO:0009790; P:embryo development; ISS:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEP:RGD.
DR   GO; GO:0030900; P:forebrain development; ISS:UniProtKB.
DR   GO; GO:0061196; P:fungiform papilla development; IMP:RGD.
DR   GO; GO:0061198; P:fungiform papilla formation; IMP:RGD.
DR   GO; GO:0061197; P:fungiform papilla morphogenesis; IMP:RGD.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0030902; P:hindbrain development; ISS:UniProtKB.
DR   GO; GO:0016539; P:intein-mediated protein splicing; IEA:InterPro.
DR   GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; ISS:UniProtKB.
DR   GO; GO:0048808; P:male genitalia morphogenesis; IMP:RGD.
DR   GO; GO:0072136; P:metanephric mesenchymal cell proliferation involved in metanephros development; ISS:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; ISS:UniProtKB.
DR   GO; GO:0030901; P:midbrain development; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000357; P:negative regulation of kidney smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000062; P:negative regulation of ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045060; P:negative thymic T cell selection; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0001841; P:neural tube formation; IMP:RGD.
DR   GO; GO:0007405; P:neuroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0048663; P:neuron fate commitment; ISS:UniProtKB.
DR   GO; GO:0007389; P:pattern specification process; ISS:UniProtKB.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:UniProtKB.
DR   GO; GO:0009949; P:polarity specification of anterior/posterior axis; ISS:UniProtKB.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0033092; P:positive regulation of immature T cell proliferation in thymus; ISS:UniProtKB.
DR   GO; GO:2000358; P:positive regulation of kidney smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000729; P:positive regulation of mesenchymal cell proliferation involved in ureter development; ISS:UniProtKB.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IDA:RGD.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:RGD.
DR   GO; GO:0070447; P:positive regulation of oligodendrocyte progenitor proliferation; IDA:RGD.
DR   GO; GO:0060406; P:positive regulation of penile erection; IMP:RGD.
DR   GO; GO:0046534; P:positive regulation of photoreceptor cell differentiation; IDA:RGD.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; ISS:UniProtKB.
DR   GO; GO:0033089; P:positive regulation of T cell differentiation in thymus; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:2000063; P:positive regulation of ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045059; P:positive thymic T cell selection; ISS:UniProtKB.
DR   GO; GO:0030850; P:prostate gland development; ISS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0030856; P:regulation of epithelial cell differentiation; IEP:RGD.
DR   GO; GO:0030162; P:regulation of proteolysis; ISS:UniProtKB.
DR   GO; GO:0048678; P:response to axon injury; IMP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IDA:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0007224; P:smoothened signaling pathway; ISS:UniProtKB.
DR   GO; GO:0021513; P:spinal cord dorsal/ventral patterning; IDA:MGI.
DR   GO; GO:0048864; P:stem cell development; ISS:UniProtKB.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISS:UniProtKB.
DR   GO; GO:0021978; P:telencephalon regionalization; IMP:RGD.
DR   GO; GO:0048538; P:thymus development; ISS:UniProtKB.
DR   GO; GO:0043586; P:tongue development; IMP:RGD.
DR   GO; GO:0043587; P:tongue morphogenesis; IMP:RGD.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0021521; P:ventral spinal cord interneuron specification; IDA:MGI.
DR   Gene3D; 2.170.16.10; -; 1.
DR   Gene3D; 3.30.1380.10; -; 1.
DR   InterPro; IPR001657; Hedgehog.
DR   InterPro; IPR028992; Hedgehog/Intein_dom.
DR   InterPro; IPR009045; Hedgehog_sig/DD-Pept_Zn-bd_dom.
DR   InterPro; IPR000320; Hedgehog_signalling_dom.
DR   InterPro; IPR001767; Hint_dom.
DR   InterPro; IPR003586; Hint_dom_C.
DR   InterPro; IPR003587; Hint_dom_N.
DR   InterPro; IPR006141; Intein_N.
DR   Pfam; PF01085; HH_signal; 1.
DR   Pfam; PF01079; Hint; 1.
DR   PIRSF; PIRSF009400; Peptidase_C46; 1.
DR   PRINTS; PR00632; SONICHHOG.
DR   SMART; SM00305; HintC; 1.
DR   SMART; SM00306; HintN; 1.
DR   SUPFAM; SSF51294; SSF51294; 1.
DR   SUPFAM; SSF55166; SSF55166; 1.
DR   PROSITE; PS50817; INTEIN_N_TER; 1.
PE   1: Evidence at protein level;
KW   Autocatalytic cleavage; Calcium; Cell membrane; Complete proteome;
KW   Developmental protein; Glycoprotein; Hydrolase; Lipoprotein; Membrane;
KW   Metal-binding; Palmitate; Protease; Reference proteome; Secreted;
KW   Signal; Zinc.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25    437       Sonic hedgehog protein.
FT                                /FTId=PRO_0000013214.
FT   CHAIN        25    198       Sonic hedgehog protein N-product.
FT                                /FTId=PRO_0000013215.
FT   CHAIN       199    437       Sonic hedgehog protein C-product.
FT                                /FTId=PRO_0000013216.
FT   COMPBIAS    383    387       Poly-Gly.
FT   METAL        90     90       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL        91     91       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL        91     91       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL        96     96       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       126    126       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       127    127       Calcium 1.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       127    127       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       130    130       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       132    132       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       141    141       Zinc. {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       148    148       Zinc. {ECO:0000250|UniProtKB:Q15465}.
FT   METAL       183    183       Zinc. {ECO:0000250|UniProtKB:Q15465}.
FT   SITE        198    199       Cleavage; by autolysis.
FT   SITE        244    244       Involved in cholesterol transfer.
FT                                {ECO:0000250}.
FT   SITE        268    268       Involved in auto-cleavage. {ECO:0000250}.
FT   SITE        271    271       Essential for auto-cleavage.
FT                                {ECO:0000250}.
FT   LIPID        25     25       N-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID       198    198       Cholesterol glycine ester. {ECO:0000250}.
FT   CARBOHYD    279    279       N-linked (GlcNAc...). {ECO:0000255}.
SQ   SEQUENCE   437 AA;  47630 MW;  0DBFC19F0D1662A0 CRC64;
     MLLLLARCFL VALASSLLVC PGLACGPGRG FGKRQHPKKL TPLAYKQFIP NVAEKTLGAS
     GRYEGKITRN SERFKELTPN YNPDIIFKDE ENTGADRLMT QRCKDKLNAL AISVMNQWPG
     VKLRVTEGWD EDGHHSEESL HYEGRAVDIT TSDRDRSKYG MLARLAVEAG FDWVYYESKA
     RIHCSVKAEN SVAAKSDGCF PGSATVHLEQ GGTKLVKDLS PGDRVLAADD QGRLLYSDFL
     TFLDRDEGAK KVFYVIETRE PRERLLLTAA HLLFVAPHND SGPTPGPSPL FASRVRPGQR
     VYVVAERGGD RRLLPAAVHS VTLREEAAGA YAPLTADGTI LINRVLASCY AVIEEHSWAH
     RAFAPFRLAH ALLAALAPAR TDGGGGGSIP APQSVAEARG AGPPAGIHWY SQLLYHIGTW
     LLDSETLHPL GMAVKSS
//
ID   EDN1_MOUSE              Reviewed;         202 AA.
AC   P22387; P70203; P97338;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 3.
DT   09-DEC-2015, entry version 142.
DE   RecName: Full=Endothelin-1;
DE            Short=ET-1;
DE   AltName: Full=Preproendothelin-1;
DE            Short=PPET1;
DE   Flags: Precursor;
GN   Name=Edn1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6 X CBA; TISSUE=Lung;
RX   PubMed=8575440; DOI=10.1111/j.1432-1033.1995.819_a.x;
RA   Chan T.S., Lin C.X., Chan W.Y., Chung S.S., Chung S.K.;
RT   "Mouse preproendothelin-1 gene. cDNA cloning, sequence analysis and
RT   determination of sites of expression during embryonic development.";
RL   Eur. J. Biochem. 234:819-826(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ; TISSUE=Lung;
RX   PubMed=8688455; DOI=10.1016/0167-4781(96)00066-8;
RA   Kurama M., Ishida N., Matsui M., Saida K., Mitsui Y.;
RT   "Sequence and neuronal expression of mouse endothelin-1 cDNA.";
RL   Biochim. Biophys. Acta 1307:249-253(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   STRAIN=BALB/cJ; TISSUE=Liver;
RX   PubMed=8824799; DOI=10.1006/geno.1996.0029;
RA   Maemura K., Kurihara H., Kurihara Y., Oda H., Ishikawa T.,
RA   Copeland N.G., Gilbert D.J., Jenkins N.A., Yazaki Y.;
RT   "Sequence analysis, chromosomal location, and developmental expression
RT   of the mouse preproendothelin-1 gene.";
RL   Genomics 31:177-184(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N-3; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21.
RC   STRAIN=BALB/cJ;
RX   PubMed=7883980; DOI=10.1172/JCI117784;
RA   Harats D., Kurihara H., Belloni P., Oakley H., Ziober A., Ackley D.,
RA   Cain G., Kurihara Y., Lawn R., Sigal E.;
RT   "Targeting gene expression to the vascular wall in transgenic mice
RT   using the murine preproendothelin-1 promoter.";
RL   J. Clin. Invest. 95:1335-1344(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-76.
RC   TISSUE=Kidney;
RX   PubMed=8238383;
RA   Chen M., Todd-Turla K., Wang W.H., Cao X., Smart A., Brosius F.C.,
RA   Killen P.D., Keiser J.A., Briggs J.P., Schnermann J.;
RT   "Endothelin-1 mRNA in glomerular and epithelial cells of kidney.";
RL   Am. J. Physiol. 265:F542-F550(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 48-77.
RX   PubMed=2768235;
RA   Saida K., Mitsui Y., Ishida N.;
RT   "A novel peptide, vasoactive intestinal contractor, of a new
RT   (endothelin) peptide family. Molecular cloning, expression, and
RT   biological activity.";
RL   J. Biol. Chem. 264:14613-14616(1989).
RN   [8]
RP   PROTEIN SEQUENCE OF 155-165, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=OF1; TISSUE=Hippocampus;
RA   Lubec G., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
CC   -!- FUNCTION: Endothelins are endothelium-derived vasoconstrictor
CC       peptides.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Highest expression in the adult is in lung.
CC       Lower levels found in heart, kidney, brain and intestine. In the
CC       embryo, expressed in outer and inner pharyngeal arch surfaces.
CC       Also expressed in endothelium of dorsal aorta and arch arteries,
CC       and in epithelium of pharyngeal pouches.
CC       {ECO:0000269|PubMed:8824799}.
CC   -!- DEVELOPMENTAL STAGE: Expression in lung is low at 17.5 dpc fetal
CC       mice and increases progressively into adulthood.
CC       {ECO:0000269|PubMed:8824799}.
CC   -!- SIMILARITY: Belongs to the endothelin/sarafotoxin family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U35233; AAA97608.1; -; mRNA.
DR   EMBL; D43775; BAA07830.1; -; mRNA.
DR   EMBL; D70842; BAA11109.1; -; Genomic_DNA.
DR   EMBL; BC029547; AAH29547.1; -; mRNA.
DR   EMBL; U07982; AAA74439.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; S66650; AAP13983.1; -; mRNA.
DR   EMBL; M26497; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS26474.1; -.
DR   PIR; S63538; S63538.
DR   RefSeq; NP_034234.1; NM_010104.3.
DR   UniGene; Mm.14543; -.
DR   STRING; 10090.ENSMUSP00000021796; -.
DR   PhosphoSite; P22387; -.
DR   MaxQB; P22387; -.
DR   PaxDb; P22387; -.
DR   PRIDE; P22387; -.
DR   Ensembl; ENSMUST00000021796; ENSMUSP00000021796; ENSMUSG00000021367.
DR   GeneID; 13614; -.
DR   KEGG; mmu:13614; -.
DR   UCSC; uc007qfl.2; mouse.
DR   CTD; 1906; -.
DR   MGI; MGI:95283; Edn1.
DR   eggNOG; ENOG410IWVG; Eukaryota.
DR   eggNOG; ENOG4111WED; LUCA.
DR   HOGENOM; HOG000231110; -.
DR   HOVERGEN; HBG051441; -.
DR   InParanoid; P22387; -.
DR   KO; K16366; -.
DR   OMA; CASQKDK; -.
DR   OrthoDB; EOG7PS1H7; -.
DR   PhylomeDB; P22387; -.
DR   TreeFam; TF333184; -.
DR   Reactome; R-MMU-375276; Peptide ligand-binding receptors.
DR   Reactome; R-MMU-416476; G alpha (q) signalling events.
DR   ChiTaRS; Edn1; mouse.
DR   NextBio; 284272; -.
DR   PRO; PR:P22387; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   Bgee; P22387; -.
DR   CleanEx; MM_EDN1; -.
DR   ExpressionAtlas; P22387; baseline and differential.
DR   Genevisible; P22387; MM.
DR   GO; GO:0045178; C:basal part of cell; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0048237; C:rough endoplasmic reticulum lumen; IEA:Ensembl.
DR   GO; GO:0033093; C:Weibel-Palade body; IEA:Ensembl.
DR   GO; GO:0005125; F:cytokine activity; ISO:MGI.
DR   GO; GO:0031707; F:endothelin A receptor binding; IPI:MGI.
DR   GO; GO:0031708; F:endothelin B receptor binding; ISO:MGI.
DR   GO; GO:0005179; F:hormone activity; ISO:MGI.
DR   GO; GO:0005102; F:receptor binding; IDA:MGI.
DR   GO; GO:0014824; P:artery smooth muscle contraction; ISO:MGI.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IMP:MGI.
DR   GO; GO:0007589; P:body fluid secretion; IMP:MGI.
DR   GO; GO:0019722; P:calcium-mediated signaling; ISO:MGI.
DR   GO; GO:0051216; P:cartilage development; IMP:MGI.
DR   GO; GO:0016049; P:cell growth; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; ISO:MGI.
DR   GO; GO:0007267; P:cell-cell signaling; ISO:MGI.
DR   GO; GO:0071277; P:cellular response to calcium ion; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071389; P:cellular response to mineralocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IMP:MGI.
DR   GO; GO:0042045; P:epithelial fluid transport; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; ISO:MGI.
DR   GO; GO:0015758; P:glucose transport; IDA:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0001821; P:histamine secretion; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0048016; P:inositol phosphate-mediated signaling; ISO:MGI.
DR   GO; GO:0060137; P:maternal process involved in parturition; IEA:Ensembl.
DR   GO; GO:0051899; P:membrane depolarization; IEA:Ensembl.
DR   GO; GO:0042474; P:middle ear morphogenesis; IMP:MGI.
DR   GO; GO:0010259; P:multicellular organismal aging; IEA:Ensembl.
DR   GO; GO:0030818; P:negative regulation of cAMP biosynthetic process; IDA:MGI.
DR   GO; GO:0032269; P:negative regulation of cellular protein metabolic process; ISO:MGI.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0051771; P:negative regulation of nitric-oxide synthase biosynthetic process; ISO:MGI.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISO:MGI.
DR   GO; GO:0014032; P:neural crest cell development; IMP:MGI.
DR   GO; GO:0030185; P:nitric oxide transport; ISO:MGI.
DR   GO; GO:0001569; P:patterning of blood vessels; IMP:MGI.
DR   GO; GO:0030072; P:peptide hormone secretion; ISO:MGI.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; ISO:MGI.
DR   GO; GO:0031583; P:phospholipase D-activating G-protein coupled receptor signaling pathway; IDA:MGI.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISO:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0045793; P:positive regulation of cell size; ISO:MGI.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISO:MGI.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway; IDA:MGI.
DR   GO; GO:0010460; P:positive regulation of heart rate; ISO:MGI.
DR   GO; GO:0046887; P:positive regulation of hormone secretion; ISO:MGI.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; ISO:MGI.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISO:MGI.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISO:MGI.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; IEA:Ensembl.
DR   GO; GO:0032308; P:positive regulation of prostaglandin secretion; IEA:Ensembl.
DR   GO; GO:0060585; P:positive regulation of prostaglandin-endoperoxide synthase activity; ISO:MGI.
DR   GO; GO:0010870; P:positive regulation of receptor biosynthetic process; ISO:MGI.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IMP:MGI.
DR   GO; GO:0060298; P:positive regulation of sarcomere organization; ISO:MGI.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISO:MGI.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0035810; P:positive regulation of urine volume; IMP:MGI.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; ISO:MGI.
DR   GO; GO:0042313; P:protein kinase C deactivation; ISO:MGI.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; IDA:MGI.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:MGI.
DR   GO; GO:0006885; P:regulation of pH; IDA:MGI.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0003100; P:regulation of systemic arterial blood pressure by endothelin; ISO:MGI.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IEA:InterPro.
DR   GO; GO:0007585; P:respiratory gaseous exchange; IMP:MGI.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IMP:MGI.
DR   GO; GO:0044321; P:response to leptin; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0010193; P:response to ozone; IEA:Ensembl.
DR   GO; GO:0034696; P:response to prostaglandin F; IEA:Ensembl.
DR   GO; GO:1902074; P:response to salt; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0043179; P:rhythmic excitation; IMP:MGI.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IMP:MGI.
DR   GO; GO:0042554; P:superoxide anion generation; IEA:Ensembl.
DR   GO; GO:0042310; P:vasoconstriction; ISO:MGI.
DR   GO; GO:0014826; P:vein smooth muscle contraction; ISO:MGI.
DR   InterPro; IPR020475; Bibrotoxin/Sarafotoxin-D.
DR   InterPro; IPR019764; Endothelin_toxin_CS.
DR   InterPro; IPR001928; Endothln-like_toxin.
DR   Pfam; PF00322; Endothelin; 1.
DR   PRINTS; PR00365; ENDOTHELIN.
DR   SMART; SM00272; END; 2.
DR   PROSITE; PS00270; ENDOTHELIN; 2.
PE   1: Evidence at protein level;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Reference proteome;
KW   Secreted; Signal; Vasoactive; Vasoconstrictor.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   PROPEP       26     50
FT                                /FTId=PRO_0000008062.
FT   PEPTIDE      53     73       Endothelin-1.
FT                                /FTId=PRO_0000008063.
FT   PROPEP       74    202
FT                                /FTId=PRO_0000008064.
FT   REGION      110    124       Endothelin-like.
FT   SITE         73     74       Cleavage; by KEL. {ECO:0000250}.
FT   DISULFID     53     67       {ECO:0000250}.
FT   DISULFID     55     63       {ECO:0000250}.
FT   CONFLICT     75     75       N -> K (in Ref. 3; BAA11109).
FT                                {ECO:0000305}.
FT   CONFLICT    103    103       A -> G (in Ref. 2; BAA07830).
FT                                {ECO:0000305}.
SQ   SEQUENCE   202 AA;  22809 MW;  3A0C1E1DFA797411 CRC64;
     MDYFPVIFSL LFVTFQGAPE TAVLGAELST GAENGVQSPP PSTPWRPRRS KRCSCSSLMD
     KECVYFCHLD IIWVNTPERV VPYGLGGSSR SKRSLKDLLP NKATDQAVRC QCAHQKDKKC
     WNFCQAGKEL RAQSTMQKSL KDSKKGKPCS KLGKKCIYQQ LVEGRKLRRL EAISNSIKAS
     FRVAKLKAEL YRDQKLTHNR AH
//
ID   MMP9_HUMAN              Reviewed;         707 AA.
AC   P14780; B2R7V9; Q3LR70; Q8N725; Q9H4Z1; Q9UCJ9; Q9UCL1; Q9UDK2;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 3.
DT   17-FEB-2016, entry version 206.
DE   RecName: Full=Matrix metalloproteinase-9;
DE            Short=MMP-9;
DE            EC=3.4.24.35;
DE   AltName: Full=92 kDa gelatinase;
DE   AltName: Full=92 kDa type IV collagenase;
DE   AltName: Full=Gelatinase B;
DE            Short=GELB;
DE   Contains:
DE     RecName: Full=67 kDa matrix metalloproteinase-9;
DE   Contains:
DE     RecName: Full=82 kDa matrix metalloproteinase-9;
DE   Flags: Precursor;
GN   Name=MMP9; Synonyms=CLG4B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 20-37, AND VARIANTS
RP   ARG-279 AND PRO-574.
RX   PubMed=2551898;
RA   Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A.,
RA   Goldberg G.I.;
RT   "SV40-transformed human lung fibroblasts secrete a 92-kDa type IV
RT   collagenase which is identical to that secreted by normal human
RT   macrophages.";
RL   J. Biol. Chem. 264:17213-17221(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1653238;
RA   Huhtala P., Tuuttila A., Chow L.T., Lohi J., Keski-Oja J.,
RA   Tryggvason K.;
RT   "Complete structure of the human gene for 92-kDa type IV collagenase.
RT   Divergent regulation of expression for the 92- and 72-kilodalton
RT   enzyme genes in HT-1080 cells.";
RL   J. Biol. Chem. 266:16485-16490(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PRO-574.
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-20; LYS-127;
RP   ARG-279; PRO-574 AND GLN-668.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-20; HIS-239;
RP   VAL-571; PRO-574 AND GLN-668.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-279 AND
RP   PRO-574.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-11.
RX   PubMed=8426746;
RA   Sato H., Seiki M.;
RT   "Regulatory mechanism of 92 kDa type IV collagenase gene expression
RT   which is associated with invasiveness of tumor cells.";
RL   Oncogene 8:395-405(1993).
RN   [9]
RP   PROTEIN SEQUENCE OF 20-39, AND GLYCOSYLATION.
RC   TISSUE=Neutrophil;
RX   PubMed=1464361;
RA   Kjeldsen L., Bjerrum O.W., Hovgaard D., Johnsen A.H., Sehested M.,
RA   Borregaard N.;
RT   "Human neutrophil gelatinase: a marker for circulating blood
RT   neutrophils. Purification and quantitation by enzyme linked
RT   immunosorbent assay.";
RL   Eur. J. Haematol. 49:180-191(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 20-37.
RX   PubMed=1653055; DOI=10.1016/1043-4666(91)90021-5;
RA   van Ranst M., Norga K., Masure S., Proost P., Vandekerckhove F.,
RA   Auwerx J., van Damme J., Opdenakker G.;
RT   "The cytokine-protease connection: identification of a 96-kD THP-1
RT   gelatinase and regulation by interleukin-1 and cytokine inducers.";
RL   Cytokine 3:231-239(1991).
RN   [11]
RP   PROTEIN SEQUENCE OF 20-34; 60-71 AND 107-118, INDUCTION, AND
RP   PROTEOLYTIC PROCESSING BY MMP3.
RX   PubMed=1371271;
RA   Ogata Y., Enghild J.J., Nagase H.;
RT   "Matrix metalloproteinase 3 (stromelysin) activates the precursor for
RT   the human matrix metalloproteinase 9.";
RL   J. Biol. Chem. 267:3581-3584(1992).
RN   [12]
RP   PROTEIN SEQUENCE OF 20-32 AND 94-111, PROTEOLYTIC PROCESSING, AND
RP   INDUCTION.
RC   TISSUE=Fibrosarcoma;
RX   PubMed=1400481;
RA   Okada Y., Gonoji Y., Naka K., Tomita K., Nakanishi I., Iwata K.,
RA   Yamashita K., Hayakawa T.;
RT   "Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase)
RT   from HT 1080 human fibrosarcoma cells. Purification and activation of
RT   the precursor and enzymic properties.";
RL   J. Biol. Chem. 267:21712-21719(1992).
RN   [13]
RP   PROTEIN SEQUENCE OF 20-27; 60-67; 94-101 AND 107-113.
RX   PubMed=7669817; DOI=10.1016/0167-4838(95)00086-A;
RA   Sang Q.X., Birkedal-Hansen H., Van Wart H.E.;
RT   "Proteolytic and non-proteolytic activation of human neutrophil
RT   progelatinase B.";
RL   Biochim. Biophys. Acta 1251:99-108(1995).
RN   [14]
RP   PROTEIN SEQUENCE OF 28-60.
RC   TISSUE=Neutrophil;
RX   PubMed=1645657; DOI=10.1111/j.1432-1033.1991.tb16027.x;
RA   Masure S., Proost P., van Damme J., Opdenakker G.;
RT   "Purification and identification of 91-kDa neutrophil gelatinase.
RT   Release by the activating peptide interleukin-8.";
RL   Eur. J. Biochem. 198:391-398(1991).
RN   [15]
RP   PROTEIN SEQUENCE OF 28-37.
RX   PubMed=1932376;
RA   Opdenakker G., Masure S., Grillet B., Van Damme J.;
RT   "Cytokine-mediated regulation of human leukocyte gelatinases and role
RT   in arthritis.";
RL   Lymphokine Cytokine Res. 10:317-324(1991).
RN   [16]
RP   PROTEIN SEQUENCE OF 93-115, FUNCTION, AND CATALYTIC ACTIVITY.
RC   TISSUE=Blood;
RX   PubMed=1480034;
RA   Tschesche H., Knaeuper V., Kraemer S., Michaelis J., Oberhoff R.,
RA   Reinke H.;
RT   "Latent collagenase and gelatinase from human neutrophils and their
RT   activation.";
RL   Matrix Suppl. 1:245-255(1992).
RN   [17]
RP   CHARACTERIZATION.
RA   Kang K., Lee D.-H.;
RT   "Purification and characterization of human 92-kDa type IV collagenase
RT   (gelatinase B).";
RL   Exp. Mol. Med. 28:161-165(1996).
RN   [18]
RP   SUBUNIT.
RX   PubMed=10644727; DOI=10.1074/jbc.275.4.2661;
RA   Olson M.W., Bernardo M.M., Pietila M., Gervasi D.C., Toth M.,
RA   Kotra L.P., Massova I., Mobashery S., Fridman R.;
RT   "Characterization of the monomeric and dimeric forms of latent and
RT   active matrix metalloproteinase-9. Differential rates for activation
RT   by stromelysin 1.";
RL   J. Biol. Chem. 275:2661-2668(2000).
RN   [19]
RP   ENZYME REGULATION.
RX   PubMed=11179305; DOI=10.1128/IAI.69.3.1402-1408.2001;
RA   Gusman H., Travis J., Helmerhorst E.J., Potempa J., Troxler R.F.,
RA   Oppenheim F.G.;
RT   "Salivary histatin 5 is an inhibitor of both host and bacterial
RT   enzymes implicated in periodontal disease.";
RL   Infect. Immun. 69:1402-1408(2001).
RN   [20]
RP   PROTEOLYTIC PROCESSING OF KISS1.
RX   PubMed=12879005; DOI=10.1038/sj.onc.1206542;
RA   Takino T., Koshikawa N., Miyamori H., Tanaka M., Sasaki T., Okada Y.,
RA   Seiki M., Sato H.;
RT   "Cleavage of metastasis suppressor gene product KiSS-1
RT   protein/metastin by matrix metalloproteinases.";
RL   Oncogene 22:4617-4626(2003).
RN   [21]
RP   INTERACTION WITH ECM1, AND ENZYME REGULATION.
RX   PubMed=16512877; DOI=10.1111/j.0906-6705.2006.00409.x;
RA   Fujimoto N., Terlizzi J., Aho S., Brittingham R., Fertala A.,
RA   Oyama N., McGrath J.A., Uitto J.;
RT   "Extracellular matrix protein 1 inhibits the activity of matrix
RT   metalloproteinase 9 through high-affinity protein/protein
RT   interactions.";
RL   Exp. Dermatol. 15:300-307(2006).
RN   [22]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO IDD.
RX   PubMed=18455130; DOI=10.1016/j.ajhg.2008.03.013;
RA   Hirose Y., Chiba K., Karasugi T., Nakajima M., Kawaguchi Y.,
RA   Mikami Y., Furuichi T., Mio F., Miyake A., Miyamoto T., Ozaki K.,
RA   Takahashi A., Mizuta H., Kubo T., Kimura T., Tanaka T., Toyama Y.,
RA   Ikegawa S.;
RT   "A functional polymorphism in THBS2 that affects alternative splicing
RT   and MMP binding is associated with lumbar-disc herniation.";
RL   Am. J. Hum. Genet. 82:1122-1129(2008).
RN   [23]
RP   INVOLVEMENT IN MANDP2.
RX   PubMed=19615667; DOI=10.1016/j.ajhg.2009.06.014;
RA   Lausch E., Keppler R., Hilbert K., Cormier-Daire V., Nikkel S.,
RA   Nishimura G., Unger S., Spranger J., Superti-Furga A., Zabel B.;
RT   "Mutations in MMP9 and MMP13 determine the mode of inheritance and the
RT   clinical spectrum of metaphyseal anadysplasia.";
RL   Am. J. Hum. Genet. 85:168-178(2009).
RN   [24]
RP   INDUCTION.
RX   PubMed=19893577; DOI=10.1038/embor.2009.233;
RA   Kawasaki Y., Tsuji S., Muroya K., Furukawa S., Shibata Y., Okuno M.,
RA   Ohwada S., Akiyama T.;
RT   "The adenomatous polyposis coli-associated exchange factors Asef and
RT   Asef2 are required for adenoma formation in Apc(Min/+)mice.";
RL   EMBO Rep. 10:1355-1362(2009).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 20-444 IN COMPLEX WITH ZINC
RP   AND MAGNESIUM IONS.
RX   PubMed=12077439; DOI=10.1107/S0907444902007849;
RA   Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J.,
RA   McQueney M.S., Cummings M.D., Romanic A.M.;
RT   "Structure of the C-terminally truncated human ProMMP9, a gelatin-
RT   binding matrix metalloproteinase.";
RL   Acta Crystallogr. D 58:1182-1192(2002).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 107-215 IN COMPLEX WITH
RP   INHIBITOR; ZINC AND CALCIUM IONS, AND MUTAGENESIS OF GLU-402.
RX   PubMed=12051944; DOI=10.1016/S0022-2836(02)00262-0;
RA   Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M.V.,
RA   Barratt D.G., Slater A.M., McPheat W.L., Waterson D., Henney A.M.,
RA   Pauptit R.A.;
RT   "Crystal structure of human MMP9 in complex with a reverse hydroxamate
RT   inhibitor.";
RL   J. Mol. Biol. 319:173-181(2002).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 513-707, AND SUBUNIT.
RX   PubMed=12126625; DOI=10.1016/S0022-2836(02)00558-2;
RA   Cha H., Kopetzki E., Huber R., Lanzendoerfer M., Brandstetter H.;
RT   "Structural basis of the adaptive molecular recognition by MMP9.";
RL   J. Mol. Biol. 320:1065-1079(2002).
RN   [28]
RP   3D-STRUCTURE MODELING.
RA   Mallena S.C., Sagajkar R.D.;
RT   "Theoretical model of human type IV collagenase precursor.";
RL   Submitted (APR-2002) to the PDB data bank.
RN   [29]
RP   VARIANTS VAL-20; LYS-82 AND ARG-279.
RX   PubMed=10598806; DOI=10.1007/s004390051124;
RA   Zhang B., Henney A., Eriksson P., Hamsten A., Watkins H., Ye S.;
RT   "Genetic variation at the matrix metalloproteinase-9 locus on
RT   chromosome 20q12.2-13.1.";
RL   Hum. Genet. 105:418-423(1999).
CC   -!- FUNCTION: May play an essential role in local proteolysis of the
CC       extracellular matrix and in leukocyte migration. Could play a role
CC       in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu
CC       bond. Cleaves type IV and type V collagen into large C-terminal
CC       three quarter fragments and shorter N-terminal one quarter
CC       fragments. Degrades fibronectin but not laminin or Pz-peptide.
CC       {ECO:0000269|PubMed:1480034}.
CC   -!- CATALYTIC ACTIVITY: Cleavage of gelatin types I and V and collagen
CC       types IV and V. {ECO:0000269|PubMed:1480034}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 2 Zn(2+) ions per subunit.;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 3 Ca(2+) ions per subunit.;
CC   -!- ENZYME REGULATION: Inhibited by histatin-3 1/24 (histatin-5).
CC       Inhibited by ECM1. {ECO:0000269|PubMed:11179305,
CC       ECO:0000269|PubMed:16512877}.
CC   -!- SUBUNIT: Exists as monomer or homodimer; disulfide-linked. Exists
CC       also as heterodimer with a 25 kDa protein. Macrophages and
CC       transformed cell lines produce only the monomeric form. Interacts
CC       with ECM1. {ECO:0000269|PubMed:10644727,
CC       ECO:0000269|PubMed:12051944, ECO:0000269|PubMed:12077439,
CC       ECO:0000269|PubMed:12126625, ECO:0000269|PubMed:16512877}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1382326, EBI-1382326;
CC       Q16819:MEP1A; NbExp=2; IntAct=EBI-1382326, EBI-8153734;
CC       Q16820:MEP1B; NbExp=2; IntAct=EBI-1382326, EBI-968418;
CC       Q8IX30:SCUBE3; NbExp=2; IntAct=EBI-1382326, EBI-4479975;
CC       P01033:TIMP1; NbExp=2; IntAct=EBI-1382326, EBI-712536;
CC       P13611:VCAN; NbExp=3; IntAct=EBI-1382326, EBI-8515977;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Produced by normal alveolar macrophages and
CC       granulocytes.
CC   -!- INDUCTION: Activated by 4-aminophenylmercuric acetate and phorbol
CC       ester. Up-regulated by ARHGEF4, SPATA13 and APC via the JNK
CC       signaling pathway in colorectal tumor cells.
CC       {ECO:0000269|PubMed:1371271, ECO:0000269|PubMed:1400481,
CC       ECO:0000269|PubMed:19893577}.
CC   -!- DOMAIN: The conserved cysteine present in the cysteine-switch
CC       motif binds the catalytic zinc ion, thus inhibiting the enzyme.
CC       The dissociation of the cysteine from the zinc ion upon the
CC       activation-peptide release activates the enzyme.
CC   -!- PTM: Processing of the precursor yields different active forms of
CC       64, 67 and 82 kDa. Sequentially processing by MMP3 yields the 82
CC       kDa matrix metalloproteinase-9. {ECO:0000269|PubMed:12879005,
CC       ECO:0000269|PubMed:1371271, ECO:0000269|PubMed:1400481}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:1464361}.
CC   -!- DISEASE: Intervertebral disc disease (IDD) [MIM:603932]: A common
CC       musculo-skeletal disorder caused by degeneration of intervertebral
CC       disks of the lumbar spine. It results in low-back pain and
CC       unilateral leg pain. {ECO:0000269|PubMed:18455130}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Metaphyseal anadysplasia 2 (MANDP2) [MIM:613073]: A bone
CC       development disorder characterized by skeletal anomalies that
CC       resolve spontaneously with age. Clinical characteristics are
CC       evident from the first months of life and include slight shortness
CC       of stature and a mild varus deformity of the legs. Patients attain
CC       a normal stature in adolescence and show improvement or complete
CC       resolution of varus deformity of the legs and rhizomelic
CC       micromelia. {ECO:0000269|PubMed:19615667}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: In the arthritis patient this enzyme might
CC       contribute to the pathogenesis of joint destruction and might
CC       constitute a useful marker of disease status.
CC   -!- SIMILARITY: Belongs to the peptidase M10A family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-II domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00479}.
CC   -!- SIMILARITY: Contains 4 hemopexin repeats. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MMP9ID41408ch20q11.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mmp9/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/mmp9/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05070; AAA51539.1; -; mRNA.
DR   EMBL; M68343; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68344; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68345; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68346; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68347; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68348; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68349; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68350; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68351; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68352; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68353; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68354; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M68355; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK313137; BAG35956.1; -; mRNA.
DR   EMBL; AF538844; AAM97934.1; -; Genomic_DNA.
DR   EMBL; DQ194553; ABA03169.1; -; Genomic_DNA.
DR   EMBL; AL162458; CAC10459.1; -; Genomic_DNA.
DR   EMBL; BC006093; AAH06093.1; -; mRNA.
DR   EMBL; D10051; BAA20967.1; -; Genomic_DNA.
DR   CCDS; CCDS13390.1; -.
DR   PIR; A34458; A34458.
DR   RefSeq; NP_004985.2; NM_004994.2.
DR   UniGene; Hs.297413; -.
DR   PDB; 1GKC; X-ray; 2.30 A; A/B=107-443.
DR   PDB; 1GKD; X-ray; 2.10 A; A/B=107-443.
DR   PDB; 1ITV; X-ray; 1.95 A; A/B=513-707.
DR   PDB; 1L6J; X-ray; 2.50 A; A=20-444.
DR   PDB; 1LKG; Model; -; A=1-707.
DR   PDB; 2OVX; X-ray; 2.00 A; A/B=110-443.
DR   PDB; 2OVZ; X-ray; 2.00 A; A/B=110-443.
DR   PDB; 2OW0; X-ray; 2.00 A; A/B=110-443.
DR   PDB; 2OW1; X-ray; 2.20 A; A/B=110-443.
DR   PDB; 2OW2; X-ray; 2.90 A; A/B=110-443.
DR   PDB; 4H1Q; X-ray; 1.59 A; A/B=110-214, A/B=391-444.
DR   PDB; 4H2E; X-ray; 2.90 A; A/B=107-461.
DR   PDB; 4H3X; X-ray; 1.76 A; A/B=107-461.
DR   PDB; 4H82; X-ray; 1.90 A; A/B/C/D=110-444.
DR   PDB; 4HMA; X-ray; 1.94 A; A/B=110-214, A/B=391-444.
DR   PDB; 4JIJ; X-ray; 1.70 A; A/B=107-444.
DR   PDB; 4JQG; X-ray; 1.85 A; A/B=107-444.
DR   PDB; 4WZV; X-ray; 1.65 A; A/B=110-444.
DR   PDB; 4XCT; X-ray; 1.30 A; A=113-444.
DR   PDBsum; 1GKC; -.
DR   PDBsum; 1GKD; -.
DR   PDBsum; 1ITV; -.
DR   PDBsum; 1L6J; -.
DR   PDBsum; 1LKG; -.
DR   PDBsum; 2OVX; -.
DR   PDBsum; 2OVZ; -.
DR   PDBsum; 2OW0; -.
DR   PDBsum; 2OW1; -.
DR   PDBsum; 2OW2; -.
DR   PDBsum; 4H1Q; -.
DR   PDBsum; 4H2E; -.
DR   PDBsum; 4H3X; -.
DR   PDBsum; 4H82; -.
DR   PDBsum; 4HMA; -.
DR   PDBsum; 4JIJ; -.
DR   PDBsum; 4JQG; -.
DR   PDBsum; 4WZV; -.
DR   PDBsum; 4XCT; -.
DR   ProteinModelPortal; P14780; -.
DR   SMR; P14780; 26-707.
DR   BioGrid; 110461; 17.
DR   DIP; DIP-29518N; -.
DR   IntAct; P14780; 10.
DR   MINT; MINT-7709677; -.
DR   STRING; 9606.ENSP00000361405; -.
DR   BindingDB; P14780; -.
DR   ChEMBL; CHEMBL2095216; -.
DR   DrugBank; DB01197; Captopril.
DR   DrugBank; DB01296; Glucosamine.
DR   DrugBank; DB00786; Marimastat.
DR   DrugBank; DB01017; Minocycline.
DR   GuidetoPHARMACOLOGY; 1633; -.
DR   MEROPS; M10.004; -.
DR   PhosphoSite; P14780; -.
DR   UniCarbKB; P14780; -.
DR   BioMuta; MMP9; -.
DR   DMDM; 269849668; -.
DR   PaxDb; P14780; -.
DR   PeptideAtlas; P14780; -.
DR   PRIDE; P14780; -.
DR   DNASU; 4318; -.
DR   Ensembl; ENST00000372330; ENSP00000361405; ENSG00000100985.
DR   GeneID; 4318; -.
DR   KEGG; hsa:4318; -.
DR   UCSC; uc002xqz.3; human.
DR   CTD; 4318; -.
DR   GeneCards; MMP9; -.
DR   H-InvDB; HIX0015874; -.
DR   HGNC; HGNC:7176; MMP9.
DR   HPA; CAB000348; -.
DR   HPA; CAB068199; -.
DR   HPA; CAB068200; -.
DR   HPA; CAB068201; -.
DR   HPA; HPA001238; -.
DR   HPA; HPA063909; -.
DR   MalaCards; MMP9; -.
DR   MIM; 120361; gene.
DR   MIM; 603932; phenotype.
DR   MIM; 613073; phenotype.
DR   neXtProt; NX_P14780; -.
DR   Orphanet; 1040; Metaphyseal anadysplasia.
DR   PharmGKB; PA30889; -.
DR   eggNOG; KOG1565; Eukaryota.
DR   eggNOG; ENOG410XQ5D; LUCA.
DR   GeneTree; ENSGT00830000128254; -.
DR   HOVERGEN; HBG052484; -.
DR   InParanoid; P14780; -.
DR   KO; K01403; -.
DR   OMA; GFCPSER; -.
DR   OrthoDB; EOG70KGNX; -.
DR   PhylomeDB; P14780; -.
DR   TreeFam; TF315428; -.
DR   BRENDA; 3.4.24.35; 2681.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   ChiTaRS; MMP9; human.
DR   EvolutionaryTrace; P14780; -.
DR   GeneWiki; MMP9; -.
DR   GenomeRNAi; 4318; -.
DR   NextBio; 16989; -.
DR   PRO; PR:P14780; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; P14780; -.
DR   CleanEx; HS_MMP9; -.
DR   Genevisible; P14780; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005518; F:collagen binding; TAS:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008237; F:metallopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0035987; P:endodermal cell differentiation; IEP:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; IEA:InterPro.
DR   GO; GO:0030225; P:macrophage differentiation; TAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:CACAO.
DR   GO; GO:2001258; P:negative regulation of cation channel activity; IDA:UniProtKB.
DR   GO; GO:2001268; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; IMP:CACAO.
DR   GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IMP:CACAO.
DR   GO; GO:0001503; P:ossification; IEA:InterPro.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IDA:CACAO.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IMP:CACAO.
DR   GO; GO:0051549; P:positive regulation of keratinocyte migration; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:CACAO.
DR   GO; GO:1900122; P:positive regulation of receptor binding; IDA:UniProtKB.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IMP:CACAO.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   Gene3D; 2.10.10.10; -; 3.
DR   Gene3D; 2.110.10.10; -; 1.
DR   Gene3D; 3.40.390.10; -; 2.
DR   InterPro; IPR000562; FN_type2_col-bd.
DR   InterPro; IPR000585; Hemopexin-like_dom.
DR   InterPro; IPR018487; Hemopexin-like_repeat.
DR   InterPro; IPR018486; Hemopexin_CS.
DR   InterPro; IPR013806; Kringle-like.
DR   InterPro; IPR024079; MetalloPept_cat_dom.
DR   InterPro; IPR028688; MMP9.
DR   InterPro; IPR001818; Pept_M10_metallopeptidase.
DR   InterPro; IPR021190; Pept_M10A.
DR   InterPro; IPR021158; Pept_M10A_Zn_BS.
DR   InterPro; IPR006026; Peptidase_Metallo.
DR   InterPro; IPR002477; Peptidoglycan-bd-like.
DR   PANTHER; PTHR10201:SF30; PTHR10201:SF30; 3.
DR   Pfam; PF00040; fn2; 3.
DR   Pfam; PF00045; Hemopexin; 4.
DR   Pfam; PF00413; Peptidase_M10; 1.
DR   Pfam; PF01471; PG_binding_1; 1.
DR   PRINTS; PR00138; MATRIXIN.
DR   SMART; SM00059; FN2; 3.
DR   SMART; SM00120; HX; 4.
DR   SMART; SM00235; ZnMc; 1.
DR   SUPFAM; SSF47090; SSF47090; 1.
DR   SUPFAM; SSF50923; SSF50923; 1.
DR   SUPFAM; SSF57440; SSF57440; 3.
DR   PROSITE; PS00546; CYSTEINE_SWITCH; 1.
DR   PROSITE; PS00023; FN2_1; 3.
DR   PROSITE; PS51092; FN2_2; 3.
DR   PROSITE; PS00024; HEMOPEXIN; 1.
DR   PROSITE; PS51642; HEMOPEXIN_2; 4.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Collagen degradation; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Extracellular matrix;
KW   Glycoprotein; Hydrolase; Metal-binding; Metalloprotease; Polymorphism;
KW   Protease; Reference proteome; Repeat; Secreted; Signal; Zinc; Zymogen.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:1371271,
FT                                ECO:0000269|PubMed:1400481,
FT                                ECO:0000269|PubMed:1464361,
FT                                ECO:0000269|PubMed:1653055,
FT                                ECO:0000269|PubMed:2551898,
FT                                ECO:0000269|PubMed:7669817}.
FT   PROPEP       20     93       Activation peptide.
FT                                /FTId=PRO_0000028754.
FT   CHAIN        94      ?       67 kDa matrix metalloproteinase-9.
FT                                /FTId=PRO_0000028755.
FT   CHAIN       107    707       82 kDa matrix metalloproteinase-9.
FT                                /FTId=PRO_0000028756.
FT   PROPEP        ?    707       Removed in 64 kDa matrix
FT                                metalloproteinase-9 and 67 kDa matrix
FT                                metalloproteinase-9.
FT                                /FTId=PRO_0000028757.
FT   DOMAIN      225    273       Fibronectin type-II 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN      283    331       Fibronectin type-II 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DOMAIN      342    390       Fibronectin type-II 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   REPEAT      518    563       Hemopexin 1.
FT   REPEAT      564    608       Hemopexin 2.
FT   REPEAT      610    657       Hemopexin 3.
FT   REPEAT      658    704       Hemopexin 4.
FT   MOTIF        97    104       Cysteine switch. {ECO:0000250}.
FT   ACT_SITE    402    402
FT   METAL        99     99       Zinc 2; in inhibited form.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   METAL       131    131       Calcium 1.
FT   METAL       165    165       Calcium 2; via carbonyl oxygen.
FT   METAL       175    175       Zinc 1; structural.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   METAL       177    177       Zinc 1; structural.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   METAL       182    182       Calcium 3.
FT   METAL       183    183       Calcium 3; via carbonyl oxygen.
FT   METAL       185    185       Calcium 3; via carbonyl oxygen.
FT   METAL       187    187       Calcium 3; via carbonyl oxygen.
FT   METAL       190    190       Zinc 1; structural.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   METAL       197    197       Calcium 2; via carbonyl oxygen.
FT   METAL       199    199       Calcium 2; via carbonyl oxygen.
FT   METAL       201    201       Calcium 2.
FT   METAL       203    203       Zinc 1; structural.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   METAL       205    205       Calcium 3.
FT   METAL       206    206       Calcium 1.
FT   METAL       208    208       Calcium 1.
FT   METAL       208    208       Calcium 3.
FT   METAL       401    401       Zinc 2; catalytic.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   METAL       405    405       Zinc 2; catalytic.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   METAL       411    411       Zinc 2; catalytic.
FT                                {ECO:0000269|PubMed:12051944,
FT                                ECO:0000269|PubMed:12077439}.
FT   SITE         59     60       Cleavage; by MMP3.
FT   SITE        106    107       Cleavage; by MMP3.
FT   CARBOHYD     38     38       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    120    120       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    127    127       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    230    256       {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DISULFID    244    271       {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DISULFID    288    314       {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DISULFID    302    329       {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DISULFID    347    373       {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DISULFID    361    388       {ECO:0000255|PROSITE-ProRule:PRU00479}.
FT   DISULFID    516    704
FT   VARIANT      20     20       A -> V (in dbSNP:rs1805088).
FT                                {ECO:0000269|PubMed:10598806,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013780.
FT   VARIANT      38     38       N -> S (in dbSNP:rs41427445).
FT                                /FTId=VAR_037004.
FT   VARIANT      82     82       E -> K (in dbSNP:rs1805089).
FT                                {ECO:0000269|PubMed:10598806}.
FT                                /FTId=VAR_013781.
FT   VARIANT     127    127       N -> K (in dbSNP:rs3918252).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_020054.
FT   VARIANT     239    239       R -> H (in dbSNP:rs28763886).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_025165.
FT   VARIANT     279    279       Q -> R (common polymorphism; may be
FT                                associated with susceptibility to IDD;
FT                                dbSNP:rs17576).
FT                                {ECO:0000269|PubMed:10598806,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2551898,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_013782.
FT   VARIANT     571    571       F -> V (in dbSNP:rs35691798).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_025166.
FT   VARIANT     574    574       R -> P (in dbSNP:rs2250889).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2551898,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024595.
FT   VARIANT     668    668       R -> Q (in dbSNP:rs17577).
FT                                {ECO:0000269|Ref.4, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014742.
FT   MUTAGEN     402    402       E->Q: Loss of activity.
FT                                {ECO:0000269|PubMed:12051944}.
FT   CONFLICT    110    110       F -> L (in Ref. 3; BAG35956).
FT                                {ECO:0000305}.
FT   HELIX        41     51       {ECO:0000244|PDB:1L6J}.
FT   HELIX        68     78       {ECO:0000244|PDB:1L6J}.
FT   HELIX        88     94       {ECO:0000244|PDB:1L6J}.
FT   STRAND      103    105       {ECO:0000244|PDB:1L6J}.
FT   STRAND      112    115       {ECO:0000244|PDB:4JIJ}.
FT   STRAND      117    125       {ECO:0000244|PDB:4XCT}.
FT   STRAND      130    132       {ECO:0000244|PDB:4WZV}.
FT   HELIX       134    149       {ECO:0000244|PDB:4XCT}.
FT   STRAND      151    153       {ECO:0000244|PDB:4WZV}.
FT   STRAND      155    158       {ECO:0000244|PDB:4XCT}.
FT   STRAND      160    162       {ECO:0000244|PDB:4JIJ}.
FT   STRAND      165    171       {ECO:0000244|PDB:4XCT}.
FT   STRAND      176    178       {ECO:0000244|PDB:4XCT}.
FT   STRAND      183    186       {ECO:0000244|PDB:4XCT}.
FT   STRAND      189    191       {ECO:0000244|PDB:4XCT}.
FT   STRAND      194    196       {ECO:0000244|PDB:4XCT}.
FT   TURN        197    200       {ECO:0000244|PDB:4XCT}.
FT   STRAND      202    205       {ECO:0000244|PDB:4XCT}.
FT   STRAND      213    216       {ECO:0000244|PDB:4XCT}.
FT   STRAND      221    225       {ECO:0000244|PDB:1L6J}.
FT   STRAND      232    238       {ECO:0000244|PDB:1L6J}.
FT   STRAND      240    243       {ECO:0000244|PDB:1L6J}.
FT   STRAND      255    261       {ECO:0000244|PDB:1L6J}.
FT   HELIX       262    265       {ECO:0000244|PDB:1L6J}.
FT   STRAND      268    270       {ECO:0000244|PDB:1L6J}.
FT   TURN        274    276       {ECO:0000244|PDB:1L6J}.
FT   STRAND      279    283       {ECO:0000244|PDB:1L6J}.
FT   STRAND      290    294       {ECO:0000244|PDB:1L6J}.
FT   STRAND      297    301       {ECO:0000244|PDB:1L6J}.
FT   STRAND      313    319       {ECO:0000244|PDB:1L6J}.
FT   HELIX       320    323       {ECO:0000244|PDB:1L6J}.
FT   STRAND      326    328       {ECO:0000244|PDB:1L6J}.
FT   HELIX       333    335       {ECO:0000244|PDB:1L6J}.
FT   TURN        340    344       {ECO:0000244|PDB:1L6J}.
FT   STRAND      349    353       {ECO:0000244|PDB:1L6J}.
FT   STRAND      356    358       {ECO:0000244|PDB:1L6J}.
FT   STRAND      372    378       {ECO:0000244|PDB:1L6J}.
FT   HELIX       379    382       {ECO:0000244|PDB:1L6J}.
FT   STRAND      385    387       {ECO:0000244|PDB:1L6J}.
FT   STRAND      392    394       {ECO:0000244|PDB:4XCT}.
FT   HELIX       395    406       {ECO:0000244|PDB:4XCT}.
FT   STRAND      408    411       {ECO:0000244|PDB:4H3X}.
FT   STRAND      420    422       {ECO:0000244|PDB:4XCT}.
FT   HELIX       433    443       {ECO:0000244|PDB:4XCT}.
FT   STRAND      444    446       {ECO:0000244|PDB:4H2E}.
FT   HELIX       450    460       {ECO:0000244|PDB:4H3X}.
FT   HELIX       515    517       {ECO:0000244|PDB:1ITV}.
FT   STRAND      522    527       {ECO:0000244|PDB:1ITV}.
FT   STRAND      530    535       {ECO:0000244|PDB:1ITV}.
FT   STRAND      538    542       {ECO:0000244|PDB:1ITV}.
FT   STRAND      545    547       {ECO:0000244|PDB:1ITV}.
FT   STRAND      551    555       {ECO:0000244|PDB:1ITV}.
FT   HELIX       556    559       {ECO:0000244|PDB:1ITV}.
FT   STRAND      568    572       {ECO:0000244|PDB:1ITV}.
FT   TURN        574    576       {ECO:0000244|PDB:1ITV}.
FT   STRAND      579    583       {ECO:0000244|PDB:1ITV}.
FT   STRAND      586    591       {ECO:0000244|PDB:1ITV}.
FT   STRAND      594    600       {ECO:0000244|PDB:1ITV}.
FT   HELIX       601    604       {ECO:0000244|PDB:1ITV}.
FT   STRAND      615    618       {ECO:0000244|PDB:1ITV}.
FT   STRAND      623    628       {ECO:0000244|PDB:1ITV}.
FT   STRAND      631    636       {ECO:0000244|PDB:1ITV}.
FT   TURN        637    640       {ECO:0000244|PDB:1ITV}.
FT   HELIX       644    646       {ECO:0000244|PDB:1ITV}.
FT   HELIX       650    653       {ECO:0000244|PDB:1ITV}.
FT   STRAND      662    667       {ECO:0000244|PDB:1ITV}.
FT   STRAND      670    675       {ECO:0000244|PDB:1ITV}.
FT   STRAND      678    683       {ECO:0000244|PDB:1ITV}.
FT   STRAND      690    696       {ECO:0000244|PDB:1ITV}.
FT   TURN        697    700       {ECO:0000244|PDB:1ITV}.
SQ   SEQUENCE   707 AA;  78458 MW;  2165AC8CA1466209 CRC64;
     MSLWQPLVLV LLVLGCCFAA PRQRQSTLVL FPGDLRTNLT DRQLAEEYLY RYGYTRVAEM
     RGESKSLGPA LLLLQKQLSL PETGELDSAT LKAMRTPRCG VPDLGRFQTF EGDLKWHHHN
     ITYWIQNYSE DLPRAVIDDA FARAFALWSA VTPLTFTRVY SRDADIVIQF GVAEHGDGYP
     FDGKDGLLAH AFPPGPGIQG DAHFDDDELW SLGKGVVVPT RFGNADGAAC HFPFIFEGRS
     YSACTTDGRS DGLPWCSTTA NYDTDDRFGF CPSERLYTQD GNADGKPCQF PFIFQGQSYS
     ACTTDGRSDG YRWCATTANY DRDKLFGFCP TRADSTVMGG NSAGELCVFP FTFLGKEYST
     CTSEGRGDGR LWCATTSNFD SDKKWGFCPD QGYSLFLVAA HEFGHALGLD HSSVPEALMY
     PMYRFTEGPP LHKDDVNGIR HLYGPRPEPE PRPPTTTTPQ PTAPPTVCPT GPPTVHPSER
     PTAGPTGPPS AGPTGPPTAG PSTATTVPLS PVDDACNVNI FDAIAEIGNQ LYLFKDGKYW
     RFSEGRGSRP QGPFLIADKW PALPRKLDSV FEERLSKKLF FFSGRQVWVY TGASVLGPRR
     LDKLGLGADV AQVTGALRSG RGKMLLFSGR RLWRFDVKAQ MVDPRSASEV DRMFPGVPLD
     THDVFQYREK AYFCQDRFYW RVSSRSELNQ VDQVGYVTYD ILQCPED
//
ID   TIE2_MOUSE              Reviewed;        1122 AA.
AC   Q02858;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 2.
DT   17-FEB-2016, entry version 162.
DE   RecName: Full=Angiopoietin-1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Endothelial tyrosine kinase;
DE   AltName: Full=HYK;
DE   AltName: Full=STK1;
DE   AltName: Full=Tunica interna endothelial cell kinase;
DE   AltName: Full=Tyrosine kinase with Ig and EGF homology domains-2;
DE   AltName: Full=Tyrosine-protein kinase receptor TEK;
DE   AltName: Full=Tyrosine-protein kinase receptor TIE-2;
DE            Short=mTIE2;
DE   AltName: Full=p140 TEK;
DE   AltName: CD_antigen=CD202b;
DE   Flags: Precursor;
GN   Name=Tek; Synonyms=Hyk, Tie-2, Tie2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ; TISSUE=Lung;
RX   PubMed=8415706; DOI=10.1073/pnas.90.20.9355;
RA   Sato T.N., Qin Y., Kozak C.A., Andus K.L.;
RT   "Tie-1 and tie-2 define another class of putative receptor tyrosine
RT   kinase genes expressed in early embryonic vascular system.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:9355-9358(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=CD-1; TISSUE=Embryonic heart;
RX   PubMed=8386827;
RA   Dumont D.J., Gradwol G.J., Fong G.-H., Auerbach R., Breitman M.L.;
RT   "The endothelial-specific receptor tyrosine kinase, tek, is a member
RT   of a new subfamily of receptors.";
RL   Oncogene 8:1293-1301(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Embryonic stem cell;
RX   PubMed=1282811; DOI=10.1016/0006-291X(92)90280-X;
RA   Horita K., Yagi T., Kohmura N., Tomooka Y., Ikawa Y., Aizawa S.;
RT   "A novel tyrosine kinase, hyk, expressed in murine embryonic stem
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 189:1747-1753(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=8217221;
RA   Runting A.S., Stacker S.A., Wilks A.F.;
RT   "Tie2, a putative protein tyrosine kinase from a new class of cell
RT   surface receptor.";
RL   Growth Factors 9:99-105(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8187650;
RA   Schnuerch H., Risau W.;
RT   "Expression of tie-2, a member of a novel family of receptor tyrosine
RT   kinases, in the endothelial cell lineage.";
RL   Development 119:957-968(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Hematopoietic stem cell;
RX   PubMed=8395828; DOI=10.1006/bbrc.1993.2045;
RA   Iwama A., Hamaguchi I., Hashiyama M., Murayama Y., Yasunaga K.,
RA   Suda T.;
RT   "Molecular cloning and characterization of mouse TIE and TEK receptor
RT   tyrosine kinase genes and their expression in hematopoietic stem
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 195:301-309(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 822-1122.
RC   STRAIN=CD-1; TISSUE=Embryonic heart;
RX   PubMed=1630810;
RA   Dumont D.J., Yamaguchi T.P., Conlon R.A., Rossant J., Breitman M.L.;
RT   "Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is
RT   expressed in endothelial cells and their presumptive precursors.";
RL   Oncogene 7:1471-1480(1992).
RN   [8]
RP   DISRUPTION PHENOTYPE, MUTAGENESIS OF LYS-853, CATALYTIC ACTIVITY, AND
RP   FUNCTION.
RX   PubMed=7958865; DOI=10.1101/gad.8.16.1897;
RA   Dumont D.J., Gradwohl G., Fong G.H., Puri M.C., Gertsenstein M.,
RA   Auerbach A., Breitman M.L.;
RT   "Dominant-negative and targeted null mutations in the endothelial
RT   receptor tyrosine kinase, tek, reveal a critical role in
RT   vasculogenesis of the embryo.";
RL   Genes Dev. 8:1897-1909(1994).
RN   [9]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=7596437; DOI=10.1038/376070a0;
RA   Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y.,
RA   Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y.;
RT   "Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in
RT   blood vessel formation.";
RL   Nature 376:70-74(1995).
RN   [10]
RP   INTERACTION WITH PIK3R1, MUTAGENESIS OF TYR-1100, AND FUNCTION IN
RP   ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1.
RX   PubMed=9632797;
RA   Kontos C.D., Stauffer T.P., Yang W.P., York J.D., Huang L.,
RA   Blanar M.A., Meyer T., Peters K.G.;
RT   "Tyrosine 1101 of Tie2 is the major site of association of p85 and is
RT   required for activation of phosphatidylinositol 3-kinase and Akt.";
RL   Mol. Cell. Biol. 18:4131-4140(1998).
RN   [11]
RP   INTERACTION WITH GRB2; GRB7, GRB14, PTPN11/SHP2 AND PIK3R1, FUNCTION
RP   IN PHOSPHORYLATION OF GRB7 AND PIK3R1, AND MUTAGENESIS OF TYR-1100.
RX   PubMed=10521483; DOI=10.1074/jbc.274.43.30896;
RA   Jones N., Master Z., Jones J., Bouchard D., Gunji Y., Sasaki H.,
RA   Daly R., Alitalo K., Dumont D.J.;
RT   "Identification of Tek/Tie2 binding partners. Binding to a
RT   multifunctional docking site mediates cell survival and migration.";
RL   J. Biol. Chem. 274:30896-30905(1999).
RN   [12]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPRB.
RX   PubMed=10557082; DOI=10.1038/sj.onc.1202992;
RA   Fachinger G., Deutsch U., Risau W.;
RT   "Functional interaction of vascular endothelial-protein-tyrosine
RT   phosphatase with the angiopoietin receptor Tie-2.";
RL   Oncogene 18:5948-5953(1999).
RN   [13]
RP   ANTI-APOPTOTIC FUNCTION.
RX   PubMed=11375937; DOI=10.1093/embo-reports/kve093;
RA   Jones N., Voskas D., Master Z., Sarao R., Jones J., Dumont D.J.;
RT   "Rescue of the early vascular defects in Tek/Tie2 null mice reveals an
RT   essential survival function.";
RL   EMBO Rep. 2:438-445(2001).
RN   [14]
RP   INTERACTION WITH ANGPT1 AND ANGPT2, AND DOMAIN.
RX   PubMed=12427764; DOI=10.1074/jbc.M208550200;
RA   Fiedler U., Krissl T., Koidl S., Weiss C., Koblizek T., Deutsch U.,
RA   Martiny-Baron G., Marme D., Augustin H.G.;
RT   "Angiopoietin-1 and angiopoietin-2 share the same binding domains in
RT   the Tie-2 receptor involving the first Ig-like loop and the epidermal
RT   growth factor-like repeats.";
RL   J. Biol. Chem. 278:1721-1727(2003).
RN   [15]
RP   PHOSPHORYLATION AT TYR-1100 AND TYR-1106, MUTAGENESIS OF LYS-853;
RP   TYR-1100 AND TYR-1106, FUNCTION IN DOK2 PHOSPHORYLATION, AND
RP   INTERACTION WITH DOK2.
RX   PubMed=12665569; DOI=10.1128/MCB.23.8.2658-2668.2003;
RA   Jones N., Chen S.H., Sturk C., Master Z., Tran J., Kerbel R.S.,
RA   Dumont D.J.;
RT   "A unique autophosphorylation site on Tie2/Tek mediates Dok-R
RT   phosphotyrosine binding domain binding and function.";
RL   Mol. Cell. Biol. 23:2658-2668(2003).
RN   [16]
RP   FUNCTION AS ANGPT4 RECEPTOR AND IN ACTIVATION OF AKT1, INTERACTION
RP   WITH ANGPT4, AND AUTOPHOSPHORYLATION.
RX   PubMed=15284220; DOI=10.1096/fj.03-1466com;
RA   Lee H.J., Cho C.H., Hwang S.J., Choi H.H., Kim K.T., Ahn S.Y.,
RA   Kim J.H., Oh J.L., Lee G.M., Koh G.Y.;
RT   "Biological characterization of angiopoietin-3 and angiopoietin-4.";
RL   FASEB J. 18:1200-1208(2004).
RN   [17]
RP   INTERACTION WITH PTPRB.
RX   PubMed=19451274; DOI=10.1083/jcb.200811159;
RA   Winderlich M., Keller L., Cagna G., Broermann A., Kamenyeva O.,
RA   Kiefer F., Deutsch U., Nottebaum A.F., Vestweber D.;
RT   "VE-PTP controls blood vessel development by balancing Tie-2
RT   activity.";
RL   J. Cell Biol. 185:657-671(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brown adipose tissue, Heart, Kidney, Lung, Pancreas, and
RC   Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [19]
RP   INTERACTION WITH GRB14, AND FUNCTION IN GRB14 PHOSPHORYLATION.
RX   PubMed=20973951; DOI=10.1186/1478-811X-8-30;
RA   Sturk C., Dumont D.J.;
RT   "Tyrosine phosphorylation of Grb14 by Tie2.";
RL   Cell Commun. Signal. 8:30-30(2010).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis,
CC       endothelial cell survival, proliferation, migration, adhesion and
CC       cell spreading, reorganization of the actin cytoskeleton, but also
CC       maintenance of vascular quiescence. Has anti-inflammatory effects
CC       by preventing the leakage of proinflammatory plasma proteins and
CC       leukocytes from blood vessels. Required for normal angiogenesis
CC       and heart development during embryogenesis. Required for post-
CC       natal hematopoiesis. After birth, activates or inhibits
CC       angiogenesis, depending on the context. Inhibits angiogenesis and
CC       promotes vascular stability in quiescent vessels, where
CC       endothelial cells have tight contacts. In quiescent vessels,
CC       ANGPT1 oligomers recruit TEK to cell-cell contacts, forming
CC       complexes with TEK molecules from adjoining cells, and this leads
CC       to preferential activation of phosphatidylinositol 3-kinase and
CC       the AKT1 signaling cascades. In migrating endothelial cells that
CC       lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the
CC       extracellular matrix, leading to the formation of focal adhesion
CC       complexes, activation of PTK2/FAK and of the downstream kinases
CC       MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of
CC       sprouting angiogenesis. ANGPT1 signaling triggers receptor
CC       dimerization and autophosphorylation at specific tyrosine residues
CC       that then serve as binding sites for scaffold proteins and
CC       effectors. Signaling is modulated by ANGPT2 that has lower
CC       affinity for TEK, can promote TEK autophosphorylation in the
CC       absence of ANGPT1, but inhibits ANGPT1-mediated signaling by
CC       competing for the same binding site. Signaling is also modulated
CC       by formation of heterodimers with TIE1, and by proteolytic
CC       processing that gives rise to a soluble TEK extracellular domain.
CC       The soluble extracellular domain modulates signaling by
CC       functioning as decoy receptor for angiopoietins. TEK
CC       phosphorylates DOK2, GRB7, GRB14, PIK3R1, SHC1 and TIE1.
CC       {ECO:0000269|PubMed:10521483, ECO:0000269|PubMed:12665569,
CC       ECO:0000269|PubMed:15284220, ECO:0000269|PubMed:20973951,
CC       ECO:0000269|PubMed:7596437, ECO:0000269|PubMed:7958865,
CC       ECO:0000269|PubMed:9632797}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:7958865}.
CC   -!- ENZYME REGULATION: Angiopoietin binding leads to receptor
CC       dimerization and activation by autophosphorylation at Tyr-990 on
CC       the kinase activation loop. {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer. Heterodimer with TIE1. Interacts with ANGPT1,
CC       ANGPT2 and ANGPT4. At cell-cell contacts in quiescent cells, forms
CC       a signaling complex composed of ANGPT1 plus TEK molecules from two
CC       adjoining cells. In the absence of endothelial cell-cell contacts,
CC       interaction with ANGPT1 mediates contacts with the extracellular
CC       matrix. Interacts (tyrosine phosphorylated) with TNIP2. Interacts
CC       (tyrosine phosphorylated) with SHC1 (via SH2 domain) (By
CC       similarity). Interacts with PTPRB; this promotes endothelial cell-
CC       cell adhesion. Interacts with DOK2, GRB2, GRB7, GRB14, PIK3R1 and
CC       PTPN11/SHP2. Colocalizes with DOK2 at contacts with the
CC       extracellular matrix in migrating cells. {ECO:0000250,
CC       ECO:0000269|PubMed:10521483, ECO:0000269|PubMed:12427764,
CC       ECO:0000269|PubMed:12665569, ECO:0000269|PubMed:15284220,
CC       ECO:0000269|PubMed:19451274, ECO:0000269|PubMed:20973951,
CC       ECO:0000269|PubMed:9632797}.
CC   -!- INTERACTION:
CC       Q60631:Grb2; NbExp=3; IntAct=EBI-7099626, EBI-1688;
CC       Q03160:Grb7; NbExp=3; IntAct=EBI-7099626, EBI-7100053;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cell junction {ECO:0000250}. Cell junction, focal
CC       adhesion {ECO:0000250}. Cytoplasm, cytoskeleton {ECO:0000250}.
CC       Secreted {ECO:0000250}. Note=Recruited to cell-cell contacts in
CC       quiescent endothelial cells. Colocalizes with the actin
CC       cytoskeleton and at actin stress fibers during cell spreading.
CC       Recruited to the lower surface of migrating cells, especially the
CC       rear end of the cell. Proteolytic processing gives rise to a
CC       soluble extracellular domain that is secreted (By similarity).
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Specifically expressed in developing vascular
CC       endothelial cells. Abundantly expressed in lung and heart,
CC       moderately in brain, liver and kidney, and weakly in thymus,
CC       spleen and testis. {ECO:0000269|PubMed:8395828}.
CC   -!- DEVELOPMENTAL STAGE: Expression detectable in day 8.5 embryos.
CC   -!- DOMAIN: The soluble extracellular domain is functionally active in
CC       angiopoietin binding and can modulate the activity of the
CC       membrane-bound form by competing for angiopoietins. {ECO:0000250}.
CC   -!- PTM: Proteolytic processing leads to the shedding of the
CC       extracellular domain (soluble TIE-2 alias sTIE-2). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner, where
CC       Tyr-990 in the kinase activation loop is phosphorylated first,
CC       followed by autophosphorylation at Tyr-1106 and at additional
CC       tyrosine residues. ANGPT1-induced phosphorylation is impaired
CC       during hypoxia, due to increased expression of ANGPT2 (By
CC       similarity). Phosphorylation is important for interaction with
CC       GRB14, PIK3R1 and PTPN11. Phosphorylation at Tyr-1100 is important
CC       for interaction with GRB2 and GRB7. Phosphorylation at Tyr-1106 is
CC       important for interaction with DOK2 and for coupling to downstream
CC       signal transduction pathways in endothelial cells.
CC       Dephosphorylated by PTPRB. {ECO:0000250,
CC       ECO:0000269|PubMed:10557082, ECO:0000269|PubMed:12665569}.
CC   -!- PTM: Ubiquitinated. The phosphorylated receptor is ubiquitinated
CC       and internalized, leading to its degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Embryonically lethal. Embryos die at about
CC       10 dpc, due to strongly decreased numbers of blood vessel
CC       endothelial cells, leading to severe hemorrhaging, and due to
CC       defects in heart trabeculae development. Mice display a general
CC       malformation of the vascular network with defective sprouting and
CC       dilated blood vessels. {ECO:0000269|PubMed:7596437,
CC       ECO:0000269|PubMed:7958865}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Tie subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X71426; CAA50557.1; -; mRNA.
DR   EMBL; X67553; CAA47857.1; -; mRNA.
DR   EMBL; D13738; BAA02883.1; -; mRNA.
DR   EMBL; S67051; AAB28663.1; -; mRNA.
DR   CCDS; CCDS71421.1; -.
DR   PIR; I54237; I54237.
DR   PIR; JH0771; JH0771.
DR   PIR; JN0712; JN0712.
DR   RefSeq; NP_001277478.1; NM_001290549.1.
DR   UniGene; Mm.14313; -.
DR   ProteinModelPortal; Q02858; -.
DR   SMR; Q02858; 23-534, 811-1119.
DR   BioGrid; 204107; 5.
DR   DIP; DIP-6050N; -.
DR   IntAct; Q02858; 7.
DR   MINT; MINT-4137861; -.
DR   STRING; 10090.ENSMUSP00000099862; -.
DR   BindingDB; Q02858; -.
DR   ChEMBL; CHEMBL5199; -.
DR   iPTMnet; Q02858; -.
DR   PhosphoSite; Q02858; -.
DR   MaxQB; Q02858; -.
DR   PaxDb; Q02858; -.
DR   PRIDE; Q02858; -.
DR   Ensembl; ENSMUST00000071168; ENSMUSP00000071162; ENSMUSG00000006386.
DR   GeneID; 21687; -.
DR   KEGG; mmu:21687; -.
DR   UCSC; uc008tsk.2; mouse.
DR   CTD; 7010; -.
DR   MGI; MGI:98664; Tek.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00830000128295; -.
DR   HOGENOM; HOG000049232; -.
DR   HOVERGEN; HBG007316; -.
DR   InParanoid; Q02858; -.
DR   KO; K05121; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   Reactome; R-MMU-210993; Tie2 Signaling.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   PRO; PR:Q02858; -.
DR   Proteomes; UP000000589; Chromosome 4.
DR   Bgee; Q02858; -.
DR   CleanEx; MM_TEK; -.
DR   ExpressionAtlas; Q02858; baseline and differential.
DR   Genevisible; Q02858; MM.
DR   GO; GO:0016324; C:apical plasma membrane; ISO:MGI.
DR   GO; GO:0009925; C:basal plasma membrane; ISO:MGI.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISO:MGI.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0005911; C:cell-cell junction; ISO:MGI.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; ISM:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISO:MGI.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0005902; C:microvillus; ISO:MGI.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; IPI:MGI.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0001525; P:angiogenesis; IMP:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IMP:MGI.
DR   GO; GO:0001935; P:endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0007507; P:heart development; IMP:UniProtKB.
DR   GO; GO:0060347; P:heart trabecula formation; IMP:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IMP:MGI.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IGI:MGI.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0001569; P:patterning of blood vessels; TAS:DFLAT.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; ISO:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:MGI.
DR   GO; GO:0002741; P:positive regulation of cytokine secretion involved in immune response; IDA:MGI.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; ISS:UniProtKB.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IGI:MGI.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; TAS:DFLAT.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0051259; P:protein oligomerization; ISO:MGI.
DR   GO; GO:0045765; P:regulation of angiogenesis; IMP:MGI.
DR   GO; GO:0030334; P:regulation of cell migration; IDA:MGI.
DR   GO; GO:0001936; P:regulation of endothelial cell proliferation; TAS:DFLAT.
DR   GO; GO:0032878; P:regulation of establishment or maintenance of cell polarity; ISS:UniProtKB.
DR   GO; GO:1901222; P:regulation of NIK/NF-kappaB signaling; IGI:MGI.
DR   GO; GO:0032526; P:response to retinoic acid; IDA:BHF-UCL.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IMP:MGI.
DR   GO; GO:0002040; P:sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; ISS:UniProtKB.
DR   GO; GO:0048014; P:Tie signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; ISS:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; IMP:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002049; Laminin_EGF.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR018941; Tyr_kin_Tie2_Ig-like_dom-1_N.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 3.
DR   Pfam; PF10430; Ig_Tie2_1; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00180; EGF_Lam; 1.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00022; EGF_1; 3.
DR   PROSITE; PS01186; EGF_2; 3.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell junction; Cell membrane; Complete proteome;
KW   Cytoplasm; Cytoskeleton; Disulfide bond; EGF-like domain;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Secreted; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     22       {ECO:0000250}.
FT   CHAIN        23   1122       Angiopoietin-1 receptor.
FT                                /FTId=PRO_0000024475.
FT   TOPO_DOM     23    746       Extracellular. {ECO:0000255}.
FT   TRANSMEM    747    767       Helical. {ECO:0000255}.
FT   TOPO_DOM    768   1122       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       44    123       Ig-like C2-type 1.
FT   DOMAIN      210    252       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      254    299       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      301    341       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      350    440       Ig-like C2-type 2.
FT   DOMAIN      444    539       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      543    635       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      640    733       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      822   1094       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     828    836       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    962    962       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     853    853       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     858    858       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     990    990       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1100   1100       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:12665569}.
FT   MOD_RES    1106   1106       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12665569}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    399    399       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    464    464       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    558    558       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    595    595       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    648    648       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    690    690       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     44    102       {ECO:0000250}.
FT   DISULFID    211    220       {ECO:0000250}.
FT   DISULFID    224    233       {ECO:0000250}.
FT   DISULFID    227    240       {ECO:0000250}.
FT   DISULFID    242    251       {ECO:0000250}.
FT   DISULFID    255    264       {ECO:0000250}.
FT   DISULFID    268    274       {ECO:0000250}.
FT   DISULFID    280    287       {ECO:0000250}.
FT   DISULFID    289    298       {ECO:0000250}.
FT   DISULFID    302    311       {ECO:0000250}.
FT   DISULFID    315    323       {ECO:0000250}.
FT   DISULFID    317    329       {ECO:0000250}.
FT   DISULFID    331    340       {ECO:0000250}.
FT   DISULFID    370    424       {ECO:0000250}.
FT   MUTAGEN     853    853       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:12665569,
FT                                ECO:0000269|PubMed:7958865}.
FT   MUTAGEN    1100   1100       Y->F: Reduced levels of
FT                                autophosphorylation. Abolishes
FT                                interaction with GRB2 and GRB7. Abolishes
FT                                phosphorylation of GRB7 and PIK3R1.
FT                                {ECO:0000269|PubMed:10521483,
FT                                ECO:0000269|PubMed:12665569,
FT                                ECO:0000269|PubMed:9632797}.
FT   MUTAGEN    1106   1106       Y->F: Reduced levels of
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:12665569}.
FT   CONFLICT    161    171       FIHSVPRHEVP -> LHPLSAPGMKYL (in Ref. 3;
FT                                BAA02883). {ECO:0000305}.
FT   CONFLICT    538    538       S -> C (in Ref. 2; CAA47857).
FT                                {ECO:0000305}.
FT   CONFLICT    736    736       A -> G (in Ref. 2; CAA47857 and 4;
FT                                AAB28663). {ECO:0000305}.
FT   CONFLICT    745    761       MLLIAILGSAGMTCITV -> DATHSHPWVWNDFASPC
FT                                (in Ref. 3; BAA02883). {ECO:0000305}.
FT   CONFLICT    786    786       N -> NV (in Ref. 3; BAA02883 and 6; no
FT                                nucleotide entry). {ECO:0000305}.
FT   CONFLICT    913    913       R -> G (in Ref. 3; BAA02883).
FT                                {ECO:0000305}.
FT   CONFLICT    925    931       AIANSTA -> CHRQQYS (in Ref. 3; BAA02883).
FT                                {ECO:0000305}.
FT   CONFLICT   1117   1117       S -> P (in Ref. 3; BAA02883).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1122 AA;  125701 MW;  F879623D103FFE96 CRC64;
     MDSLAGLVLC GVSLLLYGVV EGAMDLILIN SLPLVSDAET SLTCIASGWH PHEPITIGRD
     FEALMNQHQD PLEVTQDVTR EWAKKVVWKR EKASKINGAY FCEGRVRGQA IRIRTMKMRQ
     QASFLPATLT MTVDRGDNVN ISFKKVLIKE EDAVIYKNGS FIHSVPRHEV PDILEVHLPH
     AQPQDAGVYS ARYIGGNLFT SAFTRLIVRR CEAQKWGPDC SRPCTTCKNN GVCHEDTGEC
     ICPPGFMGRT CEKACEPHTF GRTCKERCSG PEGCKSYVFC LPDPYGCSCA TGWRGLQCNE
     ACPSGYYGPD CKLRCHCTNE EICDRFQGCL CSQGWQGLQC EKEGRPRMTP QIEDLPDHIE
     VNSGKFNPIC KASGWPLPTS EEMTLVKPDG TVLQPNDFNY TDRFSVAIFT VNRVLPPDSG
     VWVCSVNTVA GMVEKPFNIS VKVLPEPLHA PNVIDTGHNF AIINISSEPY FGDGPIKSKK
     LFYKPVNQAW KYIEVTNEIF TLNYLEPRTD YELCVQLARP GEGGEGHPGP VRRFTTASIG
     LPPPRGLSLL PKSQTALNLT WQPIFTNSED EFYVEVERRS LQTTSDQQNI KVPGNLTSVL
     LSNLVPREQY TVRARVNTKA QGEWSEELRA WTLSDILPPQ PENIKISNIT DSTAMVSWTI
     VDGYSISSII IRYKVQGKNE DQHIDVKIKN ATVTQYQLKG LEPETTYHVD IFAENNIGSS
     NPAFSHELRT LPHSPASADL GGGKMLLIAI LGSAGMTCIT VLLAFLIMLQ LKRANVQRRM
     AQAFQNREEP AVQFNSGTLA LNRKAKNNPD PTIYPVLDWN DIKFQDVIGE GNFGQVLKAR
     IKKDGLRMDA AIKRMKEYAS KDDHRDFAGE LEVLCKLGHH PNIINLLGAC EHRGYLYLAI
     EYAPHGNLLD FLRKSRVLET DPAFAIANST ASTLSSQQLL HFAADVARGM DYLSQKQFIH
     RDLAARNILV GENYIAKIAD FGLSRGQEVY VKKTMGRLPV RWMAIESLNY SVYTTNSDVW
     SYGVLLWEIV SLGGTPYCGM TCAELYEKLP QGYRLEKPLN CDDEVYDLMR QCWREKPYER
     PSFAQILVSL NRMLEERKTY VNTTLYEKFT YAGIDCSAEE AA
//
ID   NMDE1_RAT               Reviewed;        1464 AA.
AC   Q00959; O08948; Q63728;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   17-FEB-2016, entry version 152.
DE   RecName: Full=Glutamate receptor ionotropic, NMDA 2A;
DE            Short=GluN2A;
DE   AltName: Full=Glutamate [NMDA] receptor subunit epsilon-1;
DE   AltName: Full=N-methyl D-aspartate receptor subtype 2A;
DE            Short=NMDAR2A;
DE            Short=NR2A;
DE   Flags: Precursor;
GN   Name=Grin2a;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=1350383; DOI=10.1126/science.256.5060.1217;
RA   Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H.,
RA   Burnashev N., Sakmann B., Seeburg P.H.;
RT   "Heteromeric NMDA receptors: molecular and functional distinction of
RT   subtypes.";
RL   Science 256:1217-1221(1992).
RN   [2]
RP   SEQUENCE REVISION TO 595 AND 597-598.
RA   Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H.,
RA   Burnashev N., Sakmann B., Seeburg P.H.;
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Forebrain;
RX   PubMed=8428958;
RA   Ishii T., Moriyoshi K., Sugihara H., Sakurada K., Kadotani H.,
RA   Yokoi M., Akazawa C., Shigemoto R., Mizuno N., Masu M., Nakanishi S.;
RT   "Molecular characterization of the family of the N-methyl-D-aspartate
RT   receptor subunits.";
RL   J. Biol. Chem. 268:2836-2843(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RA   Boulter J.;
RT   "Nucleotide sequence of rat NMDA receptor gene NMDAR2A.";
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH DLG4.
RX   PubMed=7569905; DOI=10.1126/science.7569905;
RA   Kornau H.C., Schenker L.T., Kennedy M.B., Seeburg P.H.;
RT   "Domain interaction between NMDA receptor subunits and the
RT   postsynaptic density protein PSD-95.";
RL   Science 269:1737-1740(1995).
RN   [6]
RP   INTERACTION WITH AIP1.
RX   PubMed=9694864; DOI=10.1074/jbc.273.33.21105;
RA   Hirao K., Hata Y., Ide N., Takeuchi M., Irie M., Yao I., Deguchi M.,
RA   Toyoda A., Suedhof T.C., Takai Y.;
RT   "A novel multiple PDZ domain-containing molecule interacting with N-
RT   methyl-d-aspartate receptors and neuronal cell adhesion proteins.";
RL   J. Biol. Chem. 273:21105-21110(1998).
RN   [7]
RP   INTERACTION WITH INADL.
RX   PubMed=9647694; DOI=10.1006/mcne.1998.0679;
RA   Kurschner C., Mermelstein P.G., Holden W.T., Surmeier D.J.;
RT   "CIPP, a novel multivalent PDZ domain protein, selectively interacts
RT   with Kir4.0 family members, NMDA receptor subunits, neurexins, and
RT   neuroligins.";
RL   Mol. Cell. Neurosci. 11:161-172(1998).
RN   [8]
RP   SUBCELLULAR LOCATION, AND IDENTIFICATION IN A COMPLEX WITH GRIN1 AND
RP   GRIN3A.
RX   PubMed=11160393;
RA   Perez-Otano I., Schulteis C.T., Contractor A., Lipton S.A.,
RA   Trimmer J.S., Sucher N.J., Heinemann S.F.;
RT   "Assembly with the NR1 subunit is required for surface expression of
RT   NR3A-containing NMDA receptors.";
RL   J. Neurosci. 21:1228-1237(2001).
RN   [9]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1; GRIN3A AND PPP2CB.
RX   PubMed=11588171;
RA   Chan S.F., Sucher N.J.;
RT   "An NMDA receptor signaling complex with protein phosphatase 2A.";
RL   J. Neurosci. 21:7985-7992(2001).
RN   [10]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND GRIN3A.
RX   PubMed=12391275; DOI=10.1124/mol.62.5.1119;
RA   Al-Hallaq R.A., Jarabek B.R., Fu Z., Vicini S., Wolfe B.B.,
RA   Yasuda R.P.;
RT   "Association of NR3A with the N-methyl-D-aspartate receptor NR1 and
RT   NR2 subunits.";
RL   Mol. Pharmacol. 62:1119-1127(2002).
RN   [11]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND GRIN3A.
RX   PubMed=11929923; DOI=10.1152/jn.00531.2001;
RA   Sasaki Y.F., Rothe T., Premkumar L.S., Das S., Cui J., Talantova M.V.,
RA   Wong H.-K., Gong X., Chan S.F., Zhang D., Nakanishi N., Sucher N.J.,
RA   Lipton S.A.;
RT   "Characterization and comparison of the NR3A subunit of the NMDA
RT   receptor in recombinant systems and primary cortical neurons.";
RL   J. Neurophysiol. 87:2052-2063(2002).
RN   [12]
RP   INTERACTION WITH LRFN2.
RX   PubMed=16495444; DOI=10.1523/JNEUROSCI.3799-05.2006;
RA   Wang C.Y., Chang K., Petralia R.S., Wang Y.X., Seabold G.K.,
RA   Wenthold R.J.;
RT   "A novel family of adhesion-like molecules that interacts with the
RT   NMDA receptor.";
RL   J. Neurosci. 26:2174-2183(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-882; SER-890; SER-929;
RP   SER-1025; SER-1059; SER-1062 AND SER-1198, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A.,
RA   Lundby C., Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14
RT   different rat organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 401-802 IN COMPLEXES WITH
RP   GRIN1 AND GLUTAMATE.
RX   PubMed=16281028; DOI=10.1038/nature04089;
RA   Furukawa H., Singh S.K., Mancusso R., Gouaux E.;
RT   "Subunit arrangement and function in NMDA receptors.";
RL   Nature 438:185-192(2005).
CC   -!- FUNCTION: NMDA receptor subtype of glutamate-gated ion channels
CC       possesses high calcium permeability and voltage-dependent
CC       sensitivity to magnesium. Activation requires binding of agonist
CC       to both types of subunits.
CC   -!- SUBUNIT: Forms heteromeric channel of a zeta subunit (GRIN1), a
CC       epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third
CC       subunit (GRIN3A or GRIN3B). Found in a complex with GRIN1, GRIN3A
CC       and PPP2CB. Interacts with AIP1. Found in a complex with GRIN1 and
CC       GRIN3B. Interacts with HIP1 and NETO1. Interacts with SNX27 (via
CC       PDZ domain); the interaction is required for recycling to the
CC       plasma membrane when endocytosed and prevent degradation in
CC       lysosomes (By similarity). Interacts with PDZ domains of INADL and
CC       DLG4. Interacts with LRFN2. {ECO:0000250,
CC       ECO:0000269|PubMed:11160393, ECO:0000269|PubMed:11588171,
CC       ECO:0000269|PubMed:11929923, ECO:0000269|PubMed:12391275,
CC       ECO:0000269|PubMed:16495444, ECO:0000269|PubMed:7569905,
CC       ECO:0000269|PubMed:9647694, ECO:0000269|PubMed:9694864}.
CC   -!- INTERACTION:
CC       P31016:Dlg4; NbExp=5; IntAct=EBI-630970, EBI-375655;
CC       P05480:Src (xeno); NbExp=5; IntAct=EBI-630970, EBI-298680;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11160393};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:11160393}. Cell
CC       junction, synapse, postsynaptic cell membrane
CC       {ECO:0000269|PubMed:11160393}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:11160393}.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel
CC       (TC 1.A.10.1) family. NR2A/GRIN2A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91561; AAC03565.1; -; mRNA.
DR   EMBL; D13211; BAA02498.1; -; mRNA.
DR   EMBL; AF001423; AAB58801.1; -; mRNA.
DR   PIR; A43274; A43274.
DR   RefSeq; NP_036705.3; NM_012573.3.
DR   UniGene; Rn.9710; -.
DR   PDB; 2A5S; X-ray; 1.70 A; A=401-539.
DR   PDB; 2A5T; X-ray; 2.00 A; B=401-539.
DR   PDB; 4JWX; X-ray; 1.50 A; A=404-801.
DR   PDB; 4NF4; X-ray; 2.00 A; B=402-539, B=661-802.
DR   PDB; 4NF5; X-ray; 1.90 A; B=402-539, B=661-802.
DR   PDB; 4NF6; X-ray; 2.10 A; B=402-539, B=661-802.
DR   PDB; 4NF8; X-ray; 1.86 A; B=402-539, B=661-802.
DR   PDBsum; 2A5S; -.
DR   PDBsum; 2A5T; -.
DR   PDBsum; 4JWX; -.
DR   PDBsum; 4NF4; -.
DR   PDBsum; 4NF5; -.
DR   PDBsum; 4NF6; -.
DR   PDBsum; 4NF8; -.
DR   ProteinModelPortal; Q00959; -.
DR   SMR; Q00959; 404-801.
DR   BioGrid; 246574; 6.
DR   DIP; DIP-34031N; -.
DR   IntAct; Q00959; 5.
DR   MINT; MINT-93314; -.
DR   STRING; 10116.ENSRNOP00000042235; -.
DR   BindingDB; Q00959; -.
DR   ChEMBL; CHEMBL2096680; -.
DR   TCDB; 1.A.10.1.6; the glutamate-gated ion channel (gic) family of neurotransmitter receptors.
DR   iPTMnet; Q00959; -.
DR   PhosphoSite; Q00959; -.
DR   SwissPalm; Q00959; -.
DR   UniCarbKB; Q00959; -.
DR   PaxDb; Q00959; -.
DR   PRIDE; Q00959; -.
DR   GeneID; 24409; -.
DR   KEGG; rno:24409; -.
DR   UCSC; RGD:2737; rat.
DR   CTD; 2903; -.
DR   RGD; 2737; Grin2a.
DR   eggNOG; KOG1053; Eukaryota.
DR   eggNOG; ENOG410XNUR; LUCA.
DR   HOGENOM; HOG000113802; -.
DR   HOVERGEN; HBG052635; -.
DR   InParanoid; Q00959; -.
DR   KO; K05209; -.
DR   PhylomeDB; Q00959; -.
DR   EvolutionaryTrace; Q00959; -.
DR   NextBio; 603227; -.
DR   PRO; PR:Q00959; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0043197; C:dendritic spine; IDA:MGI.
DR   GO; GO:0043005; C:neuron projection; IDA:UniProtKB.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IDA:RGD.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; TAS:UniProtKB.
DR   GO; GO:0043195; C:terminal bouton; IDA:RGD.
DR   GO; GO:0051117; F:ATPase binding; IPI:RGD.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:RGD.
DR   GO; GO:0005234; F:extracellular-glutamate-gated ion channel activity; IEA:InterPro.
DR   GO; GO:0016595; F:glutamate binding; IMP:UniProtKB.
DR   GO; GO:0035254; F:glutamate receptor binding; IPI:RGD.
DR   GO; GO:0004970; F:ionotropic glutamate receptor activity; IDA:RGD.
DR   GO; GO:0042165; F:neurotransmitter binding; IDA:RGD.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; IDA:RGD.
DR   GO; GO:0032403; F:protein complex binding; IPI:RGD.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0005102; F:receptor binding; IPI:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0022843; F:voltage-gated cation channel activity; IMP:RGD.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0001508; P:action potential; IMP:RGD.
DR   GO; GO:0098655; P:cation transmembrane transport; IDA:GOC.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IMP:RGD.
DR   GO; GO:0071359; P:cellular response to dsRNA; IEP:RGD.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEP:RGD.
DR   GO; GO:0071396; P:cellular response to lipid; IEP:RGD.
DR   GO; GO:0071286; P:cellular response to magnesium ion; IEP:RGD.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEP:RGD.
DR   GO; GO:0071294; P:cellular response to zinc ion; IMP:RGD.
DR   GO; GO:0021987; P:cerebral cortex development; IEP:RGD.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IMP:RGD.
DR   GO; GO:0021766; P:hippocampus development; IEP:RGD.
DR   GO; GO:0034220; P:ion transmembrane transport; IMP:GOC.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; IDA:RGD.
DR   GO; GO:0007613; P:memory; IDA:UniProtKB.
DR   GO; GO:0010942; P:positive regulation of cell death; IDA:RGD.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IDA:BHF-UCL.
DR   GO; GO:0051262; P:protein tetramerization; IDA:RGD.
DR   GO; GO:0034765; P:regulation of ion transmembrane transport; IMP:GOC.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IMP:RGD.
DR   GO; GO:0014075; P:response to amine; IEP:RGD.
DR   GO; GO:0060359; P:response to ammonium ion; IEP:RGD.
DR   GO; GO:0051592; P:response to calcium ion; IEP:RGD.
DR   GO; GO:0009743; P:response to carbohydrate; IEP:RGD.
DR   GO; GO:0042220; P:response to cocaine; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0060992; P:response to fungicide; IEP:RGD.
DR   GO; GO:0009416; P:response to light stimulus; IEP:RGD.
DR   GO; GO:0010042; P:response to manganese ion; IEP:RGD.
DR   GO; GO:0051597; P:response to methylmercury; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0051707; P:response to other organism; IEP:RGD.
DR   GO; GO:0048511; P:rhythmic process; IDA:RGD.
DR   GO; GO:0021510; P:spinal cord development; IEP:RGD.
DR   GO; GO:0007268; P:synaptic transmission; IMP:RGD.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_rcpt_met.
DR   InterPro; IPR001320; Iontro_rcpt.
DR   InterPro; IPR018884; NMDAR2_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   Pfam; PF10565; NMDAR2_C; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell junction; Cell membrane;
KW   Complete proteome; Disulfide bond; Glycoprotein; Ion channel;
KW   Ion transport; Ligand-gated ion channel; Magnesium; Membrane;
KW   Metal-binding; Phosphoprotein; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Signal; Synapse; Transmembrane;
KW   Transmembrane helix; Transport; Zinc.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23   1464       Glutamate receptor ionotropic, NMDA 2A.
FT                                /FTId=PRO_0000011576.
FT   TOPO_DOM     23    555       Extracellular. {ECO:0000255}.
FT   TRANSMEM    556    576       Helical. {ECO:0000255}.
FT   TOPO_DOM    577    633       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    634    654       Helical. {ECO:0000255}.
FT   TOPO_DOM    655    816       Extracellular. {ECO:0000255}.
FT   TRANSMEM    817    837       Helical. {ECO:0000255}.
FT   TOPO_DOM    838   1464       Cytoplasmic. {ECO:0000255}.
FT   REGION      511    513       Glutamate binding.
FT   REGION      689    690       Glutamate binding.
FT   MOTIF      1462   1464       PDZ-binding.
FT   METAL       128    128       Zinc. {ECO:0000250}.
FT   METAL       283    283       Zinc. {ECO:0000250}.
FT   BINDING     518    518       Glutamate.
FT   BINDING     731    731       Glutamate; via amide nitrogen.
FT   SITE        614    614       Functional determinant of NMDA receptors.
FT                                {ECO:0000250}.
FT   MOD_RES     882    882       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES     890    890       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES     929    929       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1025   1025       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1059   1059       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1062   1062       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   MOD_RES    1198   1198       Phosphoserine.
FT                                {ECO:0000244|PubMed:22673903}.
FT   CARBOHYD     75     75       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    340    340       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    443    443       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    444    444       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    541    541       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     87    320       {ECO:0000250}.
FT   CONFLICT    246    246       L -> F (in Ref. 3; BAA02498).
FT                                {ECO:0000305}.
FT   CONFLICT    758    758       S -> T (in Ref. 3; BAA02498 and 4;
FT                                AAB58801). {ECO:0000305}.
FT   CONFLICT    990    990       E -> D (in Ref. 4; AAB58801).
FT                                {ECO:0000305}.
FT   STRAND      406    410       {ECO:0000244|PDB:4JWX}.
FT   TURN        414    416       {ECO:0000244|PDB:4JWX}.
FT   STRAND      417    421       {ECO:0000244|PDB:4JWX}.
FT   TURN        424    426       {ECO:0000244|PDB:4JWX}.
FT   STRAND      434    447       {ECO:0000244|PDB:4JWX}.
FT   STRAND      449    458       {ECO:0000244|PDB:4JWX}.
FT   HELIX       459    471       {ECO:0000244|PDB:4JWX}.
FT   STRAND      475    479       {ECO:0000244|PDB:4JWX}.
FT   STRAND      482    485       {ECO:0000244|PDB:4JWX}.
FT   HELIX       495    501       {ECO:0000244|PDB:4JWX}.
FT   STRAND      506    508       {ECO:0000244|PDB:4JWX}.
FT   HELIX       516    519       {ECO:0000244|PDB:4JWX}.
FT   STRAND      522    524       {ECO:0000244|PDB:4JWX}.
FT   STRAND      529    531       {ECO:0000244|PDB:4JWX}.
FT   STRAND      533    538       {ECO:0000244|PDB:4JWX}.
FT   HELIX       668    671       {ECO:0000244|PDB:4JWX}.
FT   HELIX       673    675       {ECO:0000244|PDB:4JWX}.
FT   STRAND      676    678       {ECO:0000244|PDB:4JWX}.
FT   HELIX       689    697       {ECO:0000244|PDB:4JWX}.
FT   HELIX       699    705       {ECO:0000244|PDB:4JWX}.
FT   HELIX       706    708       {ECO:0000244|PDB:4JWX}.
FT   HELIX       713    721       {ECO:0000244|PDB:4JWX}.
FT   STRAND      726    731       {ECO:0000244|PDB:4JWX}.
FT   HELIX       732    740       {ECO:0000244|PDB:4JWX}.
FT   STRAND      747    751       {ECO:0000244|PDB:4JWX}.
FT   HELIX       752    754       {ECO:0000244|PDB:4NF5}.
FT   HELIX       755    757       {ECO:0000244|PDB:4JWX}.
FT   STRAND      759    761       {ECO:0000244|PDB:4JWX}.
FT   STRAND      764    766       {ECO:0000244|PDB:4JWX}.
FT   HELIX       772    784       {ECO:0000244|PDB:4JWX}.
FT   HELIX       787    795       {ECO:0000244|PDB:4JWX}.
SQ   SEQUENCE   1464 AA;  165469 MW;  DC1528E1898DECA4 CRC64;
     MGRLGYWTLL VLPALLVWRD PAQNAAAEKG PPALNIAVLL GHSHDVTERE LRNLWGPEQA
     TGLPLDVNVV ALLMNRTDPK SLITHVCDLM SGARIHGLVF GDDTDQEAVA QMLDFISSQT
     FIPILGIHGG ASMIMADKDP TSTFFQFGAS IQQQATVMLK IMQDYDWHVF SLVTTIFPGY
     RDFISFIKTT VDNSFVGWDM QNVITLDTSF EDAKTQVQLK KIHSSVILLY CSKDEAVLIL
     SEARSLGLTG YDFFWIVPSL VSGNTELIPK EFPSGLISVS YDDWDYSLEA RVRDGLGILT
     TAASSMLEKF SYIPEAKASC YGQAEKPETP LHTLHQFMVN VTWDGKDLSF TEEGYQVHPR
     LVVIVLNKDR EWEKVGKWEN QTLSLRHAVW PRYKSFSDCE PDDNHLSIVT LEEAPFVIVE
     DIDPLTETCV RNTVPCRKFV KINNSTNEGM NVKKCCKGFC IDILKKLSRT VKFTYDLYLV
     TNGKHGKKVN NVWNGMIGEV VYQRAVMAVG SLTINEERSE VVDFSVPFVE TGISVMVSRS
     NGTVSPSAFL EPFSASVWVM MFVMLLIVSA IAVFVFEYFS PVGYNRNLAK GKAPHGPSFT
     IGKAIWLLWG LVFNNSVPVQ NPKGTTSKIM VSVWAFFAVI FLASYTANLA AFMIQEEFVD
     QVTGLSDKKF QRPHDYSPPF RFGTVPNGST ERNIRNNYPY MHQYMTRFNQ RGVEDALVSL
     KTGKLDAFIY DAAVLNYKAG RDEGCKLVTI GSGYIFASTG YGIALQKGSP WKRQIDLALL
     QFVGDGEMEE LETLWLTGIC HNEKNEVMSS QLDIDNMAGV FYMLAAAMAL SLITFIWEHL
     FYWKLRFCFT GVCSDRPGLL FSISRGIYSC IHGVHIEEKK KSPDFNLTGS QSNMLKLLRS
     AKNISNMSNM NSSRMDSPKR ATDFIQRGSL IVDMVSDKGN LIYSDNRSFQ GKDSIFGDNM
     NELQTFVANR HKDNLSNYVF QGQHPLTLNE SNPNTVEVAV STESKGNSRP RQLWKKSMES
     LRQDSLNQNP VSQRDEKTAE NRTHSLKSPR YLPEEVAHSD ISETSSRATC HREPDNNKNH
     KTKDNFKRSM ASKYPKDCSD VDRTYMKTKA SSPRDKIYTI DGEKEPSFHL DPPQFVENIT
     LPENVGFPDT YQDHNENFRK GDSTLPMNRN PLHNEDGLPN NDQYKLYAKH FTLKDKGSPH
     SEGSDRYRQN STHCRSCLSN LPTYSGHFTM RSPFKCDACL RMGNLYDIDE DQMLQETGNP
     ATREEVYQQD WSQNNALQFQ KNKLRINRQH SYDNILDKPR EIDLSRPSRS ISLKDRERLL
     EGNLYGSLFS VPSSKLLGNK SSLFPQGLED SKRSKSLLPD HASDNPFLHT YGDDQRLVIG
     RCPSDPYKHS LPSQAVNDSY LRSSLRSTAS YCSRDSRGHS DVYISEHVMP YAANKNTMYS
     TPRVLNSCSN RRVYKKMPSI ESDV
//
ID   FIBB_HUMAN              Reviewed;         491 AA.
AC   P02675; A0JLR9; B2R7G3; Q32Q65; Q3KPF2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 2.
DT   17-FEB-2016, entry version 195.
DE   RecName: Full=Fibrinogen beta chain;
DE   Contains:
DE     RecName: Full=Fibrinopeptide B;
DE   Contains:
DE     RecName: Full=Fibrinogen beta chain;
DE   Flags: Precursor;
GN   Name=FGB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=6688356; DOI=10.1021/bi00282a032;
RA   Chung D.W., Que B.G., Rixon M.W., Mace M. Jr., Davie E.W.;
RT   "Characterization of complementary deoxyribonucleic acid and genomic
RT   deoxyribonucleic acid for the beta chain of human fibrinogen.";
RL   Biochemistry 22:3244-3250(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2102623;
RA   Chung D.W., Harris J.E., Davie E.W.;
RT   "Nucleotide sequences of the three genes coding for human
RT   fibrinogen.";
RL   Adv. Exp. Med. Biol. 281:39-48(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chung D.W., Harris J.E., Davie E.W.;
RT   "Nucleotide sequences of the three genes coding for human
RT   fibrinogen.";
RL   (In) Liu C.Y., Chien S. (eds.);
RL   Fibrinogen, thrombosis, coagulation and fibrinolysis, pp.39-48, Plenum
RL   Press, New York (1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-100; HIS-170;
RP   LEU-265 AND LYS-478.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-60.
RX   PubMed=6575700; DOI=10.1111/j.1749-6632.1983.tb23265.x;
RA   Chung D.W., Rixon M.W., Que B.G., Davie E.W.;
RT   "Cloning of fibrinogen genes and their cDNA.";
RL   Ann. N. Y. Acad. Sci. 408:449-456(1983).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-38.
RX   PubMed=3029722; DOI=10.1093/nar/15.4.1615;
RA   Huber P., Dalmon J., Courtois G., Laurent M., Assouline Z.,
RA   Marguerie G.;
RT   "Characterization of the 5'-flanking region for the human fibrinogen
RT   beta gene.";
RL   Nucleic Acids Res. 15:1615-1625(1987).
RN   [10]
RP   PROTEIN SEQUENCE OF 31-491, AND PYROGLUTAMATE FORMATION AT GLN-31.
RX   PubMed=420779; DOI=10.1021/bi00568a011;
RA   Watt K.W.K., Takagi T., Doolittle R.F.;
RT   "Amino acid sequence of the beta chain of human fibrinogen.";
RL   Biochemistry 18:68-76(1979).
RN   [11]
RP   PROTEIN SEQUENCE OF 31-491, AND GLYCOSYLATION AT ASN-394.
RA   Henschen A., Lottspeich F., Southan C., Topfer-Petersen E.;
RT   "Human fibrinogen: sequence, sulfur bridges, glycosylation and some
RT   structural variants.";
RL   (In) Peeters H. (eds.);
RL   Protides of the biological fluids, Proc. 28th colloquium, pp.51-56,
RL   Pergamon Press, Oxford (1980).
RN   [12]
RP   PROTEIN SEQUENCE OF 31-148, AND DISULFIDE BONDS.
RX   PubMed=936108; DOI=10.1016/0049-3848(76)90245-0;
RA   Blombaeck B., Hessel B., Hogg D.;
RT   "Disulfide bridges in NH2-terminal part of human fibrinogen.";
RL   Thromb. Res. 8:639-658(1976).
RN   [13]
RP   PROTEIN SEQUENCE OF 31-44.
RA   Blombaeck B., Blombaeck M., Grondahl N.J., Guthrie C., Hinton M.;
RT   "Studies on fibrinopeptides from primates.";
RL   Acta Chem. Scand. 19:1788-1789(1965).
RN   [14]
RP   PROTEIN SEQUENCE OF 45-53.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [15]
RP   PROTEIN SEQUENCE OF 54-72; 164-178 AND 225-239, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [16]
RP   REVIEW, AND DISULFIDE BONDS.
RX   PubMed=6575689; DOI=10.1111/j.1749-6632.1983.tb23232.x;
RA   Henschen A., Lottspeich F., Kehl M., Southan C.;
RT   "Covalent structure of fibrinogen.";
RL   Ann. N. Y. Acad. Sci. 408:28-43(1983).
RN   [17]
RP   DISULFIDE BONDS.
RX   PubMed=891553; DOI=10.1111/j.1432-1033.1977.tb11704.x;
RA   Gaardlund B., Hessel B., Marguerie G., Murano G., Blombaeck B.;
RT   "Primary structure of human fibrinogen. Characterization of disulfide-
RT   containing cyanogen-bromide fragments.";
RL   Eur. J. Biochem. 77:595-610(1977).
RN   [18]
RP   DISULFIDE BONDS.
RA   Doolittle R.F., Takagi T., Watt K.W.K., Bouma H. III, Cottrell B.A.,
RA   Cassman K.G., Goldbaum D.M., Doolittle L.R., Friezner S.J.;
RT   "The structures of fibrinogen and fibrin.";
RL   (In) Magnusson S., Ottesen M., Foltmann B., Dano K., Neurath H.
RL   (eds.);
RL   Regulatory proteolytic enzymes and their inhibitors, pp.163-172,
RL   Pergamon Press, New York (1978).
RN   [19]
RP   REVIEW, ELECTRON MICROSCOPY, POLYMERIZATION, AND LIGANDS.
RX   PubMed=6383194;
RA   Doolittle R.F.;
RT   "Fibrinogen and fibrin.";
RL   Annu. Rev. Biochem. 53:195-229(1984).
RN   [20]
RP   INTERACTION WITH FBLN1.
RX   PubMed=7642629; DOI=10.1074/jbc.270.33.19458;
RA   Tran H., Tanaka A., Litvinovich S.V., Medved L.V., Haudenschild C.C.,
RA   Argraves W.S.;
RT   "The interaction of fibulin-1 with fibrinogen. A potential role in
RT   hemostasis and thrombosis.";
RL   J. Biol. Chem. 270:19458-19464(1995).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-394.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-394.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-394.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [24]
RP   CLEAVAGE BY HEMENTIN AND PLASMIN.
RX   PubMed=2143188;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A
RT   alpha COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 164-491, DISULFIDE BONDS,
RP   AND SUBUNIT.
RX   PubMed=9333233; DOI=10.1038/38947;
RA   Spraggon G., Everse S.J., Doolittle R.F.;
RT   "Crystal structures of fragment D from human fibrinogen and its
RT   crosslinked counterpart from fibrin.";
RL   Nature 389:455-462(1997).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 164-491 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, GLYCOSYLATION AT ASN-394, SUBUNIT, COILED
RP   COIL DOMAIN, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9628725; DOI=10.1021/bi9804129;
RA   Everse S.J., Spraggon G., Veerapandian L., Riley M., Doolittle R.F.;
RT   "Crystal structure of fragment double-D from human fibrin with two
RT   different bound ligands.";
RL   Biochemistry 37:8637-8642(1998).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 164-491 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, GLYCOSYLATION AT ASN-394, SUBUNIT,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND COILED COIL DOMAIN.
RX   PubMed=10074346; DOI=10.1021/bi982626w;
RA   Everse S.J., Spraggon G., Veerapandian L., Doolittle R.F.;
RT   "Conformational changes in fragments D and double-D from human
RT   fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide.";
RL   Biochemistry 38:2941-2946(1999).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 31-491 IN COMPLEX WITH
RP   CALCIUM, DISULFIDE BONDS, GLYCOSYLATION AT ASN-394, SUBUNIT,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND COILED COIL DOMAIN.
RX   PubMed=19296670; DOI=10.1021/bi802205g;
RA   Kollman J.M., Pandi L., Sawaya M.R., Riley M., Doolittle R.F.;
RT   "Crystal structure of human fibrinogen.";
RL   Biochemistry 48:3877-3886(2009).
RN   [31]
RP   VARIANT BALTIMORE-2 LYS-478.
RX   PubMed=3194892; DOI=10.1016/0049-3848(88)90096-5;
RA   Schmelzer C.H., Ebert R.F., Bell W.R.;
RT   "A polymorphism at B beta 448 of fibrinogen identified during
RT   structural studies of fibrinogen Baltimore II.";
RL   Thromb. Res. 52:173-177(1988).
RN   [32]
RP   VARIANT ISE ARG-45.
RX   PubMed=2018836;
RA   Yoshida N., Wada H., Morita K., Hirata H., Matsuda M., Yamazumi K.,
RA   Asakura S., Shirakawa S.;
RT   "A new congenital abnormal fibrinogen Ise characterized by the
RT   replacement of B beta glycine-15 by cysteine.";
RL   Blood 77:1958-1963(1991).
RN   [33]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN THR-98.
RX   PubMed=1634610; DOI=10.1172/JCI115841;
RA   Koopman J., Haverkate F., Lord S.T., Grimbergen J., Mannucci P.M.;
RT   "Molecular basis of fibrinogen Naples associated with defective
RT   thrombin binding and thrombophilia. Homozygous substitution of B beta
RT   68 Ala-->Thr.";
RL   J. Clin. Invest. 90:238-244(1992).
RN   [34]
RP   VARIANTS IJMUIDEN CYS-44 AND NIJMEGEN CYS-74.
RX   PubMed=1565641; DOI=10.1073/pnas.89.8.3478;
RA   Koopman J., Haverkate F., Grimbergen J., Engesser L., Novakova I.,
RA   Kerst A.F.J.A., Lord S.T.;
RT   "Abnormal fibrinogens IJmuiden (B beta Arg14-->Cys) and Nijmegen (B
RT   beta Arg44-->Cys) form disulfide-linked fibrinogen-albumin
RT   complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3478-3482(1992).
RN   [35]
RP   VARIANT NEW YORK-1 39-GLY--LEU-102 DEL.
RX   PubMed=3156856;
RA   Liu C.Y., Koehn J.A., Morgan F.J.;
RT   "Characterization of fibrinogen New York 1. A dysfunctional fibrinogen
RT   with a deletion of B beta(9-72) corresponding exactly to exon 2 of the
RT   gene.";
RL   J. Biol. Chem. 260:4390-4396(1985).
RN   [36]
RP   VARIANTS GLU-2; LEU-265 AND LYS-478.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [37]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [38]
RP   VARIANTS CAFBN ARG-383 AND ASP-430.
RX   PubMed=10666208;
RA   Duga S., Asselta R., Santagostino E., Zeinali S., Simonic T.,
RA   Malcovati M., Mannucci P.M., Tenchini M.L.;
RT   "Missense mutations in the human beta fibrinogen gene cause congenital
RT   afibrinogenemia by impairing fibrinogen secretion.";
RL   Blood 95:1336-1341(2000).
RN   [39]
RP   VARIANT CAFBN CYS-196.
RX   PubMed=11468164; DOI=10.1182/blood.V98.3.661;
RA   Lounes K.C., Lefkowitz J.B., Henschen-Edman A.H., Coates A.I.,
RA   Hantgan R.R., Lord S.T.;
RT   "The impaired polymerization of fibrinogen Longmont
RT   (Bbeta166Arg-->Cys) is not improved by removal of disulfide-linked
RT   dimers from a mixture of dimers and cysteine-linked monomers.";
RL   Blood 98:661-666(2001).
RN   [40]
RP   VARIANT CAFBN GLN-202.
RX   PubMed=15070683; DOI=10.1182/blood-2003-10-3725;
RA   Asselta R., Duga S., Spena S., Peyvandi F., Castaman G., Malcovati M.,
RA   Mannucci P.M., Tenchini M.L.;
RT   "Missense or splicing mutation? The case of a fibrinogen Bbeta-chain
RT   mutation causing severe hypofibrinogenemia.";
RL   Blood 103:3051-3054(2004).
RN   [41]
RP   VARIANTS CAFBN ARG-95 AND LYS-407, AND CHARACTERIZATION OF VARIANTS
RP   CAFBN ARG-95 AND LYS-407.
RX   PubMed=25427968; DOI=10.1160/TH14-07-0629;
RA   Asselta R., Plate M., Robusto M., Borhany M., Guella I., Solda G.,
RA   Afrasiabi A., Menegatti M., Shamsi T., Peyvandi F., Duga S.;
RT   "Clinical and molecular characterisation of 21 patients affected by
RT   quantitative fibrinogen deficiency.";
RL   Thromb. Haemost. 113:567-576(2015).
CC   -!- FUNCTION: Cleaved by the protease thrombin to yield monomers
CC       which, together with fibrinogen alpha (FGA) and fibrinogen gamma
CC       (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a
CC       major function in hemostasis as one of the primary components of
CC       blood clots. In addition, functions during the early stages of
CC       wound repair to stabilize the lesion and guide cell migration
CC       during re-epithelialization. Was originally thought to be
CC       essential for platelet aggregation, based on in vitro studies
CC       using anticoagulated blood. However subsequent studies have shown
CC       that it is not absolutely required for thrombus formation in vivo.
CC       Enhances expression of SELP in activated platelets. Maternal
CC       fibrinogen is essential for successful pregnancy. Fibrin
CC       deposition is also associated with infection, where it protects
CC       against IFNG-mediated hemorrhage. May also facilitate the
CC       antibacterial immune response via both innate and T-cell mediated
CC       pathways. {ECO:0000250|UniProtKB:E9PV24}.
CC   -!- SUBUNIT: Heterohexamer; disulfide linked. Contains 2 sets of 3
CC       non-identical chains (alpha, beta and gamma). The 2 heterotrimers
CC       are in head to head conformation with the N-termini in a small
CC       central domain. {ECO:0000269|PubMed:10074346,
CC       ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9333233,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-1034445, EBI-6377335;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10074346,
CC       ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725}.
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       {ECO:0000269|PubMed:10074346, ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- DOMAIN: A long coiled coil structure formed by 3 polypeptide
CC       chains connects the central nodule to the C-terminal domains
CC       (distal nodules). The long C-terminal ends of the alpha chains
CC       fold back, contributing a fourth strand to the coiled coil
CC       structure. {ECO:0000269|PubMed:10074346,
CC       ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725}.
CC   -!- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin,
CC       which cleaves fibrinopeptides A and B from alpha and beta chains,
CC       and thus exposes the N-terminal polymerization sites responsible
CC       for the formation of the soft clot. The soft clot is converted
CC       into the hard clot by factor XIIIA which catalyzes the epsilon-
CC       (gamma-glutamyl)lysine cross-linking between gamma chains
CC       (stronger) and between alpha chains (weaker) of different
CC       monomers. {ECO:0000269|PubMed:2143188}.
CC   -!- DISEASE: Congenital afibrinogenemia (CAFBN) [MIM:202400]: Rare
CC       autosomal recessive disorder is characterized by bleeding that
CC       varies from mild to severe and by complete absence or extremely
CC       low levels of plasma and platelet fibrinogen.
CC       {ECO:0000269|PubMed:10666208, ECO:0000269|PubMed:11468164,
CC       ECO:0000269|PubMed:25427968}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Patients
CC       with congenital fibrinogen abnormalities can manifest different
CC       clinical pictures. Some cases are clinically silent, some show a
CC       tendency toward bleeding and some show a predisposition for
CC       thrombosis with or without bleeding.
CC   -!- DISEASE: Dysfibrinogenemia, congenital (DYSFIBRIN) [MIM:616004]: A
CC       disorder characterized by qualitative abnormalities
CC       (dysfibrinogenemia) of the circulating fibrinogen. Affected
CC       individuals are frequently asymptomatic, but some patients have
CC       bleeding diathesis, thromboembolic complications, or both. In some
CC       cases, dysfibrinogenemia is associated with low circulating
CC       fibrinogen levels (hypodysfibrinogenemia).
CC       {ECO:0000269|PubMed:1634610}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00739}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH07030.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=FGB";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibrinogen entry;
CC       URL="https://en.wikipedia.org/wiki/Fibrinogen";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/fgb/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00129; AAA52429.1; -; mRNA.
DR   EMBL; J00131; AAA98115.1; -; Genomic_DNA.
DR   EMBL; J00130; AAA98115.1; JOINED; Genomic_DNA.
DR   EMBL; J00132; AAA98116.1; -; Genomic_DNA.
DR   EMBL; J00133; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M64983; AAA18024.2; -; Genomic_DNA.
DR   EMBL; AF388026; AAK62470.1; -; Genomic_DNA.
DR   EMBL; AK312972; BAG35810.1; -; mRNA.
DR   EMBL; CH471056; EAX04932.1; -; Genomic_DNA.
DR   EMBL; BC007030; AAH07030.1; ALT_SEQ; mRNA.
DR   EMBL; BC106760; AAI06761.1; -; mRNA.
DR   EMBL; BC107766; AAI07767.1; -; mRNA.
DR   EMBL; AH002694; AAA52445.1; -; Genomic_DNA.
DR   EMBL; X05018; CAA28674.1; -; Genomic_DNA.
DR   CCDS; CCDS3786.1; -.
DR   PIR; B43568; FGHUB.
DR   RefSeq; NP_001171670.1; NM_001184741.1.
DR   RefSeq; NP_005132.2; NM_005141.4.
DR   UniGene; Hs.300774; -.
DR   PDB; 1FZA; X-ray; 2.90 A; B/E=164-491.
DR   PDB; 1FZB; X-ray; 2.90 A; B/E=164-491.
DR   PDB; 1FZC; X-ray; 2.30 A; B/E=164-491.
DR   PDB; 1FZE; X-ray; 3.00 A; B/E=164-491.
DR   PDB; 1FZF; X-ray; 2.70 A; B/E=164-491, M/N/S/T=45-48.
DR   PDB; 1FZG; X-ray; 2.50 A; B/E=164-491.
DR   PDB; 1LT9; X-ray; 2.80 A; B/E=179-491.
DR   PDB; 1LTJ; X-ray; 2.80 A; B/E=179-491.
DR   PDB; 1N86; X-ray; 3.20 A; B/E=164-491, I/J=45-51.
DR   PDB; 1N8E; X-ray; 4.50 A; B/E=164-491.
DR   PDB; 1RE3; X-ray; 2.45 A; B/E=179-491.
DR   PDB; 1RE4; X-ray; 2.70 A; B/E=179-491.
DR   PDB; 1RF0; X-ray; 2.81 A; B/E=179-491.
DR   PDB; 1RF1; X-ray; 2.53 A; B/E=179-491.
DR   PDB; 2A45; X-ray; 3.65 A; H/K=45-135.
DR   PDB; 2FFD; X-ray; 2.89 A; B/E=179-491.
DR   PDB; 2H43; X-ray; 2.70 A; B/E=164-491.
DR   PDB; 2HLO; X-ray; 2.60 A; B/E=164-491.
DR   PDB; 2HOD; X-ray; 2.90 A; B/E/H/K=164-491.
DR   PDB; 2HPC; X-ray; 2.90 A; B/E/H/K=164-491.
DR   PDB; 2OYH; X-ray; 2.40 A; B/E=179-491.
DR   PDB; 2OYI; X-ray; 2.70 A; B/E=179-491.
DR   PDB; 2Q9I; X-ray; 2.80 A; B/E=164-491.
DR   PDB; 2XNX; X-ray; 3.30 A; B/E/H/K=164-491.
DR   PDB; 2XNY; X-ray; 7.50 A; B/E=164-491.
DR   PDB; 2Z4E; X-ray; 2.70 A; B/E=164-489.
DR   PDB; 3BVH; X-ray; 2.60 A; B/E=191-488.
DR   PDB; 3E1I; X-ray; 2.30 A; B/E=164-491.
DR   PDB; 3GHG; X-ray; 2.90 A; B/E/H/K=31-491.
DR   PDB; 3H32; X-ray; 3.60 A; B/E=31-488.
DR   PDB; 3HUS; X-ray; 3.04 A; B/E=179-491.
DR   PDBsum; 1FZA; -.
DR   PDBsum; 1FZB; -.
DR   PDBsum; 1FZC; -.
DR   PDBsum; 1FZE; -.
DR   PDBsum; 1FZF; -.
DR   PDBsum; 1FZG; -.
DR   PDBsum; 1LT9; -.
DR   PDBsum; 1LTJ; -.
DR   PDBsum; 1N86; -.
DR   PDBsum; 1N8E; -.
DR   PDBsum; 1RE3; -.
DR   PDBsum; 1RE4; -.
DR   PDBsum; 1RF0; -.
DR   PDBsum; 1RF1; -.
DR   PDBsum; 2A45; -.
DR   PDBsum; 2FFD; -.
DR   PDBsum; 2H43; -.
DR   PDBsum; 2HLO; -.
DR   PDBsum; 2HOD; -.
DR   PDBsum; 2HPC; -.
DR   PDBsum; 2OYH; -.
DR   PDBsum; 2OYI; -.
DR   PDBsum; 2Q9I; -.
DR   PDBsum; 2XNX; -.
DR   PDBsum; 2XNY; -.
DR   PDBsum; 2Z4E; -.
DR   PDBsum; 3BVH; -.
DR   PDBsum; 3E1I; -.
DR   PDBsum; 3GHG; -.
DR   PDBsum; 3H32; -.
DR   PDBsum; 3HUS; -.
DR   ProteinModelPortal; P02675; -.
DR   SMR; P02675; 88-488.
DR   BioGrid; 108535; 111.
DR   DIP; DIP-385N; -.
DR   IntAct; P02675; 16.
DR   STRING; 9606.ENSP00000306099; -.
DR   BindingDB; P02675; -.
DR   ChEMBL; CHEMBL2364709; -.
DR   DrugBank; DB00364; Sucralfate.
DR   iPTMnet; P02675; -.
DR   PhosphoSite; P02675; -.
DR   SwissPalm; P02675; -.
DR   UniCarbKB; P02675; -.
DR   BioMuta; FGB; -.
DR   DMDM; 399492; -.
DR   DOSAC-COBS-2DPAGE; P02675; -.
DR   OGP; P02675; -.
DR   REPRODUCTION-2DPAGE; IPI00298497; -.
DR   REPRODUCTION-2DPAGE; P02675; -.
DR   SWISS-2DPAGE; P02675; -.
DR   UCD-2DPAGE; P02675; -.
DR   PaxDb; P02675; -.
DR   PeptideAtlas; P02675; -.
DR   PRIDE; P02675; -.
DR   Ensembl; ENST00000302068; ENSP00000306099; ENSG00000171564.
DR   GeneID; 2244; -.
DR   KEGG; hsa:2244; -.
DR   UCSC; uc003ioa.4; human.
DR   CTD; 2244; -.
DR   GeneCards; FGB; -.
DR   HGNC; HGNC:3662; FGB.
DR   HPA; CAB008624; -.
DR   HPA; HPA001900; -.
DR   HPA; HPA001901; -.
DR   MalaCards; FGB; -.
DR   MIM; 134830; gene.
DR   MIM; 202400; phenotype.
DR   MIM; 616004; phenotype.
DR   neXtProt; NX_P02675; -.
DR   Orphanet; 98880; Familial afibrinogenemia.
DR   Orphanet; 98881; Familial dysfibrinogenemia.
DR   Orphanet; 248408; Familial hypodysfibrinogenemia.
DR   Orphanet; 101041; Familial hypofibrinogenemia.
DR   PharmGKB; PA163; -.
DR   eggNOG; KOG2579; Eukaryota.
DR   eggNOG; ENOG410ZYS4; LUCA.
DR   HOGENOM; HOG000059561; -.
DR   HOVERGEN; HBG005707; -.
DR   InParanoid; P02675; -.
DR   KO; K03904; -.
DR   OMA; TIHNGMF; -.
DR   OrthoDB; EOG7X9G60; -.
DR   PhylomeDB; P02675; -.
DR   TreeFam; TF336658; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   ChiTaRS; FGB; human.
DR   EvolutionaryTrace; P02675; -.
DR   GeneWiki; Fibrinogen_beta_chain; -.
DR   GenomeRNAi; 2244; -.
DR   NextBio; 35459926; -.
DR   PMAP-CutDB; P02675; -.
DR   PRO; PR:P02675; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P02675; -.
DR   CleanEx; HS_FGB; -.
DR   ExpressionAtlas; P02675; baseline and differential.
DR   Genevisible; P02675; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0005198; F:structural molecule activity; IDA:BHF-UCL.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0072378; P:blood coagulation, fibrin clot formation; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0043623; P:cellular protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0044320; P:cellular response to leptin stimulus; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; IDA:UniProtKB.
DR   GO; GO:0043152; P:induction of bacterial agglutination; IDA:CACAO.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0031639; P:plasminogen activation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0070527; P:platelet aggregation; IDA:BHF-UCL.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IDA:BHF-UCL.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; NAS:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0051258; P:protein polymerization; IDA:BHF-UCL.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   Gene3D; 3.90.215.10; -; 1.
DR   Gene3D; 4.10.530.10; -; 1.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR014715; Fibrinogen_a/b/g_C_2.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR012290; Fibrinogen_a/b/g_coil_dom.
DR   InterPro; IPR020837; Fibrinogen_CS.
DR   Pfam; PF08702; Fib_alpha; 1.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   SMART; SM00186; FBG; 1.
DR   SUPFAM; SSF56496; SSF56496; 1.
DR   PROSITE; PS00514; FIBRINOGEN_C_1; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Blood coagulation; Coiled coil;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Hemostasis; Immunity; Innate immunity;
KW   Polymorphism; Pyrrolidone carboxylic acid; Reference proteome;
KW   Secreted; Signal.
FT   SIGNAL        1     30       {ECO:0000269|PubMed:420779,
FT                                ECO:0000269|PubMed:936108,
FT                                ECO:0000269|Ref.11, ECO:0000269|Ref.13}.
FT   PEPTIDE      31     44       Fibrinopeptide B.
FT                                {ECO:0000269|PubMed:12665801}.
FT                                /FTId=PRO_0000009070.
FT   CHAIN        45    491       Fibrinogen beta chain.
FT                                /FTId=PRO_0000009071.
FT   DOMAIN      232    488       Fibrinogen C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00739}.
FT   REGION       45     47       Beta-chain polymerization, binding distal
FT                                domain of another fibrin.
FT   COILED      157    222       {ECO:0000305|PubMed:10074346,
FT                                ECO:0000305|PubMed:19296670,
FT                                ECO:0000305|PubMed:9628725}.
FT   SITE         44     45       Cleavage; by thrombin; to release
FT                                fibrinopeptide B.
FT   SITE        152    153       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   SITE        160    161       Cleavage; by hementin; to prevent blood
FT                                coagulation.
FT   SITE        163    164       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   MOD_RES      31     31       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:420779}.
FT   CARBOHYD    394    394       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:9628725,
FT                                ECO:0000269|Ref.11}.
FT   DISULFID     95     95       Interchain (with C-55 in alpha chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID    106    106       Interchain (with C-68 in alpha chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID    110    110       Interchain (with C-45 in gamma chain).
FT                                {ECO:0000305|PubMed:6575689}.
FT   DISULFID    223    223       Interchain (with C-184 in alpha chain).
FT                                {ECO:0000244|PDB:1FZC,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    227    227       Interchain (with C-161 in gamma chain).
FT   DISULFID    231    316       {ECO:0000244|PDB:1FZC,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    241    270       {ECO:0000244|PDB:1FZC,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    424    437       {ECO:0000244|PDB:1FZC,
FT                                ECO:0000269|PubMed:10074346,
FT                                ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   VARIANT       2      2       K -> E (in dbSNP:rs6053).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014169.
FT   VARIANT      39    102       Missing (in New York-1).
FT                                {ECO:0000269|PubMed:3156856}.
FT                                /FTId=VAR_002402.
FT   VARIANT      44     44       R -> C (in Christchurch-2, Seattle-1 and
FT                                Ijmuiden). {ECO:0000269|PubMed:1565641}.
FT                                /FTId=VAR_002403.
FT   VARIANT      45     45       G -> R (in Ise).
FT                                {ECO:0000269|PubMed:2018836}.
FT                                /FTId=VAR_002404.
FT   VARIANT      74     74       R -> C (in Nijmegen).
FT                                {ECO:0000269|PubMed:1565641}.
FT                                /FTId=VAR_002405.
FT   VARIANT      95     95       C -> R (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; decreased fibrinogen
FT                                complex assembly; no effect on fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072724.
FT   VARIANT      98     98       A -> T (in DYSFIBRIN; fibrinogen Naples
FT                                and Milano-2; associated with defective
FT                                thrombin binding and thrombophilia).
FT                                {ECO:0000269|PubMed:1634610}.
FT                                /FTId=VAR_002406.
FT   VARIANT     100    100       P -> S (in dbSNP:rs2227434).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_013091.
FT   VARIANT     170    170       N -> H (in dbSNP:rs2227409).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_013092.
FT   VARIANT     196    196       R -> C (in CAFBN; fibrinogen Longmont).
FT                                {ECO:0000269|PubMed:11468164}.
FT                                /FTId=VAR_016908.
FT   VARIANT     202    202       L -> Q (in CAFBN).
FT                                {ECO:0000269|PubMed:15070683}.
FT                                /FTId=VAR_072620.
FT   VARIANT     265    265       P -> L (in dbSNP:rs6054).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_013093.
FT   VARIANT     365    365       A -> T (in Pontoise-2).
FT                                /FTId=VAR_002407.
FT   VARIANT     383    383       L -> R (in CAFBN; abolishes fibrinogen
FT                                secretion).
FT                                {ECO:0000269|PubMed:10666208}.
FT                                /FTId=VAR_016909.
FT   VARIANT     407    407       T -> K (in CAFBN; homozygous;
FT                                heterozygous; no effect on fibrinogen
FT                                complex assembly; impaired fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072725.
FT   VARIANT     430    430       G -> D (in CAFBN; abolishes fibrinogen
FT                                secretion).
FT                                {ECO:0000269|PubMed:10666208}.
FT                                /FTId=VAR_016910.
FT   VARIANT     478    478       R -> K (in Baltimore-2; dbSNP:rs4220).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:3194892,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_002408.
FT   CONFLICT    138    139       SQ -> QS (in Ref. 11; AA sequence and 12;
FT                                AA sequence). {ECO:0000305}.
FT   CONFLICT    145    146       FQ -> QF (in Ref. 10; AA sequence, 11; AA
FT                                sequence and 12; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    192    192       P -> A (in Ref. 1; AAA52429).
FT                                {ECO:0000305}.
FT   CONFLICT    245    245       I -> T (in Ref. 7; AAI07767).
FT                                {ECO:0000305}.
FT   TURN        100    102       {ECO:0000244|PDB:3GHG}.
FT   HELIX       109    145       {ECO:0000244|PDB:3GHG}.
FT   HELIX       147    167       {ECO:0000244|PDB:3GHG}.
FT   HELIX       172    180       {ECO:0000244|PDB:3GHG}.
FT   TURN        182    189       {ECO:0000244|PDB:1FZC}.
FT   HELIX       190    222       {ECO:0000244|PDB:1FZC}.
FT   STRAND      224    226       {ECO:0000244|PDB:2HOD}.
FT   STRAND      233    235       {ECO:0000244|PDB:1FZC}.
FT   STRAND      238    240       {ECO:0000244|PDB:1FZC}.
FT   HELIX       241    246       {ECO:0000244|PDB:1FZC}.
FT   STRAND      253    257       {ECO:0000244|PDB:1FZC}.
FT   STRAND      261    263       {ECO:0000244|PDB:2OYH}.
FT   STRAND      266    271       {ECO:0000244|PDB:1FZC}.
FT   HELIX       274    276       {ECO:0000244|PDB:1FZC}.
FT   STRAND      279    288       {ECO:0000244|PDB:1FZC}.
FT   HELIX       296    301       {ECO:0000244|PDB:1FZC}.
FT   STRAND      302    304       {ECO:0000244|PDB:1FZF}.
FT   STRAND      306    308       {ECO:0000244|PDB:1FZC}.
FT   STRAND      311    315       {ECO:0000244|PDB:2H43}.
FT   STRAND      321    323       {ECO:0000244|PDB:1FZC}.
FT   HELIX       326    334       {ECO:0000244|PDB:1FZC}.
FT   STRAND      335    337       {ECO:0000244|PDB:2HOD}.
FT   STRAND      339    345       {ECO:0000244|PDB:1FZC}.
FT   STRAND      347    349       {ECO:0000244|PDB:1FZA}.
FT   STRAND      351    361       {ECO:0000244|PDB:1FZC}.
FT   HELIX       364    366       {ECO:0000244|PDB:1FZC}.
FT   STRAND      370    379       {ECO:0000244|PDB:1FZC}.
FT   HELIX       382    385       {ECO:0000244|PDB:1FZC}.
FT   STRAND      388    390       {ECO:0000244|PDB:2HPC}.
FT   HELIX       392    396       {ECO:0000244|PDB:1FZC}.
FT   STRAND      404    407       {ECO:0000244|PDB:2HOD}.
FT   STRAND      408    410       {ECO:0000244|PDB:1FZB}.
FT   HELIX       420    422       {ECO:0000244|PDB:2OYI}.
FT   TURN        424    428       {ECO:0000244|PDB:1FZC}.
FT   STRAND      435    437       {ECO:0000244|PDB:1FZC}.
FT   STRAND      439    441       {ECO:0000244|PDB:3E1I}.
FT   STRAND      448    451       {ECO:0000244|PDB:3BVH}.
FT   TURN        454    456       {ECO:0000244|PDB:1FZC}.
FT   STRAND      457    461       {ECO:0000244|PDB:3HUS}.
FT   STRAND      464    467       {ECO:0000244|PDB:3E1I}.
FT   HELIX       468    471       {ECO:0000244|PDB:1FZC}.
FT   STRAND      473    475       {ECO:0000244|PDB:2OYH}.
FT   STRAND      478    485       {ECO:0000244|PDB:1FZC}.
SQ   SEQUENCE   491 AA;  55928 MW;  B92FFB9976AB53C5 CRC64;
     MKRMVSWSFH KLKTMKHLLL LLLCVFLVKS QGVNDNEEGF FSARGHRPLD KKREEAPSLR
     PAPPPISGGG YRARPAKAAA TQKKVERKAP DAGGCLHADP DLGVLCPTGC QLQEALLQQE
     RPIRNSVDEL NNNVEAVSQT SSSSFQYMYL LKDLWQKRQK QVKDNENVVN EYSSELEKHQ
     LYIDETVNSN IPTNLRVLRS ILENLRSKIQ KLESDVSAQM EYCRTPCTVS CNIPVVSGKE
     CEEIIRKGGE TSEMYLIQPD SSVKPYRVYC DMNTENGGWT VIQNRQDGSV DFGRKWDPYK
     QGFGNVATNT DGKNYCGLPG EYWLGNDKIS QLTRMGPTEL LIEMEDWKGD KVKAHYGGFT
     VQNEANKYQI SVNKYRGTAG NALMDGASQL MGENRTMTIH NGMFFSTYDR DNDGWLTSDP
     RKQCSKEDGG GWWYNRCHAA NPNGRYYWGG QYTWDMAKHG TDDGVVWMNW KGSWYSMRKM
     SMKIRPFFPQ Q
//
ID   DL_DROME                Reviewed;         833 AA.
AC   P10041; Q6T3F7; Q6T3G1; Q6T3G7; Q6T3G8; Q6T3H0; Q6T3H3; Q6T3I3;
AC   Q6T3I5; Q6T3I7; Q6T3J1; Q6T3J2; Q6T3J3; Q6T3J4; Q6T3K0; Q6T3K1;
AC   Q6T3K9; Q6T3L5; Q6T3L7; Q6T3L9; Q6T3M2; Q6T3M4; Q6T3M7; Q6T3N1;
AC   Q6T3N3; Q6T3N5; Q6T3N7; Q6T4M9; Q6T4N0; Q6T4N1; Q6T4N2; Q6T4N3;
AC   Q6T4N4; Q6T4N6; Q95RM9; Q99108; Q9VDY2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   20-JAN-2016, entry version 177.
DE   RecName: Full=Neurogenic locus protein delta;
DE   Flags: Precursor;
GN   Name=Dl; ORFNames=CG3619;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, DEVELOPMENTAL STAGE,
RP   AND VARIANTS ALA-652 AND MET-662.
RC   TISSUE=Embryo;
RX   PubMed=16453806;
RA   Vaessin H., Bremer K.A., Knust E., Campos-Ortega J.A.;
RT   "The neurogenic gene Delta of Drosophila melanogaster is expressed in
RT   neurogenic territories and encodes a putative transmembrane protein
RT   with EGF-like repeats.";
RL   EMBO J. 6:3431-3440(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-812.
RC   STRAIN=Oregon-R; TISSUE=Embryo;
RX   PubMed=3149249; DOI=10.1101/gad.2.12b.1723;
RA   Kopczynski C.C., Alton A.K., Fechtel K., Kooh P.J., Muskavitch M.A.T.;
RT   "Delta, a Drosophila neurogenic gene, is transcriptionally complex and
RT   encodes a protein related to blood coagulation factors and epidermal
RT   growth factor of vertebrates.";
RL   Genes Dev. 2:1723-1735(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=NapaValley1, NapaValley10, NapaValley11, NapaValley12,
RC   NapaValley2, NapaValley3, NapaValley4, NapaValley5, NapaValley6,
RC   NapaValley7, NapaValley8, NapaValley9, nps_1, nps_13, nps_14, nps_15,
RC   nps_16, nps_17, nps_18, nps_19, nps_2, nps_20, nps_21, nps_23, nps_24,
RC   nps_25, nps_26, nps_27, nps_28, nps_29, nps_3, nps_30, nps_31, nps_32,
RC   nps_33, nps_34, nps_35, nps_36, nps_37, nps_38, nps_39, nps_4, nps_40,
RC   nps_41, nps_42, nps_43, nps_44, nps_45, nps_46, nps_47, nps_48,
RC   nps_49, nps_5, nps_50, nps_6, sonoma_002, sonoma_003, sonoma_004,
RC   sonoma_005, sonoma_006, sonoma_007, sonoma_008, sonoma_009,
RC   sonoma_010, sonoma_013, sonoma_014, sonoma_015, sonoma_016,
RC   sonoma_017, sonoma_019, sonoma_022, sonoma_023, sonoma_024,
RC   sonoma_031, sonoma_032, sonoma_033, sonoma_034, sonoma_036,
RC   sonoma_038, sonoma_039, sonoma_040, sonoma_045, sonoma_046,
RC   sonoma_048, sonoma_050, sonoma_051, sonoma_053, sonoma_054,
RC   sonoma_055, sonoma_058, sonoma_059, sonoma_061, sonoma_064,
RC   sonoma_073, sonoma_074, sonoma_081, sonoma_085, sonoma_086,
RC   sonoma_087, sonoma_094, sonoma_095, sonoma_097, sonoma_101,
RC   sonoma_106, sonoma_107, sonoma_111, sonoma_116, sonoma_117, and
RC   sonoma_119;
RX   PubMed=15020426; DOI=10.1534/genetics.166.1.291;
RA   Genissel A., Pastinen T., Dowell A., Mackay T.F.C., Long A.D.;
RT   "No evidence for an association between common nonsynonymous
RT   polymorphisms in delta and bristle number variation in natural and
RT   laboratory populations of Drosophila melanogaster.";
RL   Genetics 166:291-306(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [5]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Berkeley; TISSUE=Embryo;
RA   Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.W.,
RA   Champe M., Chavez C., Dorsett V., Dresnek D., Farfan D., Frise E.,
RA   George R.A., Gonzalez M., Guarin H., Kronmiller B., Li P.W., Liao G.,
RA   Miranda A., Mungall C.J., Nunoo J., Pacleb J.M., Paragas V., Park S.,
RA   Patel S., Phouanenavong S., Wan K.H., Yu C., Lewis S.E., Rubin G.M.,
RA   Celniker S.E.;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 195-833.
RC   STRAIN=Berkeley; TISSUE=Embryo;
RX   PubMed=12537569; DOI=10.1186/gb-2002-3-12-research0080;
RA   Stapleton M., Carlson J.W., Brokstein P., Yu C., Champe M.,
RA   George R.A., Guarin H., Kronmiller B., Pacleb J.M., Park S., Wan K.H.,
RA   Rubin G.M., Celniker S.E.;
RT   "A Drosophila full-length cDNA resource.";
RL   Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 422-621.
RC   TISSUE=Embryo;
RX   PubMed=3107986;
RA   Knust E., Dietrich U., Tepass U., Bremer K.A., Weigel D., Vaessin H.,
RA   Campos-Ortega J.A.;
RT   "EGF homologous sequences encoded in the genome of Drosophila
RT   melanogaster, and their relation to neurogenic genes.";
RL   EMBO J. 6:761-766(1987).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH DL.
RX   PubMed=10935637; DOI=10.1038/35019075;
RA   Bruckner K., Perez L., Clausen H., Cohen S.;
RT   "Glycosyltransferase activity of Fringe modulates Notch-Delta
RT   interactions.";
RL   Nature 406:411-415(2000).
RN   [10]
RP   PATTERN OF TRANSCRIPTION, AND CHARACTERIZATION.
RX   PubMed=2128477;
RA   Haenlin M., Kramatschek B., Campos-Ortega J.A.;
RT   "The pattern of transcription of the neurogenic gene Delta of
RT   Drosophila melanogaster.";
RL   Development 110:905-914(1990).
RN   [11]
RP   INTERACTION WITH MIB, AND UBIQUITINATION.
RX   PubMed=15829515; DOI=10.1242/dev.01825;
RA   Lai E.C., Roegiers F., Qin X., Jan Y.N., Rubin G.M.;
RT   "The ubiquitin ligase Drosophila Mind bomb promotes Notch signaling by
RT   regulating the localization and activity of Serrate and Delta.";
RL   Development 132:2319-2332(2005).
RN   [12]
RP   UBIQUITINATION.
RX   PubMed=15760269; DOI=10.1371/journal.pbio.0030096;
RA   Le Borgne R., Remaud S., Hamel S., Schweisguth F.;
RT   "Two distinct E3 ubiquitin ligases have complementary functions in the
RT   regulation of delta and serrate signaling in Drosophila.";
RL   PLoS Biol. 3:688-696(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-666, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RC   TISSUE=Embryo;
RX   PubMed=18327897; DOI=10.1021/pr700696a;
RA   Zhai B., Villen J., Beausoleil S.A., Mintseris J., Gygi S.P.;
RT   "Phosphoproteome analysis of Drosophila melanogaster embryos.";
RL   J. Proteome Res. 7:1675-1682(2008).
CC   -!- FUNCTION: Acts as a ligand for Notch (N) receptor. Essential for
CC       proper differentiation of ectoderm. Dl is required for the correct
CC       separation of neural and epidermal cell lineages. Fringe (fng)
CC       acts in the Golgi to determine the type of O-linked fucose on the
CC       EGF modules in N, altering the ability of N to bind with Delta
CC       (Dl). O-fut1 also has a role in modulating the interaction.
CC       {ECO:0000269|PubMed:10935637}.
CC   -!- SUBUNIT: Interacts with N via the EGF repeats and the N EGF
CC       repeats. {ECO:0000269|PubMed:10935637,
CC       ECO:0000269|PubMed:15829515}.
CC   -!- INTERACTION:
CC       P07207:N; NbExp=2; IntAct=EBI-115346, EBI-103438;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Detected in all areas with neurogenic
CC       abilities, for example the neurogenic ectoderm and the primordia
CC       of the sense organs. Later expression is restricted to those cells
CC       that have adopted a neural fate. {ECO:0000269|PubMed:16453806}.
CC   -!- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically.
CC       Expression is highest early in embryonic development (stage 5) and
CC       reduces to a low level during larval stages.
CC       {ECO:0000269|PubMed:16453806}.
CC   -!- PTM: Ubiquitinated by Mib, leading to its endocytosis and
CC       subsequent degradation. {ECO:0000269|PubMed:15760269,
CC       ECO:0000269|PubMed:15829515}.
CC   -!- MISCELLANEOUS: Separation of neuroblasts from the ectoderm into
CC       the inner part of embryo is one of the first steps of CNS
CC       development in insects, this process is under control of the
CC       neurogenic genes.
CC   -!- MISCELLANEOUS: Notch and Serrate may interact at the protein
CC       level, it is conceivable that the Serrate and Delta proteins may
CC       compete for binding with the Notch protein.
CC   -!- SIMILARITY: Contains 1 DSL domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00377}.
CC   -!- SIMILARITY: Contains 9 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL28817.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06289; CAA29617.1; -; mRNA.
DR   EMBL; Y00222; CAA68369.1; -; mRNA.
DR   EMBL; AY437145; AAR21453.1; -; Genomic_DNA.
DR   EMBL; AY437140; AAR21453.1; JOINED; Genomic_DNA.
DR   EMBL; AY437141; AAR21453.1; JOINED; Genomic_DNA.
DR   EMBL; AY437142; AAR21453.1; JOINED; Genomic_DNA.
DR   EMBL; AY437143; AAR21453.1; JOINED; Genomic_DNA.
DR   EMBL; AY437144; AAR21453.1; JOINED; Genomic_DNA.
DR   EMBL; AY437151; AAR21454.1; -; Genomic_DNA.
DR   EMBL; AY437146; AAR21454.1; JOINED; Genomic_DNA.
DR   EMBL; AY437147; AAR21454.1; JOINED; Genomic_DNA.
DR   EMBL; AY437148; AAR21454.1; JOINED; Genomic_DNA.
DR   EMBL; AY437149; AAR21454.1; JOINED; Genomic_DNA.
DR   EMBL; AY437150; AAR21454.1; JOINED; Genomic_DNA.
DR   EMBL; AY437157; AAR21455.1; -; Genomic_DNA.
DR   EMBL; AY437152; AAR21455.1; JOINED; Genomic_DNA.
DR   EMBL; AY437153; AAR21455.1; JOINED; Genomic_DNA.
DR   EMBL; AY437154; AAR21455.1; JOINED; Genomic_DNA.
DR   EMBL; AY437155; AAR21455.1; JOINED; Genomic_DNA.
DR   EMBL; AY437156; AAR21455.1; JOINED; Genomic_DNA.
DR   EMBL; AY437163; AAR21456.1; -; Genomic_DNA.
DR   EMBL; AY437158; AAR21456.1; JOINED; Genomic_DNA.
DR   EMBL; AY437159; AAR21456.1; JOINED; Genomic_DNA.
DR   EMBL; AY437160; AAR21456.1; JOINED; Genomic_DNA.
DR   EMBL; AY437161; AAR21456.1; JOINED; Genomic_DNA.
DR   EMBL; AY437162; AAR21456.1; JOINED; Genomic_DNA.
DR   EMBL; AY437169; AAR21457.1; -; Genomic_DNA.
DR   EMBL; AY437164; AAR21457.1; JOINED; Genomic_DNA.
DR   EMBL; AY437165; AAR21457.1; JOINED; Genomic_DNA.
DR   EMBL; AY437166; AAR21457.1; JOINED; Genomic_DNA.
DR   EMBL; AY437167; AAR21457.1; JOINED; Genomic_DNA.
DR   EMBL; AY437168; AAR21457.1; JOINED; Genomic_DNA.
DR   EMBL; AY437175; AAR21458.1; -; Genomic_DNA.
DR   EMBL; AY437170; AAR21458.1; JOINED; Genomic_DNA.
DR   EMBL; AY437171; AAR21458.1; JOINED; Genomic_DNA.
DR   EMBL; AY437172; AAR21458.1; JOINED; Genomic_DNA.
DR   EMBL; AY437173; AAR21458.1; JOINED; Genomic_DNA.
DR   EMBL; AY437174; AAR21458.1; JOINED; Genomic_DNA.
DR   EMBL; AY437181; AAR21459.1; -; Genomic_DNA.
DR   EMBL; AY437176; AAR21459.1; JOINED; Genomic_DNA.
DR   EMBL; AY437177; AAR21459.1; JOINED; Genomic_DNA.
DR   EMBL; AY437178; AAR21459.1; JOINED; Genomic_DNA.
DR   EMBL; AY437179; AAR21459.1; JOINED; Genomic_DNA.
DR   EMBL; AY437180; AAR21459.1; JOINED; Genomic_DNA.
DR   EMBL; AY437187; AAR21460.1; -; Genomic_DNA.
DR   EMBL; AY437182; AAR21460.1; JOINED; Genomic_DNA.
DR   EMBL; AY437183; AAR21460.1; JOINED; Genomic_DNA.
DR   EMBL; AY437184; AAR21460.1; JOINED; Genomic_DNA.
DR   EMBL; AY437185; AAR21460.1; JOINED; Genomic_DNA.
DR   EMBL; AY437186; AAR21460.1; JOINED; Genomic_DNA.
DR   EMBL; AY437193; AAR21461.1; -; Genomic_DNA.
DR   EMBL; AY437188; AAR21461.1; JOINED; Genomic_DNA.
DR   EMBL; AY437189; AAR21461.1; JOINED; Genomic_DNA.
DR   EMBL; AY437190; AAR21461.1; JOINED; Genomic_DNA.
DR   EMBL; AY437191; AAR21461.1; JOINED; Genomic_DNA.
DR   EMBL; AY437192; AAR21461.1; JOINED; Genomic_DNA.
DR   EMBL; AY437199; AAR21462.1; -; Genomic_DNA.
DR   EMBL; AY437194; AAR21462.1; JOINED; Genomic_DNA.
DR   EMBL; AY437195; AAR21462.1; JOINED; Genomic_DNA.
DR   EMBL; AY437196; AAR21462.1; JOINED; Genomic_DNA.
DR   EMBL; AY437197; AAR21462.1; JOINED; Genomic_DNA.
DR   EMBL; AY437198; AAR21462.1; JOINED; Genomic_DNA.
DR   EMBL; AY437205; AAR21463.1; -; Genomic_DNA.
DR   EMBL; AY437200; AAR21463.1; JOINED; Genomic_DNA.
DR   EMBL; AY437201; AAR21463.1; JOINED; Genomic_DNA.
DR   EMBL; AY437202; AAR21463.1; JOINED; Genomic_DNA.
DR   EMBL; AY437203; AAR21463.1; JOINED; Genomic_DNA.
DR   EMBL; AY437204; AAR21463.1; JOINED; Genomic_DNA.
DR   EMBL; AY437211; AAR21464.1; -; Genomic_DNA.
DR   EMBL; AY437206; AAR21464.1; JOINED; Genomic_DNA.
DR   EMBL; AY437207; AAR21464.1; JOINED; Genomic_DNA.
DR   EMBL; AY437208; AAR21464.1; JOINED; Genomic_DNA.
DR   EMBL; AY437209; AAR21464.1; JOINED; Genomic_DNA.
DR   EMBL; AY437210; AAR21464.1; JOINED; Genomic_DNA.
DR   EMBL; AY437217; AAR21465.1; -; Genomic_DNA.
DR   EMBL; AY437212; AAR21465.1; JOINED; Genomic_DNA.
DR   EMBL; AY437213; AAR21465.1; JOINED; Genomic_DNA.
DR   EMBL; AY437214; AAR21465.1; JOINED; Genomic_DNA.
DR   EMBL; AY437215; AAR21465.1; JOINED; Genomic_DNA.
DR   EMBL; AY437216; AAR21465.1; JOINED; Genomic_DNA.
DR   EMBL; AY437223; AAR21466.1; -; Genomic_DNA.
DR   EMBL; AY437218; AAR21466.1; JOINED; Genomic_DNA.
DR   EMBL; AY437219; AAR21466.1; JOINED; Genomic_DNA.
DR   EMBL; AY437220; AAR21466.1; JOINED; Genomic_DNA.
DR   EMBL; AY437221; AAR21466.1; JOINED; Genomic_DNA.
DR   EMBL; AY437222; AAR21466.1; JOINED; Genomic_DNA.
DR   EMBL; AY437229; AAR21467.1; -; Genomic_DNA.
DR   EMBL; AY437224; AAR21467.1; JOINED; Genomic_DNA.
DR   EMBL; AY437225; AAR21467.1; JOINED; Genomic_DNA.
DR   EMBL; AY437226; AAR21467.1; JOINED; Genomic_DNA.
DR   EMBL; AY437227; AAR21467.1; JOINED; Genomic_DNA.
DR   EMBL; AY437228; AAR21467.1; JOINED; Genomic_DNA.
DR   EMBL; AY437235; AAR21468.1; -; Genomic_DNA.
DR   EMBL; AY437230; AAR21468.1; JOINED; Genomic_DNA.
DR   EMBL; AY437231; AAR21468.1; JOINED; Genomic_DNA.
DR   EMBL; AY437232; AAR21468.1; JOINED; Genomic_DNA.
DR   EMBL; AY437233; AAR21468.1; JOINED; Genomic_DNA.
DR   EMBL; AY437234; AAR21468.1; JOINED; Genomic_DNA.
DR   EMBL; AY438104; AAR21469.1; -; Genomic_DNA.
DR   EMBL; AY438105; AAR21470.1; -; Genomic_DNA.
DR   EMBL; AY438106; AAR21471.1; -; Genomic_DNA.
DR   EMBL; AY438107; AAR21472.1; -; Genomic_DNA.
DR   EMBL; AY438108; AAR21473.1; -; Genomic_DNA.
DR   EMBL; AY438109; AAR21474.1; -; Genomic_DNA.
DR   EMBL; AY438110; AAR21475.1; -; Genomic_DNA.
DR   EMBL; AY438111; AAR21476.1; -; Genomic_DNA.
DR   EMBL; AY438112; AAR21477.1; -; Genomic_DNA.
DR   EMBL; AY438113; AAR21478.1; -; Genomic_DNA.
DR   EMBL; AY438114; AAR21479.1; -; Genomic_DNA.
DR   EMBL; AY438115; AAR21480.1; -; Genomic_DNA.
DR   EMBL; AY438116; AAR21481.1; -; Genomic_DNA.
DR   EMBL; AY438117; AAR21482.1; -; Genomic_DNA.
DR   EMBL; AY438118; AAR21483.1; -; Genomic_DNA.
DR   EMBL; AY438119; AAR21484.1; -; Genomic_DNA.
DR   EMBL; AY438120; AAR21485.1; -; Genomic_DNA.
DR   EMBL; AY438121; AAR21486.1; -; Genomic_DNA.
DR   EMBL; AY438122; AAR21487.1; -; Genomic_DNA.
DR   EMBL; AY438123; AAR21488.1; -; Genomic_DNA.
DR   EMBL; AY438124; AAR21489.1; -; Genomic_DNA.
DR   EMBL; AY438125; AAR21490.1; -; Genomic_DNA.
DR   EMBL; AY438126; AAR21491.1; -; Genomic_DNA.
DR   EMBL; AY438127; AAR21492.1; -; Genomic_DNA.
DR   EMBL; AY438128; AAR21493.1; -; Genomic_DNA.
DR   EMBL; AY438129; AAR21494.1; -; Genomic_DNA.
DR   EMBL; AY438130; AAR21495.1; -; Genomic_DNA.
DR   EMBL; AY438131; AAR21496.1; -; Genomic_DNA.
DR   EMBL; AY438132; AAR21497.1; -; Genomic_DNA.
DR   EMBL; AY438133; AAR21498.1; -; Genomic_DNA.
DR   EMBL; AY438134; AAR21499.1; -; Genomic_DNA.
DR   EMBL; AY438135; AAR21500.1; -; Genomic_DNA.
DR   EMBL; AY438136; AAR21501.1; -; Genomic_DNA.
DR   EMBL; AY438137; AAR21502.1; -; Genomic_DNA.
DR   EMBL; AY438138; AAR21503.1; -; Genomic_DNA.
DR   EMBL; AY438139; AAR21504.1; -; Genomic_DNA.
DR   EMBL; AY438140; AAR21505.1; -; Genomic_DNA.
DR   EMBL; AY438141; AAR21506.1; -; Genomic_DNA.
DR   EMBL; AY438147; AAR09172.1; -; Genomic_DNA.
DR   EMBL; AY438148; AAR09173.1; -; Genomic_DNA.
DR   EMBL; AY438149; AAR09174.1; -; Genomic_DNA.
DR   EMBL; AY438150; AAR09175.1; -; Genomic_DNA.
DR   EMBL; AY438151; AAR09176.1; -; Genomic_DNA.
DR   EMBL; AY438152; AAR09177.1; -; Genomic_DNA.
DR   EMBL; AY438153; AAR09178.1; -; Genomic_DNA.
DR   EMBL; AY438154; AAR09179.1; -; Genomic_DNA.
DR   EMBL; AY438155; AAR09180.1; -; Genomic_DNA.
DR   EMBL; AY438156; AAR09181.1; -; Genomic_DNA.
DR   EMBL; AY438157; AAR09182.1; -; Genomic_DNA.
DR   EMBL; AY438158; AAR09183.1; -; Genomic_DNA.
DR   EMBL; AY438159; AAR09184.1; -; Genomic_DNA.
DR   EMBL; AY438160; AAR09185.1; -; Genomic_DNA.
DR   EMBL; AY438161; AAR09186.1; -; Genomic_DNA.
DR   EMBL; AY438162; AAR09187.1; -; Genomic_DNA.
DR   EMBL; AY438163; AAR09188.1; -; Genomic_DNA.
DR   EMBL; AY438164; AAR09189.1; -; Genomic_DNA.
DR   EMBL; AY438165; AAR09190.1; -; Genomic_DNA.
DR   EMBL; AY438166; AAR09191.1; -; Genomic_DNA.
DR   EMBL; AY438167; AAR09192.1; -; Genomic_DNA.
DR   EMBL; AY438168; AAR09193.1; -; Genomic_DNA.
DR   EMBL; AY438169; AAR09194.1; -; Genomic_DNA.
DR   EMBL; AY438170; AAR09195.1; -; Genomic_DNA.
DR   EMBL; AY438171; AAR09196.1; -; Genomic_DNA.
DR   EMBL; AY438172; AAR09197.1; -; Genomic_DNA.
DR   EMBL; AY438173; AAR09198.1; -; Genomic_DNA.
DR   EMBL; AY438174; AAR09199.1; -; Genomic_DNA.
DR   EMBL; AY438175; AAR09200.1; -; Genomic_DNA.
DR   EMBL; AY438176; AAR09201.1; -; Genomic_DNA.
DR   EMBL; AY438177; AAR09202.1; -; Genomic_DNA.
DR   EMBL; AY438178; AAR09203.1; -; Genomic_DNA.
DR   EMBL; AY438179; AAR09204.1; -; Genomic_DNA.
DR   EMBL; AY438180; AAR09205.1; -; Genomic_DNA.
DR   EMBL; AY438181; AAR09206.1; -; Genomic_DNA.
DR   EMBL; AY438182; AAR09207.1; -; Genomic_DNA.
DR   EMBL; AY438183; AAR09208.1; -; Genomic_DNA.
DR   EMBL; AY438184; AAR09209.1; -; Genomic_DNA.
DR   EMBL; AY438185; AAR09210.1; -; Genomic_DNA.
DR   EMBL; AY438186; AAR09211.1; -; Genomic_DNA.
DR   EMBL; AY438187; AAR09212.1; -; Genomic_DNA.
DR   EMBL; AY438188; AAR09213.1; -; Genomic_DNA.
DR   EMBL; AY438189; AAR09214.1; -; Genomic_DNA.
DR   EMBL; AY438190; AAR09215.1; -; Genomic_DNA.
DR   EMBL; AY438191; AAR09216.1; -; Genomic_DNA.
DR   EMBL; AY438192; AAR09217.1; -; Genomic_DNA.
DR   EMBL; AY438193; AAR09218.1; -; Genomic_DNA.
DR   EMBL; AY438194; AAR09219.1; -; Genomic_DNA.
DR   EMBL; AY438195; AAR09220.1; -; Genomic_DNA.
DR   EMBL; AY438196; AAR09221.1; -; Genomic_DNA.
DR   EMBL; AY438197; AAR09222.1; -; Genomic_DNA.
DR   EMBL; AY438198; AAR09223.1; -; Genomic_DNA.
DR   EMBL; AY438199; AAR09224.1; -; Genomic_DNA.
DR   EMBL; AY438200; AAR09225.1; -; Genomic_DNA.
DR   EMBL; AY438201; AAR09226.1; -; Genomic_DNA.
DR   EMBL; AY438202; AAR09227.1; -; Genomic_DNA.
DR   EMBL; BK004004; DAA02303.1; -; Genomic_DNA.
DR   EMBL; AE014297; AAF55657.1; -; Genomic_DNA.
DR   EMBL; BT003267; AAO25024.1; -; mRNA.
DR   EMBL; AY061269; AAL28817.1; ALT_INIT; mRNA.
DR   EMBL; X05140; CAA28786.1; -; mRNA.
DR   PIR; A31246; A31246.
DR   PIR; A43564; A43564.
DR   PIR; S00670; S00670.
DR   PIR; S19087; S19087.
DR   RefSeq; NP_001247193.1; NM_001260264.2.
DR   RefSeq; NP_477264.1; NM_057916.4.
DR   RefSeq; NP_732412.1; NM_169853.3.
DR   UniGene; Dm.7687; -.
DR   PDB; 4XIB; X-ray; 2.15 A; C=680-690.
DR   PDBsum; 4XIB; -.
DR   ProteinModelPortal; P10041; -.
DR   SMR; P10041; 23-573.
DR   BioGrid; 67310; 59.
DR   DIP; DIP-22726N; -.
DR   IntAct; P10041; 2.
DR   MINT; MINT-773349; -.
DR   STRING; 7227.FBpp0083153; -.
DR   iPTMnet; P10041; -.
DR   PaxDb; P10041; -.
DR   EnsemblMetazoa; FBtr0083739; FBpp0083153; FBgn0000463.
DR   EnsemblMetazoa; FBtr0083740; FBpp0083154; FBgn0000463.
DR   EnsemblMetazoa; FBtr0304658; FBpp0293200; FBgn0000463.
DR   GeneID; 42313; -.
DR   KEGG; dme:Dmel_CG3619; -.
DR   FlyBase; FBgn0000463; Dl.
DR   eggNOG; ENOG410IR7B; Eukaryota.
DR   eggNOG; ENOG410XUNS; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   InParanoid; P10041; -.
DR   KO; K06051; -.
DR   OMA; ECVCANG; -.
DR   OrthoDB; EOG7GQXZ5; -.
DR   PhylomeDB; P10041; -.
DR   Reactome; R-DME-1980148; Signaling by NOTCH3.
DR   Reactome; R-DME-2979096; NOTCH2 Activation and Transmission of Signal to the Nucleus.
DR   SignaLink; P10041; -.
DR   ChiTaRS; Dl; fly.
DR   GenomeRNAi; 42313; -.
DR   NextBio; 828182; -.
DR   PMAP-CutDB; P10041; -.
DR   PRO; PR:P10041; -.
DR   Proteomes; UP000000803; Chromosome 3R.
DR   Bgee; P10041; -.
DR   ExpressionAtlas; P10041; differential.
DR   Genevisible; P10041; DM.
DR   GO; GO:0005912; C:adherens junction; IDA:FlyBase.
DR   GO; GO:0009986; C:cell surface; IDA:FlyBase.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:FlyBase.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:FlyBase.
DR   GO; GO:0005768; C:endosome; IDA:FlyBase.
DR   GO; GO:0016021; C:integral component of membrane; NAS:FlyBase.
DR   GO; GO:0005886; C:plasma membrane; IDA:FlyBase.
DR   GO; GO:0035003; C:subapical complex; IDA:FlyBase.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005112; F:Notch binding; IDA:FlyBase.
DR   GO; GO:0005102; F:receptor binding; NAS:FlyBase.
DR   GO; GO:0007015; P:actin filament organization; IMP:FlyBase.
DR   GO; GO:0048800; P:antennal morphogenesis; IMP:FlyBase.
DR   GO; GO:0007475; P:apposition of dorsal and ventral imaginal disc-derived wing surfaces; IMP:FlyBase.
DR   GO; GO:0008356; P:asymmetric cell division; TAS:FlyBase.
DR   GO; GO:0007298; P:border follicle cell migration; IMP:FlyBase.
DR   GO; GO:0007155; P:cell adhesion; TAS:FlyBase.
DR   GO; GO:0001708; P:cell fate specification; TAS:FlyBase.
DR   GO; GO:0008407; P:chaeta morphogenesis; IMP:FlyBase.
DR   GO; GO:0042676; P:compound eye cone cell fate commitment; TAS:FlyBase.
DR   GO; GO:0048749; P:compound eye development; TAS:FlyBase.
DR   GO; GO:0046667; P:compound eye retinal cell programmed cell death; TAS:FlyBase.
DR   GO; GO:0007451; P:dorsal/ventral lineage restriction, imaginal disc; TAS:FlyBase.
DR   GO; GO:0007398; P:ectoderm development; TAS:FlyBase.
DR   GO; GO:0042067; P:establishment of ommatidial planar polarity; TAS:FlyBase.
DR   GO; GO:0001736; P:establishment of planar polarity; NAS:FlyBase.
DR   GO; GO:0030718; P:germ-line stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0008347; P:glial cell migration; IMP:FlyBase.
DR   GO; GO:0007480; P:imaginal disc-derived leg morphogenesis; IMP:FlyBase.
DR   GO; GO:0036011; P:imaginal disc-derived leg segmentation; IMP:FlyBase.
DR   GO; GO:0007476; P:imaginal disc-derived wing morphogenesis; IMP:FlyBase.
DR   GO; GO:0008586; P:imaginal disc-derived wing vein morphogenesis; TAS:FlyBase.
DR   GO; GO:0007474; P:imaginal disc-derived wing vein specification; NAS:FlyBase.
DR   GO; GO:0046331; P:lateral inhibition; IMP:FlyBase.
DR   GO; GO:0007498; P:mesoderm development; IMP:FlyBase.
DR   GO; GO:0035157; P:negative regulation of fusion cell fate specification; NAS:FlyBase.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IMP:FlyBase.
DR   GO; GO:0035155; P:negative regulation of terminal cell fate specification, open tracheal system; NAS:FlyBase.
DR   GO; GO:0007399; P:nervous system development; NAS:FlyBase.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:FlyBase.
DR   GO; GO:0016318; P:ommatidial rotation; NAS:FlyBase.
DR   GO; GO:0007314; P:oocyte anterior/posterior axis specification; TAS:FlyBase.
DR   GO; GO:0030720; P:oocyte localization involved in germarium-derived egg chamber formation; IMP:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IMP:FlyBase.
DR   GO; GO:0007424; P:open tracheal system development; NAS:FlyBase.
DR   GO; GO:0030707; P:ovarian follicle cell development; IMP:FlyBase.
DR   GO; GO:0030713; P:ovarian follicle cell stalk formation; IMP:FlyBase.
DR   GO; GO:0007422; P:peripheral nervous system development; IMP:FlyBase.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:FlyBase.
DR   GO; GO:0007464; P:R3/R4 cell fate commitment; NAS:FlyBase.
DR   GO; GO:0045465; P:R8 cell differentiation; NAS:FlyBase.
DR   GO; GO:0007460; P:R8 cell fate commitment; TAS:FlyBase.
DR   GO; GO:0045468; P:regulation of R8 cell spacing in compound eye; NAS:FlyBase.
DR   GO; GO:0016330; P:second mitotic wave involved in compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0007423; P:sensory organ development; IMP:FlyBase.
DR   GO; GO:0048863; P:stem cell differentiation; IMP:FlyBase.
DR   GO; GO:0007419; P:ventral cord development; NAS:FlyBase.
DR   GO; GO:0048190; P:wing disc dorsal/ventral pattern formation; IMP:FlyBase.
DR   InterPro; IPR001774; DSL.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011651; Notch_ligand_N.
DR   Pfam; PF01414; DSL; 1.
DR   Pfam; PF00008; EGF; 7.
DR   Pfam; PF07657; MNNL; 1.
DR   SMART; SM00051; DSL; 1.
DR   SMART; SM00181; EGF; 5.
DR   SMART; SM00179; EGF_CA; 4.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 3.
DR   PROSITE; PS51051; DSL; 1.
DR   PROSITE; PS00022; EGF_1; 9.
DR   PROSITE; PS01186; EGF_2; 9.
DR   PROSITE; PS50026; EGF_3; 7.
DR   PROSITE; PS01187; EGF_CA; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Developmental protein;
KW   Differentiation; Disulfide bond; EGF-like domain; Glycoprotein;
KW   Membrane; Neurogenesis; Notch signaling pathway; Phosphoprotein;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    833       Neurogenic locus protein delta.
FT                                /FTId=PRO_0000007505.
FT   TOPO_DOM     19    594       Extracellular. {ECO:0000255}.
FT   TRANSMEM    595    617       Helical. {ECO:0000255}.
FT   TOPO_DOM    618    833       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      182    226       DSL. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00377}.
FT   DOMAIN      227    258       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      256    289       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      291    329       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      331    372       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      374    416       EGF-like 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      418    451       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      453    489       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      491    527       EGF-like 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      529    565       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   MOD_RES     666    666       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18327897}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    137    137       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    167    167       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    184    193       {ECO:0000250}.
FT   DISULFID    197    209       {ECO:0000250}.
FT   DISULFID    217    226       {ECO:0000250}.
FT   DISULFID    231    240       {ECO:0000250}.
FT   DISULFID    235    246       {ECO:0000250}.
FT   DISULFID    248    257       {ECO:0000250}.
FT   DISULFID    260    271       {ECO:0000250}.
FT   DISULFID    266    277       {ECO:0000250}.
FT   DISULFID    279    288       {ECO:0000250}.
FT   DISULFID    295    307       {ECO:0000250}.
FT   DISULFID    301    317       {ECO:0000250}.
FT   DISULFID    319    328       {ECO:0000250}.
FT   DISULFID    335    348       {ECO:0000250}.
FT   DISULFID    342    360       {ECO:0000250}.
FT   DISULFID    362    371       {ECO:0000250}.
FT   DISULFID    378    388       {ECO:0000250}.
FT   DISULFID    383    404       {ECO:0000250}.
FT   DISULFID    406    415       {ECO:0000250}.
FT   DISULFID    422    433       {ECO:0000250}.
FT   DISULFID    427    439       {ECO:0000250}.
FT   DISULFID    441    450       {ECO:0000250}.
FT   DISULFID    457    468       {ECO:0000250}.
FT   DISULFID    462    477       {ECO:0000250}.
FT   DISULFID    479    488       {ECO:0000250}.
FT   DISULFID    495    506       {ECO:0000250}.
FT   DISULFID    500    515       {ECO:0000250}.
FT   DISULFID    517    526       {ECO:0000250}.
FT   DISULFID    533    544       {ECO:0000250}.
FT   DISULFID    538    553       {ECO:0000250}.
FT   DISULFID    555    564       {ECO:0000250}.
FT   VARIANT     398    398       K -> R (in strain: sonoma_017).
FT   VARIANT     443    443       A -> T (in strain: sonoma_009,
FT                                sonoma_051, sonoma_053 and sonoma_054).
FT   VARIANT     461    461       Q -> K (in strain: sonoma_010,
FT                                sonoma_013, sonoma_019 and sonoma_117).
FT   VARIANT     652    652       G -> A (in strain: NapaValley5,
FT                                NapaValley12, sonoma_015, sonoma_016,
FT                                sonoma_023, sonoma_032, sonoma_034,
FT                                sonoma_038, sonoma_040, sonoma_045,
FT                                sonoma_048, sonoma_050, sonoma_061,
FT                                sonoma_073, sonoma_081, sonoma_085,
FT                                sonoma_094, sonoma_097 and sonoma_119).
FT                                {ECO:0000269|PubMed:16453806}.
FT   VARIANT     662    662       L -> M (in strain: sonoma_008,
FT                                sonoma_015, sonoma_016, sonoma_032,
FT                                sonoma_034, sonoma_038, sonoma_040,
FT                                sonoma_045, sonoma_048, sonoma_050,
FT                                sonoma_061, sonoma_073, sonoma_081,
FT                                sonoma_085, sonoma_094 and sonoma_097).
FT                                {ECO:0000269|PubMed:16453806}.
FT   VARIANT     761    761       A -> T (in strain: sonoma_006, sonoma_022
FT                                and sonoma_040).
FT   VARIANT     787    787       S -> G (in strain: nps_6, nps_18, nps_34,
FT                                sonoma_048 and sonoma_050).
FT   VARIANT     800    800       G -> R (in strain: sonoma_002).
FT   VARIANT     812    812       V -> A (in strain: nps_19, nps_21,
FT                                nps_25, nps_26, nps_27, nps_30, nps_31,
FT                                nps_33, nps_35, nps_42, nps_43, nps_45,
FT                                nps_47, sonoma_002, sonoma_003,
FT                                sonoma_004, sonoma_005, sonoma_006,
FT                                sonoma_007, sonoma_008, sonoma_009,
FT                                sonoma_014, sonoma_016, sonoma_017,
FT                                sonoma_022, sonoma_024, sonoma_032,
FT                                sonoma_033, sonoma_036, sonoma_038,
FT                                sonoma_045, sonoma_051, sonoma_053,
FT                                sonoma_054, sonoma_055, sonoma_059,
FT                                sonoma_061, sonoma_064, sonoma_081,
FT                                sonoma_086, sonoma_087, sonoma_094,
FT                                sonoma_095, sonoma_097, sonoma_106,
FT                                sonoma_107 and sonoma_119).
FT                                {ECO:0000269|PubMed:3149249}.
FT   CONFLICT    437    438       GK -> ET (in Ref. 8; CAA28786).
FT                                {ECO:0000305}.
FT   CONFLICT    443    443       A -> S (in Ref. 8; CAA28786).
FT                                {ECO:0000305}.
FT   CONFLICT    459    459       G -> A (in Ref. 8; CAA28786).
FT                                {ECO:0000305}.
FT   CONFLICT    490    490       S -> T (in Ref. 8; CAA28786).
FT                                {ECO:0000305}.
FT   CONFLICT    591    591       T -> A (in Ref. 8; CAA28786).
FT                                {ECO:0000305}.
SQ   SEQUENCE   833 AA;  88841 MW;  EDBA107A0003D9A1 CRC64;
     MHWIKCLLTA FICFTVIVQV HSSGSFELRL KYFSNDHGRD NEGRCCSGES DGATGKCLGS
     CKTRFRVCLK HYQATIDTTS QCTYGDVITP ILGENSVNLT DAQRFQNKGF TNPIQFPFSF
     SWPGTFSLIV EAWHDTNNSG NARTNKLLIQ RLLVQQVLEV SSEWKTNKSE SQYTSLEYDF
     RVTCDLNYYG SGCAKFCRPR DDSFGHSTCS ETGEIICLTG WQGDYCHIPK CAKGCEHGHC
     DKPNQCVCQL GWKGALCNEC VLEPNCIHGT CNKPWTCICN EGWGGLYCNQ DLNYCTNHRP
     CKNGGTCFNT GEGLYTCKCA PGYSGDDCEN EIYSCDADVN PCQNGGTCID EPHTKTGYKC
     HCANGWSGKM CEEKVLTCSD KPCHQGICRN VRPGLGSKGQ GYQCECPIGY SGPNCDLQLD
     NCSPNPCING GSCQPSGKCI CPAGFSGTRC ETNIDDCLGH QCENGGTCID MVNQYRCQCV
     PGFHGTHCSS KVDLCLIRPC ANGGTCLNLN NDYQCTCRAG FTGKDCSVDI DECSSGPCHN
     GGTCMNRVNS FECVCANGFR GKQCDEESYD SVTFDAHQYG ATTQARADGL TNAQVVLIAV
     FSVAMPLVAV IAACVVFCMK RKRKRAQEKD DAEARKQNEQ NAVATMHHNG SGVGVALASA
     SLGGKTGSNS GLTFDGGNPN IIKNTWDKSV NNICASAAAA AAAAAAADEC LMYGGYVASV
     ADNNNANSDF CVAPLQRAKS QKQLNTDPTL MHRGSPAGSS AKGASGGGPG AAEGKRISVL
     GEGSYCSQRW PSLAAAGVAG ACSSQLMAAA SVAGSGAGTA QQQRSVVCGT PHM
//
ID   ALK_HUMAN               Reviewed;        1620 AA.
AC   Q9UM73; Q4ZFX9; Q53QQ6; Q53RZ4; Q59FI3; Q9Y4K6;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   20-JAN-2016, entry version 163.
DE   RecName: Full=ALK tyrosine kinase receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Anaplastic lymphoma kinase;
DE   AltName: CD_antigen=CD246;
DE   Flags: Precursor;
GN   Name=ALK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   GLYCOSYLATION, AND VARIANT VAL-1461.
RX   PubMed=9174053; DOI=10.1038/sj.onc.1201062;
RA   Morris S.W., Naeve C.W., Mathew P., James P.L., Kirstein M.N., Cui X.,
RA   Witte D.P.;
RT   "ALK, the chromosome 2 gene locus altered by the t(2;5) in non-
RT   Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase
RT   that is highly related to leukocyte tyrosine kinase (LTK).";
RL   Oncogene 14:2175-2188(1997).
RN   [2]
RP   ERRATUM.
RA   Morris S.W., Naeve C.W., Mathew P., James P.L., Kirstein M.N., Cui X.,
RA   Witte D.P.;
RL   Oncogene 15:2883-2883(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-1461; ARG-1491 AND
RP   GLU-1529.
RX   PubMed=9053841; DOI=10.1038/sj.onc.1200849;
RA   Iwahara T., Fujimoto J., Wen D., Cupples R., Bucay N., Arakawa T.,
RA   Mori S., Ratzkin B., Yamamoto T.;
RT   "Molecular characterization of ALK, a receptor tyrosine kinase
RT   expressed specifically in the nervous system.";
RL   Oncogene 14:439-449(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-1461;
RP   ARG-1491 AND GLU-1529.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA], CHROMOSOMAL TRANSLOCATION WITH
RP   NPM1, AND VARIANT VAL-1461.
RX   PubMed=8122112; DOI=10.1126/science.8122112;
RA   Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G.,
RA   Shapiro D.N., Saltman D.L., Look A.T.;
RT   "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in
RT   non-Hodgkin's lymphoma.";
RL   Science 263:1281-1284(1994).
RN   [7]
RP   FUNCTION AS AN ONCOGENE.
RX   PubMed=11387242;
RA   Simonitsch I., Polgar D., Hajek M., Duchek P., Skrzypek B., Fassl S.,
RA   Lamprecht A., Schmidt G., Krupitza G., Cerni C.;
RT   "The cytoplasmic truncated receptor tyrosine kinase ALK homodimer
RT   immortalizes and cooperates with ras in cellular transformation.";
RL   FASEB J. 15:1416-1418(2001).
RN   [8]
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=11121404; DOI=10.1074/jbc.M007333200;
RA   Souttou B., Carvalho N.B., Raulais D., Vigny M.;
RT   "Activation of anaplastic lymphoma kinase receptor tyrosine kinase
RT   induces neuronal differentiation through the mitogen-activated protein
RT   kinase pathway.";
RL   J. Biol. Chem. 276:9526-9531(2001).
RN   [9]
RP   INTERACTION WITH PTN, AND FUNCTION.
RX   PubMed=11278720; DOI=10.1074/jbc.M010660200;
RA   Stoica G.E., Kuo A., Aigner A., Sunitha I., Souttou B., Malerczyk C.,
RA   Caughey D.J., Wen D., Karavanov A., Riegel A.T., Wellstein A.;
RT   "Identification of anaplastic lymphoma kinase as a receptor for the
RT   growth factor pleiotrophin.";
RL   J. Biol. Chem. 276:16772-16779(2001).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION WITH ALO17 AND CARS.
RX   PubMed=12112524; DOI=10.1002/gcc.10033;
RA   Cools J., Wlodarska I., Somers R., Mentens N., Pedeutour F., Maes B.,
RA   De Wolf-Peeters C., Pauwels P., Hagemeijer A., Marynen P.;
RT   "Identification of novel fusion partners of ALK, the anaplastic
RT   lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory
RT   myofibroblastic tumor.";
RL   Genes Chromosomes Cancer 34:354-362(2002).
RN   [11]
RP   FUNCTION.
RX   PubMed=11809760; DOI=10.1074/jbc.M112354200;
RA   Powers C., Aigner A., Stoica G.E., McDonnell K., Wellstein A.;
RT   "Pleiotrophin signaling through anaplastic lymphoma kinase is rate-
RT   limiting for glioblastoma growth.";
RL   J. Biol. Chem. 277:14153-14158(2002).
RN   [12]
RP   FUNCTION.
RX   PubMed=12107166; DOI=10.1074/jbc.M203963200;
RA   Bowden E.T., Stoica G.E., Wellstein A.;
RT   "Anti-apoptotic signaling of pleiotrophin through its receptor,
RT   anaplastic lymphoma kinase.";
RL   J. Biol. Chem. 277:35862-35868(2002).
RN   [13]
RP   INTERACTION WITH MDK, AND FUNCTION.
RX   PubMed=12122009; DOI=10.1074/jbc.M205749200;
RA   Stoica G.E., Kuo A., Powers C., Bowden E.T., Sale E.B., Riegel A.T.,
RA   Wellstein A.;
RT   "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a
RT   growth factor for different cell types.";
RL   J. Biol. Chem. 277:35990-35998(2002).
RN   [14]
RP   INTERACTION WITH CBL; IRS1; PIK3R1; PLCG1 AND SHC1, AND FUNCTION IN
RP   PHOSPHORYLATION OF CBL; IRS1 AND SHC1.
RX   PubMed=15226403; DOI=10.1242/jcs.01183;
RA   Motegi A., Fujimoto J., Kotani M., Sakuraba H., Yamamoto T.;
RT   "ALK receptor tyrosine kinase promotes cell growth and neurite
RT   outgrowth.";
RL   J. Cell Sci. 117:3319-3329(2004).
RN   [15]
RP   SUBSTRATE SPECIFICITY, AND PHOSPHORYLATION AT TYR-1278.
RX   PubMed=15938644; DOI=10.1021/bi0472954;
RA   Donella-Deana A., Marin O., Cesaro L., Gunby R.H., Ferrarese A.,
RA   Coluccia A.M., Tartari C.J., Mologni L., Scapozza L.,
RA   Gambacorti-Passerini C., Pinna L.A.;
RT   "Unique substrate specificity of anaplastic lymphoma kinase (ALK):
RT   development of phosphoacceptor peptides for the assay of ALK
RT   activity.";
RL   Biochemistry 44:8533-8542(2005).
RN   [16]
RP   ROLE IN GLIOBLASTOMA.
RX   PubMed=15908427; DOI=10.1074/jbc.M502614200;
RA   Lu K.V., Jong K.A., Kim G.Y., Singh J., Dia E.Q., Yoshimoto K.,
RA   Wang M.Y., Cloughesy T.F., Nelson S.F., Mischel P.S.;
RT   "Differential induction of glioblastoma migration and growth by two
RT   forms of pleiotrophin.";
RL   J. Biol. Chem. 280:26953-26964(2005).
RN   [17]
RP   SUBCELLULAR LOCATION, SUBUNIT, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=16317043; DOI=10.1242/jcs.02695;
RA   Gouzi J.Y., Moog-Lutz C., Vigny M., Brunet-de Carvalho N.;
RT   "Role of the subcellular localization of ALK tyrosine kinase domain in
RT   neuronal differentiation of PC12 cells.";
RL   J. Cell Sci. 118:5811-5823(2005).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1078; TYR-1096; TYR-1131
RP   AND TYR-1604, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [19]
RP   CHROMOSOMAL TRANSLOCATION WITH SEC31A.
RX   PubMed=16161041; DOI=10.1002/ijc.21490;
RA   Panagopoulos I., Nilsson T., Domanski H.A., Isaksson M., Lindblom P.,
RA   Mertens F., Mandahl N.;
RT   "Fusion of the SEC31L1 and ALK genes in an inflammatory
RT   myofibroblastic tumor.";
RL   Int. J. Cancer 118:1181-1186(2006).
RN   [20]
RP   INTERACTION WITH FRS2 AND SHC1, PHOSPHORYLATION AT TYR-1507,
RP   MUTAGENESIS OF TYR-1507, AND FUNCTION IN PHOSPHORYLATION OF FRS2;
RP   MAPK1/ERK2; MAPK3/ERK1 AND SHC1.
RX   PubMed=17274988; DOI=10.1016/j.febslet.2007.01.039;
RA   Degoutin J., Vigny M., Gouzi J.Y.;
RT   "ALK activation induces Shc and FRS2 recruitment: Signaling and
RT   phenotypic outcomes in PC12 cells differentiation.";
RL   FEBS Lett. 581:727-734(2007).
RN   [21]
RP   PHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=17681947; DOI=10.1074/jbc.M704505200;
RA   Perez-Pinera P., Zhang W., Chang Y., Vega J.A., Deuel T.F.;
RT   "Anaplastic lymphoma kinase is activated through the
RT   pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling
RT   pathway: an alternative mechanism of receptor tyrosine kinase
RT   activation.";
RL   J. Biol. Chem. 282:28683-28690(2007).
RN   [22]
RP   INTERACTION WITH IRS1 AND SHC, PHOSPHORYLATION AT TYR-1096, AND
RP   FUNCTION.
RX   PubMed=16878150; DOI=10.1038/sj.onc.1209840;
RA   Kuo A.H., Stoica G.E., Riegel A.T., Wellstein A.;
RT   "Recruitment of insulin receptor substrate-1 and activation of NF-
RT   kappaB essential for midkine growth signaling through anaplastic
RT   lymphoma kinase.";
RL   Oncogene 26:859-869(2007).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=19459784; DOI=10.1042/BJ20090387;
RA   Palmer R.H., Vernersson E., Grabbe C., Hallberg B.;
RT   "Anaplastic lymphoma kinase: signalling in development and disease.";
RL   Biochem. J. 420:345-361(2009).
RN   [24]
RP   STRUCTURE BY NMR OF 1571-1589.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the complex of the PTB domain of SNT-2 and 19-
RT   residue peptide (aa 1571-1589) of HALK.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 1072-1410.
RX   PubMed=20632993; DOI=10.1042/BJ20100609;
RA   Lee C.C., Jia Y., Li N., Sun X., Ng K., Ambing E., Gao M.Y., Hua S.,
RA   Chen C., Kim S., Michellys P.Y., Lesley S.A., Harris J.L.,
RA   Spraggon G.;
RT   "Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic
RT   domain.";
RL   Biochem. J. 430:425-437(2010).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 1094-1407 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=20695522; DOI=10.1021/bi1005514;
RA   Bossi R.T., Saccardo M.B., Ardini E., Menichincheri M., Rusconi L.,
RA   Magnaghi P., Orsini P., Avanzi N., Borgia A.L., Nesi M., Bandiera T.,
RA   Fogliatto G., Bertrand J.A.;
RT   "Crystal structures of anaplastic lymphoma kinase in complex with ATP
RT   competitive inhibitors.";
RL   Biochemistry 49:6813-6825(2010).
RN   [27]
RP   STRUCTURE BY NMR OF 1571-1589.
RX   PubMed=20454865; DOI=10.1007/s10969-010-9091-x;
RA   Koshiba S., Li H., Motoda Y., Tomizawa T., Kasai T., Tochio N.,
RA   Yabuki T., Harada T., Watanabe S., Tanaka A., Shirouzu M., Kigawa T.,
RA   Yamamoto T., Yokoyama S.;
RT   "Structural basis for the recognition of nucleophosmin-anaplastic
RT   lymphoma kinase oncoprotein by the phosphotyrosine binding domain of
RT   Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated
RT   target-2.";
RL   J. Struct. Funct. Genomics 11:125-141(2010).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1093-1411 IN COMPLEX WITH
RP   CRIZOTINIB.
RA   Mctigue M., Deng Y., Liu W., Brooun A.;
RT   "Structure of L1196M mutant anaplastic lymphoma kinase in complex with
RT   crizotinib.";
RL   Submitted (MAY-2011) to the PDB data bank.
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1069-1411 IN COMPLEX WITH
RP   INHIBITOR, AND ENZYME REGULATION.
RX   PubMed=21575866; DOI=10.1016/j.ccr.2011.04.004;
RA   Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T.,
RA   Fukami T.A., Oikawa N., Tsukuda T., Ishii N., Aoki Y.;
RT   "CH5424802, a selective ALK inhibitor capable of blocking the
RT   resistant gatekeeper mutant.";
RL   Cancer Cell 19:679-690(2011).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-90; LEU-163; GLN-296; ALA-476;
RP   PHE-560; ILE-680; THR-704; SER-877; MET-1012; ASP-1121; THR-1274;
RP   LEU-1328; ASN-1416; LYS-1419; ARG-1429; ARG-1491 AND GLU-1529.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [31]
RP   VARIANTS NBLST3 ASN-1091; ALA-1128; ARG-1166; ASN-1171; ILE-1174;
RP   PRO-1192; CYS-1245; VAL-1245 THR-1250 AND GLN-1275.
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
RN   [32]
RP   VARIANTS NBLST3 VAL-1174; LEU-1174; CYS-1174; PRO-1192; GLN-1275 AND
RP   SER-1278, AND VARIANT LEU-1275.
RX   PubMed=18923523; DOI=10.1038/nature07398;
RA   Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A.,
RA   de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G.,
RA   Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S.,
RA   Amiel J., Delattre O.;
RT   "Somatic and germline activating mutations of the ALK kinase receptor
RT   in neuroblastoma.";
RL   Nature 455:967-970(2008).
RN   [33]
RP   VARIANTS NBLST3 MET-1151; LEU-1174; THR-1234; CYS-1245 AND GLN-1275.
RX   PubMed=18923525; DOI=10.1038/nature07397;
RA   George R.E., Sanda T., Hanna M., Froehling S., Luther W. II, Zhang J.,
RA   Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S.,
RA   Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L.,
RA   Greulich H., Morris S.W., Meyerson M., Look A.T.;
RT   "Activating mutations in ALK provide a therapeutic target in
RT   neuroblastoma.";
RL   Nature 455:975-978(2008).
RN   [34]
RP   CHARACTERIZATION OF VARIANTS NBLST3 LEU-1174; VAL-1174 AND GLN-1275.
RX   PubMed=21242967; DOI=10.1038/onc.2010.595;
RA   Mazot P., Cazes A., Boutterin M.C., Figueiredo A., Raynal V.,
RA   Combaret V., Hallberg B., Palmer R.H., Delattre O.,
RA   Janoueix-Lerosey I., Vigny M.;
RT   "The constitutive activity of the ALK mutated at positions F1174 or
RT   R1275 impairs receptor trafficking.";
RL   Oncogene 30:2017-2025(2011).
CC   -!- FUNCTION: Neuronal orphan receptor tyrosine kinase that is
CC       essentially and transiently expressed in specific regions of the
CC       central and peripheral nervous systems and plays an important role
CC       in the genesis and differentiation of the nervous system.
CC       Transduces signals from ligands at the cell surface, through
CC       specific activation of the mitogen-activated protein kinase (MAPK)
CC       pathway. Phosphorylates almost exclusively at the first tyrosine
CC       of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK
CC       induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as
CC       well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a
CC       receptor for ligands pleiotrophin (PTN), a secreted growth factor,
CC       and midkine (MDK), a PTN-related factor, thus participating in PTN
CC       and MDK signal transduction. PTN-binding induces MAPK pathway
CC       activation, which is important for the anti-apoptotic signaling of
CC       PTN and regulation of cell proliferation. MDK-binding induces
CC       phosphorylation of the ALK target insulin receptor substrate
CC       (IRS1), activates mitogen-activated protein kinases (MAPKs) and
CC       PI3-kinase, resulting also in cell proliferation induction. Drives
CC       NF-kappa-B activation, probably through IRS1 and the activation of
CC       the AKT serine/threonine kinase. Recruitment of IRS1 to activated
CC       ALK and the activation of NF-kappa-B are essential for the
CC       autocrine growth and survival signaling of MDK.
CC       {ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720,
CC       ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760,
CC       ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009,
CC       ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15908427,
CC       ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150,
CC       ECO:0000269|PubMed:17274988}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Activated by ligand-binding and subsequent
CC       phosphorylation. Inactivated through dephosphorylation by receptor
CC       protein tyrosine phosphatase beta and zeta complex (PTPRB/PTPRZ1)
CC       when there is no stimulation by a ligand. Staurosporine,
CC       crizotinib and CH5424802 act as inhibitors of ALK kinase activity.
CC       {ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:17681947,
CC       ECO:0000269|PubMed:21575866}.
CC   -!- SUBUNIT: Homodimer. Homodimerizes when bound to ligand. Interacts
CC       with FRS2, IRS1, MDK, PTN and SHC1. Interacts with CBL, PIK3R1 and
CC       PLCG1 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Self; NbExp=10; IntAct=EBI-357361, EBI-357361;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-357361, EBI-352572;
CC       P23471:PTPRZ1; NbExp=2; IntAct=EBI-357361, EBI-2263175;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16317043,
CC       ECO:0000269|PubMed:9174053}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:9174053}.
CC       Note=Membrane attachment was crucial for promotion of neuron-like
CC       differentiation and cell proliferation arrest through specific
CC       activation of the MAP kinase pathway.
CC   -!- TISSUE SPECIFICITY: Expressed in brain and CNS. Also expressed in
CC       the small intestine and testis, but not in normal lymphoid cells.
CC       {ECO:0000269|PubMed:9174053}.
CC   -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which
CC       activates kinase activity. In cells not stimulated by a ligand,
CC       receptor protein tyrosine phosphatase beta and zeta complex
CC       (PTPRB/PTPRZ1) dephosphorylates ALK at the sites in ALK that are
CC       undergoing autophosphorylation through autoactivation.
CC       Phosphorylation at Tyr-1507 is critical for SHC1 association.
CC       {ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:15938644,
CC       ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988,
CC       ECO:0000269|PubMed:17681947}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:9174053}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALK is found in a
CC       form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with
CC       NPM1. The resulting chimeric NPM1-ALK protein homodimerize and the
CC       kinase becomes constitutively activated. The constitutively active
CC       fusion proteins are responsible for 5-10% of non-Hodgkin
CC       lymphomas.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALK is associated
CC       with inflammatory myofibroblastic tumors (IMTs). Translocation
CC       t(2;11)(p23;p15) with CARS; translocation t(2;4)(p23;q21) with
CC       SEC31A.
CC   -!- DISEASE: Note=A chromosomal aberration involving ALK is associated
CC       with anaplastic large-cell lymphoma (ALCL). Translocation
CC       t(2;17)(p23;q25) with ALO17.
CC   -!- DISEASE: Neuroblastoma 3 (NBLST3) [MIM:613014]: A common neoplasm
CC       of early childhood arising from embryonic cells that form the
CC       primitive neural crest and give rise to the adrenal medulla and
CC       the sympathetic nervous system. {ECO:0000269|PubMed:18724359,
CC       ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=The ALK signaling pathway plays an important role in
CC       glioblastoma, the most common malignant brain tumor of adults and
CC       one of the most lethal cancers. It regulates both glioblastoma
CC       migration and growth.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 LDL-receptor class A domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 MAM domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00128}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92714.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ALKID10.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U62540; AAB71619.1; -; mRNA.
DR   EMBL; U66559; AAC51104.1; -; mRNA.
DR   EMBL; AB209477; BAD92714.1; ALT_INIT; mRNA.
DR   EMBL; AC106870; AAX93126.1; -; Genomic_DNA.
DR   EMBL; AC093756; AAX88892.1; -; Genomic_DNA.
DR   EMBL; AC074096; AAY15027.1; -; Genomic_DNA.
DR   CCDS; CCDS33172.1; -.
DR   RefSeq; NP_004295.2; NM_004304.4.
DR   UniGene; Hs.654469; -.
DR   PDB; 2KUP; NMR; -; B=1571-1589.
DR   PDB; 2KUQ; NMR; -; A=1571-1589.
DR   PDB; 2XB7; X-ray; 2.50 A; A=1094-1407.
DR   PDB; 2XBA; X-ray; 1.95 A; A=1094-1407.
DR   PDB; 2XP2; X-ray; 1.90 A; A=1093-1411.
DR   PDB; 2YFX; X-ray; 1.70 A; A=1093-1411.
DR   PDB; 2YHV; X-ray; 1.90 A; A=1093-1411.
DR   PDB; 2YJR; X-ray; 1.90 A; A=1093-1411.
DR   PDB; 2YJS; X-ray; 1.90 A; A=1093-1411.
DR   PDB; 2YS5; NMR; -; B=1571-1589.
DR   PDB; 2YT2; NMR; -; A=1571-1589.
DR   PDB; 3AOX; X-ray; 1.75 A; A=1069-1411.
DR   PDB; 3L9P; X-ray; 1.80 A; A=1072-1410.
DR   PDB; 3LCS; X-ray; 1.95 A; A=1072-1410.
DR   PDB; 3LCT; X-ray; 2.10 A; A=1072-1410.
DR   PDB; 4ANL; X-ray; 1.70 A; A=1093-1411.
DR   PDB; 4ANQ; X-ray; 1.76 A; A=1093-1411.
DR   PDB; 4ANS; X-ray; 1.85 A; A=1093-1411.
DR   PDB; 4CCB; X-ray; 2.03 A; A=1093-1411.
DR   PDB; 4CCU; X-ray; 2.00 A; A=1093-1411.
DR   PDB; 4CD0; X-ray; 2.23 A; A=1093-1411.
DR   PDB; 4CLI; X-ray; 2.05 A; A=1093-1411.
DR   PDB; 4CLJ; X-ray; 1.66 A; A=1093-1411.
DR   PDB; 4CMO; X-ray; 2.05 A; A=1093-1411.
DR   PDB; 4CMT; X-ray; 1.73 A; A=1093-1411.
DR   PDB; 4CMU; X-ray; 1.80 A; A=1093-1411.
DR   PDB; 4CNH; X-ray; 1.90 A; A/B=1093-1411.
DR   PDB; 4CTB; X-ray; 1.79 A; A=1093-1411.
DR   PDB; 4CTC; X-ray; 2.03 A; A=1093-1411.
DR   PDB; 4DCE; X-ray; 2.03 A; A/B=1078-1410.
DR   PDB; 4FNW; X-ray; 1.75 A; A=1084-1410.
DR   PDB; 4FNX; X-ray; 1.70 A; A=1084-1410.
DR   PDB; 4FNY; X-ray; 2.45 A; A=1084-1410.
DR   PDB; 4FNZ; X-ray; 2.60 A; A=1084-1410.
DR   PDB; 4FOB; X-ray; 1.90 A; A=1058-1410.
DR   PDB; 4FOC; X-ray; 1.70 A; A=1058-1410.
DR   PDB; 4FOD; X-ray; 2.00 A; A=1078-1410.
DR   PDB; 4JOA; X-ray; 2.70 A; A=1072-1410.
DR   PDB; 4MKC; X-ray; 2.01 A; A=1072-1410.
DR   PDB; 4TT7; X-ray; 2.10 A; A=1095-1410.
DR   PDBsum; 2KUP; -.
DR   PDBsum; 2KUQ; -.
DR   PDBsum; 2XB7; -.
DR   PDBsum; 2XBA; -.
DR   PDBsum; 2XP2; -.
DR   PDBsum; 2YFX; -.
DR   PDBsum; 2YHV; -.
DR   PDBsum; 2YJR; -.
DR   PDBsum; 2YJS; -.
DR   PDBsum; 2YS5; -.
DR   PDBsum; 2YT2; -.
DR   PDBsum; 3AOX; -.
DR   PDBsum; 3L9P; -.
DR   PDBsum; 3LCS; -.
DR   PDBsum; 3LCT; -.
DR   PDBsum; 4ANL; -.
DR   PDBsum; 4ANQ; -.
DR   PDBsum; 4ANS; -.
DR   PDBsum; 4CCB; -.
DR   PDBsum; 4CCU; -.
DR   PDBsum; 4CD0; -.
DR   PDBsum; 4CLI; -.
DR   PDBsum; 4CLJ; -.
DR   PDBsum; 4CMO; -.
DR   PDBsum; 4CMT; -.
DR   PDBsum; 4CMU; -.
DR   PDBsum; 4CNH; -.
DR   PDBsum; 4CTB; -.
DR   PDBsum; 4CTC; -.
DR   PDBsum; 4DCE; -.
DR   PDBsum; 4FNW; -.
DR   PDBsum; 4FNX; -.
DR   PDBsum; 4FNY; -.
DR   PDBsum; 4FNZ; -.
DR   PDBsum; 4FOB; -.
DR   PDBsum; 4FOC; -.
DR   PDBsum; 4FOD; -.
DR   PDBsum; 4JOA; -.
DR   PDBsum; 4MKC; -.
DR   PDBsum; 4TT7; -.
DR   ProteinModelPortal; Q9UM73; -.
DR   SMR; Q9UM73; 1096-1399.
DR   BioGrid; 106739; 62.
DR   DIP; DIP-5954N; -.
DR   IntAct; Q9UM73; 7.
DR   MINT; MINT-1133857; -.
DR   STRING; 9606.ENSP00000373700; -.
DR   BindingDB; Q9UM73; -.
DR   ChEMBL; CHEMBL2111387; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB09063; Ceritinib.
DR   DrugBank; DB08865; Crizotinib.
DR   GuidetoPHARMACOLOGY; 1839; -.
DR   iPTMnet; Q9UM73; -.
DR   PhosphoSite; Q9UM73; -.
DR   BioMuta; ALK; -.
DR   DMDM; 296439447; -.
DR   PaxDb; Q9UM73; -.
DR   PRIDE; Q9UM73; -.
DR   DNASU; 238; -.
DR   Ensembl; ENST00000389048; ENSP00000373700; ENSG00000171094.
DR   GeneID; 238; -.
DR   KEGG; hsa:238; -.
DR   UCSC; uc002rmy.3; human.
DR   CTD; 238; -.
DR   GeneCards; ALK; -.
DR   GeneReviews; ALK; -.
DR   H-InvDB; HIX0024259; -.
DR   H-InvDB; HIX0030037; -.
DR   HGNC; HGNC:427; ALK.
DR   HPA; HPA010694; -.
DR   MalaCards; ALK; -.
DR   MIM; 105590; gene.
DR   MIM; 613014; phenotype.
DR   neXtProt; NX_Q9UM73; -.
DR   Orphanet; 300895; ALK-positive anaplastic large cell lymphoma.
DR   Orphanet; 364043; ALK-positive large B-cell lymphoma.
DR   Orphanet; 178342; Inflammatory myofibroblastic tumor.
DR   Orphanet; 635; Neuroblastoma.
DR   Orphanet; 357191; Selection of therapeutic option in non-small cell lung carcinoma.
DR   PharmGKB; PA24719; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; ENOG410XPVX; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000231766; -.
DR   HOVERGEN; HBG018726; -.
DR   InParanoid; Q9UM73; -.
DR   KO; K05119; -.
DR   OMA; NAIMLSK; -.
DR   OrthoDB; EOG7GN2KT; -.
DR   PhylomeDB; Q9UM73; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   SignaLink; Q9UM73; -.
DR   ChiTaRS; ALK; human.
DR   EvolutionaryTrace; Q9UM73; -.
DR   GeneWiki; Anaplastic_lymphoma_kinase; -.
DR   GenomeRNAi; 238; -.
DR   NextBio; 948; -.
DR   PRO; PR:Q9UM73; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; Q9UM73; -.
DR   CleanEx; HS_ALK; -.
DR   ExpressionAtlas; Q9UM73; baseline and differential.
DR   Genevisible; Q9UM73; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005622; C:intracellular; TAS:GOC.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004704; F:NF-kappaB-inducing kinase activity; TAS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0048666; P:neuron development; TAS:UniProtKB.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; TAS:GOC.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:GOC.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 4.10.400.10; -; 1.
DR   InterPro; IPR026830; ALK.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR000998; MAM_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF276; PTHR24416:SF276; 1.
DR   Pfam; PF00629; MAM; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49899; SSF49899; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   PROSITE; PS50060; MAM_2; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Chromosomal rearrangement;
KW   Complete proteome; Disease mutation; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19   1620       ALK tyrosine kinase receptor.
FT                                /FTId=PRO_0000016740.
FT   TOPO_DOM     19   1038       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1039   1059       Helical. {ECO:0000255}.
FT   TOPO_DOM   1060   1620       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      264    427       MAM 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00128}.
FT   DOMAIN      437    473       LDL-receptor class A.
FT   DOMAIN      478    636       MAM 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00128}.
FT   DOMAIN     1116   1392       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1197   1199       ATP.
FT   REGION     1197   1199       Inhibitor binding.
FT   COMPBIAS    816    940       Gly-rich.
FT   ACT_SITE   1249   1249       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1124   1124       ATP; via carbonyl oxygen.
FT   BINDING    1150   1150       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING    1150   1150       Inhibitor. {ECO:0000269|PubMed:20695522,
FT                                ECO:0000269|PubMed:21575866}.
FT   BINDING    1199   1199       Inhibitor; via amide nitrogen.
FT                                {ECO:0000269|PubMed:20695522,
FT                                ECO:0000269|PubMed:21575866}.
FT   BINDING    1203   1203       Inhibitor. {ECO:0000269|PubMed:20695522,
FT                                ECO:0000269|PubMed:21575866}.
FT   BINDING    1210   1210       Inhibitor. {ECO:0000269|PubMed:20695522,
FT                                ECO:0000269|PubMed:21575866}.
FT   BINDING    1270   1270       ATP.
FT   MOD_RES    1078   1078       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES    1092   1092       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P97793}.
FT   MOD_RES    1096   1096       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455,
FT                                ECO:0000269|PubMed:16878150}.
FT   MOD_RES    1131   1131       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES    1278   1278       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15938644}.
FT   MOD_RES    1507   1507       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17274988}.
FT   MOD_RES    1604   1604       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   CARBOHYD    169    169       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    244    244       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    285    285       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    324    324       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    424    424       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    445    445       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    563    563       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    571    571       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    627    627       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    709    709       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    808    808       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    863    863       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    864    864       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    886    886       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    986    986       N-linked (GlcNAc...). {ECO:0000255}.
FT   VARIANT      90     90       S -> L (in dbSNP:rs34617074).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041477.
FT   VARIANT     163    163       V -> L (in dbSNP:rs55697431).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041478.
FT   VARIANT     296    296       E -> Q (in dbSNP:rs56077855).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041479.
FT   VARIANT     476    476       V -> A (in dbSNP:rs35093491).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041480.
FT   VARIANT     560    560       L -> F (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041481.
FT   VARIANT     680    680       T -> I (in dbSNP:rs35228363).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041482.
FT   VARIANT     704    704       A -> T (in dbSNP:rs34829159).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041483.
FT   VARIANT     868    868       L -> Q (in dbSNP:rs55941323).
FT                                /FTId=VAR_061288.
FT   VARIANT     877    877       A -> S (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041484.
FT   VARIANT    1012   1012       T -> M (in dbSNP:rs35073634).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041485.
FT   VARIANT    1091   1091       D -> N (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18724359}.
FT                                /FTId=VAR_063850.
FT   VARIANT    1121   1121       G -> D (in dbSNP:rs55760835).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041486.
FT   VARIANT    1128   1128       G -> A (in NBLST3).
FT                                {ECO:0000269|PubMed:18724359}.
FT                                /FTId=VAR_063851.
FT   VARIANT    1151   1151       T -> M (in NBLST3).
FT                                {ECO:0000269|PubMed:18923525}.
FT                                /FTId=VAR_063852.
FT   VARIANT    1166   1166       M -> R (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18724359}.
FT                                /FTId=VAR_063853.
FT   VARIANT    1171   1171       I -> N (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18724359}.
FT                                /FTId=VAR_063854.
FT   VARIANT    1174   1174       F -> C (in NBLST3).
FT                                {ECO:0000269|PubMed:18923523}.
FT                                /FTId=VAR_063855.
FT   VARIANT    1174   1174       F -> I (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18724359}.
FT                                /FTId=VAR_063856.
FT   VARIANT    1174   1174       F -> L (in NBLST3; somatic mutation;
FT                                constitutively activated; retained in the
FT                                endoplasmic reticulum and Golgi
FT                                compartments).
FT                                {ECO:0000269|PubMed:18923523,
FT                                ECO:0000269|PubMed:18923525,
FT                                ECO:0000269|PubMed:21242967}.
FT                                /FTId=VAR_063857.
FT   VARIANT    1174   1174       F -> V (in NBLST3; somatic mutation;
FT                                constitutively activated; retained in the
FT                                endoplasmic reticulum and Golgi
FT                                compartments).
FT                                {ECO:0000269|PubMed:18923523,
FT                                ECO:0000269|PubMed:21242967}.
FT                                /FTId=VAR_063858.
FT   VARIANT    1192   1192       R -> P (in NBLST3).
FT                                {ECO:0000269|PubMed:18724359,
FT                                ECO:0000269|PubMed:18923523}.
FT                                /FTId=VAR_063859.
FT   VARIANT    1234   1234       A -> T (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18923525}.
FT                                /FTId=VAR_063860.
FT   VARIANT    1245   1245       F -> C (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18724359,
FT                                ECO:0000269|PubMed:18923525}.
FT                                /FTId=VAR_063861.
FT   VARIANT    1245   1245       F -> V (in NBLST3; somatic mutation).
FT                                /FTId=VAR_063862.
FT   VARIANT    1250   1250       I -> T (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18724359}.
FT                                /FTId=VAR_063863.
FT   VARIANT    1274   1274       A -> T (in dbSNP:rs45502292).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041487.
FT   VARIANT    1275   1275       R -> L (observed in neuroblastoma).
FT                                {ECO:0000269|PubMed:18923523}.
FT                                /FTId=VAR_063864.
FT   VARIANT    1275   1275       R -> Q (in NBLST3; constitutively
FT                                activated; retained in the endoplasmic
FT                                reticulum and Golgi compartments).
FT                                {ECO:0000269|PubMed:18724359,
FT                                ECO:0000269|PubMed:18923523,
FT                                ECO:0000269|PubMed:18923525,
FT                                ECO:0000269|PubMed:21242967}.
FT                                /FTId=VAR_063865.
FT   VARIANT    1278   1278       Y -> S (in NBLST3; somatic mutation).
FT                                {ECO:0000269|PubMed:18923523}.
FT                                /FTId=VAR_063866.
FT   VARIANT    1328   1328       M -> L (in dbSNP:rs56160491).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041488.
FT   VARIANT    1376   1376       F -> S (in dbSNP:rs17694720).
FT                                /FTId=VAR_055987.
FT   VARIANT    1416   1416       K -> N (in dbSNP:rs55782189).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041489.
FT   VARIANT    1419   1419       E -> K (in dbSNP:rs56181542).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041490.
FT   VARIANT    1429   1429       Q -> R (in dbSNP:rs55906201).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041491.
FT   VARIANT    1461   1461       I -> V (in dbSNP:rs1670283).
FT                                {ECO:0000269|PubMed:8122112,
FT                                ECO:0000269|PubMed:9053841,
FT                                ECO:0000269|PubMed:9174053,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_031042.
FT   VARIANT    1491   1491       K -> R (in dbSNP:rs1881420).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9053841,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_031043.
FT   VARIANT    1529   1529       D -> E (in dbSNP:rs1881421).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9053841,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_031044.
FT   VARIANT    1599   1599       P -> H (in dbSNP:rs1881423).
FT                                /FTId=VAR_055988.
FT   MUTAGEN    1507   1507       Y->F: Impairs interaction with SHC1.
FT                                {ECO:0000269|PubMed:17274988}.
FT   CONFLICT     36     36       P -> S (in Ref. 1; AAB71619).
FT                                {ECO:0000305}.
FT   HELIX      1087   1092       {ECO:0000244|PDB:3AOX}.
FT   STRAND     1096   1098       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1101   1103       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1105   1107       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1113   1115       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1116   1121       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1126   1128       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1130   1135       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1137   1140       {ECO:0000244|PDB:3LCS}.
FT   STRAND     1145   1151       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1158   1173       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1182   1186       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1188   1191       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1193   1197       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1204   1210       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1215   1217       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1223   1242       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1252   1254       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1255   1258       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1260   1263       {ECO:0000244|PDB:4DCE}.
FT   STRAND     1266   1268       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1272   1278       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1280   1282       {ECO:0000244|PDB:3LCT}.
FT   HELIX      1288   1290       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1293   1295       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1298   1303       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1308   1323       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1335   1343       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1356   1365       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1370   1372       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1376   1388       {ECO:0000244|PDB:4CLJ}.
FT   HELIX      1390   1393       {ECO:0000244|PDB:4CLJ}.
FT   STRAND     1574   1576       {ECO:0000244|PDB:2KUP}.
FT   STRAND     1582   1584       {ECO:0000244|PDB:2YT2}.
SQ   SEQUENCE   1620 AA;  176442 MW;  0733D6C4FD212F41 CRC64;
     MGAIGLLWLL PLLLSTAAVG SGMGTGQRAG SPAAGPPLQP REPLSYSRLQ RKSLAVDFVV
     PSLFRVYARD LLLPPSSSEL KAGRPEARGS LALDCAPLLR LLGPAPGVSW TAGSPAPAEA
     RTLSRVLKGG SVRKLRRAKQ LVLELGEEAI LEGCVGPPGE AAVGLLQFNL SELFSWWIRQ
     GEGRLRIRLM PEKKASEVGR EGRLSAAIRA SQPRLLFQIF GTGHSSLESP TNMPSPSPDY
     FTWNLTWIMK DSFPFLSHRS RYGLECSFDF PCELEYSPPL HDLRNQSWSW RRIPSEEASQ
     MDLLDGPGAE RSKEMPRGSF LLLNTSADSK HTILSPWMRS SSEHCTLAVS VHRHLQPSGR
     YIAQLLPHNE AAREILLMPT PGKHGWTVLQ GRIGRPDNPF RVALEYISSG NRSLSAVDFF
     ALKNCSEGTS PGSKMALQSS FTCWNGTVLQ LGQACDFHQD CAQGEDESQM CRKLPVGFYC
     NFEDGFCGWT QGTLSPHTPQ WQVRTLKDAR FQDHQDHALL LSTTDVPASE SATVTSATFP
     APIKSSPCEL RMSWLIRGVL RGNVSLVLVE NKTGKEQGRM VWHVAAYEGL SLWQWMVLPL
     LDVSDRFWLQ MVAWWGQGSR AIVAFDNISI SLDCYLTISG EDKILQNTAP KSRNLFERNP
     NKELKPGENS PRQTPIFDPT VHWLFTTCGA SGPHGPTQAQ CNNAYQNSNL SVEVGSEGPL
     KGIQIWKVPA TDTYSISGYG AAGGKGGKNT MMRSHGVSVL GIFNLEKDDM LYILVGQQGE
     DACPSTNQLI QKVCIGENNV IEEEIRVNRS VHEWAGGGGG GGGATYVFKM KDGVPVPLII
     AAGGGGRAYG AKTDTFHPER LENNSSVLGL NGNSGAAGGG GGWNDNTSLL WAGKSLQEGA
     TGGHSCPQAM KKWGWETRGG FGGGGGGCSS GGGGGGYIGG NAASNNDPEM DGEDGVSFIS
     PLGILYTPAL KVMEGHGEVN IKHYLNCSHC EVDECHMDPE SHKVICFCDH GTVLAEDGVS
     CIVSPTPEPH LPLSLILSVV TSALVAALVL AFSGIMIVYR RKHQELQAMQ MELQSPEYKL
     SKLRTSTIMT DYNPNYCFAG KTSSISDLKE VPRKNITLIR GLGHGAFGEV YEGQVSGMPN
     DPSPLQVAVK TLPEVCSEQD ELDFLMEALI ISKFNHQNIV RCIGVSLQSL PRFILLELMA
     GGDLKSFLRE TRPRPSQPSS LAMLDLLHVA RDIACGCQYL EENHFIHRDI AARNCLLTCP
     GPGRVAKIGD FGMARDIYRA SYYRKGGCAM LPVKWMPPEA FMEGIFTSKT DTWSFGVLLW
     EIFSLGYMPY PSKSNQEVLE FVTSGGRMDP PKNCPGPVYR IMTQCWQHQP EDRPNFAIIL
     ERIEYCTQDP DVINTALPIE YGPLVEEEEK VPVRPKDPEG VPPLLVSQQA KREEERSPAA
     PPPLPTTSSG KAAKKPTAAE ISVRVPRGPA VEGGHVNMAF SQSNPPSELH KVHGSRNKPT
     SLWNPTYGSW FTEKPTKKNN PIAKKEPHDR GNLGLEGSCT VPPNVATGRL PGASLLLEPS
     SLTANMKEVP LFRLRHFPCG NVNYGYQQQG LPLEAATAPG AGHYEDTILK SKNSMNQPGP
//